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RA A MULTIFACETED DISEASE THAT REQUIRES NOVEL CONSIDERATIONS FOR 
EVALUATING COST EFFECTIVENESS OF INTERVENTIONS
Evidence suggests that rheumatoid arthritis (RA) as a disease has been present since 
ancient times [1]. In more recent history, RA has been described by Sydenham, Fuller, 
Heberden and Beauvais using various terms such as rheumatic gout, chronic rheuma-
tism, rheumalgia, scorbutic rheumatism, asthenic gout [2-5]. Beauvais is credited with 
describing the typical RA case with pathology suggesting this disease has a separate 
entity compared to gout [5]. Garrod named it RA in his treatise of 1859 and presented 
the diﬀ erential diagnosis for the disease with illustrations [6].
Our understanding of RA and the immunologic mechanisms driving the disease has 
greatly increased over the years. RA is currently described as a chronic progressive 
inﬂ ammatory disease of the joint synovium, leading to progressive disability and loss 
of function. In addition to inﬂ ammation in the joints, RA is also associated with bone 
loss, erosions, and osteoporosis [7,8]. Apart from the eﬀ ect in the joints, RA is often 
associated with extra-articular manifestations. These extra-articular manifestations 
aﬀ ect various tissues and organ systems, such as the lungs and the cardio-vascular 
system, and are distinct from the common co-morbidities occurring in the same 
bodily compartments [9]. Given the debilitating impact of RA on the joints and other 
organ systems it is not surprising that RA ranks high on the global disability list [10].
Apart from the clinical burden that RA poses, there is a substantial economic burden 
associated with RA [11]. Numerous studies with varying methodology have reported 
the direct and indirect costs of RA and these have been summarized in recent publica-
tions [12,13]. Given the diﬀ erences in methodologies, objectives, and countries, the 
cost-of-illness studies in RA report wide variation in average cost, particularly in regard 
to productivity losses. A 2008 publication reported total costs of RA from a societal 
perspective to be €45.3 billion in Europe and €41.6 billion in the United States (US). 
Indirect costs constituted 32%, while medical costs were 21% and drug costs were 
around 19%. In Sweden, the rheumatology quality register estimated the total direct 
costs of RA to be €524 million in 2009 [14]. The US Center for Disease Control (CDC) 
reported 9,100 hospitalizations with RA listed as the principal diagnosis with total 
hospital charges of $374 million (mean charge of $41,000 per person) [15]. Women 
and people 45 years and older accounted for the majority of these stays. Since RA 
aﬀ ects patients during their most productive working years (average age of onset is 
45 years), work productivity losses due to RA are generally high [16].
RA treatments include corticosteroids (CS), non-steroidal anti-inﬂ ammatory drugs 
(NSAIDs), and disease-modifying antirheumatic drugs (DMARDs). The term DMARD 
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is applied to medications that can alter the course of the disease and thus prevent 
joint erosion. Traditional or conventional (c)DMARDs include gold, sulfasalazine, 
azathioprine, cyclophosphamide, antimalarials and methotrexate. Biologic (b)
DMARDs were introduced around 2000; these agents have greatly improved overall 
clinical outcomes, and health related quality of life (HRQOL) of patients. However, 
these therapies are expensive compared to the cDMARDs. With the introduction of 
the bDMARDs, the cost of managing RA patients has shifted from hospital settings 
to outpatient ambulatory setting [17,18]. This cost shift is viewed favorably by hospital 
payers and DRG committees. Recently, biosimilars have been approved by regulatory 
and payer authorities in the EU and have considerable lower cost. Introduction of bi-
osimilars has the potential to reduce cost to the overall health system and signiﬁ cantly 
increase aﬀ ordability of bDMARDs. In parallel, new therapies as well as combination 
therapies (of diﬀ erent bDMARDs or of bDMARDs in combination with synthetic (sc)
DMARDs) targeting multiple immune pathways are being developed and entering 
the market. In this type of environment, tools that enable a broader and more precise 
estimation of cost and beneﬁ ts will reduce the risk of ineﬃ  cient resource allocation.
This thesis builds towards taking a more comprehensive approach in evaluating ben-
eﬁ ts and costs of future therapies in RA. It focuses on multiple aspects of the disease 
such as treatment target measures, the heterogeneous nature of RA in terms of base-
line patient characteristics (through considerations of subgroups) and outcomes that 
are not joint-related. By focusing on these aspects of the disease, a case is built for 
the incorporation of appropriate treatment response, the need to identify subgroups 
of RA patients at risk of rapid progression of disease and consideration of outcomes 
that are not joint related in future economic evaluations. Deliberation of these aspects 
when performing economic evaluations of interventions in RA could facilitate stratiﬁ -
cation of cost-eﬀ ectiveness analysis by subgroups and a more complete evaluation of 
beneﬁ ts versus cost of interventions. This could pave the way for policies leading to 
personalized medicine in RA by incorporation of genetic, environmental and clinical/
biochemical proﬁ ling into economic modeling. To support the more comprehensive 
evaluation approach, this thesis is divided into 4 parts:
Part I: Real world evidence on treatment targets and outcomes
Part II: Presence of multiple poor prognostic factors
Part III: Extra-articular manifestation of cardiovascular risk in RA
Part IV: Improvements of future cost eﬀ ectives studies in RA
For each part, we brieﬂ y summarize the most important evidence and then explain 
what this thesis adds to the existing evidence.
11General Introduction ○
1
PART I: REAL WORLD EVIDENCE ON TREATMENT TARGETS AND OUTCOMES
The consensus treatment guidelines by the EU League Against Rheumatism (EULAR 
2016) focus on the joint-aspect of the disease and have advocated a treat to target ap-
proach [19]. The 2016 EULAR guidelines recommend two treatment targets: remission, 
especially in DMARD-naïve patients, and low disease activity, primarily in patients who 
failed previous therapies. Regarding remission, the EULAR and American College of 
Rheumatology (ACR) have agreed on Boolean* and index-based deﬁ nitions, the latter 
based on the Simpliﬁ ed or Clinical Disease Activity Index** (SDAI, CDAI). Multiple 
studies have demonstrated that attaining a state of remission or low disease activity 
leads to better structural and functional outcomes than allowing residual disease activ-
ity. The hypothesis that an improved outcome can be achieved by employing a strategy 
of intensive outpatient management of patients with RA was tested in a single-blind 
randomized controlled trial involving 183 patients.[20] Intensive management was 
based on monthly review of disease activity using the Disease Activity Score (DAS), 
escalation of DMARD therapy in patients with persistent disease activity (DAS>2.4) 
according to a treatment protocol, liberal use of intramuscular triamcinolone in the 
ﬁ rst three months of a new DMARD being prescribed, and intra-articular injections 
of triamcinolone into swollen joints. Based on the ﬁ ndings the authors concluded 
that intensive outpatient management of RA substantially improves disease activity, 
radiographic disease progression, physical function, and HRQOL at no additional 
cost. Similarly, the eﬃ  cacy and safety of adalimumab plus methotrexate (ADA+MTX) 
compared with methotrexate monotherapy in achieving stable low disease activity 
(LDA; DAS in 28 joints using C-reactive protein level (DAS28-CRP <3.2 at weeks 22 
and 26) and clinical, radiographic and functional outcomes in methotrexate-naive 
patients with early active RA was studied in 1032 patients. In this trial patients were 
randomly assigned 1:1 to ADA+MTX or placebo plus methotrexate (PBO+MTX) for 26 
weeks. Post-hoc analyses compared patients achieving stable remission using DAS28-
CRP and 2010 ACR/EULAR criteria with those achieving LDA. Patients achieving 
ACR/EULAR remission, particularly in the PBO+MTX group, had some advantage in 
radiographic outcomes compared with patients who only achieved LDA. Similar ﬁ nd-
ings were observed by other investigators [21]. However, the majority of this empirical 
evidence is based on randomized controlled trials [22-24]. Limited data is available 
on patients with established RA in routine clinical practice to support the beneﬁ ts 
of achieving diﬀ erent deﬁ nitions of target measures of disease activity in relation to 
functional status, HRQOL, and health care resource utilization.
In chapter 2 of the thesis, we utilized real life data from clinical practice to conduct 
an observational study to assess the potential clinical implications of achieving dif-
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ferent disease states (remission, low, moderate and severe disease activity states), 
based on various measures of disease activity. This analysis tested the hypothesis 
that achieving target measures of disease activity would lead to improved outcomes 
in clinical practice in a longitudinal cohort of RA patients. Disease activity measures 
used in this analysis were those recommended by EULAR/ACR guidelines and in-
cluded the DAS28-CRP <2.6, the SDAI ≤3.3, or the CDAI ≤2.8. Outcomes evaluated in 
this analysis included both clinical i.e. physical functioning (daily activities) according 
to the modiﬁ ed Health Assessment Questionnaire (mHAQ), HRQOL measured by 
EuroQol 5-domain (EQ-5D) measure and economic i.e. resource utilization indicators 
like hospitalizations and durable medical equipment (DME) use.
PART II: PRESENCE OF MULTIPLE POOR PROGNOSTIC FACTORS
Early in the disease course of RA, various factors associated with a poor prognosis of 
disease have been identiﬁ ed. These include certain genotypes, young age at disease 
onset, high disease activity based composite measures, high acute phase reactant 
levels (CRP), erythrocyte sedimentation rate (ESR), presence of rheumatoid factors 
(RF) and/or anti-citrullinated protein antibody (ACPA), especially at high levels, 
presence of early erosions and failure of two or more cDMARDs [24]. Contemporary 
RA management guidelines recommend more intensive treatment of patients with 
poor prognostic factors. The 2016 EULAR RA treatment guidelines recommend the 
addition of a bDMARD or a cDMARD when poor prognostic factors are present and 
treatment target is not achieved with the ﬁ rst CS strategy [16]. The EULAR Guideline 
Task Force desired to give stratiﬁ cation of RA patients based on prognostic factors 
more prominence and hence called this out as a separate recommendation.
These prognostic factors are correlated and there is suﬃ  cient evidence in the literature 
indicating that ACPA positivity is associated with erosive disease as shown by panel A 
of ﬁ gure 1, where the Sharp-Van der Heijde scores increase over time in ACPA positive 
patients. In addition to this there is also evidence that ACPA positivity is more strongly 
associated with erosion than RF positivity (panel B, ﬁ gure 1) [25,26]. As per treatment 
guidelines, patients with multiple poor prognostic factors have a poor prognosis. The 
impact of the multiple prognostic factors on rapid radiographic progression has been 
evaluated in various risk prediction models and have been discussed in detail in a 
review manuscript, [27-32] Though these models provide estimates of the probability 
of having rapid radiologic progression at one year if one predictor or a combination 
of predictors are present, their validation with an external dataset has not been posi-
tive [33]. The prognostic factors for rapid radiographic progression in these models 
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include serum levels of RF (2 of the 4 models), ACPA (2 of the 4 models), CRP (all 4 
models), baseline joint counts (2 of the 4 models) and baseline erosions (2 of the 4 
models). All of these models use data from early RA patients either from RCTs or from 
RA registries. Thus, limited empirical data exists in established RA on the impact of 
combinations of prognostic factors on clinical and economic outcomes.
Part II of the thesis focuses on the impact of having multiple poor prognostic factors 
on clinical and economic outcomes in established RA.
The following research hypothesis were tested in the various studies conducted in 
this Part:
Figure 1: Association of seropositivity with erosions in early RA patients*
Radiological destruction patients with and without anti-cyclic-citrulli-n ted peptide antibioticsin patients with and without anti- y lic-citrulli-
nated peptide antibodies.Total Sharp–van der Heijde scores (mean ± 
standard error of the mean) at inclusion and at 2 and 4 years follow-up 
in rheumatoid arthritis patients with (CCP+) and without (CCP-) anti-
cyclic-citrullinated peptide antibodies.
* Figures reproduced under the following approval “BioMed Central Ltd. (http://creativecommons.org/li-
censes/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is cited” and lic # 4280361405715 with Ann Rheum Dis
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a) Established RA patients that are ACPA positive, have increased odds of erosive 
disease and greater bone loss [hand Digital X-Ray Bone Mineral Density (DXR–
BMD)]), indicating prognostic factors are inter-related.
b) Reduction in ACPA titer is associated with reduction in disease activity and re-
source utilization.
c) The presence of multiple poor prognostic factors leads to poor clinical and eco-
nomic outcomes in RA patients.
d) The presence of poor prognostic factors in RA patients leads to treatment accelera-
tion in clinical practice setting.
Data from real world RA registries were used to address the above hypotheses. Recent 
studies have suggested that ACPA can stimulate bone loss by inducing the diﬀ erentia-
tion of precursors into bone-resorbing osteoclasts [33]. In patients who are positive 
for ACPA, structural bone damage can start even before the clinical onset of RA [34].
In chapter 3 we present results from the study evaluating the associations between 
presence of ACPA/RF seropositivity and the binary outcome variable of the presence 
or absence of joint erosions as well as the loss of bone mineral density on DXR. In 
chapter 4, we assess the association between the change in the level of auto-antibody 
i.e. ACPA on disease activity as well on resource utilization and work activity. In chap-
ter 5, we evaluate the impact of having multiple poor prognostic factors of ACPA/RF 
seropositivity and erosions on outcomes. The outcomes evaluated in this analysis 
included remission and LDA based on the composite measures of disease activity 
[DAS28-CRP < 2.6 or SDAI ≤ 3.3], hospitalization, the use of durable medical equip-
ment use (canes, wheelchairs, walkers etc.) and employment status (proportions 
employed, retired, disabled, and earning <$50,000 annually). In chapter 6, we evaluate 
the impact of having multiple poor prognostic factors on initiating treatment with 
bDMARDs as well as clinical and work productivity outcomes. Patients in this study 
were categorized at baseline based on number of prognostic factors present into 0-1, 2 
and 3+ groups using the 2008 ACR treatment recommendations. As per the 2008 ACR 
criteria the following factors were considered as poor prognostic factors: functional 
limitation (based on mHAQ > 0.5), extra-articular disease (Sjögren’s syndrome, RA 
lung disease and/or nodules), seropositivity (RF and/or ACPA), and erosions (as per 
radiograph at enrollment).
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PART III: EXTRA-ARTICULAR MANIFESTATION OF CARDIOVASCULAR (CV) RISKS 
IN RA
RA is a systemic autoimmune disease associated with extra-articular RA manifesta-
tions. Extra-articular manifestations of RA eﬀ ects various tissues. Extra-articular 
manifestation is associated with increased comorbidity and premature mortality 
[35]. Severe extra-articular manifestations are also associated with an increased risk 
of cardiovascular disease (CVD) in patients with RA [36]. The 2009 EULAR recom-
mendations for CV risk management identiﬁ ed the following disease-speciﬁ c criteria 
for higher CV risk in RA patients: disease duration of >10 years, RF or ACPA positivity 
and the presence of certain extra-articular manifestations.
CV events represent a signiﬁ cant and important outcome in RA patients. There is a 
general consensus that RA patients have a substantially increased risk of CVD versus 
the general population, leading to reduced life expectancy, diminished HRQOL, and 
increased health care costs [37]. Coronary artery and cerebrovascular atherosclero-
sis (CVA) are likely to occur in RA patients earlier than in general population [38]. 
Epidemiological studies have indicated the relative risk of acute myocardial infarction 
(AMI) in RA patients to be 1.5 to 2.0 and for stroke to be 1.4 – 2.7 fold higher [39,40]. 
Investigators have found that several treatment regimens for RA modify the traditional 
CV risk factors and CV morbidity/mortality. A positive association between AMI and 
CS use was reported in a study of patients in the National Data Bank for Rheumatic 
Diseases [41]. CS might increase CV risk by increasing the prevalence of hypertension, 
diabetes, and hyperlipidemia. Methotrexate, the most frequently used DMARD for 
the treatment of RA, has been associated with a lower risk of CV death, CV morbidity, 
AMI, and heart failure compared to other treatments [42, 43]. Recent meta-analysis 
reported that in cohort studies, anti-TNF therapy was associated with a reduced risk 
for all CV events, AMI and CVA but these ﬁ ndings are not consistent [44, 45]. The re-
cent published phase III RCT with an anti-interleukin 1 beta compound demonstrated 
that reducing inﬂ ammation among men and women who have had a prior event can 
reduce the risk of another CV event happening in the future [46].
Chapters 7 to 9 focus on the CV manifestation in RA, primarily because CV events 
have substantial implications for costs, survival as well as quality of life. Since RA is 
associated with a 50 to 60% increase in risk of CV death, the aim of chapter 7 was 
to evaluate, whether the increased CV risk in RA patients can be explained by the 
lack of appropriate management of traditional CV risk factors (such as hypertension, 
smoking and cholesterol). We tested the hypothesis that traditional risk factors are 
managed poorly in RA patients compared to matched non-RA patients. We utilized 
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data from two large health systems i.e. the UK and the US (Southern California). In UK 
analysis, RA patients were matched 1:4 to non-RA patients based on their year of entry 
into the database, CV risk category based on National Cholesterol Education Program 
classiﬁ cation, treatment status at index date and a propensity score estimating the 
probability of having RA. In the US analysis, two RA cohorts were identiﬁ ed, the ﬁ rst 
was matched to the general population (general controls) in a ratio of 1:4. The second 
RA cohort was matched to individuals with a diagnosis of osteoarthritis in a ratio of 
1:1 [47].
If CV events are to be incorporated in the economic evaluation of RA treatments, then 
it would be important to understand the predictors and risk modiﬁ ers of CV events 
and the impact of treatment on these predictors and risk modiﬁ ers. The 2009 EULAR 
recommendations for CVD risk management suggested a multiplication factor of 1.5 
to the CVD risk calculated using traditional risk calculators such as the Framingham 
and SCORE algorithms [48, 49] However, these algorithms were not developed in 
RA-speciﬁ c populations and recent attempts to develop RA-speciﬁ c CV risk calculators 
have encountered mixed success [50, 51]. Thus, another aspect of CV manifestation of 
RA investigated in chapter 8 of this thesis was the performance of CV risk prediction 
algorithms in RA. We tested the hypothesis that markers of inﬂ ammation such as 
CRP improve the CV risk prediction in RA and thus could help explain some of the 
increased CV risk in RA patients. We conducted a retrospective analysis, using clinical 
practice data from the UK to test this hypothesis.
The ﬁ nal chapter in this Part focuses on the association between lowering low-density 
lipoproteins cholesterol (LDL-C) levels and CV outcomes among RA patients. Elevated 
cholesterol is a risk factor for increased CV events in the general population; however, 
a growing level of evidence suggests a complex relationship between lipid levels and 
CV risk in patients with RA [52]. There is considerable evidence that an atherogenic 
lipid proﬁ le may be detected in patients with early RA. For example, treatment-naïve 
active RA patients with disease duration of less than one year exhibited signiﬁ cantly 
higher total cholesterol (TC) and LDL-C with lower high-density lipoproteins (HDL-C) 
levels when compared to matched controls and the ratio of TC to HDL-C was less 
favorable in RA patients [53]. These ﬁ ndings are potentially due to the altered lipid 
metabolism from systemic inﬂ ammation, drug therapy, and several genetic factors in 
RA. The evidence regarding the beneﬁ ts of lowering elevated LDL-C in patients with 
RA is not clear. The hydroxymethylglutaryl CoA reductase inhibitor (statin) therapy has 
been shown to be beneﬁ cial in primary and secondary prevention of CV diseases in 
the general population [54]. Although several post-hoc analysis suggest potential CV 
protective eﬀ ects of statin therapy in RA, there has been no RCT evaluating this ques-
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tions (a recent prospective RCT was terminated early owing to low CV event rates) 
[55]. Thus in chapter 9 we investigated whether a lower LDL-C in RA patients was 
associated with any reductions in CV events. We utilized data from a US managed 
care setting on RA subjects and age- and sex-matched controls who are prescribed 
statin therapy.
PART IV: IMPROVEMENT IN FUTURE COST EFFECTIVES ANALYSIS IN RA
Various types of economic models have been developed in RA with the primary 
objective to evaluate the cost and beneﬁ ts of treatments in RA and estimate the cost-
eﬀ ectiveness of interventions including bDMARDs and cDMARDs. A comprehensive 
overview of these modeling approaches were published in 2014 [56, 57]. These 
economic models have used a number of diﬀ erent RA disease activity measures, 
including the EULAR, ACR criteria and various composite disease activity measures 
that were mentioned in Part I of this thesis, to determine the number of patients 
responding to and continuing treatment (i.e. treatment response). In general, these 
models convert the change in disease activity measure after treatment initiation into a 
change in HAQ score and focus on the progression of HAQ scores for the population 
over time. The HAQ scores are then generally mapped to the patient’s HRQOL, mor-
tality rates and resource use, using validated mapping algorithms [58]. Thus, models 
used in RA generally are able to simulate the experiences of RA patients by replicating 
the clinical reality of the disease using clinical eﬃ  cacy data from trials to assess the 
initial response to a treatment and then using limited data from registries to model 
long-term disease progression.
In the ﬁ rst section (chapter 10) of this Part, we use an individual patient simulation 
model to simulate the impact of treatment in subgroups of RA patients with various 
titers of ACPA, a marker of poor prognosis as stated in Part II. In this analysis we 
evaluated the cost-eﬀ ectiveness to two branded bDMARDs with diﬀ erent mechanism 
of actions. The model concept was similar to that of the ‘Birmingham rheumatoid 
arthritis model’ with certain elements incorporated from the ‘The Sheﬃ  eld rheuma-
toid arthritis health economic model’ and was programmed in Microsoft Excel [59, 
60]. The model tracked a large number of individual patients with diﬀ erent baseline 
characteristics (age, gender, and HAQ score) over a lifetime, with the follow-up time 
being divided into six-month cycles. The outcome of the analysis was quality adjusted 
life year (QALY) gained in RA patients stratiﬁ ed according to baseline ACPA levels.
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The current modeling approach has advantages and has served to establish economic 
beneﬁ ts of bDMARDs, in moderate to severe RA patients who inadequately respond 
to methotrexate. In our opinion previously, published models have potential room for 
improvement. The current modeling approaches in RA do not account for the fact that 
RA is a heterogeneous condition and has impact on extra-articular regions. In chapter 
11, we propose a new conceptual model for evaluation of the cost-eﬀ ectiveness of 
RA interventions. The conceptual framework was developed by following recom-
mendations from the International Society of Pharmacoeconomics and Outcomes 
Research-Society of Medical Decision Making (ISPOR-SMDM) Modeling Good 
Research Practices Task Force-2. The process involved scoping the decision problem 
by a working group and drafting a preliminary cost-eﬀ ectiveness model framework. 
An expert panel reviewed and provided input on the conceptual model. The revised 
conceptual framework incorporates the ﬁ ndings from Part I to Part III and proposes a 
more comprehensive approach in evaluating beneﬁ ts and costs of future therapies in 
RA. The proposed conceptual framework concurs with some of the recommendations 
of the consensus recommendations from the 2015 ‘Consensus Working Party’ [60]. 
However, there are some major diﬀ erences between the Consensus Working Party’s 
recommendations and the current proposed conceptual model. Overall, the proposed 
conceptual model reﬂ ects on six preselected areas and could serve as a foundation 
for developing future cost-eﬀ ectiveness models for the 21th century drug treatment in 
moderate to severe RA patients.
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ABSTRACT
Objective. To evaluate associations between achieving guideline-recommended 
targets of disease activity, deﬁ ned by Disease Activity Score 28-C-reactive protein 
(DAS28-CRP) < 2.6, Simpliﬁ ed Disease Activity Index (SDAI) ≤ 3.3, or Clinical Disease 
Activity Index (CDAI) ≤ 2.8, and other health outcomes in a longitudinal, observational 
study. Methods. Other deﬁ ned thresholds included low, moderate, or severe disease 
activity (LDA, MDA, SDA). To control for intraclass correlation and estimate eﬀ ects 
of independent variables on outcomes of the Modiﬁ ed Health Assessment Question-
naire (MHAQ), EuroQol-5D (EQ-5D; a quality-of-life measure), hospitalization, and 
durable-medical-equipment (DME) use, we employed mixed models for continu-
ous outcomes and generalized estimating equations for binary outcomes. Results. 
Among 1,297 subjects, achievement (vs. non-achievement) of recommended disease 
targets was associated with enhanced physical functioning and lower health resource 
utilization. After controlling for baseline covariates, achievement of disease targets 
(vs. LDA) was associated with signiﬁ cantly enhanced physical functioning based on 
SDAI ≤ 3.3 (∆MHAQ = −0.047; P = 0.0100) and CDAI ≤ 2.8 (−0.073; P = 0.0003) 
but not DAS28-CRP < 2.6 (−0.022; P = 0.1735). Target attainment was associated 
with signiﬁ cantly improved EQ-5D (0.022−0.096; P < 0.0030 vs. LDA, MDA, or SDA). 
Patients achieving guideline-recommended disease targets were 36%−45% less likely 
to be hospitalized (P < 0.0500) and 23%−45% less likely to utilize DME (P < 0.0100). 
Conclusion. Attaining recommended target disease-activity measures was associated 
with enhanced physical functioning and HRQOL. Some health outcomes were similar 
in subjects attaining guideline targets versus LDA. Achieving LDA is a worthy clinical 
objective in some patients.
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INTRODUCTION
Rheumatoid arthritis (RA) aﬀ ects 0.5%−1.0% of adults in industrialized societies [1]. 
This chronic, systemic, inﬂ ammatory disorder causes erosive damage to articular 
cartilage and subchondral bone, with joint swelling, deformity, pain, stiﬀ ness, and 
fatigue. Many patients with RA experience diminished health-related quality of life 
(HRQOL) as well as increased disability and comorbidities. Because of related disabil-
ity, reduced worker productivity, expensive biologic drug therapy, institutionalization, 
joint-replacement surgery, and increased use of durable medical equipment (DME), 
RA is a costly condition, accounting for annual health-care expenditures of approxi-
mately $128 billion in the United States [2-4].
Although there is no cure for RA, treatment with disease-modifying antirheumatic 
drugs (DMARDs) and biologic DMARDs (bio−DMARDs) has improved health out-
comes for RA patients. Increasingly, treatments oriented toward prespeciﬁ ed disease 
targets are emerging as the prevailing RA management paradigm. This treat-to-target 
approach involves aiming for a prespeciﬁ ed target of disease activity, frequently moni-
toring disease levels, and titrating medication regimens to goals (where therapies are 
acceptably tolerated). Such strategies have proved to be more eﬀ ective than routine 
care, with randomized controlled trials (RCTs) and other studies supporting their 
value in attenuating RA signs and symptoms, ameliorating functional status, and 
mitigating or halting radiographic progression [5-8].
The most desirable target measure of disease activity is remission, which signiﬁ es 
a condition of negligible or no inﬂ ammatory activity, total arrest of structural joint 
damage, and the optimum achievable reversal of disability [6, 8-11]. In previous con-
sensus guidelines, remission was operationally deﬁ ned as a Disease Activity Score 
28-C-reactive protein (DAS28-CRP) < 2.6 [12]. However, some patients with DAS28-
CRP < 2.6 experience residual disease activity, including inﬂ ammation, pain, and joint 
tenderness and swelling in ankle and foot joints [5, 13-18]. Although DAS28-CRP < 2.6 
no longer constitutes remission, it remains a valid treatment target.
In more recent times, more stringent consensus deﬁ nitions of remission have been 
developed that are both index based (Simpliﬁ ed Disease Activity Index [SDAI] score ≤ 
3.3 [13, 19]) and Boolean based. The Boolean-based deﬁ nition [13] requires a score of 
≤1 on each of the following items: tender joint count 28 (TJC28), swollen joint count 
28 (SJC28), CRP (in mg/dL), and patient global assessment (on a 0 to 10-cm visual 
analog scale [13, 19]).
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Clinical studies have increasingly included diﬀ erent target measures of disease activity 
as primary eﬃ  cacy endpoints [20-23]. Because such trials typically include “selected” 
patient populations with high adherence, severe RA activity, and short study dura-
tions, their ﬁ ndings may be less generalizable to clinical practice compared with data 
from observational studies [7, 24-29].
Limited empirical evidence is available concerning patients with established RA in 
routine clinical practice to support the beneﬁ ts of achieving diﬀ erent deﬁ nitions of tar-
get measures of disease activity in relation to functional status, HRQOL, and health-
care resource utilization. To our knowledge, no observational study has assessed the 
potential clinical implications of achieving each of these diﬀ erent disease activity cut 
points across various eﬃ  cacy and resource-use outcome measures.
To close this gap in knowledge, we sought to evaluate associations between achieving 
diﬀ erent deﬁ nitions of target measures of disease activity and the following health 
outcomes in a longitudinal, observational study of a clinically representative RA 
patient cohort: 1) physical functioning (daily activities) according to the Modiﬁ ed 
Health Assessment Questionnaire (MHAQ), 2) HRQOL according to the EuroQol-5D 
(EQ-5D), and 3) health-care resource utilization according to hospitalizations and 
DME use.
PATIENTS AND METHODS
We utilized data from the Brigham and Women’s Hospital Rheumatoid Arthritis 
Sequential Study (BRASS; ClinicalTrials.gov Identiﬁ er NCT01793103), which was initi-
ated in 2003−2004. Details concerning the study design have been reported elsewhere 
[30-32]. (For further details, see http://www.brassstudy.org.) The BRASS Registry is 
a single-center, prospective, observational, longitudinal cohort of >1,200 adults with 
established or recent-onset RA who are being followed by a hospital-based practice of 
21 rheumatologist in Boston. Physicians assessed patient demographic and clinical 
characteristics, disease activity, and laboratory parameters at baseline and annually 
thereafter. Follow-up postal questionnaires to assess patient-reported outcomes were 
also mailed to patients every 6 months. In the BRASS Registry, disease activity was 
evaluated during each annual rheumatology visit. However, because visits seldom 
occurred exactly at 12 months, for this analysis windows of 6 months (± 3 months) 
around the 12-month physician visits were created to evaluate annual disease activity. 
In addition, windows of 3 months (± 1.5 months) were created around the 6-month 
patient survey. Thus, the follow-up time was divided into distinct intervals: time in-
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terval 1 extended from 5 to 8 months (midpoint = 6 months); interval 2, from 9 to 
15 months (midpoint = 12 months); interval 3, from 16 to 20 months (midpoint = 
18 months); interval 4, from 21 to 27 months (midpoint = 24 months), and so on, 
extending up to 5 years.
Measures of disease activity assessed annually by physicians included the DAS28-
CRP, SDAI, and Clinical Disease Activity Index (CDAI). Three diﬀ erent desired target 
measures of disease activity were considered in the current analysis: DAS28-CRP < 
2.6, SDAI ≤ 3.3, and CDAI ≤ 2.8 [33-35]. These disease targets were categorized as 
having been met or not met: DAS28-CRP < 2.6 versus ≥ 2.6, SDAI ≤ 3.3 versus > 3.3, 
and CDAI ≤ 2.8 versus > 2.8.
In addition to categorizing and comparing disease activity in a binary manner, we 
also compared achievement of the target measures to attainment of multiple other 
cut points. Achievement of DAS28-CRP < 2.6 was compared to attainment of LDA 
(2.6 < DAS28-CRP ≤ 3.2), moderate disease activity (MDA; 3.2 < DAS28-CRP ≤ 5.1), 
or severe disease activity (SDA; DAS28-CRP > 5.1) [33, 35]. Similarly, achievement 
of SDAI ≤ 3.3 was compared to attainment of LDA (3.3 < SDAI ≤ 11.0), MDA (11.0 
< SDAI ≤ 26), or SDA (SDAI > 26) [36, 37]. Finally, achievement of CDAI ≤ 2.8 was 
compared to attainment of LDA (2.8 < CDAI ≤ 10.0), MDA (10.0 < CDAI ≤ 22.0), or 
SDA (CDAI > 22.0) [34].
The patient-reported outcomes of physical functioning, as measured by the MHAQ, 
HRQOL as measured by the EQ-5D using US population-based preference weights, 
[36] and health-care resource utilization as measured by whether patients did (or did 
not) use DME or were (or were not) hospitalized, were captured during the 6-month 
postal survey. The patient-reported outcome measures incorporated within the BRASS 
case report forms were validated questionnaires that have been widely used in other 
RA registries as well as clinical trial settings [33-35, 37]. DME included walkers, wheel-
chairs, standers, and patient lifts.
Ethics
The BRASS Registry has been conducted in accordance with International Society 
for Pharmacoepidemiology Guidelines for Good Pharmacoepidemiology Practices, 
applicable regulatory requirements, and ethical tenets originating in the Declaration 
of Helsinki. The study protocol and informed-consent document were reviewed and 
approved by the Brigham and Women’s Hospital Institutional Review Board. All pa-
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tients provided written informed consent before participating in the BRASS Registry. 
Anonymous (de-identiﬁ ed) patient data in the present study were compliant with the 
Health Insurance Portability and Accountability Act. Maintenance of patient conﬁ -
dentiality was assured by assigning each subject a randomized identiﬁ cation number 
upon enrollment in the BRASS Registry.
Statistical analyses
Baseline characteristics were expressed as means (SDs) and numbers (%). Univariate 
and multivariate analyses were conducted to evaluate associations between achieve-
ment of prespeciﬁ ed, guideline-recommended target measures of disease activity 
(independent variables of interest) and the outcome measures of MHAQ (continuous 
variable), EQ-5D (continuous variable), DME use (categorical variable), and all-cause 
hospitalization (categorical variable; dependent variables).
Univariate analyses involved comparisons of mean scores on the MHAQ and EQ-5D, 
in patients who either did or did not achieve the above deﬁ nitions of targets for the 
DAS28-CRP, SDAI, and CDAI, using Student’s t-test and analysis of variance (ANOVA) 
for comparing these measures in individuals attaining target, LDA, MDA, or SDA. 
Similarly, proportions of patients using DME or being hospitalized were compared, 
in patients who either did or did not achieve the above deﬁ nitions of targets, using 
the Chi-square test and visual-inspection comparisons between individuals attaining 
guideline-recommended targets, LDA, MDA, or SDA.
To control for intraclass correlation of the panel data in BRASS, we used mixed models 
with Toeplitz covariance structure to estimate both the eﬀ ects of the achievement of 
target measures or other levels of disease activity on the dependent variables—the 
primary outcome measure of physical functioning assessed by the MHAQ and the 
secondary outcome measure of HRQOL assessed by the EQ-5D. Generalized esti-
mating equations (GEEs) with binomial distribution, and logit link function, were 
utilized for binary outcomes such as DME use and all-cause hospitalization. Baseline 
covariates included in these models were sociodemographic, laboratory measures, 
subjective (patient-reported), and physician-diagnosed comorbidities (Supplementary 
Appendix Table1). A purposeful selection method was used for identifying variables 
to be considered for the multivariate models; that is, we included in the multivariate 
model only variables that had some association with the outcome variable (i.e. had 
a P value of ≤ 0.10, which was the prespeciﬁ ed threshold). The selection of the ﬁ nal 
model was based on evaluation of overall model ﬁ t statistics and included an iterative 
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model selection (backward as well as stepwise) process and examination of variables 
that were associated with outcomes.
Analyses were conducted using SAS PROC MIXED and PROC GENMOD procedures 
(SAS Institute Inc., Cary, NC) for continuous and categorical outcome variables.
RESULTS
Baseline characteristics of the 1,297 included subjects (n =1,067 [82.3%] women) are 
summarized in Table 1. The mean (SD) age was 56.6 (14.1) years, and the mean (SD) 
symptom duration was 15.3 (13.0) years. Most (70.7%) patients were seropositive 
and/or had received DMARDs (86.7%) —with some patients receiving bio−DMARDs 
Table 1. Baseline Characteristics
Characteristic Mean (SD) No. (%)
Age, yr (n = 1297) 56.6 (14.1)
Symptom duration, yr (n =1286) 15.3 (13.0)
Body mass index, kg/m² (n =1227) 26.8 (5.7)
Diastolic blood pressure, mmHg (n =1157) 75.8 (10)
DAS28-CRP (n =1255) 3.8 (1.6)
Swollen joints, total (n =1295) 6.9 (7.2)
Painful joints, total (n =1295) 7.7 (7.9)
Total SP joints (n =1295) 14.7 (14.2)
Female gender (n =1297) 1,067 (82.3)
Anti−CCP positive (n =1117) 703 (62.9)
RF positive (n =1092) 693 (63.5)
Seropositive (n =1128) 797 (70.7)
MHAQ (n =1220) 0.43 (0.46)
RA disease target measures: (n =1297)
DAS < 2.6 389 (30.0)
CDAI ≤ 2.8 134 (10.3)
SDAI ≤ 3.3 91 (7.0)
DMARD at baseline (n =1297) 1,124 (86.7)
Biologic DMARD at baseline (n =1297) 477 (36.8)
CCP, cyclic citrullinated protein; CDAI, Clinical Disease Activity Index;
CRP, C-reactive protein; DAS28-CRP, Disease Activity Score 28-C-reactive protein;
DMARD, disease-modifying antirheumatic drug; MHAQ, Modiﬁ ed Health Assessment Questionnaire; RADAI, 
Rheumatoid Arthritis Disease Activity Index; RF, rheumatoid factor; SDAI, Simpliﬁ ed Disease Activity Index;
SP, swollen and painful.
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(n = 477; 36.8% of entire population) — at baseline. In addition, some patients had 
DAS28-CRP < 2.6 (n = 389; 30.0%), SDAI ≤ 3.3 (n = 91; 7.0%), or CDAI ≤ 2.8 (n = 134; 
10.3%) at baseline
Primary outcome measure: physical functioning (MHAQ)
Subjects who achieved target measures of disease activity (i.e. DAS28-CRP < 2.6, 
SDAI ≤ 3.3, CDAI ≤ 2.8) experienced improved physical functioning on the MHAQ 
compared to subjects who did not attain these target measures (Figure 1). In ad-
dition, BRASS registrants with incrementally worse disease activity levels (i.e. LDA, 
MDA, SDA) experienced decreased physical functioning on the MHAQ compared 
to patients attaining the foregoing target measures (Figure 2). After controlling for 
baseline covariates in the mixed models, we found that achievement of DAS28-CRP < 
2.6 was associated with a mean reduction (improvement) of 0.0823 in MHAQ scores 
Figure 1. Mean longitudinal Modiﬁ ed Health Assessment Questionnaire (MHAQ) disability scores, EQ-5D 
health-related quality of life scores, and durable-medical-equipment (DME) use among patients with DAS28-
CRP < 2.6, SDAI ≤ 3.3, or CDAI ≤ 2.8 (light-gray bars) compared to those attaining higher (i.e. more severe) 
target measures of disease activity (dark-gray bars).
DAS28-CRP ≥2.6, SDAI > 3.3, and CDAI > 2.8. CDAI, Clinical Disease Activity Index; DAS28-CRP-28, Disease 
Activity Score-28-C-reactive protein; EQ-5D, EuroQol-5D; SDAI, Simpliﬁ ed Disease Activity Index
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(P < 0.0001) compared to not achieving DAS28-CRP < 2.6. Similarly, achieving (vs. 
not achieving) SDAI ≤ 3.3 or CDAI < 2.8 was associated with reductions in MHAQ of 
0.0834 (P < 0.0001) and 0.1035 (P < 0.0001), respectively (Table 2).
Compared to individuals with LDA, subjects who achieved these target measures 
of disease activity had mean reductions (improvements) on MHAQ of 0.0221 (P = 
0.1735), 0.0471 (P = 0.0100), and 0.0734 (P = 0.0003) based on DAS28-CRP, SDAI, 
and CDAI criteria, respectively. When compared to individuals with MDA, subjects 
achieving these same target measures of disease activity experienced mean reduc-
tions on MHAQ of 0.0875 (P < 0.0001), 0.0909 (P < 0.0001), and 0.1192 (P < 0.0001) 
based on DAS28-CRP, SDAI, and CDAI criteria, respectively. Similar ﬁ ndings on physi-
cal functioning were observed in BRASS registrants achieving the target measures 
of disease activity compared to SDA (Table 2): signiﬁ cant improvements in MHAQ 
across DAS28-CRP, SDAI, and CDAI categories (P < 0.0001 for each comparison).
Fig 2 Mean longitudinal Modiﬁ ed Health Assessment Questionnaire (MHAQ) disability scores, EQ-5D health-
related quality of life scores, and durable-medical-equipment (DME) use among patients with DAS28-CRP < 
2.6, SDAI ≤ 3.3, or CDAI ≤ 2.8 (light-gray bars) compared to low disease activity (LDA; dark-gray bars), moder-
ate disease activity (MDA; solid-black bars), and severe disease activity (SDA; hatched bars).
CDAI, Clinical Disease Activity Index; DAS28-CRP, Disease Activity Score 28-C-reactive protein; SDAI, Simpli-
ﬁ ed Disease Activity Index
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Other covariates signiﬁ cantly associated with improved MHAQ scores across all 
three composite measures included prior treatment with methotrexate (MTX), lower 
baseline MHAQ score (i.e. less physical dysfunction at baseline), shorter RA duration, 
an absence of osteoporosis, and being a former (vs. current) smoker (Supplementary 
Appendix Table 2).
Secondary outcome measures: HRQOL (EQ-5D) and health-care resource use
Similar ﬁ ndings to MHAQ were evident concerning HRQOL on the EQ-5D and health-
care resource use (DME and hospitalizations). Subjects who achieved guideline-
recommended targets measures of disease activity experienced enhanced HRQOL 
and decreased resource use, compared to those who did not attain these targets, 
during each year of follow-up (Figure 1). (Numbers of patients who achieved [or did 
not achieve] targets at each time point are tabulated in Supplementary Appendix Table 
3.)
Conversely, with each increasing (worsening) measure of disease activity (i.e. LDA, 
MDA, SDA), subjects experienced decreased HRQOL and increased resource use 
Table 2. Improvements in Physical Functioning (MHAQ) and Quality of Life (EQ-5D) Based on Achieving 
Target Measures of Disease Activity by Different Deﬁ nitions
Mean difference in MHAQ based on:
DAS28- CRP
categories
P SDAI
categories
P CDAI
categories
P
Achieving target (vs. not achieving) −0.0823 <0.0001 −0.0834 <0.0001 −0.1035 <0.0001
Achieving target (vs. achieving LDA) −0.0221 0.1735 −0.0471 0.0100 −0.0734 0.0003
Achieving target (vs. achieving MDA) −0.0875 <0.0001 −0.0909 <0.0001 −0.1192 <0.0001
Achieving target (vs. achieving SDA) −0.2040 <0.0001 −0.1476 <0.0001 −0.1611 <0.0001
Mean difference in EQ-5D based on:
DAS28- CRP
categories
P SDAI
categories
P CDAI
categories
P
Achieving target (vs. not achieving) 0.04780 <0.0001 0.06580 <0.0001 0.0735 <0.0001
Achieving target (vs. achieving LDA) 0.02247 0.0026 0.05180 <0.0001 0.06117 <0.0001
Attaining target (vs. achieving MDA) 0.05143 <0.0001 0.06656 <0.0001 0.08014 <0.0001
Attaining target (vs. achieving SDA) 0.08492 <0.0001 0.09145 <0.0001 0.09602 <0.0001
CDAI, Clinical Disease Activity Index; DAS28-CRP, Disease Activity Score 28-C-reactive protein; EQ-5D, Euro-
Qol-5D;HAQ, Modiﬁ ed Health Assessment Questionnaire; SDAI, Simpliﬁ ed Disease Activity Index. Targets: 
DAS28-CRP < 2.6, SDAI ≤ 3.3 or CDAI ≤ 2.8. LDA, low disease activity: 2.6 < DAS28-CRP ≤ 3.2; 3.3 < SDAI ≤ 
11.0; 2.8 < CDAI ≤ 10. MDA, moderate disease activity: 3.2 < DAS28-CRP ≤ 5.1; 11 < SDAI ≤ 26; 10 < CDAI ≤ 
22. SDA, severe disease activity:DAS28-CRP > 5.1; SDAI > 26.0; CDAI >22.
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compared to their counterparts who achieved the target measures (Figure 2). After 
controlling for baseline covariates in mixed models, we found that subjects who 
achieved (vs. did not achieve) the foregoing target measures of disease activity expe-
rienced signiﬁ cant improvements on the EQ-5D across all three composite indices: 
increases of 0.0478 to 0.0735 (P < 0.0001 for each; Table 2). Subjects who achieved 
the target measures of disease activity for DAS28-CRP, SDAI, and CDAI experienced 
signiﬁ cantly improved HRQOL compared to individuals with LDA, MDA, or SDA 
(each P < 0.0030).
Subjects who attained guideline-recommended target measures of disease activity 
also had signiﬁ cantly (or borderline-signiﬁ cantly) lower odds of DME use and hos-
pitalization (Table 3). The probability of DME use in subjects who achieved (vs. did 
Table 3. Improvements in Resource Utilization Based on Achieving Target Measures of Disease Activity by 
Different Deﬁ nitions
Odds Ratios for Durable Medical Equipment (DME) Use Based on:
DAS28- CRP
categories
95% CI SDAI
categories
95% CI CDAI
categories
95% CI
Achieving target (vs. not 
 achieving)
0.77 0.64−0.94 0.61 0.46−0.82 0.55 0.40−0.75
Achieving target (vs. achieving 
LDA)
0.79 0.60−1.00 0.64 0.46−0.88 0.61 0.43−0.86
Achieving target (vs. achieving 
MDA)
0.84 0.67−1.00 0.70 0.50−0.96 0.55 0.39−0.77
Achieving target (vs. achieving 
SDA)
0.60 0.45−0.80 0.51 0.37−0.70 0.45 0.32−0.63
Odds Ratios for All-Cause Hospitalization Based on:
DAS28- CRP
categories
95% CI SDAI
categories
95% CI CDAI
categories
95% CI
Achieving target (vs. not achiev-
ing)
0.64 0.51−0.80 0.61 0.46−0.82 0.55 0.40−0.75
Achieving target (vs. achieving 
LDA)
0.73 0.51−1.05 0.73 0.44−1.21 0.66 0.40−1.10
Achieving target (vs. achieving 
MDA)
0.72 0.54−0.95 0.55 0.33−0.91 0.55 0.33−0.92
Achieving target (vs. achieving 
SDA)
0.38 0.27−0.52 0.39 0.24−0.64 0.44 0.27−0.27
CDAI, Clinical Disease Activity Index; CI, conﬁ dence interval; DAS28-CRP, Disease Activity Score 28-C-eactive 
protein; LDA, low disease activity; MDA, moderate disease activity; SDA, severe disease activity; SDAI, Simpli-
ﬁ ed Disease Activity Index. Targets: DAS28-CRP < 2.6, SDAI ≤ 3.3, or CDAI ≤ 2.8. LDA, low disease activity: 2.6 
< DAS28-CRP ≤ 3.2; 3.3 < SDAI ≤ 11.0; 2.8 < CDAI ≤ 10. MDA, moderate disease activity: 3.2 < DAS28-CRP ≤ 
5.1; 11 < SDAI ≤ 26; 10 < CDAI ≤ 22. SDA, severe disease activity: DAS28-CRP > 5.1; SDAI > 26.0; CDAI >22.
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not achieve) the targets was reduced by approximately 23%−45% for: DAS28-CRP < 
2.6 (odds ratio [OR] = 0.77; P = 0.0086), SDAI ≤ 3.3 (OR = 0.61; P = 0.0011), and 
CDAI ≤ 2.8 (OR = 0.55; P = 0.0002). Reductions in the odds of DME use were also 
observed when subjects achieving target measures were compared to those with LDA 
on the SDAI and CDAI: decreases of 36%−39%. Across all three-disease measures, 
subjects who achieved the desired targets had signiﬁ cantly reduced odds of DME 
use compared to individuals with SDA (reductions of 40%−55%; P < 0.0090 for each 
comparison; Table 3).
Findings on the odds of hospitalization were similar to the data on DME use (Table 3). 
The odds of hospitalization were signiﬁ cantly decreased, by approximately 36%−45%, 
among subjects who achieved (vs. did not achieve) the target measures of disease ac-
tivity. Similar, signiﬁ cant reductions in the odds of hospitalization were also observed 
when comparing subjects who achieved the desired targets to their counterparts with 
MDA or SDA (but not LDA) across all measures. .
As with the MHAQ data, baseline covariates signiﬁ cantly associated with improved 
HRQOL on the EQ-5D included lower MHAQ scores (i.e. less physical dysfunction) 
and shorter RA duration across all three disease measures (Supplementary Appendix 
Table 4). A history of MTX therapy was also associated with a signiﬁ cant improvement 
in EQ-5D (+0.018; P ≤ 0.0021) for DAS28-CRP < 2.6 but was not uniformly signiﬁ cantly 
associated with improvements in EQ-5D according to SDAI or CDAI disease targets 
(P > 0.07 for each).
DISCUSSION
This longitudinal observational cohort study demonstrated that achieving (vs. not 
achieving) guideline-recommended target measures of disease activity of DAS28-CRP 
< 2.6, SDAI ≤ 3.3, and/or CDAI ≤ 2.8 was associated with signiﬁ cant improvements in 
physical functioning, HRQOL, and health-care resource utilization. Our ﬁ ndings are 
consistent with consensus guidelines, which have been evolving toward a strategy of 
treating RA to targets. Recently, a EULAR panel stated that LDA “deﬁ ned by composite 
measures is a good alternative goal for … patients who cannot attain remission even 
today, especially those with long-standing disease who … constitute the majority of 
patients in clinical care.[5]”
In this context, subjects who achieved the most desirable target of DAS28-CRP < 2.6 
in our study did not diﬀ er signiﬁ cantly compared to those with LDA (2.6 ≤ DAS28-CRP 
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< 3.2) in terms of physical functioning as measured by the MHAQ. Attainment of 
DAS28-CRP <2.6, SDAI ≤ 3.3, or CDAI ≤ 2.8 did not result in signiﬁ cant reductions in 
hospitalization compared to achievement of LDA (although there were trends toward 
reduced odds of hospitalization in subjects achieving target measures across all three 
indices) but did diﬀ er in HRQOL and DME use (signiﬁ cant or borderline-signiﬁ cant 
diﬀ erences between DAS28-CRP < 2.6, SDAI ≤ 3.3, or CDAI ≤ 2.8 vs. LDA, MDA, 
or SDA). Our ﬁ ndings thus suggest that diﬀ erentiation on outcome measures for 
achieving target measures versus LDA is not uniform. We also observed that attain-
ment of LDA (vs. MDA or SDA) was associated with favorable clinical and economic 
outcomes.
Most of the diﬀ erences in outcomes observed between groups were both statistically 
signiﬁ cant and clinically relevant, in that they met minimum important diﬀ erences 
(MIDs). Even though there is no consensus concerning the MID for MHAQ in clinical 
practice settings, a −0.09 change in the HAQ-DI has been associated with “somewhat 
improved” outcomes [38]. Assuming that a change of −0.09 is the MID for MHAQ, 
most of the comparisons in Table 2 either approach or are above this threshold, except 
for comparisons between achieving guideline-recommended disease targets and LDA, 
where only the CDAI−based comparisons approached this diﬀ erence.
To our knowledge, no investigators have reported an MID for the EQ-5D in RA. How-
ever, work done in other disease states indicates that the MID is a change of 0.05−0.08 
on the EQ-5D [39]. Based on an MID of 0.05, all comparisons in our analysis evalu-
ating attainment of target versus LDA, MDA, and SDA (based on CDAI and SDAI) 
crossed the MID. On the other hand, consistent with the MHAQ – based analysis, 
DAS28-CRP − based comparisons crossed or approached the MID, with the exception 
of attaining target compared to LDA. Taken together, these ﬁ ndings support both the 
value of treating to targets and the assertion that LDA is a plausible alternative clinical 
objective for treat-to-target strategies when guideline recommended goals cannot be 
achieved in clinical practice.
In our study, previous treatment with MTX was associated with signiﬁ cantly enhanced 
physical functioning on the MHAQ, while duration of RA, baseline MHAQ, current 
(vs. former) smoking, and osteoporosis (vs. absence of osteoporosis) were associ-
ated with signiﬁ cantly worse physical functioning. These ﬁ ndings extend data from a 
Swedish case-control study, which determined that smoking was dose dependently 
associated with occurrence of anti-cyclic citrullinated peptide (anti−CCP) antibodies 
[40]. An interaction between human leukocyte antigen-D (HLA-DR) shared-epitope 
genes and smoking triggered immune responses only in patients positive for anti−
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CCP. In this context, most (63%) of our patients were anti−CCP positive at baseline. 
Finally, a study of patients with LDA or MDA revealed a signiﬁ cant association between 
radiographic damage in RA and low femoral-neck bone mineral density [41].
All outcome measures did not perform consistently in discriminating dependent 
variables of physical functioning, HRQOL and health-care resource utilization across 
guideline-recommended target measures and levels of disease activity in our study. 
Previous reports indicated that data from all three indices are overall highly inter-
correlated and show similarly high C-statistics (area under the curve values > 0.80) 
for receiver-operating-characteristic curves when using, as “gold standards,” clini-
cians’ decisions either to initiate DMARDs or to increase their dosages. The SDAI 
and CDAI include both patient and evaluator ratings of global disease activity, which 
are frequently discrepant [36]. Perhaps the inclusion of both perspectives on global 
disease activity in the SDAI and CDAI (but not DAS28-CRP) renders these indices 
more eﬀ ective assessments of physical functioning on the MHAQ (vs. DAS28-CRP).
Data concerning improvements in patient-reported and resource-use outcomes 
based on achievement of speciﬁ c levels of disease activity in patients with established 
or chronic RA are limited. Most studies were conducted in subjects with recent-onset 
RA [26-28, 42, 43]. Unlike many RCTs involving individuals with recent-onset RA, 
the BRASS Registry was an observational cohort study that included subjects with a 
mean age of 56.6 years and a mean RA duration of 15.3 years. At baseline, the mean 
DAS28-CRP was 3.8 (consistent with moderate RA), fewer than 11% of subjects were 
in CDAI or SDAI remission, approximately 87% received conventional DMARDs, and 
37% received bio−DMARDs. Given these characteristics, we consider our ﬁ ndings to 
be generalizable to most established−RA populations typically encountered in clinical 
practices.
To our knowledge, this is the only study that formally evaluated associations between 
achievement of guideline-recommended targets and the likelihood of using durable 
equipment, such as canes, walkers, and wheelchairs. Utilization of DME was signiﬁ -
cantly (or borderline signiﬁ cantly) reduced in subjects with DAS28-CRP < 2.6, SDAI 
≤ 3.3, or CDAI ≤ 2.8 (vs. LDA, MDA, or SDA on each of these measures). BRASS 
registrants who achieved (vs. did not achieve) guideline disease targets were at signiﬁ -
cantly (up to 45%) reduced odds of DME use and hospitalization. The magnitudes of 
these beneﬁ ts were stronger with SDAI and CDAI compared to DAS28-CRP for DME 
use.
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In a somewhat similar, but smaller (N = 356), study of patients with established RA, 
Radner and Austrian co-workers recently demonstrated signiﬁ cant beneﬁ ts associated 
with achieving a guideline-recommended disease target (vs. LDA) in subjects with a 
baseline mean age of 59.9 years and a mean disease duration of 11.5 years [6]. This 
trial assessed changes in dependent variables, including physical functioning, HRQOL 
(by EQ-5D and 36-Item Short Form Health Survey [SF-36]), worker productivity, overall 
activity impairment, and health-care costs, as functions of the independent variable of 
achieving SDAI ≤ 3.3 (vs. LDA or moderate to severe disease activity [SDAI > 11]) but 
not the other disease targets evaluated in our study (i.e. DAS28-CRP, CDAI). Unlike 
our investigation, the study by Radner’s group pooled data for patients with MDA and 
SDA because there were small numbers of patients with SDA. Patients achieving SDAI 
≤ 3.3 in Radner’s investigation had signiﬁ cantly better physical functioning, work pro-
ductivity, and superior HRQOL compared to those achieving LDA. When explaining 
their ﬁ ndings, Radner’s group suggested that the long RA duration may have resulted 
in an overall very disabled cohort. In this same European study, subjects with more 
severe levels of disease had higher total direct costs as well as costs for both sick leave 
and disability [6]. These ﬁ ndings were extended by the Dutch Rheumatoid Arthritis 
Monitoring (DREAM) study which demonstrated a larger gain in quality-adjusted life 
years with a treat-to-target (versus usual-care) clinical approach and an incremental 
cost-eﬀ ectiveness ratio of €3,591 per subject in remission after 2 years with the treat-
to-target strategy [7].
The observational nature of our study permitted enrollment of a large number of 
subjects who were followed over prolonged intervals (up to 5 years). In theory, our 
ﬁ ndings may have been inﬂ uenced by selection bias, in that patients who responded 
to postal surveys and/or visited clinics to measure disease activity might have diﬀ ered 
from non-respondents. DME use and hospitalization were self-reported, opening 
the possibility of recall bias or nonrandom missing values. Nonrandom patient attri-
tion also could also have introduced biases. A previous study of the BRASS Registry 
identiﬁ ed disease duration, disease activity, and diﬀ erences in drug therapy to be 
associated with attrition. However, during the years included in the current analysis, 
patient follow-up in the BRASS Registry was highly acceptable.32 Of approximately 
1,300 patients enrolled in the BRASS Registry, 83% had follow-up data at year 1, 78% 
at year 2, 73% at year 3, 77% at year 4, and 76% at year 5. Hence, we believe that the 
impact of patient attrition on the ﬁ ndings of our analysis was small.
Findings from observational studies are typically more generalizable to usual-care 
settings compared with RCTs. On the other hand, observational analyses are of an 
inherently associational nature and cannot conclusively assign causality or rule out 
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certain biases, even though we controlled for all relevant baseline covariates. Longitu-
dinal studies such as ours are also potentially subject to limitations related to missing 
data. Outcome measures within a single individual over time are also intercorrelated. 
To handle these issues, mixed models such as those employed in our represent poten-
tially advantageous approaches because all available data are included, irrespective 
of whether subjects had unequal numbers of observations or unequal time intervals 
between them.
Finally, we did not evaluate associations between achievement of diﬀ erent disease 
cut points and other patient-reported outcomes, such as pain, depression, anxiety, or 
fatigue, as well as objective measures such as radiographic progression.
In conclusion, this longitudinal observational study of a typical RA cohort (BRASS 
Registry) demonstrated beneﬁ ts of treat-to-target strategies, with clinical objectives 
of DAS28-CRP < 2.6, SDAI ≤ 3.3, and CDAI ≤ 2.8, in enhancing physical function and 
HRQOL, as well as reducing DME use and hospitalization. Evidence also supported 
the value of treat-to-target strategies with an objective of low (vs. moderate or severe) 
disease activity. Our ﬁ nding are compatible with the use of guideline-recommended 
target measures of disease activity as treatment objectives in clinical practice as well 
as LDA in patients who cannot attain guideline-recommended targets. Additional 
studies are needed to evaluate associations between achievement of diﬀ erent target 
measures of disease activity and other patient-reported (e.g. pain, fatigue) and radio-
graphic (e.g. Total Sharp Score) outcomes, as well as actual costs rather than the odds 
of DME use and hospitalization, in other typical clinical settings.
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SUPPLEMENTARY MATERIALS
Supplementary Table 1. Baseline Covariates
Categories Variables Levels
Sociodemo-
graphic
Gender Male, Female
Marital status Never married, Married, Separated, Divorced, Widowed/wid-
ower, Cohabitating
Age Measured in years
Years of RA disease Duration of RA from year of diagnosis
Year of RA symptoms Duration of RA symptoms from date of symptom reporting
Education Less than high school, High school, Some college, Graduated 
from junior college
Undergraduate degree, Attended advanced-degree program, 
Completed advanced-degree program
Body mass index, kg/
m²
<18.5 (underweight), 18.5−24.9 (normal), 25.0−29.9 (over-
weight), 30.0−39.9 (moderately to severely obese), ≥40 (ex-
tremely obese)
Race/ethnicity Caucasian, African-American, Asian, Hispanic
Smoking status Never, former, current (number of years smoking for ever-
smokers)
Health insurance Insured (yes/no [Y/N]); Private, Public
Social support Number of close family members, Number of close friends
Diseases of family 
history
Alzheimer’s (Y/N), Diabetes (Y/N), Cardiovascular disease 
(Y/N),
Systemic lupus erythematosus (SLE; Y/N), Irritable-bowel dis-
ease (Y/N), Rheumatoid arthritis (Y/N)
Patient Report-
ed Outcomes
Functional status MHAQ, Activities of daily living, Duruoz’s Hand Index, Soller-
man Function Test
Patient ratings of 
global disease activity
Measured using a visual analog scale (VAS)
Patient ratings of pain Measured using a VAS
Patient-reported 
health-related quality 
of life (HRQOL)
Patient-reported HRQOL measured by the EuroQol (EQ-5D), 
36-Item Short Form Health Survey (SF-36), and SF-12
Sleep Sleep measured using the Medical Outcomes Study Sleep Scale
Fatigue Measured using a VAS
Mental health/cogni-
tive measures
Patient Health Questionnaire (PHQ)
Generalized Anxiety Disorder 7-Item (GAD-7 Scale)
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Supplementary Table 1. (continued)
Categories Variables Levels
Clinical Mea-
sures
Lung function Dyspnea ratings
Biochemical indices/
inﬂ ammatory biomark-
ers
C-reactive protein (CRP), Erythrocyte sedimentation rate (ESR),
Rheumatoid factor (RF)
Vaccinations before 
onset of rheumatoid 
arthritis (RA)
Varicella, Hepatitis A, Hepatitis B, Pneumonia, Rubella, Tetanus, 
Inﬂ uenza
Dental evaluation Gum disease (Y/N), Bone loss (Y/N), Periodontal treatment 
(Y/N)
Physician-diagnosed 
comorbid conditions
Cardiovascular: Angina (Y/N), Myocardial infarction (Y/N)
Neurologic: Dementia (Y/N), Demyelinating illness (Y/N), 
Psychiatric illness (Y/N)
Pulmonary: Infectious pneumonitis (Y/N), Drug-induced pneu-
monitis (Y/N), Asthma (Y/N), Chronic obstructive pulmonary 
disease (Y/N)
Renal: Nephrotic syndrome (Y/N), Elevated creatinine/renal 
insufﬁ ciency (Y/N)
Musculoskeletal: Fibromyalgia (Y/N), SLE (Y/N), Degenerative 
joint disease (Y/N), Osteoporosis/bone fractures (Y/N)
Endocrine: Grave’s disease (Y/N), Hashimoto’s thyroid (Y/N)
Hematologic/oncologic: Lymphoma (Y/N), Other cancers (Y/N), 
Aplastic anemia (Y/N), Thrombocytopenia (Y/N)
Gastrointestinal (GI): Peptic ulcer (Y/N), Viral hepatitis (Y/N), 
Drug-induced hepatitis (Y/N), Other liver disease (Y/N), Crohn’s 
disease (Y/N), Ulcerative colitis (Y/N), Inﬂ ammatory bowel 
disease (Y/N), Pancreatitis (Y/N), GI perforations or obstruc-
tions (Y/N)
Surgery-related 
variables
Total number of surgeries; types of surgery
Treatments RA−speciﬁ c therapies Biologic disease-modifying antirheumatic drugs (bio-DMARDs; 
Y/N)
Non−bio-DMARDs (Y/N), Methotrexate (Y/N)
Concomitant medica-
tions
Pain treatments: Steroids (Y/N), Nonsteroidal anti-inﬂ ammatory 
drugs (NSAIDs; Y/N)
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Supplementary Table 2. Associations Between Different Baseline/Patient Factors and Changes in Physical 
Functioning (MHAQ)*
Variable
Attainment of different target measures of disease activity
(Target Deﬁ nitions:)
DAS28-CRP < 2.6 SDAI ≤ 3.3 CDAI ≤ 2.8
MHAQ
estimate
P MHAQ
estimate
P MHAQ
estimate
P
Female gender 0.021 0.3805 0.014 0.5348 0.013 0.5909
RA duration 0.004 <0.0001 0.005 <0.0001 0.005 <0.0001
Baseline MHAQ 0.547 <0.0001 0.563 <0.0001 0.563 <0.0001
Current smoker (vs. former) 0.087 0.0140 0.084 0.0136 0.089 0.0096
Never (vs. former) smoker −0.014 0.4685 −0.008 0.6698 −0.011 0.5653
Physician diagnosis of osteoporosis 0.068 0.0280 0.066 0.0232 0.066 0.0237
Baseline MTX (vs. no MTX) −0.032 0.0239 −0.034 0.0109 −0.033 0.0161
*Data are per 1-unit increases in variables within regression equations, after controlling for baseline covariates.
CDAI, Clinical Disease Activity Index; DAS28-CRP, Disease Activity Score 28-C-reactive protein; MHAQ, Modi-
ﬁ ed Health Assessment Questionnaire; MTX, methotrexate; RA, rheumatoid arthritis; SDAI, Simpliﬁ ed Dis-
ease Activity Index.
Supplementary Table 3. Numbers of Patients With Rheumatoid Arthritis (RA) Who Were (or Were Not) at 
Targets at Each Time Point (Supplement to Figure 1)
DAS28-CRP
RA status Year 1 Year 2 Year 3 Year 4 Year 5
At Target 311 255 185 221 205
Not at Target 480 402 310 256 277
SDAI
RA status Year 1 Year 2 Year 3 Year 4 Year 5
At Target 98 98 58 70 63
Not at Target 729 616 477 461 440
CDAI
RA status Year 1 Year 2 Year 3 Year 4 Year 5
At Target 88 88 46 60 57
Not at Target 739 626 489 471 446
CDAI, Clinical Disease Activity Index; CRP, C-reactive protein;
DAS28-CRP, Disease Activity Score 28-CRP; SDAI, Simpliﬁ ed Disease Activity Index.
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Supplementary Table 4. Associations Between Different Baseline/Patient Factors and Changes in Health-Re-
lated Quality of Life (EQ-5D)*
Variable
Target measures of disease activity:
DAS28-CRP < 2.6 SDAI ≤ 3.3 CDAI ≤ 2.8
EQ-5D Estimate P EQ-5D Estimate P EQ-5D Estimate P
Female gender −0.004 0.6503 −0.015 0.2034 −0.013 0.2724
RA duration −0.001 0.0473 −0.001 <0.0001 −0.001 0.0002
Baseline MHAQ −0.137 <0.0001 −0.153 <0.0001 −0.150 <0.0001
Baseline MTX
(vs. no MTX)
0.018 0.0021 0.012 0.0855 0.012 0.0740
*Data are per 1-unit increases in variables within regression equations, after controlling for baseline covariates.
CDAI, Clinical Disease Activity Index; DAS28-CRP, Disease Activity Score 28-C-reactive protein; EQ-5D, Euro-
Qol-5D; MHAQ, Modiﬁ ed Health Assessment Questionnaire; MTX, methotrexate; RA, rheumatoid arthritis; 
SDAI, Simpliﬁ ed Disease Activity Index.
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ABSTRACT
Introduction: To assess the relationship between low bone mineral density (BMD), an-
ticyclic citrullinated peptide-2 (anti-CCP2) antibodies, and disease activity in patients 
with established rheumatoid arthritis (RA). Methods: Patients enrolled in a single-
center, observational cohort registry of patients with RA. Eligible patients had known 
BMD, as measured by digital X-ray radiogrammetry (DXR–BMD), and anti-CCP2 
antibody measurements at the same time point or within 6 months. Anti-CCP2–im-
munoglobulin (Ig)G positive (+) patients (≥ 20 U/mL) were distributed into three 
equal groups (Gp1–3), representing increasing anti-CCP2 antibody concentrations. 
Associations between BMD and anti-CCP2 antibody status and titer were explored in 
multivariate regression analyses controlling for covariates (including age, duration of 
RA, use of steroids, use of osteoporosis medication). Association between disease 
activity (DAS28 [CRP]<2.6) and bone loss was also explored. Results: A total of 149 
patients (all women) were included (47 anti-CCP2 antibody negative [-], 102 anti-
CCP2+ [34\titer group]). Mean disease duration was greater in the three anti-CCP2+ 
groups vs. the anti-CCP2- group. DXR BMD was lower in the anti-CCP2+ vs. the anti-
CCP2- groups (Gp1–3 vs. anti-CCP2-: P < 0.0001 for left and right hands). DXR–BMD 
decreased with increasing anti-CCP2 titer (P < 0.001 for left and right hands). Patients 
with low DXR–BMD were less likely to have a DAS28 (CRP) < 2.6 (P = 0.0181). Conclu-
sion: Among patients with established RA, data suggest that anti-CCP2+ patients, 
particularly those with high anti-CCP2 antibody titers, have lower hand BMD, and 
patients with lower hand BMD are less likely to have low disease activity.
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INTRODUCTION
Rheumatoid arthritis (RA) is associated with bone loss, erosions, and osteoporosis 
[1–3]. Several studies suggest that both erosive RA and osteoporosis share a common 
cellular pathway, which involves inﬂ ammatory activation of osteoclasts and decreased 
osteoblast activation [4, 5]. Low bone mineral density (BMD) in patients with RA 
increases the risk of fractures and overall mortality, especially in postmenopausal 
women [6–8]. Hand BMD loss, as measured by digital X-ray radiogrammetry (DXR)—
a sensitive quantitative method for detecting early bone loss by measuring the cortical 
bone of metacarpal diaphysis—is an independent predictor of radiographic joint 
damage progression, including erosions [9–11].
A comparison of DXR and dual-energy X-ray bsorptiometry (DXA) revealed that DXR 
appears to be more sensitive than DXA in detecting early bone loss in patients with 
RA [9]. Several studies have demonstrated a treatment eﬀ ect of conventional and bio-
logic diseasemodifying antirheumatic drugs (bDMARDs) on BMD loss using DXR [4, 
12–17]; however, data are limited on identifying factors that are associated with BMD 
loss. Given the correlation of DXR–BMD with increased fracture risk and mortality [7, 
8], it would be beneﬁ cial to identify a reliable prognostic factor that is associated with 
hand BMD loss and treatment outcomes in patients with RA. The identiﬁ cation of 
such prognostic factors could assist rheumatologists in identifying patients at risk of 
radiographic progression and inform treatment decisions, with the aim of preventing 
bone erosion.
Anti-citrullinated protein antibody (ACPA) positivity is associated with poor prognosis 
in RA, and testing for ACPA has become standard practice in the diagnosis of RA [18, 
19]. Recent studies have suggested that ACPA can stimulate bone loss by inducing the 
diﬀ erentiation of precursors into bone-resorbing osteoclasts [20, 21]. In patients who 
are positive for anticyclic citrullinated peptide-2 (anti-CCP2, a surrogate of ACPA) anti-
bodies, structural bone damage can start before the clinical onset of RA [22]. Elevated 
anti-CCP2 antibody levels have been found to be independent predictors of localized 
hand DXR–BMD loss in patients with early RA [23]. Furthermore, analysis of data from 
the Pavia Early Arthritis Clinic, a singlecenter cohort of patients, showed that anti-CCP2 
antibodies and rheumatoid factor were associated with systemic bone loss in patients 
with early, untreated RA [24]. However, the relationship between hand BMD loss and 
anti-CCP2 antibodies in patients with established RA is unclear. Data from a recent 
single-center population study using DXA–BMD showed a negative, titer-dependent 
eﬀ ect of ACPA on systemic bone mass at femoral sites in patients with established RA 
[5]. This analysis was performed to assess the association between hand DXR–BMD 
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and anti-CCP2 antibody status, DXR–BMD and anti-CCP2 titer, as well as DXR–BMD 
and RA disease activity among patients with established RA.
METHODS
Study Population
The Brigham and Women’s Hospital Rheumatoid Arthritis Sequential Study (BRASS; 
ClinicalTrials.gov identiﬁ er NCT01793103) registry was initiated in 2003. Details 
regarding the design of the registry have been reported previously [25–27]. BRASS 
is a single-center, prospective, observational, longitudinal cohort of more than 1400 
adults with established or recent-onset RA who are being followed in a hospital-based 
practice of 21 rheumatologists in Boston, Massachusetts. The BRASS Registry has 
been conducted in accordance with International Society for Pharmacoepidemiology 
Guidelines for Good Pharmacoepidemiology Practices, applicable regulatory require-
ments, and ethical tenets originating in the Declaration of Helsinki. The study pro-
tocol and informed consent document were reviewed and approved by the Brigham 
and Women’s Hospital Institutional Review Board (approval number 2002P001763). 
All patients provided written informed consent before participating in the BRASS 
Registry. The present study population represents a subset of the BRASS cohort, and 
eligible patients had DXR–BMD and anti-CCP2 antibody measurements at the same 
time point or within 6 months.
Measures and Data Collection
Patient demographic data and clinical characteristics, disease activity, and labora-
tory parameters were assessed at baseline and annually thereafter. Digitized hand 
radiographs were collected at baseline and at 2, 5, 7, 10, and 12 years and will be 
collected to at least 15 years (Fig. 1). Hand BMD was measured at the metacarpal 
bones of the second, third, and fourth digits using DXR–BMD (DXR-online, Sectra 
Imtec AB, Linkoping, Sweden) as described previously [28]. Anti-CCP2 antibody level 
was measured using a validated ELISA (Inova Diagnostics, San Diego, California, 
USA until its discontinuation in 2011; thereafter Euro-Diagnostica [distributed by IBL-
America, Minneapolis, Minnesota, USA]). Patient-reported outcomes were assessed 
with a follow-up questionnaire every 6 months (Fig. 1)
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Study Outcomes
Patient demographic data and clinical characteristics were reported by anti-CCP2 
antibody status (anti-CCP2 positive [+] and anti-CCP2 negative [-]), and anti-CCP2 an-
tibody titer group (Group [Gp] 1–3). Anti-CCP2 antibody status was deﬁ ned either as 
anti-CCP2+ (≥ 20 U/mL) or anti-CCP2- (< 20 U/mL). Anti-CCP2+ patients were divided 
equally into three subgroups based on the tertiles of anti-CCP2 antibody titers as Gp1, 
20–96.6 U/mL; Gp2, 96.7–309.6 U/mL, and Gp3, 309.7–580 U/mL. Mean DXR–BMD 
was reported by anti-CCP2 antibody status and titer groups. The association between 
Disease Activity Score in 28 joints (DAS28) (C-reactive protein [CRP]) <2.6 and bone 
loss was analyzed in patients with DXR–BMD <0.5 g/cm2 (left or right hand) vs. ≥ 0.5 
g/cm2 (both hands).
Statistical Analysis
A cross-sectional analysis was performed on available data for DXR–BMD and anti-
CCP2 antibody level measured within 6 months of the DXR–BMD measurement. For 
descriptive statistics, Wilcoxon rank-sum test (or Kruskal–Wallis test) was used for 
continuous variables and Pearson’s Chi-square test for categorical variables. Associa-
Fig. 1 BRASS* study design.
* BRASS Brigham and Women’s Hospital Rheumatoid Arthritis Sequential Study
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tions between DXR–BMD (left, right, and combined [average of left and right hands]) 
and anti-CCP2 antibody status and titer (Gp1–3) were explored in multivariate analyses 
using linear regression controlling for covariates of age, duration of RA, body mass 
index (BMI), DAS28 (CRP), smoking status, use of steroids, bDMARDs, and osteopo-
rosis medication. With DXR–BMD as the dependent variable, we explored anti-CCP2 
antibody level as a continuous variable (linear trend) in relation to DXR–BMD, and 
explored anti-CCP2 antibody status as a categorical variable and included diﬀ erent 
anti-CCP2 antibody groups as reference groups. Associations between DXR–BMD and 
DAS28 (CRP) < 2.6 in patients with DXR–BMD ≥ 0.5 and < 0.5 g/cm2 were explored 
using a logistic model controlling for covariates of age, duration of RA, BMI, smoking 
status, use of steroids, bDMARDs, and osteoporosis medication.
RESULTS
Patient Disposition and Patient Characteristics by Anti-CCP2 Antibody Status and 
Titer Group
A total of 149 patients (all postmenopausal women) had an anti-CCP2 antibody 
measurement within 6 months of a DXR–BMD measurement: 47 (31.5%) were anti-
CCP2-; 102 (68.5%) were anti-CCP2+. Sample sizes for the left and right hands were 
similar. Of the 102 patients with anti-CCP2+ status, 34 were included in each titer 
group (Gp1, Gp2, and Gp3). Patient characteristics by anti-CCP2 antibody status 
and titer group are shown in Table 1. Age, BMI, DAS28 (CRP), smoking status, use 
of steroids, bDMARDs, and osteoporosis medication did not diﬀ er signiﬁ cantly by 
anti-CCP2 antibody status (±) or between groups (Table 1). Mean duration of RA was 
diﬀ erent between the groups (P < 0.05); a longer duration of RA was also reported in 
anti-CCP2+ Patients vs. anti-CCP2- patients (Table 1; P < 0.05). However, there was no 
clear pattern of disease duration between anti-CCP2 titer groups.
DXR–BMD by Anti-CCP2 Antibody Titer Group
In the univariate analysis, DXR–BMD was lower in the anti-CCP2 group vs. the 
anti-CCP2- titer groups (Gp1–3 vs. anti-CCP2-: P<0.0001 for left and right hands). 
DXR–BMD decreased with increasing anti-CCP2 antibody titer for the left hand (mean 
[SD]; anti-CCP2- group, 0.56 [0.08]; Gp1, 0.51 [0.09]; Gp2, 0.51 [0.08]; Gp3, 0.48 [0.1]), 
and right hand (0.58 [0.08]; 0.52 [0.09]; 0.52 [0.08]; 0.49 [0.1], respectively) (Fig. 2).
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Associations Between DXR–BMD and Anti-CCP2 Antibody Status: Multivariate 
Analysis
When anti-CCP2 antibody level was used as a continuous variable, combined hand 
DXR–BMD was negatively associated with anti-CCP2. For every 10-unit increase 
in anti-CCP2 antibody level, DXR–BMD decreased by 0.0014 units (P < 0.001; see 
Supplementary Table 1). The overall model ﬁ t based on adjusted R² for the total hand 
DXR–BMD model was 0.406. When anti-CCP2 antibody status was used as a categori-
cal variable, combined hand DXR–BMD was associated with anti-CCP2+ Gp1–3 vs. 
Table 1. Patient characteristics by anti-CCP2 antibody status and titer group
Anti-
CCP2–
n = 47
Anti-
CCP2+
n = 102
Anti-CCP2+
Gp1
n = 34
Anti-CCP2+
Gp2
n = 34
Anti-CCP2+,
Gp3
n = 34
Overall
population
N = 149
Anti-CCP2 anti-
body range, U/mL
3.0–15.4 20.0–580 20.0–96.6 96.7–309.6 309.7–580 3–580
Anti-CCP2 anti-
body level, U/mL, 
mean (SD)
5.1 
(2.9)**
226.4 
(157.0)**
55.2 (21.4)** 208.1 
(61.4)**
415.7 (61.2)** 156.6 
(165.7)
Age, years, mean 
(SD)
60.3 (8.4) 61.9 (9.6) 60.4 (9.0) 62.0 (9.5) 63.4 (10.3) 61.4 (9.3)
RA duration, years, 
mean (SD)
12.2 
(12.0)*
16.7 
(10.8)*
18.0 (11.3)* 15.1 (8.7)* 17.0 (12.1)* 15.3 (11.3)
BMI, kg/m², mean 
(SD)
27.3 (5.8) 26.9 (5.9) 26.0 (4.8) 25.6 (4.9) 29.2 (7.1) 27.0 (5.9)
DAS28 (CRP), 
mean (SD)
3.5 (1.4) 4.0 (1.5) 3.9 (1.5) 4.0 (1.6) 4.1 (1.5) 3.8 (1.5)
Steroid use, n (%)
 Never 10 (21.3) 18 (17.6) 6 (17.6) 6 (17.6) 6 (17.6) 28 (18.8)
 1–6 months 12 (25.5) 29 (28.4) 8 (23.5) 13 (38.2) 8 (23.5) 41 (27.5)
 >6 months 25 (53.2) 55 (53.9) 20 (58.8) 15 (44.1) 20 (58.8) 80 (53.7)
Ever/current 
smoker, n (%)
23 (48.9) 55 (53.9) 16 (47.1) 19 (55.9) 20 (58.8) 78 (52.3)
Biologic DMARD, 
n (%)
20 (42.6) 51 (50.0) 17 (50.0) 19 (55.9) 15 (44.1) 71 (47.7)
Osteoporosis 
medication, n (%)
6 (12.8) 15 (14.7) 6 (17.6) 7 (20.6) 2 (5.9) 21 (14.1)
*P < 0.05; **P < 0.001 comparing anti-CCP2– versus anti-CCP2+ or between the three anti-CCP2+ groups.
Anti-CCP2 antibody status was deﬁ ned as either anti-CCP2+ (≥20 U/mL) or anti-CCP2– (<20 U/mL)
Anti-CCP2 anti-cyclic citrullinated peptide-2 antibody, anti-CCP2– anti-CCP2 antibody negative, anti-CCP2+ 
anti-CCP2 antibody positive, BMI body mass index, CRP C-reactive protein, DAS28 Disease Activity Score in 28 
joints, DMARD disease-modifying antirheumatic drug, Gp group, RA rheumatoid arthritis
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Fig. 2 Association between DXR–BMD and anti-CCP2 antibody status and titer in A left hand and B right hand.
?
Number of patients in each titer group: anti-CCP2–, n = 47; Gp1, n = 34; GP2, n = 34; Gp3, n = 34. Timeframe 
between DXR–BMD and anti-CCP2 measurements (months [SD]) were 0.6 (1.4) for anti-CCP2–, 1.8 (2.3) for 
Gp1, 1.1 (1.8) for GP2, and 1.0 (1.7) for Gp3 (P > 0.05 for comparison between the anti-CCP2+ groups and 
the anti-CCP2– group)
Anti-CCP2 anti-cyclic citrullinated peptide-2 antibodies, anti-CCP2– anti-CCP2 antibody negative, anti-CCP2+ 
anti-CCP2 antibody positive, DXR–BMD digital X-ray radiogrammetry–bone mineral density, Gp group
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anti-CCP2- (P < 0.001; Table 2). Combined hand DXR–BMD was negatively associated 
with each individual anti-CCP2 antibody titer group (Gp1, Gp2, or Gp3) vs. anti-CCP2- 
(P < 0.05). Adjusted R² for the total hand DXR–BMD model was 0.426. This negative 
association between DXR–BMD and each individual anti-CCP2 antibody titer group 
vs. anti-CCP2- remained signiﬁ cant in the multivariate analysis (Table 2).
Results for individual hands were similar to those for the combined analysis (Table 2 
and Supplementary Table 1). When anti-CCP2 antibody level was used as a continu-
ous variable, for every 10-unit increase in anti-CCP2, DXR–BMD for the left or right 
hand decreased by 0.0014 units (P < 0.001; see Supplementary Table 1). Similarly, 
when anti-CCP2 antibody status was used as a categorical variable, left or right hand 
DXR–BMD was associated with anti-CCP2+ Gp1–Gp3 vs. anti-CCP2- (P < 0.001; 
Table 2). DXR–BMD was negatively associated with age, duration of RA, and use of 
osteoporosis medication. In the model with anti-CCP2 antibody status as a categorical 
variable, steroid use >6 months was also a signiﬁ cant factor for DXR–BMD (left or 
average; Table 2).
Table 2. Exploration of anti-CCP2 antibody status and titer as a categorical variable in relation to DXR–BMD
Variable Left-hand DXR–BMD Right-hand DXR–BMD Average of left and right
hands
Coeﬃ   -
cient
P value Adjusted
P valuec
Coeﬃ   -
cient
P value Adjusted
P valuec
Coeﬃ   -
cient
P value Adjusted
P valuec
Anti-CCP2– (vs. 
anti-CCP2+ 
Gp1–3)a
0.0523 < 0.001 0.0007 0.0586 < 0.001 0.0001 0.0568 < 0.001 0.0001
Anti-CCP2+ Gp1 
(vs. anti-CCP2–)a
−0.0475 0.007 0.029 −0.0555 0.002 0.0089 –0.0542 0.002 0.0097
Anti-CCP2+ Gp2 
(vs. anti-CCP2–)a
−0.0394 0.020 0.0608 −0.0477 0.006 0.0183 –0.0464 0.005 0.0166
Anti-CCP2+ Gp3 
(vs. anti-CCP2–)a
−0.0683 < 0.001 0.0005 −0.0715 < 0.001 0.0003 –0.0686 < 0.001 0.0002
Anti-CCP2+ Gp1 
(vs. Gp3)a
0.0208 0.268 0.268 0.0161 0.395 0.395 0.0144 0.442 0.442
Anti-CCP2+ Gp2 
(vs. Gp3)a
0.0289 0.113 0.226 0.0238 0.201 0.395 0.0221 0.215 0.43
Anti-CCP2+ Gp3 
(vs. anti-CCP2−, 
Gp1, and Gp2)a
−0.0442 0.004 0.0188 −0.0433 0.006 0.0183 –0.0422 0.006 0.0166
Age, years –0.0037 < 0.001 – –0.0036 < 0.001 – –0.0036 < 0.001 –
RA duration, years –0.0013 0.030 – –0.0013 0.026 – –0.001 0.081 –
BMI, kg/m² 0.0018 0.112 – 0.0021 0.063 – 0.0016 0.148 –
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Association Between Disease Activity and Bone Loss
Evaluation of the association between DXR–BMD and disease activity indicates that 
patients with low DXR–BMD were less likely to have a DAS28 (CRP) < 2.6 (DXR–BMD 
≥ 0.5, 36.5% vs. DXR–BMD < 0.5, 18.8%; P = 0.0181) (Fig. 3). After controlling for 
confounding factors, the odds of having a DAS28 (CRP) < 2.6 were signiﬁ cantly lower 
for patients with DXR–BMD<0.5 (n = 64) vs. ≥ 0.5 (n = 85; odds ratio 0.355 [95% CI 
0.126–0.998]; P = 0.0496).
Table 2. (continued)
Variable Left-hand DXR–BMD Right-hand DXR–BMD Average of left and right
hands
Coeﬃ   -
cient
P value Adjusted
P valuec
Coeﬃ   -
cient
P value Adjusted
P valuec
Coeﬃ   -
cient
P value Adjusted
P valuec
DAS28 (CRP) –0.0023 0.603 – –0.0014 0.760 – –0.0015 0.736 –
Steroid use 1–6 
months (vs. 
never)
–0.0248 0.174 – –0.0014 0.940 – –0.0076 0.664 –
Steroid use >6 
months (vs. 
never)
–0.0358 0.040 – –0.0324 0.061 – –0.0346 0.038 –
Smoker (ever/cur-
rent vs. never)
–0.0059 0.637 – –0.0125 0.324 – –0.0103 0.400 –
Biologic DMARD 
(yes vs. no)
–0.013 0.332 – 0.0118 0.378 – 0.0042 0.746 –
Osteoporosis 
medication (yes 
vs. no)
–0.0481 0.008 – –0.0477 0.009 – –0.0469 0.008 –
R², adjustedb 0.399 – – 0.421 – – 0.426 – –
aFour separate models with different reference groups or comparisons as speciﬁ ed in the table for each of the 
three outcomes. bThe model included all covariates in the table (age, duration of RA, BMI, smoking status, use 
of steroids, bDMARDs, and osteoporosis medication) and three dummy variables for the three anti-CCP2+ 
groups (vs anti-CCP2–). cP values were adjusted for multiple comparison based on Hochberg’s method that 
controls the familywise error rate under independence[29]
Anti-CCP2 antibody status was deﬁ ned as either anti-CCP2+ (≥20 U/mL) or anti-CCP2– (<20 U/mL). Anti-
CCP2+ titer groups were deﬁ ned as Gp1, 20.0–96.6 U/mL; Gp2, 96.7–309.6 U/mL; or Gp3, 309.7–580 U/mL
Anti-CCP2 anti-cyclic citrullinated peptide-2 antibody, anti-CCP2– anti-CCP antibody negative, anti-CCP2+ anti-
CCP2 antibody positive, BMI body mass index, BMD bone mineral density, CRP C-reactive protein, DAS28 
Disease Activity Score in 28 joints, DMARD disease-modifying antirheumatic drug, DXR digital X-ray radio-
grammetry, Gp group, RA rheumatoid arthritis
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DISCUSSION
Our results show that, among patients with long-standing RA, hand DXR–BMD is 
negatively associated with the presence of anti-CCP2 antibodies. Patients with anti-
CCP2+ status, particularly those with high anti-CCP2 antibody titers, had lower hand 
BMD; therefore, as anti-CCP2 antibody titers increased, hand BMD decreased. This is 
consistent with previous studies in patients with early RA, demonstrating a correlation 
between elevated anti-CCP2 antibody baseline levels and DXR–BMD loss [23, 24].
In the present analysis, patients with low DXR–BMD were less likely to have low 
disease activity. Similar observations have also been reported in patients with early RA 
[30], suggesting an association between disease activity and bone loss. Hand BMD 
loss has also been shown to indicate an increased risk of erosive disease [10, 11, 31, 
32]. Data from an observational study demonstrated that BMD loss at 6 months was 
associated with higher erosion scores, and a higher proportion of patients with BMD 
loss at 6 months had at least one erosion and a higher risk of erosion progression at 
12 months [31]. Furthermore, although there is evidence that hand joint damage in 
RA is related to use and hand dominance [33], our data show that bone loss occurs in 
both hands, which is consistent with RA being deﬁ ned as a symmetrical disease. Such 
Fig. 3 Association between DXR–BMD and DAS28 (CRP) <2.6.
CRP C-reactive protein, DAS28 Disease Activity in 28 joints, DXR–BMD digital X-ray radiogrammetry–bone 
mineral density
58 ○ Chapter 3
patients with low hand BMD may be at an increased risk of vertebral and non-vertebral 
fractures [6, 7].
Pro-inﬂ ammatory cytokines are generally the key drivers of articular and extra-articular 
bone damage [34–36]. However, recent evidence has shown that RA-associated auto-
antibodies, such as ACPA, can directly induce bone loss by stimulating osteoclast dif-
ferentiation [20, 21]. In vivo, human ACPA causes bone loss in immune-deﬁ cient mice 
[20]. ACPA has been shown to be associated with bone loss as demonstrated through 
DXR–BMD in this study as well as DXA–BMD in a separate study [24]. Patients with 
ACPA develop cortical thinning, leading to a decrease in bone mass and increasing 
the risk of bone erosions [3, 22]. Given the evidence suggesting that ACPA is a key 
driver of bone loss [23, 24], treatment options for RA that reduce ACPA titers and 
induce seroconversion may be eﬀ ective in lowering the risk of bone loss. This should 
be explored in future clinical trials.
The strength of this analysis is that these data are from an observational cohort of pa-
tients with RA, including clinical measures such as serological status and DXR–BMD. 
Limitations of this analysis include those inherent in observational cross-sectional 
studies, including the absence of a comparator (e.g., DXR–BMD in healthy, postmeno-
pausal women) and hand radiographs and ACPA testing may not have been done on 
the same day. Even though our statistical models controlled for several covariates and 
observed signiﬁ cant relationships between DXR–BMD and ACPA or disease activity, 
this does not imply causation or rule out certain biases without further controlled 
analyses. Confounding by unmeasured variables should also be considered when 
evaluating these results. The selection of < 0.5 as compared with ≥ 0.5 g/cm2 in rela-
tion to DAS28 (CRP) < 2.6 should also be considered as a potential limitation. How-
ever, the cutoﬀ  was selected in reference to the DXR–BMD median of Gp3 and needs 
further validation in future studies. In addition, antibodies to individual citrullinated 
proteins (e.g. ﬁ brin, ﬁ laggrin, vimentin) or other serological markers (e.g., rheumatoid 
factor) were not evaluated. The patient population primarily reﬂ ects postmenopausal 
women; therefore, future studies should be conducted in pre- and postmenopausal 
women as these results may have implications for osteoporosis prevention.
CONCLUSIONS
Our results show that, in routine clinical practice, anti-CCP2 antibody positivity in pa-
tients with established RA is associated with lower hand BMD, and patients with hand 
bone loss were less likely to have low disease activity. This suggests that DXR–BMD 
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and anti-CCP2 antibody status could help identify patients at risk for joint progression 
and fracture; however, a direct causal relationship cannot necessarily be implied from 
this cross-sectional analysis. Disease-modifying treatment for RA that not only targets 
inﬂ ammation but improves cortical bone density should be considered in order to 
achieve better prevention of bone erosions in patients with RA.
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SUPPLEMENTARY MATERIAL
Supplementary Table 1 Exploration of anti-CCP2 as a continuous variable (linear trend) in relation to DXR–
BMD
Variable
Left-hand
DXR–BMD
Right-hand
DXR–BMD
Average of
left and right hands
Coeﬃ  cient P value Coeﬃ  cient P value Coeﬃ  cient P value
Anti-CCP2 per 10-unit increase −0.0014 < 0.001 −0.0014 < 0.001 –0.0014 < 0.001
Age, years –0.0036 < 0.001 –0.0035 < 0.001 –0.0035 < 0.001
RA duration, years –0.0015 0.010 –0.0016 0.008 –0.0012 0.034
BMI, kg/m2 0.0019 0.089 0.0023 0.043 0.0018 0.100
DAS28 (CRP) –0.0036 0.415 –0.0027 0.545 –0.0025 0.570
Steroid use 1–6 months (vs. never) –0.022 0.231 0.0004 0.984 –0.0055 0.757
Steroid use >6 months (vs. never) –0.0335 0.055 –0.0297 0.090 –0.0311 0.065
Smoker (ever/current vs. never) –0.0085 0.497 –0.0149 0.247 –0.0133 0.283
Biologic DMARD (yes vs. no) –0.0128 0.339 0.0105 0.436 0.0042 0.750
Osteoporosis medication (yes vs. no) –0.0481 0.008 –0.0493 0.008 –0.499 0.005
R2, adjusted 0.388 0.399 0.406
Anti-CCP2 anti-cyclic citrullinated peptide-2, BMI body mass index, CRP C-reactive protein, DAS28 Disease 
Activity Score in 28 joints, DMARD disease-modifying antirheumatic drug, DXR–BMD digital X-ray radiogram-
metry–bone mineral density, RA rheumatoid arthritis
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ABSTRACT
Here, we evaluate associations between changes in anti-citrullinated protein antibody 
(ACPA) levels and outcomes, including durable medical equipment (DME) use, hos-
pitalizations, and disease activity, in patients with established rheumatoid arthritis. 
Patients from the Brigham and Women’s Hospital Rheumatoid Arthritis Sequential 
Study who had ACPA measurements at baseline and month 12 were included. Chang-
es in ACPA levels from baseline to month 12 were categorized as decrease (>10%), 
no change (−10% to +10%), or increase (> +10%). DME use and hospitalizations 
were assessed twice-yearly using patient questionnaires; disease activity was assessed 
annually. Binary multivariate logistic regression was used to analyze the relationship 
between changes in ACPA levels and DME use and hospitalizations; linear regression 
was used to assess the relationship with disease activity. Of 840 patients included in 
the analysis, 291 (34.6%), 266 (31.7%), and 283 (33.7%) had a decrease, no change, 
or increase in ACPA levels, respectively. Decrease in ACPA levels was associated with 
reduction in DME use (adjusted odds ratio [aOR]: 0.64; 95% conﬁ dence interval [CI]: 
0.44–0.93; P = 0.019) and hospitalizations (aOR: 0.62; 95% CI: 0.41–0.95; P = 0.029) 
versus no change or increase. Adjusted mean changes in disease activity score in 28 
joints (C-reactive protein), total and swollen joint counts, and pain scores were signiﬁ -
cantly greater in patients with decreased ACPA levels versus those with no change or 
increase (P < 0.05). Among patients with established rheumatoid arthritis, reductions 
in ACPA levels of >10% were associated with reductions in DME use, hospitalizations, 
and disease activity.
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INTRODUCTION
Anti-citrullinated protein antibodies (ACPAs) are sensitive and highly speciﬁ c bio-
markers for the diagnosis of rheumatoid arthritis (RA) that are present years before 
the onset of clinical RA [1, 2]. ACPA assessment has become standard practice in the 
diagnosis of RA, partly due to superior assay speciﬁ city and similar sensitivity as de-
tection techniques for rheumatoid factor (RF) [3]. ACPA positivity has been associated 
with more severe, erosive disease than is seen in ACPA-negative patients [4, 5]. A high 
ACPA concentration, beyond ACPA positivity, is indicative of more rapid radiographic 
progression, worse disease severity, and greater bone loss in RA patients [4, 6].
ACPA levels ﬂ uctuate over time, with an increase observed prior to the onset of clinical 
symptoms [7], and patients are known to seroconvert or enter immunologic remission 
following treatment [8]. However, the impact of these changes has been little studied. 
There is limited information on changes in ACPA levels in clinical practice settings, and 
whether an association exists between changes in ACPA levels and measures of resource 
use or disease activity. The objective of this analysis was to evaluate the association be-
tween changes in ACPA levels and resource use (including durable medical equipment 
[DME] use and hospitalizations), and disease activity in patients with established RA.
MATERIALS AND METHODS
Study design
Details regarding the design of the Brigham and Women’s Hospital Rheumatoid Ar-
thritis Sequential Study (BRASS) registry have been reported previously [9-11]. Brieﬂ y, 
the BRASS registry is a single-center, prospective, observational, longitudinal cohort 
of >1300 adults with established or recent-onset RA who are being followed up by a 
hospital-based practice of 21 rheumatologists in Boston, Massachusetts, USA. Patient 
demographics and clinical characteristics, disease activity, and laboratory parameters 
were assessed at baseline and annually thereafter. Patients followed the treatment 
plan provided by their rheumatologist when they enrolled in the study and throughout 
follow-up. Patients were eligible for the current analysis if they had documented ACPA 
values at baseline and the month 12 follow-up visit.
This study was performed in accordance with the Declaration of Helsinki and was ap-
proved by the Partners Institutional Review Board at Brigham and Women’s Hospital. 
All patients gave signed informed consent.
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Measures and data collection
ACPA levels were measured using a validated enzyme-linked immunosorbent assay 
(Inova Diagnostics, San Diego, California, USA, until discontinuation in 2011; after 
Euro-Diagnostica, distributed by IBL-America, Minneapolis, Minnesota, USA). RF was 
measured by an immunoturbidimetric method using a Cobas Integra 700 Analyser 
(Roche Diagnostics, Indianapolis, Indiana, USA). ACPA and RF seropositivity were 
deﬁ ned as ≥20 and >15 U/mL, respectively. Total swollen and tender joint counts 
(SJC/TJC), Disease Activity Score in 28 joints, C-reactive protein (DAS28 [CRP]), and 
clinical disease activity index (CDAI) and simpliﬁ ed disease activity index (SDAI) 
scores were assessed by investigators at each annual visit. Pain and active arthritis 
on the day of assessment were assessed by the patient using a scale from 0 to 10, 
with 0 indicating not active/no pain and 10 indicating extremely active/extreme pain. 
Follow-up postal questionnaires were completed by patients biannualy to determine 
work productivity, use of DME (including canes, stands, walkers, wheelchairs, and 
commodes), hospitalizations, other resource use, and clinical and societal variables.
Study outcomes
The main independent variable of interest was the change in ACPA levels from baseline 
to month 12 (categorized as decrease [>10%], no change [−10% to +10%], or increase 
[> +10%]). The dependent variables evaluated included the proportion of patients us-
ing DME or being hospitalized during the 12-month follow-up, and the mean change 
from baseline to month 12 in disease activity (DAS28 [CRP], SDAI, CDAI, SJC/TJC) 
and pain.
Statistical analysis
Descriptive statistics are used to describe baseline characteristics. Baseline charac-
teristics were compared using the Chi-square test for categorical variables and the 
Wilcoxon sum rank test for continuous variables. A P value of <0.05 (two-sided) was 
considered statistically signiﬁ cant. Multivariate logistic regression analyses were used 
to determine the relationship between change in ACPA levels and binary outcome 
variables (i.e., DME use and hospitalizations), and linear regression analyses were 
used to investigate the relationship between change in ACPA levels and disease ac-
tivity measures, controlling for baseline covariates (age, sex, race, body mass index 
[BMI], RA duration, number of comorbidities, and previous biologic disease-modifying 
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antirheumatic drug [DMARD] treatment; baseline disease activity was also a covariate 
for the logistic regression analysis). All odds ratios (OR) and mean changes from 
baseline were adjusted for baseline covariates. All statistical analyses were performed 
using SAS® version 9.4 (SAS institute Inc., Cary, NC, USA).
RESULTS
Baseline patient characteristics by change in ACPA levels
A total of 840/1350 (62%) patients in the BRASS registry had baseline and month 12 
ACPA values, and were included in the analysis (Table 1). Overall, 291 (34.6%), 266 
(31.7%), and 283 (33.7%) patients in the current study had a decrease, no change, or 
increase in ACPA levels, respectively. The mean (standard deviation) change in ACPA 
levels was −35.4 (19.3), −0.5 (4.9), and 196.8 (1368.8) U/mL for the patients with a 
decrease, no change and increase in ACPA levels, respectively (P < 0.001). At baseline, 
there was no signiﬁ cant diﬀ erence in mean age, sex, BMI, duration of RA, number of 
comorbidities, prior use of biologic DMARDs, or disease activity scores among the 
change in ACPA level groups. The proportion of patients who were ACPA positive at 
baseline was, however, signiﬁ cantly diﬀ erent across the three ACPA groups (decrease, 
69.4%; no change, 62.8%; increase, 59.4%; P = 0.039).
Table 1. Baseline patient characteristics by change in ACPA levels
Characteristic Change in ACPA level P valuea Total
included
(n = 840)
Total
BRASS
cohortb
(n = 1350)
P valuec
Decrease
(< −10%)
(n = 291)
No change
(–10% to 
+10%)
(n = 266)
Increase
(> +10%)
(n = 283)
Age, years
 Mean (SD) 56.6 (13.1) 57.4 (13.1) 55.8 (14.3) 0.452 56.6 (13.5) 56.5 (14.1)
0.898
Sex, n (%)
 Female
 Male
240 (82.5)
51 (17.5)
217 (81.6)
49 (18.4)
239 (84.5)
44 (15.5)
0.656
696 (82.9)
144 (17.1)
1112 (82.4)
238 (17.6)
0.547
Race, n (%)
 White
 Other
272 (93.5)
17 (5.8)
245 (92.1)
20 (7.5)
261 (92.2)
20 (7.1)
0.719
778 (92.6)
57 (6.8)
1238 (91.7)
102 (7.6)
0.163
BMI, kg/m²
 n
 Mean (SD)
278
26.9 (5.3)
256
26.8 (5.7)
273
26.3 (5.2)
0.411
807
26.7 (5.4)
1275
26.8 (5.7)
0.710
Duration of RA, years
 Mean (SD) 12.9 (12.1) 14.1 (11.7) 13.3 (12.4)
0.257
13.4 (12.1) 12.9 (12.0)d
0.009
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Those patients excluded (n = 510) from the full BRASS cohort (n = 1350) for this 
analysis had a shorter mean duration of RA (11.9 years) than those patients included 
(13.4 years; P = 0.009). In addition, the baseline mean DAS28 (CRP) score of the 
excluded patients was signiﬁ cantly lower (3.5) than that of the patients included in 
this study (3.9; P < 0.001).
Table 1. (continued)
Characteristic Change in ACPA level P valuea Total
included
(n = 840)
Total
BRASS
cohortb
(n = 1350)
P valuec
Decrease
(< −10%)
(n = 291)
No change
(–10% to 
+10%)
(n = 266)
Increase
(> +10%)
(n = 283)
No. comorbidities
 Mean (SD) 1.9 (1.5) 1.9 (1.4) 1.9 (1.4)
0.595
1.9 (1.4) 1.9 (1.5)
0.999
Biologic DMARD, 
n (%)
 Yes
 No
139 (47.8)
152 (52.2)
118 (44.4)
148 (55.6)
119 (42.0)
164 (58.0)
0.383
376 (44.8)
464 (55.2)
608 (45.0)
742 (55.0)
0.794
DAS28 (CRP)
 Mean (SD) 3.9 (1.6) 4.0 (1.5) 3.8 (1.6)
0.193
3.9 (1.6) 3.7 (1.6)e
<0.001
SDAI
 n
 Mean (SD)
273
23.7 (18.2)
245
23.7 (16.4)
260
22.1 (17.5)
0.316
778
23.2 (17.4)
1187
22.0 (17.3)
<0.001
CDAI
 n
 Mean (SD)
273
22.8 (17.5)
245
22.8 (16.1)
260
21.1 (16.5)
0.347
778
22.2 (16.7)
1205
21.1 (16.7)
<0.001
SJC/TJC
 Mean (SD) 15.8 (14.8) 16.0 (13.6) 14.5 (13.7)
0.305
15.4 (14.1) 14.3 (14.1)d
<0.001
Active arthritis, 0–10 
scale
 n
 Mean (SD)
279
3.7 (2.8)
247
3.5 (2.8)
260
3.4 (2.7)
0.517
786
3.5 (2.8)
1219
3.6 (2.8)
0.843
Pain, 0–10 scale
 n
 Mean (SD)
279
3.5 (2.7)
248
3.3 (2.7)
260
3.2 (2.7)
0.476
787
3.3 (2.7)
1220
3.3 (2.8)
0.725
ACPA anti-citrullinated protein antibody, BRASS Brigham and Women’s Hospital Rheumatoid Arthritis Sequen-
tial Study, SD standard deviation, BMI body mass index, RA rheumatoid arthritis, DMARD disease-modifying 
antirheumatic drug, DAS28 disease activity score in 28 joints, CRP C-reactive protein, SDAI simpliﬁ ed disease 
activity index, CDAI clinical disease activity index, SJC/TJC swollen and tender joint count
aIncluding patients who did not have ACPA measurement at baseline and month 12
bOverall difference between the three ACPA groups
cIncluded vs not included
dn = 1349
en = 1328
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Association between resource use and change in ACPA levels
During the 12-month follow-up, DME use was 23.4%, 30.1%, and 28.6%, and the 
hospitalization rate was 13.4%, 16.5%, and 20.1% in patients with a decrease, no 
change, or increase in ACPA levels, respectively. Multivariate analysis demonstrated 
that a decrease in ACPA levels was associated with a reduction in DME use (adjusted 
OR [aOR]: 0.62; 95% conﬁ dence interval [CI] 0.40–0.94; P = 0.026) and hospitaliza-
tions (aOR: 0.54; 95% CI: 0.33–0.86; P = 0.010) compared with an increase in ACPA 
levels (Fig. 1); there was no signiﬁ cant diﬀ erence in DME use (aOR: 0.92; 95% CI 
0.61–1.40; P = 0.708) or hospitalizations (aOR: 0.74; 95% CI 0.47–1.16; P = 0.185) 
between no change and an increase in ACPA levels (Fig. 1). After controlling for base-
line covariates, the aORs associated with a decrease versus no change or an increase 
in ACPA levels were 0.64 (95% CI: 0.44–0.93; P = 0.019) for DME use and 0.62 (95% 
CI: 0.41–0.95; P = 0.029) for hospitalizations. Further controlling for ACPA positivity 
at baseline, the aORs associated with a decrease versus no change or an increase in 
ACPA levels were 0.66 (95% CI 0.45, 0.96; P = 0.028) for DME use and 0.63 (95% CI 
Figure 1: Odds ratios for (A) DME use and (B) hospitalization by ACPA change from baseline to 12 months 
and by baseline characteristics
?
ACPA anti-citrullinated protein antibodies, CI conﬁ dence interval, BMI body mass index, RA rheumatoid arthri-
tis, DAS28 disease activity score in 28 joints, CRP C-reactive protein, DMARD disease-modifying antirheumatic 
drug, DME durable medical equipment
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0.41, 0.96; P = 0.032) for hospitalizations. Changes in RF levels were associated with 
DME use (aOR: 0.62; 95% CI: 0.39–0.99; P = 0.044) but not with hospitalizations 
(aOR: 0.79; 95% CI: 0.47–1.34; P = 0.383).
Association between disease activity and change in ACPA levels
The r² values for DAS28 (CRP), CDAI, SJC/TJC, SDAI, and pain were 0.27, 0.31, 0.30, 
0.32, and 0.34, respectively, indicating a good ﬁ t for the multivariate regression mod-
els. The adjusted mean changes from baseline in DAS28 (CRP), SJC/TJC, and pain 
in patients with a decrease in ACPA levels (> 10%) were signiﬁ cantly greater than in 
those patients with an increase (> +10%) or no change in ACPA (P < 0.05; Fig. 2). A 
similar trend was observed for SDAI and CDAI, where there were greater adjusted 
mean changes from baseline to month 12 in patients with a decrease in ACPA levels 
compared with those with an increase or no change in ACPA (SDAI: −6.448 versus 
−4.763, P = 0.099; CDAI: −6.259 versus −4.577, P = 0.087; Fig. 2). Multivariate analysis 
Figure 2: Adjusted mean (95% CI) change from baseline in disease activity and pain (visual analog scale, 
0–100 mm) in patients with a decrease versus no change or an increase in ACPA levels
?
DAS28 disease activity score in 28 joints, CRP C-reactive protein, SDAI simpliﬁ ed disease activity index, CDAI 
clinical disease activity index, SJC/TJC swollen and tender joint count, CI conﬁ dence interval, ACPA anti-citrul-
linated protein antibody
*P < 0.05, indicates difference between patients with a decrease in ACPA levels versus no change or an in-
crease in ACPA
71Association of changes in anti-citrullinated protein antibody levels with resource use and disease activity measures ○
4
also showed that changes in DAS28 (CRP), SDAI, CDAI, SJC/TJC, and pain scores 
were all signiﬁ cantly associated with their respective baseline score (all P < 0.001), RA 
duration (all P < 0.001 except for pain, P = 0.042) and prior use of biologic DMARDs 
(all P < 0.05). None of the disease activity outcomes was signiﬁ cantly associated with 
age or race; SDAI was signiﬁ cantly associated with comorbidities (P = 0.032), SJC/TJC 
with sex (P = 0.035), and pain with BMI (P < 0.001).
DISCUSSION
This study demonstrates that among patients with established RA, decreases in ACPA 
levels were associated with reductions in DME use, hospitalizations, and disease 
activity (assessed using a range of standard composite measures).
In current clinical practice, ACPA levels are measured only as part of the diagnostic 
work-up for RA and there is limited information on changes in ACPA over time. How-
ever, data from clinical trials show that RA therapies such as abatacept and rituximab 
can decrease the levels of anti-cyclic citrullinated peptide in patients with RA [8, 12]. In 
addition, abatacept and adalimumab have demonstrated superior eﬃ  cacy in patients 
with RA who are seropositive for anti-cyclic citrullinated peptide compared with those 
who are seronegative [13] and, in a prospective analysis of a phase III trial evaluating 
therapy reduction in patients with RA in ongoing remission, relapse following treat-
ment reduction or withdrawal was associated with ACPA positivity [14]. Hence, the 
measurement of ACPA levels throughout disease progression could potentially be 
used to determine how a patient will respond to a particular treatment, thus helping 
physicians make more informed treatment decisions. However, the implications of 
changes in ACPA levels within clinical practice have not been previously studied. The 
present study is the ﬁ rst to highlight the association between outcomes and changes 
in ACPA levels.
The 2016 update to the European League Against Rheumatism (EULAR) guidelines 
recommends the addition of a biologic DMARD or JAK inhibitor for patients with an 
inadequate response to methotrexate and who have poor prognostic factors (i.e., RF/
ACPA positivity [particularly those with high levels], high disease activity, early joint 
damage, or failure of at least two conventional synthetic DMARDs) [15], demonstrat-
ing the increasing importance of ACPA in treatment decision-making. However, there 
is currently no guidance on which biologic DMARD should be given to patients with 
poor prognostic factors, including ACPA. Further investigations are necessary to bet-
ter understand the changes in ACPA levels during RA progression and treatment.
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The current data are from an observational cohort of patients with RA; such studies al-
low large numbers of patients to be observed over longer durations of time compared 
with randomized controlled trials. In addition, data collected from observational stud-
ies are more reﬂ ective of real-world clinical practice than those derived from clinical 
trials. A further strength of this study is that it was conducted at a single site, which 
limits methodologic heterogeneity compared with multicenter studies, avoiding po-
tential diﬀ erences in study procedures and personnel training.
This observational study reports the analysis of cross-sectional data, which is associ-
ated with a number of limitations including the lack of a comparator. The associations 
between ACPA levels and DME use and hospitalizations were expressed as categorical 
(rather than continuous) variables, and therefore may not indicate the full extent of 
any correlation. In addition, confounding by unmeasured variables should also be 
considered when evaluating these results. Other limitations of this study include the 
self-reporting of DME use and hospitalizations, which introduces the possibility of 
recall bias, and the lack of adjustment for speciﬁ c biologic treatments, preventing 
explorations of treatment eﬀ ect.
The results of the current study show that reductions in ACPA levels are associated 
with increased clinical beneﬁ t and decreased healthcare resource utilization in a real-
world setting. Similar associations were seen between RF levels and DME use but 
not hospitalizations. These results could help inform physicians regarding treatment 
decisions, speciﬁ cally when selecting treatments for patients with higher ACPA levels. 
Further research is necessary to evaluate the signiﬁ cance of these ﬁ ndings.
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ABSTRACT
Objectives: To evaluate associations between the presence of anti-cyclic citrullinated 
protein antibodies (anti-CCP) and rheumatoid factor (RF) and other outcomes, in-
cluding joint erosions and both clinical and economic endpoints, in patients with 
rheumatoid arthritis (RA). Methods: Data from the Brigham and Women’s Hospital 
Rheumatoid Arthritis Sequential Study (BRASS), a prospective registry of adult RA 
patients with established or recent-onset RA, were analyzed. Logistic regression 
models were constructed to test associations between anti-CCP/RF seropositivity and 
erosive disease and the presence of anti-CCP/RF seropositivity plus erosive disease 
and (1) RA severity; (2) hospitalizations; (3) durable medical equipment (DME) use; 
and (4) worker productivity (e.g., employment status). Covariates in these models 
included patient age, gender, race, body mass index (BMI), number of comorbidities, 
and treatment. Results: Among 1309 registrants, those who were positive (vs. nega-
tive) for anti-CCP were 2.72 times more likely to have erosions (OR = 2.72; 95% CI: 
1.77−4.18; P < 0.001). Individuals positive (vs. negative) for RF were 36% more likely 
to have erosions (95% CI: 0.88−2.08; P = 0.162). Patients with anti-CCP seropositiv-
ity and erosions were signiﬁ cantly more likely to: (1) have higher disease activity as 
measured by the Disease Activity Score in 28 joints C-reactive protein (DAS28-CRP ≥ 
2.6); (2) be hospitalized; (3) use DME; and (4) be unemployed, disabled, or long-term 
disabled. Conclusions: For the ﬁ rst time in a “real-world” setting including patients 
with both recent-onset and chronic RA, this study demonstrated that the combination 
of anti-CCP seropositivity and erosions were signiﬁ cantly associated with more ad-
verse clinical and health-economic consequences, including a lower probability of low 
disease activity and higher health resource utilization, despite use of biologic disease-
modifying antirheumatic drugs by many patients. This dual presentation may signal 
a need for more intensive therapies, even when observed in patients with chronic, as 
well as recent-onset, RA.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, systemic progressive condition that aﬀ ects 
approximately 0.5–1.0% of western industrialized societies, including approximately 
1.5 million US residents [1]. This immune-mediated inﬂ ammatory disease has a vari-
able natural history and prognosis; some patients (or sub-populations) experience 
an overall more aggressive disease trajectory with diﬀ erent patterns of articular and 
extra-articular damage, more rapid radiographic progression, and a poorer prognosis 
(including worse treatment responses) compared to others [2–6].
In patients with early RA, various factors have been associated with a poor progno-
sis, including certain genotypes and young age at disease onset. Contemporary RA 
management guidelines recommend more intensive treatment of patients with poor 
prognostic factors [7, 8]; clinical practice guidelines from the American College of 
Rheumatology (ACR) have placed less emphasis [and the European League Against 
Rheumatism (EULAR) more emphasis] on the clinical role of prognostic factors. Bio-
logic disease-modifying antirheumatic drugs (bio-DMARDs), with or without metho-
trexate (MTX) or other conventional DMARDs, are recommended for patients with 
high disease activity and poor prognostic factors. These factors include early-onset 
damage to joints and autoantibodies to cyclic citrullinated protein [anti-cyclic citrul-
linated protein antibodies (anti-CCP; and other citrullinated proteins] and rheumatoid 
factor (RF), which are believed to play a role in disease pathogenesis [7, 9–11]. In fact, 
some of these prognostic factors are interrelated. For example, anti-CCP production 
is associated with more erosive disease, rapid radiographic progression, and/or extra-
articular manifestations; whereas elevated acute-phase reactants are often associated 
with higher disease activity [12–19].
Data concerning the impact of combinations of prognostic factors (anti-CCP, RF, and 
joint erosions) on other health outcomes are limited. The objective of the current 
study was twofold: to evaluate the association between (1) anti-CCP/RF seropositivity 
and joint erosions and between (2) the impact of these prognostic factors when pres-
ent together on disease activity, resource use, and work productivity.
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PATIENTS AND METHODS
Study design and setting
We utilized data from the Brigham and Women’s Hospital (BWH) Rheumatoid Arthri-
tis Sequential Study (BRASS). This prospective registry commenced in March 2003 
(http://www. brassstudy.org) [20–22].
Study participants
The BRASS Registry is a single-center, prospective, observational, longitudinal cohort 
of 41,300 adults with established or recent-onset RA who are being followed by a 
hospital-based practice of 21 rheumatologists at BWH in Boston. To be eligible for 
inclusion in the registry, patients had to have a conﬁ rmed diagnosis of RA by an 
independent rheumatologist. BRASS registrants included in the current analysis had 
available baseline data for pivotal variables, including anti-CCP and RF.
The BRASS Registry has been conducted in accordance with International Society 
for Pharmacoepidemiology Guidelines for Good Pharmacoepidemiology Practices, 
applicable regulatory requirements, and ethical tenets originating in the Declaration 
of Helsinki. The study protocol and informed consent document were reviewed and 
approved by the BWH Institutional Review Board.
In accordance with local regulations, participants in the BRASS Registry provided 
written informed consent before enrolling into the study and having any study as-
sessment or procedure. Investigators ensured that patients were clearly and fully 
informed about the purposes of the study, potential risks, and the subject’s rights and 
responsibilities when participating in this study.
De-identiﬁ ed patient data in the present study were compliant with the Health Insur-
ance Portability and Accountability Act. Maintenance of patient conﬁ dentiality was as-
sured by assigning each subject a randomized identiﬁ cation number upon enrollment 
in the BRASS Registry, and limiting access to these numbers.
In terms of patient follow-up, physicians evaluated patient demographic and clinical 
characteristics, disease activity, and laboratory parameters at baseline and annually 
thereafter. Total swollen and painful joint counts (TJC) were measured by the inves-
tigator at each annual visit. Anti-CCP levels at baseline and annual follow-up visits 
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over time (1−5 years) were measured using validated enzyme-linked immunosorbent 
assays [ELISAs; from Inova Diagnostics (San Diego, CA) and Euro-Diagnostica (IBL—
American, Minneapolis, MN)] [23].
Certain outcomes, such as disease activity measures, were assessed at 12-month 
intervals, during annual rheumatologist visits. Follow-up postal questionnaires to as-
sess patient-reported outcomes and other clinical and societal variables were mailed 
to patients. These outcomes included worker productivity, hospitalization, and use of 
durable medical equipment (DME), which included stands, walkers, and wheelchairs.
Variables
Consistent with the study’s objectives, we evaluated associations between (1) sero-
positivity (anti-CCP+/RF+) and joint erosions at baseline. Seropositivity for anti-CCP 
was deﬁ ned as a minimum value of 20 U/mL and seropositivity for RF as a value 
greater than 15 U/mL. Also assessed were associations between seropositivity (± 
erosions) and (1) a Disease Activity Score in 28 joints C-reactive protein (DAS28-
CRP) o 2.6 or a Simpliﬁ ed Disease Activity Index (SDAI) score of ≤3.3 (associated 
with remission); (2) health care resource utilization in terms of whether patients were 
hospitalized or used DME, and (3) worker productivity in terms of numbers of days 
lost as well as the number (%) of BRASS registrants who were employed, retired, 
short-term disabled, long-term disabled, or had an annual family income of $50,000. 
Hospitalization and DME use represent direct costs of RA, whereas days of work lost 
and proportions of patients employed, retired, disabled, and/or earning low incomes 
are considered indirect costs.
Statistical analysis
Descriptive statistics included the Wilcoxon rank sum test for continuous variables 
and Pearson χ² for categorical variables. Logistic regression models were constructed 
to test associations between anti-CCP/RF seropositivity and the binary outcome vari-
able of the presence or absence of joint erosions. Models also tested associations 
between the presence of these prognostic factors and the categorical variables of: (1) 
having DAS28-CRP < 2.6 or SDAI ≤ 3.3 (SDAI remission), (2) hospitalization (yes or 
no), (3) DME use (yes or no), and (4) employment status (proportions employed, 
retired, disabled and earning oF $50,000 annually). For associations between anti-
CCP/RF seropositivity and/or joint erosions and the likelihood of having a DAS28-CRP 
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score < 2.6 or SDAI ≤ 3.3 (SDAI remission), forest plots based on logistic regression 
models were constructed showing odds ratios (OR) and 95% conﬁ dence intervals 
(CIs). Covariates in these models included patient age, gender, race, body mass index 
(BMI), number of comorbidities, and treatment. An a priori two-sided α = 0.05 was 
speciﬁ ed for statistical signiﬁ cance. Analyses were conducted using SAS PROC GLM 
and PROC LOGISTIC procedures (SAS Institute Inc., Cary, NC) for continuous and 
categorical outcome variables.
RESULTS
Descriptive data
A total of 1309 patients were included. Table 1 summarizes characteristics of RA pa-
tients included in the analysis according to baseline anti-CCP, RF, and erosion status. 
Patients who were positive (vs. negative) for anti-CCP, RF, and erosions at baseline 
tended to have a signiﬁ cantly:
• Longer history of RA (15.0 vs. 9.6 years for anti-CCP; 14.8 vs. 10.1 years for RF; and 
17.2 vs. 7.3 years for erosions; each P < 0.001 for pairwise comparisons),
• Greater number of comorbidities (2.1 vs. 1.7 for anti-CCP and RF; and 2.2 vs. 1.6 
for erosions; each P < 0.001 for pairwise comparisons); and
• Higher mean CRP levels (10.1 vs. 7.6 mg/L for anti-CCP; 10.3 vs. 7.9 mg/L for RF; 
and 11.6 vs. 5.6 mg/L for erosions; each P < 0.001).
Compared to all other BRASS study participant, patients who were anti-CCP positive 
with joint erosions were signiﬁ cantly older [mean (SD) age = 59.0 (12.9) vs. 54.8 (14.5) 
years; P < 0.001]; had higher RA activity as measured using the DAS28-CRP [mean 
(SD) = 4.3 (1.6) vs. 3.4 (1.5); P < 0.001], Clinical Disease Activity Index [CDAI; mean 
(SD) = 26.9 (17.7) vs. 17.3 (15.0); P < 0.001], and SDAI [mean (SD) = 28.0 (18.4) vs. 
18.1 (15.5); P < 0.001]; and were signiﬁ cantly more likely to be using bio-DMARDs 
(59.6% vs. 38.2%; P < 0.001). The remaining BRASS population included patients 
who were seropositive only, patients with only joint erosions, and those who were 
seronegative and did not have joint erosions (Table 2).
Outcome data
In general, we observed consistently signiﬁ cant associations between anti-CCP and 
clinical disease activity and erosions, whether RF was or was not included in models 
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(Appendices Table A1 through A9). In a logistic model that included RF and anti-
CCP (Table A9), BRASS registrants who were positive (vs. negative) for anti-CCP were 
nearly 3 times more likely to have erosions (OR = 2.72; 95% CI: 1.77−4.18; P < 0.001). 
Individuals positive (vs. negative) for RF were 36% more likely to have erosions (95% 
CI: 0.88−2.08; P = 0.162).
In the logistic model that included both RF and anti-CCP, patients positive for anti-CCP 
were 39% less likely (OR = 0.61; 95% CI: 0.41−0.90; P = 0.012) to have DAS28-CRP 
< 2.6 than their anti-CCP- counterparts, whereas RF+ (vs. RF-) patients were 2% less 
likely (OR = 0.98; 95% CI: 0.66–1.44; P = 0.899; Table A7). With respect to the SDAI, 
anti-CCP+ (vs. anti-CCP-) registrants were signiﬁ cantly less likely to have SDAI ≤ 3.3, 
whereas RF+ (vs. RF-) individuals were not (Appendix Table A8).
Among those with both anti-CCP and RF data (N = 1274), 53.9% were anti-CCP+/RF+, 
7.6% were anti-CCP+/RF-, 7.8% were anti- CCP-/RF+ and 30.6% were anti-CCP-/RF-. 
The adjusted ORs for anti-CCP+/RF+, anti-CCP+/RF- and anti-CCP-/RF+ compared 
to anti-CCP-/RF- were 0.59 (95% CI: 0.42−0.83), 0.67 (0.38−1.19), 1.07 (0.63−1.82) 
for DAS28-CRP < 2.6, and 0.53 (0.32−0.87), 0.28 (0.10−0.75) and 1.23 (0.59−2.57) for 
SDAI ≤ 3.3, respectively.
Table 2. BRASS registrant characteristics according to baseline status of anti-cyclic citrullinated protein anti-
bodies (anti-CCP) and erosions, on univariate analyses
Characteristic Anti-CCP+ / Erosion+
(N=498)
All other RA patients
(N=727)
P
Mean (SD) age, yr 59.0 (12.9) 54.8 (14.5) <0.001
No. (%) female 420 (84.3) 593 (81.6) 0.208
Mean (SD) BMI, kg/m² 26.7 (5.7) 27.0 (5.7) 0.345
No. (%) receiving bio−DMARDs 297 (59.6) 278 (38.2) <0.001
Mean (SD) DAS28−CRP 4.3 (1.6) 3.4 (1.5) <0.001
Mean (SD) CDAI 26.9 (17.7) 17.3 (15.0) <0.001
Mean (SD), SDAI 28.0 (18.4) 18.1 (15.5) <0.001
Mean (SD) TJC 19.2 (15.3) 11.1 (12.3) <0.001
Anti-CCP, anti-cyclic citrullinated protein antibody; bio-DMARD, biologic disease-modifying antirheumatic 
drug; BMI, body mass index; CDAI, Clinical Disease Activity Index; DAS28-CRP, Disease Activity Score in 28 
joints C-reactive protein; MHAQ, Modiﬁ ed Health Assessment Questionnaire; SDAI, Simpliﬁ ed Disease Activ-
ity Index; TJC, total swollen and painful joint count.
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Associations of baseline anti-CCP and erosion status with disease activity
We evaluated the eﬀ ect of having the prognostic factors in combination (i.e., both 
anti-CCP positivity and joint erosions) compared to having these individually (i.e., 
anti-CCP positivity only or joint erosions only). From this comparison, we observed 
that patients with multiple prognostic factors had an even lower odds of experiencing 
DAS28-CRP < 2.6, even after treatment with standard-of-care bio-DMARDs (Fig. 1A). 
As compared to those without anti-CCP and without erosions (anti-CCP-/Erosion-), the 
OR for DAS28-CRP < 2.6 was 0.25 (95% CI: 0.16−0.38; P < 0.001) for those with both 
anti-CCP+ and erosions (anti-CCP+/Erosion+), 0.61 (95% CI: 0.41−0.92; P = 0.018) 
for those with anti-CCP+ only (anti-CCP+/Erosion-), and 0.45 (95% CI: 0.27−0.75; P 
= 0.002) for those with erosions only (anti-CCP-/Erosion+). Patients who were both 
anti-CCP+/Erosion+ (not just anti-CCP+ or Erosion+) were also signiﬁ cantly less likely 
to experience low disease activity according to the SDAI (Fig. 1B). As compared to 
those without anti-CCP and without erosions (anti-CCP-/Erosion-), the OR for SDAI ≤ 
3.3 was 0.19 (95% CI: 0.10−0.37; P < 0.001) for those with both anti-CCP and erosions 
(or anti-CCP+ /Erosion+), 0.62 (95% CI: 0.33 −1.14; P = 0.122) for those with anti-CCP 
only (anti-CCP+/ Erosion-) and 0.49 (95% CI: 0.24−1.02; P = 0.057) for those with 
erosions only (anti-CCP-/Erosion+).
Figure 1. Anti-CCP+/erosion+ patients have high disease activity even after treated with standard-of-care bio-
logical disease-modifying antirheumatic drugs.
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Forest plots of odds ratios [ORs; with 95% conﬁ dence intervals (CIs)] for multivariate analyses of BRASS 
registrants who were positive for anti-cyclic citrullinated protein antibodies (anti-CCP) and erosions at base-
line compared to their counterparts without these baseline features. anti-CCP+ and erosion+ registrants were 
signiﬁ cantly less likely to have a Disease Activity Score in 28 joints C-reactive protein (DAS28-CRP) < 2.6 (up-
per panel) and Simple Disease Activity Index (SDAI) ≤ 3.3 (SDAI remission; lower panel). *Compared to the 
referent of anti-CCP−/Erosions−.
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As compared to those with RF-/Erosion-, the OR for DAS28-CRP < 2.6 was 0.28 (95% 
CI: 0.18–0.44; P < 0.001) for those with RF+/ Erosion+, 0.72 (95% CI: 0.48−1.08; P 
= 0.113) for those with RF+ / Erosion- and 0.42 (95% CI: 0.25−0.71; P = 0.001) for 
those with RF-/Erosion+. The corresponding OR for SDAI ≤ 3.3 was 0.30 (95% CI: 
0.15–0.59; P < 0.001) for those with RF+/Erosion+, 0.63 (95% CI: 0.36−1.10; P = 0.105) 
for those with RF+ /Erosion- and 0.35 (95% CI: 0.16−0.75; P = 0.007) for those with 
RF-/Erosion+.
Associations of baseline anti-CCP and erosion status with direct and indirect 
resource use
RA patients who were anti-CCP positive and had erosive disease at baseline had 
signiﬁ cantly higher frequencies of hospitalization and DME use (Fig. 2) compared to 
the rest of the BRASS cohort.
Figure 2. Health-care resource utilization among BRASS registrants who were positive for anti-cyclic citrul-
linated protein antibodies (anti-CCP) and erosions at baseline compared to their counterparts without these 
baseline features.
DISCUSSION
This was the ﬁ rst study to evaluate the clinical, direct medical resource use, and 
indirect costs of RA in patients with poor prognostic factors (seropositivity/erosions) 
in a longitudinal study of a large, real-world population of patients with established 
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RA. Clinically, seropositive patients with joint erosions were signiﬁ cantly less likely 
(than their counterparts without these prognostic factors) to have DAS28-CRP < 2.6 or 
SDAI ≤ 3.3. With regard to direct health care costs, the likelihoods of hospitalization 
and DME use were signiﬁ cantly higher in patients with adverse prognostic factors. 
With respect to indirect health care costs, greater proportions of patients without the 
adverse prognostic factors were employed and lower proportions were on short-term 
and long-term disabilities and in the lower income bracket.
These ﬁ ndings are unprecedented in demonstrating that a combination of anti-CCP 
seropositivity and erosions at baseline augurs a more adverse disease trajectory and 
may signal more marked needs for health-care resources even in patients who do not 
necessarily have recent-onset or early disease that falls within the long-established 
“clinical window.” A potential clinical implication of our results is that a combina-
tion of adverse prognostic risk factors may warrant more intensive therapy involving 
combinations of treatment modalities, including MTX, potentially high-dose-tapering 
corticosteroids, and DMARDs.
Potentially validating the premise that anti-CCP+ patients derive special beneﬁ t 
from more intensive therapy were ﬁ ndings reported by the randomized controlled 
CARDERA (Combination Anti-Rheumatic Drugs in Early RA) trial investigators. In a 
prospective, factorial-designed trial of 467 early-RA patients, antiCCP+ patients who 
received the most intensive, triple DMARD therapy, including MTX and prednisolone, 
experienced the smallest increases (i.e., least severe erosions) in mean Larsen scores 
over 2 years: 3.66 (95% CI: 2.27−5.05) compared to 9.58 (95% CI: 6.76−12.39) for MTX 
alone [23]. Regardless of treatment intensity, anti-CCP+ patients experienced modest 
radiologic progression in the CARDERA trial.
Also in the CARDERA trial, only anti-CCP+ patients had signiﬁ cant improvements in 
DAS-28 at 6 months when treated with binary or ternary regimens including predniso-
lone [23]. In fact, the CARDERA study found that MTX monotherapy actually resulted 
in worsening of radiologic damage in anti-CCP+ patients. In fact, only RA patients 
with elevations in this biomarker signiﬁ cantly beneﬁ ted from triple therapy, and the 
investigators reported improved health status and decreased disease activity only in 
anti-CCP+ patients receiving high-dose corticosteroids [23]. The CARDERA study data 
in turn extended conclusions of the Induction Therapy with Methotrexate and Pred-
nisone in Rheumatoid or Very Early Arthritic Disease (IMPROVED; http://www.isrctn. 
com/ISRCTN11916566) and Behandel Strategieën (BeST) studies. The IMPROVED trial 
demonstrated that reductions in disease activity were more marked, and the likelihood 
of disease remission signiﬁ cantly greater, in anti-CCP+ (vs. anti-CCP−) patients with RA 
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or undiﬀ erentiated inﬂ ammatory arthritis who received high-dose corticosteroids [24]. 
The BeST trial found that the likelihood of radiologic progression was increased nearly 
13-fold [odds ratio (OR) = 12.6; 95% CI: 3.0−51.9] in patients receiving monotherapy 
but much less so in those receiving both DMARDS and corticosteroids (OR =1.7; 95% 
CI: 0.5−5.4) [25,26]. Unlike our trial, however, neither of these studies—or any others 
to our knowledge—have established signiﬁ cant associations between a combination 
of anti-CCP seropositivity and the presence of erosions at baseline and both a reduced 
likelihood of low disease activity and an increase in health resource utilization (includ-
ing hospital admissions) among real-world patients with heterogeneous RA histories.
Elevations in the anti-CCP biomarker may even inform treatment decisions related to 
selecting bio-DMARDs. Studies have suggested that anti-CCP+ patients experience 
superior treatment outcomes in response to T-cell inhibition with abatacept or B-
cell inhibition with rituximab, whereas anti-CCP- patients may experience improved 
outcomes in response to tumor necrosis factor-α (TNF-α) inhibitors [27–30].
Paralleling our ﬁ ndings, a study of 276 adults with RA also found that combinations 
of risk factors presaged less favorable outcomes [31]. Signiﬁ cantly more marked 
decrements in functional status and more severe disease were observed in patients 
who were seropositive for both anti-CCP and RF. Although these patients received 
more intensive therapy with MTX and combination DMARDs, a smaller proportion of 
them experienced disease remission at 1 year compared to those who were anti-CCP-/
RF- (12% vs. 18%). Proportions of patients with hand erosions were 77% in the anti-
CCP+/RF+ group, 73% in the anti-CCP-/RF+ group, 83% in the anti-CCP+/RF- group 
but only 32% in the anti-CCP-/RF- group (P < 0.001 for trend) [31].
In general, prognostic factors are important because they assist in categorizing poten-
tial outcomes and stratifying treatment of patients, which in turn enables better clini-
cal management by providing appropriate resources for patients who need them most 
or who are more likely to beneﬁ t. Much research has been devoted to understanding 
poor prognostic factors in an early-RA setting, with the motivation that early control 
of systemic rheumatoid inﬂ ammation can delay or even prevent irreversible clinical 
complications of bone and joint damage. However, there is limited information on 
the importance of prognostic factors in established RA and more importantly, there is 
no study that evaluated the impact of combined prognostic factors on disease activity. 
Established RA is not a homogeneous disease, given that our registry study showed 
that, even among established-RA patients, adverse prognostic factors have important 
ramiﬁ cations. The ﬁ ndings also point to a major potentially unmet treatment need in 
RA. Although seropositive patients with erosive joints were signiﬁ cantly more likely 
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(vs. the rest of the cohort) to be taking standard-of-care bio-DMARDs [e.g., TNF-α 
inhibitors], they were still signiﬁ cantly less likely to have DAS28-CRP < 2.6 compared 
to their counterparts without these adverse prognostic factors.
The published RA literature refers to serologic, genetic, clinical, radiologic, and im-
munologic prognostic factors. Our analysis focused on immunologic, serologic, and 
radiologic factors and evaluated associations between the combination of these fac-
tors and clinical outcomes. Overall, our ﬁ ndings are in line with those in the recent RA 
literature [32–36]. Echoing our results, a systematic review by Jilani and Mackworth-
Young determined that anti-CCP positivity was a strong predictor of erosive disease, 
and anti-CCP+ patients were 4 times more likely to have erosive disease compared 
to anti-CCP- patients. In addition to anti-CCP, baseline erosions conferred additive 
prognostic information over that of elevated anti-CCP alone in predicting joint ero-
sions [34]. Previous investigators in the BRASS Registry reported that the presence 
of the HLA-DRB1 shared epitope was associated with a nearly 2-fold increased risk 
of anti-CCP (OR = 1.8; 95% CI: 1.24−2.66) and was also signiﬁ cantly related to an 
erosive phenotype. However, the latter association was abrogated after conditioning 
the results on anti-CCP levels. Taken together, these ﬁ ndings pointed toward a “causal 
pathway” for anti-CCP in predicting erosions [34,37].
Also compatible with our ﬁ ndings were results from a study revealing that anti-CCP 
had a higher predictive value for erosions than RF, as well as CRP and ESR [38]. In our 
study, decreases (vs. increases) in anti-CCP, but not RF, over time were associated 
with signiﬁ cantly lower odds of both hospitalization and DME use. There is some 
controversy concerning the relative clinical or prognostic value of anti-CCP and RF. 
Several studies have challenged the predictive value of RF, whereas the presence of 
anti-CCP autoantibodies has been associated nearly uniformly with erosive RA and, 
according to certain investigators, “have established themselves as the single most 
reliable prognostic factor in clinical practice” [39]. On the other hand, a recent study 
by Aletaha’s group reported that RF+ patients had the most active RA, irrespective 
of anti-CCP levels [40]. However, this analysis was based on clinical trial data with a 
complex analysis involving propensity scores to match patients based on anti-CCP 
and RF while controlling for anti-CCP levels, age, and duration of disease. A major 
limitation is that this analysis excluded approximately 64% of the patients; of those 
included, 82% were both anti-CCP and RF positive.
Our data suggest that anti-CCP seropositivity, either alone or in combination with 
other prognostic factors, most likely drove the observed ﬁ ndings on disease activity. 
Although we found that double seropositivity (anti-CCP+/RF+) compared to double 
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sero-negativity (anti-CCP-/RF-) was associated with the lowest odds of attaining RA 
remission, the inconsistent results regarding RF+ in relation to SDAI when consider-
ing anti-CCP in the analysis may be due to insuﬃ  cient sample size and/or to the 
fact that SDAI may be a more stringent measure of disease activity and remission 
compared to DAS (especially DAS < 2.6 for remission, in which there may be residual 
disease). Published ﬁ ndings suggest that anti-CCP and RF seropositivity are related: 
patients who are anti-CCP seropositive are more likely to be RF seropositive as well 
[41], making it further diﬃ  cult to parse out the biologic eﬀ ect of anti-CCP+ and RF+.
Taken together with published data, our ﬁ ndings suggest that it is important to assess 
prognostic factors in patients with RA (even in more established, rather than only in 
early disease). Evaluating patients for anti-CCP seropositivity and joint erosions may 
assist in targeting therapy to minimize clinical, health-economic, and socioeconomic 
consequences of RA. Recent evidence suggests that treatment outcomes may vary 
depending on the presence of these prognostic factors [29].
The prospective, longitudinal, observational nature of the BRASS Registry is central to 
both its strengths and limitations. Such studies enable large cohorts of patients to be 
observed over longer durations as compared with randomized controlled trials (RCTs). 
To date, published data on the eﬀ ects of bio-DMARDs on anti-CCP derive largely from 
RCTs, especially in early-RA cohorts [42–44]. Whereas RCTs are typically conducted in 
highly selected patient populations, including individuals with minimal comorbidities 
and high treatment adherence, observational studies such as the BRASS Registry may 
be more generalizable to naturalistic care settings involving more heterogeneous 
patient populations with established RA. Observational studies are also more likely 
to include dynamic treatment strategies compared to the more rigid, protocol-based 
treatment strategies of RCTs.
The BRASS Registry treatment center also has a high (80−90%) patient retention rate, 
supporting the stability of longitudinal data (i.e., minimizing patient attrition eﬀ ects) 
and the reliability of temporal trends. Finally, the study was conducted at a single site 
(BWH), limiting methodological heterogeneity compared to a multicenter study with 
potential diﬀ erences in study procedures and personnel training.
However, observational analyses are of an inherently associational nature and cannot 
conclusively assign causality or rule out certain biases, even though our statistical 
models controlled for many relevant baseline covariates. Confounding by unmea-
sured variables (e.g., treatment adherence and socioeconomic status) also cannot 
be excluded. Our study documented associations between anti-CCP seropositivity 
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and baseline erosions and both hospitalization and DME use expressed as categori-
cal (binary), rather than continuous, variables. DME use and hospitalization were 
self-reported, opening the possibility of recall bias. Given the observational, largely 
descriptive and associational nature of our work, which did not test speciﬁ c hypoth-
eses, we did not seek to rigorously determine patient sample size. No attempt was 
undertaken to limit biases using propensity score matching, nonrandom missing 
data using mixed models, or intracorrelated patient data over time using generalized 
estimating equations or generalized linear models.
Unlike certain other investigators, we did not evaluate antibodies to individual citrul-
linated proteins (e.g., ﬁ brin, ﬁ laggrin, and vimentin) or other potentially suitable 
serological markers, such as cartilage oligometric matrix protein (CIOMP) and matrix 
metal-loproteinase [13,45]. Evaluating associations between anti-CCP and extra-artic-
ular manifestations and other RA signs (e.g., nodules) and symptoms also exceeded 
the purview of our study [46]. Other, potential statistical limitations include the fact 
that our analysis did not control for multiple comparisons or intracorrelation of each 
registrant’s data over time, and that numbers of study participants with available anti-
CCP data at later years were relatively small. Finally, given the advanced, tertiary-care 
setting of the BRASS Registry, socioeconomic status (including household income), 
resources to aﬀ ord care, and health literacy may skew the data toward more (rather 
than less) favorable outcomes compared to other patient populations. It is possible 
that a family (household) income of less than $50,000/year is not the most sensitive 
and speciﬁ c index or marker of disability and may indicate an inability to ﬁ nd employ-
ment rather than an inability to work. It is not entirely clear if personal, rather than 
family or household; income might represent a more appropriate metric. On the other 
hand, we ﬁ nd it reassuring that signiﬁ cant diﬀ erences in employment, retirement, and 
disability (and long-term-disability) status and anti-CCP/ erosion positivity were in 
the same overall direction as a family income of less than $50,000: 38.7% of BRASS 
registrants with anti-CCP/erosion positivity were employed (P < 0.05 vs. 53.5% for 
the rest of the RA subjects), 32.5% were retired (P < 0.05 vs. 22.1%), and 14.1% were 
disabled (P < 0.05 vs. 7.4%; Fig. 3).
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Figure 3. Worker productivity among BRASS registrants who were positive for anti-cyclic citrullinated protein 
antibodies (anti-CCP) and erosions compared to their counterparts without these baseline features.
CONCLUSIONS
In this prospective observational study of a diverse patient population (i.e., adults 
with both established and early RA), baseline anti-CCP levels (especially when com-
bined with baseline erosions) were associated with threefold adverse outcomes: 
clinical, health-economic, and socioeconomic. Clinically, higher anti-CCP levels were 
associated with greater disease activity and lower odds of having DAS28-CRP o 2.6, 
even after therapy with standard-of-care bio-DMARDs (e.g., TNF-α inhibitors). The 
unique value of this study was in identifying that patients with a combination of both 
anti-CCP seropositivity and erosions experienced signiﬁ cantly more adverse clinical 
(e.g., likelihood of low disease activity), health-economic (e.g., hospitalization and 
durable-medical-equipment use) and socioeconomic (i.e., reduced worker productiv-
ity) outcomes in a naturalistic, longitudinal setting that is likely highly generalizable 
to ambulatory-care practices. Further research is needed to determine the actual cost 
consequences of these ﬁ ndings, from the perspectives of diﬀ erent stakeholders (e.g., 
patients, providers, payers, and society). These ﬁ ndings point to a potentially unmet 
treatment need and the importance of assessing prognostic factors, even in patients 
who have had RA for several years.
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APPENDICES: ASSOCIATIONS INVOLVING POTENTIAL PROGNOSTIC FACTORS 
IN DIFFERENT LOGISTIC REGRESSION ANALYSES
Table A1. Odds Ratios for DAS28-CRP < 2.6 - anti-CCP with Covariates
Variables Odds Ratio 95% CI P
Anti-CCP+ (vs. Anti-CCP−) 0.61 0.45−0.83 0.001
Age per 5-yr increase 0.98 0.93−1.04 0.577
Female (vs. male) 0.99 0.68−1.45 0.977
White (vs. other races) 0.78 0.44−1.38 0.392
BMI per 5-kg/m² increase 0.83 0.72−0.95 0.008
RA duration per 5-yr increase 0.90 0.84−0.97 0.005
No. of comorbidities 0.87 0.77−0.99 0.040
Any bio−DMARD (vs. no bio−DMARD) 1.90 1.41−2.57 <0.001
MHAQ 0.16 0.10-0.25 <0.001
Anti-CCP, anti-cyclic citrullinated protein antibodies; BMI, body mass index; DAS28-CRP, Disease Activity 
Score in 28 joints C-reactive protein; DMARD, disease-modifying antirheumatic drug; MHAQ, Modiﬁ ed Health 
Assessment Questionnaire; RA, rheumatoid arthritis.
Table A2. Odds Ratios for SDAI≤3.3 - anti-CCP with Covariates
Variables Odds Ratio 95% CI P
Anti-CCP+ (vs. Anti-CCP−) 0.46 0.30−0.73 <0.001
Age per 5-yr increase 1.01 0.93−1.10 0.779
Female (vs. male) 0.98 0.56−1.72 0.949
White (vs. others) 0.57 0.23−1.39 0.218
BMI per 5-kg/m² increase 0.70 0.55−0.90 0.005
RA duration per 5-yr increase 0.78 0.69−0.89 <0.001
No. of comorbidities 0.73 0.56−0.96 0.022
Any bio−DMARD (vs. no bio−DMARD) 2.15 1.37−3.37 <0.001
MHAQ 0.00 0.00-0.02 <0.001
Anti-CCP, anti-cyclic citrullinated protein antibodies; BMI, body mass index; DMARD, disease-modifying anti-
rheumatic drug; MHAQ, Modiﬁ ed Health Assessment Questionnaire; RA, rheumatoid arthritis; SDAI, Simple 
Disease Activity Index.
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Table A3. Odds Ratios for Erosions - anti-CCP with Covariates
Variables Odds Ratio 95% CI P
Anti-CCP+ (vs. Anti-CCP−) 3.29 2.38−4.55 <0.001
Age per 5-yr increase 1.15 1.08−1.22 <0.001
Female (vs. male) 0.92 0.60−1.41 0.692
White (vs. others) 0.98 0.54−1.76 0.942
BMI per 5-kg/m² increase 0.82 0.71−0.94 0.006
RA duration per 5-yr increase 1.43 1.31−1.56 <0.001
No. of comorbidities 1.06 0.92−1.22 0.437
Any bio−DMARD (vs. no bio−DMARD) 2.14 1.54−2.99 <0.001
MHAQ 1.64 1.12-2.41 0.011
Anti-CCP, anti-cyclic citrullinated protein antibodies; BMI, body mass index; RA, rheumatoid arthritis; MHAQ, 
Modiﬁ ed Health Assessment Questionnaire; RA, rheumatoid arthritis.
Table A4. Odds Ratios for DAS28-CRP < 2.6 - RF with Covariates
Variables Odds Ratio 95% CI P
RF+ (vs. RF−) 0.72 0.53−0.96 0.027
Age per 5-yr increase 0.99 0.93−1.04 0.641
Female (vs. male) 1.04 0.72−1.52 0.820
White (vs. others) 0.86 0.48−1.53 0.599
BMI per 5-kg/m² increase 0.83 0.72−0.95 0.009
RA duration per 5-yr increase 0.90 0.83−0.96 0.003
No. of comorbidities 0.85 0.74−0.97 0.015
Any bio−DMARD (vs. no bio−DMARD) 1.88 1.40−2.54 <0.001
MHAQ 0.17 0.11−0.27 <0.001
Anti-CCP, anti-cyclic citrullinated protein antibodies; BMI, body mass index; DAS28-CRP, Disease Activity in 28 
joints C-reactive protein; MHAQ, Modiﬁ ed Health Assessment Questionnaire; RA, rheumatoid arthritis; RF, 
rheumatoid factor.
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Table A5. Odds Ratios for SDAI ≤3.3 - RF with Covariates
Variables Odds Ratio 95% CI P
RF+ (vs. RF−) 0.78 0.50−1.21 0.270
Age per 5-yr increase 1.01 0.93−1.09 0.878
Female (vs. male) 0.99 0.57−1.74 0.986
White (vs. others) 0.64 0.26−1.58 0.338
BMI per 5-kg/m² increase 0.70 0.55−0.90 0.004
RA duration per 5-yr increase 0.76 0.66−0.87 <0.001
No. of comorbidities 0.66 0.49−0.89 0.006
Any bio−DMARD (vs. no bio−DMARD) 1.88 1.20−2.92 0.006
MHAQ 0.01 0.00−0.02 <0.001
Covariates include age, BMI, and RA duration per 5 yr. BMI, body mass index; RA, rheumatoid arthritis; RF, 
rheumatoid factor; MHAQ, Modiﬁ ed Health Assessment Questionnaire; RA, rheumatoid arthritis; RF, rheu-
matoid factor; SDAI, Simple Disease Activity Index.
Table A6. Odds Ratios for Erosions - RF with Covariates
Variables Odds Ratio 95% CI P
RF+ (vs. RF−) 2.55 1.85−3.51 <0.001
Age per 5-yr increase 1.14 1.07−1.22 <0.001
Female (vs. male) 0.86 0.57−1.32 0.496
White (vs. others) 0.87 0.48−1.56 0.632
BMI per 5-kg/m² increase 0.80 0.69−0.92 0.002
RA duration per 5-yr increase 1.43 1.31−1.57 <0.001
No. of comorbidities 1.08 0.94−1.25 0.281
Any bio−DMARD (vs. no bio−DMARD) 2.23 1.61−3.10 <0.001
MHAQ 1.51 1.04-2.20 0.031
BMI, body mass index; DMARD, disease-modifying antirheumatic drugs; MHAQ, Modiﬁ ed Health Assess-
ment Questionnaire; RA, rheumatoid arthritis; RF, rheumatoid factor.
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Table A7. Odds Ratios for DAS28-CRP < 2.6 - anti-CCP and RF with Covariates
Variables Odds Ratio 95% CI P
RF+ (vs. RF−) 0.98 0.66−1.44 0.899
Anti-CCP+ (vs. Anti-CCP−) 0.61 0.41−0.90 0.012
Age per 5-yr increase 0.98 0.93−1.04 0.568
Female (vs. male) 0.99 0.68−1.45 0.972
White (vs. others) 0.78 0.44−1.40 0.408
BMI per 5-kg/m² increase 0.84 0.72−0.96 0.013
RA duration per 5-yr increase 0.90 0.84−0.97 0.007
No. of comorbidities 0.86 0.75−0.98 0.023
Any bio−DMARD (vs. no bio−DMARD) 1.96 1.44−2.66 <0.001
MHAQ 0.17 0.11-0.26 <.001
Covariates include age, BMI, and RA duration per 5 years. Anti-CCP, anti-cyclic citrullinated protein antibodies; 
BMI, body mass index; DAS28-CRP, Disease Activity in 28 joints C-reactive protein; MHAQ, Modiﬁ ed Health 
Assessment Questionnaire; RA, rheumatoid arthritis; RF, rheumatoid factor.
Table A8. Odds Ratios for SDAI ≤3.3 - anti-CCP and RF with Covariates
Variables Odds Ratio 95% CI P
RF+ (vs. RF−) 1.45 0.82−2.56 0.205
Anti-CCP+ (vs. Anti-CCP−) 0.37 0.21−0.66 <0.001
Age per 5-yr increase 1.01 0.93−1.10 0.814
Female (vs. male) 0.94 0.53−1.66 0.836
White (vs. others) 0.53 0.22−1.32 0.175
BMI per 5-kg/m² increase 0.71 0.56−0.92 0.009
RA duration per 5-yr increase 0.78 0.68−0.89 <0.001
No. of comorbidities 0.65 0.48−0.88 0.006
Any bio−DMARD (vs. no bio−DMARD) 2.20 1.39−3.49 <0.001
MHAQ 0.01 0.00−0.02 <0.001
Anti-CCP, anti-cyclic citrullinated protein antibodies; BMI, body mass index; DMARD, disease-modifying anti-
rheumatic drug; MHAQ, Modiﬁ ed Health Assessment Questionnaire; RA, rheumatoid arthritis; RF, rheuma-
toid factor; SDAI, Simple Disease Activity Index.
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Table A9. Odds Ratios for Erosions - anti-CCP and RF with Covariates
Variables Odds Ratio 95% CI P
RF+ (vs. RF−) 1.36 0.88−2.08 0.162
Anti-CCP+ (vs. Anti-CCP−) 2.72 1.77−4.18 <0.001
Age per 5-yr increase 1.15 1.08−1.23 <0.001
Female (vs. male) 0.92 0.59−1.42 0.696
White (vs. others) 0.97 0.53−1.75 0.908
BMI per 5-kg/m² increase 0.80 0.69−0.92 0.002
RA duration per 5-yr increase 1.42 1.30−1.55 <0.001
No. of comorbidities 1.07 0.93−1.24 0.341
Any bio−DMARD (vs. no bio−DMARD) 2.14 1.53−2.99 <0.001
MHAQ 1.61 1.10−2.37 0.015
Anti-CCP, anti-cyclic citrullinated protein antibodies; BMI, body mass index; DMARD, disease-modifying anti-
rheumatic drug; MHAQ, Modiﬁ ed Health Assessment Questionnaire; RA, rheumatoid arthritis; RF, rheuma-
toid factor; SDAI, Simple Disease Activity Index.
Table A10. Summary of Tables A1−A9 for anti-CCP and RF: Odds Ratios for DAS28-CRP < 2.6, SDAI ≤ 3.3, 
and Erosions
Anti-CCP+ vs. Anti-CCP− RF+ vs. RF−
Separate models for Anti-CCP and RF
DAS28-CRP < 2.6* 0.61 (0.45−0.83) 0.72 (0.53−0.96)
SDAI ≤ 3.3* 0.46 (0.30−0.73) 0.78 (0.50−1.21)
Erosion 3.29 (2.38−4.55) 2.55 (1.85−3.51)
Anti-CCP and RF in one model
DAS28-CRP < 2.6 0.61 (0.41−0.90) 0.98 (0.66−1.44)
SDAI ≤ 3.3 0.37 (0.21−0.66) 1.45 (0.82−2.56)
Erosion 2.72 (1.77−4.18) 1.36 (0.88−2.08)
DAS28-CRP, Disease Activity Score in 28 joints C-reactive protein; SDAI, Simple Disease Activity Index.
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ABSTRACT
Objectives. To characterize patients with rheumatoid arthritis (RA) by number of 
poor prognostic factors (PPFs: functional limitation, extra-articular disease, sero-
positivity, erosions) and evaluate treatment acceleration, clinical outcomes, and work 
status over 12 months by number of PPFs. Methods. Using the Corrona RA registry 
(01/2005–12/2015), biologic-naive patients with diagnosed RA having 12-month (± 
3 months) follow-up were identiﬁ ed and categorized by PPFs (0–1, 2, ≥3). Changes 
in medication, Clinical Disease Activity Index (CDAI), and work status (baseline–12 
months) were evaluated using linear and logistic regression models. Results. 3458 
patients met the selection criteria; 1489 (43.1%), 1214 (35.1%), and 755 (21.8%) had 
0–1, 2, or ≥3 PPFs, respectively. At baseline, patients with ≥3 PPFs were older, and had 
longer RA duration and higher CDAI versus those with 0–1 PPFs. In 0–1, 2, and ≥3 
PPF groups, respectively, 20.9%, 23.2%, and 26.5% of patients received ≥1 biologic 
(p = 0.011). Biologic/targeted synthetic disease-modifying anti-rheumatic drug (tsD-
MARD) use was similar in patients with/without PPFs (p = 0.57). After adjusting for 
baseline CDAI, mean (standard error) change in CDAI was −4.95 (0.24), −4.53 (0.27), 
and −2.52 (0.34) for 0–1, 2, and ≥3 PPF groups, respectively. More patients were work-
ing at baseline but not at 12-month follow-up in 2 (13.9%) and ≥3 (12.5%) versus 
0–1 (7.3%) PPF group. Conclusions. Despite high disease activity and worse clinical 
outcomes, number of PPFs did not signiﬁ cantly predict biologic/tsDMARD use. This 
may warrant reconsideration of the importance of PPFs in treat-to-target approaches.
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INTRODUCTION
The rate of disease progression in patients with rheumatoid arthritis (RA) is depen-
dent on several factors and varies between patients [1.2].Factors associated with a 
poor prognosis in patients with RA, which predict a more rapid and aggressive disease 
course, include, but are not limited to, functional limitation (evaluated by the Health 
Assessment Questionnaire [HAQ] - Disability Index or similar validated tools), extra-
articular disease (Sjögren’s syndrome, RA lung disease, and/or nodules), seropositiv-
ity (rheumatoid factor or anti-cyclic citrullinated peptide antibodies), or the presence 
of radiographic bone erosions [3].
The presence of multiple poor prognostic factors in patients with recent-onset RA 
has been associated with increased risk of disease progression in both clinical trials 
and observational studies [4,5]. The European League Against Rheumatism guidelines 
(2010 and 2013) recommend more aggressive management for patients with RA who 
have poor prognostic factors [2.6]. This was also true for the American College of 
Rheumatology (ACR) 2008 guidelines and the 2012 update, in which management 
was determined by disease duration, disease activity, current medication regimen, 
and presence of poor prognostic factors [3,7]. However, current (2015) ACR guide-
lines [1] focus on patient disease activity and a treat-to-target method for all patients 
regardless of prognosis.
Limited real-world data, based on studies with small patient numbers, exist on the 
impact of poor prognostic factors on treatment decisions and outcomes in patients 
with newly diagnosed RA [8,9]. Furthermore, to our knowledge there are no studies 
evaluating the proportion of patients with poor prognostic factors in patients with 
longer-standing RA.
This analysis had 2 objectives: to characterize a cohort of patients with RA in a typi-
cal practice setting based on the number of poor prognostic factors (deﬁ ned by the 
presence of functional limitation, extra-articular disease, seropositivity, and erosive 
changes) and to evaluate treatment acceleration, clinical outcomes, and work status 
by number of poor prognostic factors over 12 months in this cohort.
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MATERIALS AND METHODS
Patient population
The Corrona RA registry is an ongoing, independent, prospective, national, obser-
vational cohort. Patients are recruited from 169 private and academic practice sites 
across 40 states in the US, with 656 participating rheumatologists. As of June 30, 
2016, the Corrona database included information on approximately 43,009 patients 
with RA. Data on 326,613 patient visits and approximately 145,527 patient-years of 
followup observation time have been collected. The average length of patient followup 
is 4.13 years (median 3.33 years).
The registry was set up in accordance with the Declaration of Helsinki. All partici-
pating investigators were required to obtain full board approval for conducting non-
interventional research involving human subjects with a limited dataset. Sponsor 
approval and continuing review was obtained through a central Institutional Review 
Board (IRB; New England Independent Review Board, NEIRB No. 120160610). For 
academic investigative sites that did not receive a waiver to use the central IRB, full 
board approval was obtained from the respective governing IRBs and documentation 
of approval was submitted to Corrona, LLC prior to initiating any study procedures. All 
registry patients were required to provide written informed consent and authorization 
prior to participating.
Study population
This analysis included patients diagnosed with RA (excluding early undiﬀ erentiated 
arthritis) by their rheumatologist who were 18 years of age or older, and naive to 
therapy with biologics and/or targeted synthetic disease-modifying antirheumatic 
drugs (tsDMARDs; tofacitinib was the only approved tsDMARD at the time of this 
analysis) at the time of enrollment in the Corrona RA registry between January 1, 
2005 and December 1, 2015. Eligible patients had a follow-up visit at 12 months (± 3 
months) and Clinical Disease Activity Index (CDAI) measured at baseline (i.e., enroll-
ment) and at the 12-month follow-up. Work status was also assessed at both baseline 
and the 12-month follow-up. The index date was the date of enrollment.
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Measures and data collection
Patients were characterized at baseline in terms of RA prognosis based on the 2008 
ACR treatment recommendations [7], including functional limitation (based on modi-
ﬁ ed HAQ disability index > 0.5) [10,11], extra-articular disease (Sjögren’s syndrome, 
RA lung disease, and/or nodules), seropositivity (rheumatoid factor and/or anti-cyclic 
citrullinated peptide antibodies), and erosions (as per radiograph at enrollment). If 
patients met none of the 4 criteria, they would be classiﬁ ed as having 0 poor prog-
nostic factors; similarly, if they had met 1, 2, 3, or 4 criteria they would be classiﬁ ed as 
having 1, 2, 3, or 4 poor prognostic factors. Due to sample size limitations, patients 
were then categorized into groups having 0–1, 2, or ≥3 poor prognostic factors; each 
of the 4 categories contributed 1 point. Patients with missing information for any 
factor were excluded from the analysis.
Study outcomes
Baseline characteristics were evaluated and stratiﬁ ed by poor prognostic factors. To 
ensure an adequate sample size for statistical analysis, treatment changes over a 
duration of 12 months (± 3 months) were investigated. The primary outcome was the 
process measure of initiating a biologic or tsDMARD by poor prognostic factor group, 
as well as the process measure of any treatment acceleration (addition of, or switch-
ing to, a conventional synthetic [cs]DMARD, and/or initiation of a diﬀ erent biologic 
or tsDMARD) of medication used at enrollment. Use of biologic/tsDMARD treatment 
was assessed from baseline to the 12-month follow-up visit (± 3 months). Speciﬁ cally, 
patients were grouped into “no biologic use” or “use of 1 or more biologic” over 
the 12-month period (0 or ≥1 categories). Secondary outcomes included change in 
disease activity at 12 months, assessed by the change from baseline in CDAI in all 
patients, and achievement of low disease activity (LDA)/remission (CDAI ≤ 10) in 
patients with moderate or high disease activity at baseline. Other secondary outcomes 
included a dichotomous variable for work status, constructed with “yes” deﬁ ned as 
paid full-time or part-time working, and “no” including those patients who were not 
working or who worked at home or were students, disabled, or retired. Changes in 
work status from baseline to the 12-month follow-up were evaluated.
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Statistical analysis
Baseline diﬀ erences between poor prognostic factor groups in treatment acceleration, 
disease activity, and work status were evaluated via chi-square tests for categorical 
variables and Wilcoxon rank sum tests for continuous variables due to the skewed 
nature of the data. Logistic regression models (unadjusted and adjusted for age, sex, 
duration of RA, and baseline CDAI) evaluated the association of poor prognostic 
factors with receipt of biologics/tsDMARDs as well as any treatment acceleration. 
Linear regression models (unadjusted and adjusted for baseline CDAI) evaluated the 
impact of poor prognostic factors on change in CDAI. Logistic regression models 
(unadjusted and adjusted for baseline CDAI) evaluated the impact of poor prognostic 
factor category on LDA/remission in patients with moderate or high disease activity 
at baseline.
The relationship between poor prognostic factor groups and work status was inves-
tigated at baseline and the 12-month followup using chi-square tests. A frequency-
matching approach (coarsened exact matching) was used to match patients across 
poor prognostic factor categories according to age group (18–44, 45–54, 55–64, 
65–74, ≥75 years), as the relationship between poor prognostic factor category and 
work status could be driven by age diﬀ erence (retirees are generally older). The sample 
size for each age category was the size of the smallest poor prognostic factor category. 
To assess whether the relationship between work status at baseline and follow-up dif-
fered according to number of poor prognostic factors, the Cochran–Mantel–Haenszel 
test was performed for all patients.
RESULTS
Patient disposition and baseline characteristics
Of the 18,408 patients aged 18 years or older who were enrolled in the Corrona RA 
registry from January 1, 2005 through December 1, 2015 and had disease duration 
information at enrollment and a 12-month follow-up visit, 3458 met the selection 
criteria (Figure 1). Of these, 1489 (43.1%), 1214 (35.1%), and 755 (21.8%) were cat-
egorized into prognosis groups of 0–1, 2, or ≥3 poor prognostic factors, respectively.
Baseline demographic data and clinical characteristics indicated that patients with 
a greater number of poor prognostic factors were older, had a longer duration of 
RA, and had higher CDAI compared with those with fewer poor prognostic factors 
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(Table 1). Of note, an additional 4930 patients had incomplete information on poor 
prognostic factors at enrollment (3588 patients had no seropositive status informa-
tion and 1342 patients had incomplete other poor prognostic factors at enrollment). 
These 4930 patients were demographically similar to the group of 3458 patients with 
poor prognostic factors; 74% of the 3458 with poor prognostic factors were female 
compared with 75% of those without prognostic information. Mean age (standard 
deviation [SD]; 59.0 [13.2] versus 60.1 [13.5] years) and baseline disease activity as 
measured by the CDAI (9.0 [16.9] versus 8.6 [14.8]) were also similar between these 
two groups. Median (interquartile range) disease duration was slightly shorter in the 
group with poor prognostic factors: 2 (7) versus 3 (9) years.
Figure 1. Criteria for study inclusion.
Of note, 4930 patients had incomplete information on poor prognostic factors (PPF) at enrollment. Of these, 
3588 patients had no seropositive status information and 1342 patients had incomplete other poor prognostic 
factors at enrollment. Among the 1342 patients with incomplete PPFs, the majority (1315 of the 1342 patients) 
had erosive disease information missing, 22 were missing functional limitation and 5 were missing functional 
limitation and erosive disease. CDAI: Clinical Disease Activity Index; RA: rheumatoid arthritis.
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Table 1. Baseline demographic data and clinical characteristics.
0–1 Poor Prog-
nostic Factors
(n = 1489)
2 Poor Prog-
nostic Factors
(n = 1214)
≥3 Poor Prog-
nostic Factors
(n = 755)
p
Demographic data
 Age, yrs, median (IQR) 58 (19) 60 (18) 63 (18) < 0.001
 Sex, female, n (%) 1070 (71.9) 887 (73.1) 600 (79.5) < 0.001
 Race, white, n (%) 1290 (86.8)* 1008 (83.3)† 608 (80.6)‡ 0.001
 Work status, n (%) < 0.001
 Full-time 706 (47.4) 501 (41.3) 225 (29.8)
 Part-time 126 (8.5) 87 (7.2) 54 (7.2)
 Other
  Working at home 145 (9.7) 117 (9.6) 82 (10.9)
  Student 16 (1.1) 7 (0.6) 1 (0.1)
  Disabled 51 (3.4) 96 (7.9) 111 (14.7)
  Retired 445 (29.9) 406 (33.4) 282 (37.4)
Medical comorbidities and lifestyle
 Smoking status, n (%) < 0.001
  Never 867 (58.6)§ 652 (54.0)‖ 377 (50.0)‡
  Former 421 (28.4)§ 360 (29.8)‖ 230 (30.5)‡
  Current 192 (13.0)§ 196 (16.2)‖ 147 (19.5)‡
 History of CV disease, n (%) 69 (4.6) 65 (5.4) 61 (8.1) 0.003
  History of cancer (excluding NMSC), 
n (%)
109 (7.3) 108 (8.9) 84 (11.1) 0.010
 History of serious infections¶¶), n (%) 44 (3.8%)¶ 46 (5.2%)** 26 (5.2%)†† 0.21
 Poor prognostic factors, n (%)
  Functional limitation 56 (3.8) 331 (27.3) 434 (57.5) < 0.001
  Extra-articular disease 109 (7.3) 570 (47.0) 655 (86.8) < 0.001
  Seropositivity 1003 (67.4) 1108 (91.3) 736 (97.5) < 0.001
  Erosions 63 (4.2) 419 (34.5) 554 (73.4) < 0.001
 Duration of RA, yrs, median (IQR) 1 (4) 2 (7) 4 (11) < 0.001
RA medications, n (%)
 Current MTX use 1059 (71.1) 916 (75.5) 583 (77.2) 0.003
 Current prednisone use 392 (26.3) 359 (29.6) 240 (31.8) 0.018
 Prior number of csDMARDs 0.001
  0 1263 (84.8) 1027 (84.6) 595 (78.8)
  1 180 (12.1) 156 (12.9) 122 (16.2)
  ≥2 46 (3.1) 31 (2.6) 38 (5.0)
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Change in treatment acceleration from baseline to 12-month follow-up by number of 
poor prognostic factors
The proportion of patients with biologic treatment during the 12-month follow=up 
period was lowest in the group with 0–1 poor prognostic factors and highest in the 
group with 3+ poor prognostic factors. In the 0–1, 2, and ≥3 poor prognostic factor 
groups, respectively, 20.9%, 23.2%, and 26.5% of patients received 1 or more biologic 
(p = 0.011). In the 0–1, 2, and ≥3 poor prognostic factor groups, respectively, 38.5%, 
40.6%, and 41.7% of patients initiated treatment with any DMARD (p = 0.30).
Adjusted analyses controlling for age, sex, duration of RA, and CDAI showed that 
there was no statistically signiﬁ cant relationship between poor prognostic factor 
category and the ability to predict biologic/tsDMARD use at the 12-month follow-up 
(≥3 poor prognostic factors vs 0–1 poor prognostic factors: odds ratio [OR] 1.08; 95% 
conﬁ dence interval [CI] 0.85–1.37; p = 0.57; Figure 2A). The proportion of patients 
with any treatment acceleration from baseline to the 12-month follow-up was similar 
between poor prognostic factor groups, with no signiﬁ cant relationship between 
poor prognostic factor category and treatment acceleration in both unadjusted and 
adjusted models (Figure 2B).
Table 1. (continued)
0–1 Poor Prog-
nostic Factors
(n = 1489)
2 Poor Prog-
nostic Factors
(n = 1214)
≥3 Poor Prog-
nostic Factors
(n = 755)
p
RA disease activity, median (IQR)
 mHAQ 0 (0.25) 0.14 (0.63) 0.63 (0.88) < 0.001
 CDAI 7 (13.0) 9.6 (17.5) 14 (20.5) < 0.001
 Patient pain (0–100) 20 (35)‡‡ 26 (43)§§ 40 (55)‖‖ < 0.001
Chi-square tests for categorical variables and Wilcoxon rank sum tests for continuous variables were per-
formed; p values were based on omnibus tests of any difference among the 3 groups. * n = 1486; † n = 1210; 
‡ n = 754; § n = 1480; ‖ n = 1208; ¶ n = 1159; ** n = 877; †† n = 502; ‡‡ n = 1484; §§ n = 1209; ‖‖ n = 750. ¶¶ Data 
on the history of serious infections were limited (collected only from June 2008). CDAI: Clinical Disease Activ-
ity Index; csDMARD: conventional synthetic disease-modifying antirheumatic drug; CV: cardiovascular; IQR: 
interquartile range; mHAQ: modiﬁ ed Health Assessment Questionnaire; MTX: methotrexate; NMSC: non-
melanoma skin cancer; RA: rheumatoid arthritis.
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Change in disease activity from baseline to 12-month follow-up by number of poor 
prognostic factors
After adjusting for CDAI at baseline, the mean (standard error) change in CDAI from 
Figure 2. Logistic regression analysis of (A) biologic/tsDMARD initiation during the 12-month followup ac-
cording to poor prognostic factor category and (B) any treatment acceleration from baseline to 12-month fol-
lowup according to poor prognostic factor category (0–1, n = 1489; 2, n = 1214; ≥3, n = 755).
*p value was calculated based on an overall likelihood ratio test of the impact of poor prognosis on biologic 
use by 12-month followup. †Adjusted for age, sex, duration of RA, and CDAI. ‡Addition of, or switching to, a 
conventional synthetic DMARD, and/or initiation of a biologic or tsDMARD . CDAI: Clinical Disease Activity 
Index; CI: conﬁ dence interval; OR: odds ratio; RA: rheumatoid arthritis; tsDMARD: targeted synthetic disease-
modifying antirheumatic drug.
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baseline to the 12-month follow-up was −4.95 (0.24), −4.53 (0.27), and −2.52 (0.34) 
for the 0–1, 2, and ≥3 poor prognostic factor groups, respectively (p < 0.001). Patients 
with moderate and/or severe disease activity at baseline (n = 1611) with ≥3 poor 
prognostic factors were approximately half as likely to reach LDA/remission at the 
12-month follow-up as patients with 0–1 poor prognostic factors (OR 0.46; 95% CI 
0.36–0.60; p < 0.001; Figure 3). After adjusting for CDAI at baseline, results remained 
similar (OR 0.51; 95% CI 0.39–0.66; p < 0.001) as the LDA/remission assessment 
included only patients with moderate and/or severe disease activity.
Change in work status from baseline to 12-month follow-up by number of poor 
prognostic factors
At baseline, 46.6%, 43.7%, and 37.0% of patients with 0–1, 2, and ≥3 poor prognostic 
factors, respectively, reported working full- or part-time. At the 12-month follow-up, 
these ﬁ gures were 44.8%, 40.8%, and 35.6%, respectively. After adjusting for age at 
baseline, a lower proportion of patients in the worst prognosis category were working 
full- or part-time compared with those in the best prognosis category (p < 0.001 at 
baseline and p = 0.001 at follow-up; Table 2).
Figure 3. Logistic regression analysis of achievement of LDA/remission during the 12-month followup by 
number of poor prognostic factors.*
* Among patients who had moderate and/or severe disease activity at baseline (0–1 poor prognostic factors, n 
= 547; 2 poor prognostic factors, n = 594; ≥3 poor prognostic factors, n = 470). † p value was calculated based 
on an overall likelihood ratio test of the impact of poor prognosis on achievement of LDA/remission during the 
12-month followup. ‡Adjusted for CDAI at baseline. CDAI: clinical disease activity index; CI: conﬁ dence interval; 
LDA: low disease activity; OR: odds ratio.
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Figure 4. Work status (full-time/part-time versus all other categories) at baseline and 12-month followup by 
poor prognosis category (N = 3458).
Table 2. Work status (full-time/part-time versus all other categories) at baseline and 12-month follow-up by 
poor prognosis category after adjusting for age.
Poor Prognostic Factors (N = 2265)
0–1
n = 755
2
n = 755
≥3
n = 755
p*
Work status at baseline
Full-time/part-time, n (%) 352 (46.6) 330 (43.7) 279 (37.0)
< 0.001All others, n (%)† 403 (53.4) 425 (56.3) 476 (63.0)
Work status at 12-month followup
Full-time/part-time, n (%) 338 (44.8) 308 (40.8) 269 (35.6)
0.001
All others, n (%)† 417 (55.2) 447 (59.2) 486 (64.4)
* p value was calculated based on chi-square tests of the relationship between work status and poor progno-
sis category. † All others include those reporting working at home and those who were reported as students, 
disabled, or retired.
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The proportion of patients whose work status changed over time (baseline to 12-month 
follow-up) diﬀ ered according to the number of poor prognostic factors (Cochran–Man-
tel–Haenszel test; p < 0.001). The proportion of patients working both at baseline and 
at the 12-month follow-up visit was highest (92.6%) in those with 0–1 poor prognostic 
factors compared with the 2 and ≥3 groups (86.1% and 87.5%, respectively; Figure 
4). In the less favorable poor prognostic factor groups (2 and ≥3), higher proportions 
of patients were working at baseline but not at the 12-month follow-up (13.9% and 
12.5%) compared with those in the best prognosis group (7.3%; Figure 4).
DISCUSSION
In this population of adult patients with RA, who were biologic- and tsDMARD-naive 
at enrollment into the Corrona registry, the number of poor prognostic factors did not 
inﬂ uence treatment decisions. However, a greater number of poor prognostic factors 
was associated with worse clinical outcomes, as well as ability to work, at 12 months. 
In adjusted analyses, the changes in both CDAI and LDA/remission from baseline 
to the 12-month follow-up were signiﬁ cantly lower in patients with a greater number 
of poor prognostic factors compared with those with 0–1 poor prognostic factors. 
In addition, the proportion of patients with RA in full- or part-time employment was 
directly associated with the number of poor prognostic factors.
This was the largest real-world study to date to evaluate poor prognostic factors in 
patients with RA. These results highlight the burden of poor prognostic factors in 
patients with RA and the importance of evaluating these factors even in an established 
disease, which is common practice in other therapeutic areas such as cardiovascu-
lar disease. Our results suggest that, despite the worse outcomes in patients with 
a greater number of poor prognostic factors, the presence of these factors did not 
signiﬁ cantly predict treatment accelerations in terms of the initiation of biologics or 
the addition/switching of therapies.
While the underlying mechanisms that result in patients with poor prognostic factors 
having worse clinical outcomes are unknown, they warrant further investigation. In 
the meantime, providers may wish to reconsider how they approach treatment deci-
sions for patients with poor prognostic factors (e.g., it may be appropriate to follow 
these patients more closely than patients without poor prognostic factors). Current 
treatment guidelines recommend treating patients to achieve a speciﬁ c target, such as 
remission or LD [1,2,6], and, consistent with this treat-to-target approach, physicians 
should routinely assess disease activity and adjust therapy until the speciﬁ c target is 
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achieved. As our results indicate, attainment of LDA was inversely associated with the 
number of prognostic factors. It may be beneﬁ cial to consider the use of prognostic 
factors to guide treatment decisions. Furthermore, providers should engage patients 
in conversations about poor prognostic factors and how they may wish to tailor their 
RA care based on this information.
A strength of this study is that Corrona is the largest national US registry in RA that 
contains both patient- and provider-reported measures and represents a typical 
practice setting in the US. This was a real-world cohort of patients with varying dura-
tions of RA; hence, ﬁ ndings are more generalizable compared with controlled studies. 
However, given the observational nature of the design, there may be unmeasured 
confounding. In addition, operationalization of some of the outcome variables, such 
as work status, might underestimate the full productivity of patients with RA, as this 
study focused on full- or part-time paid work only and classiﬁ ed patients working at 
home and students as “not working”. Corrona is a US registry, and it is possible that 
the results may diﬀ er in other countries [12]. Additionally, this study focused on only 
a subset of poor prognostic factors, since this is not a widely accepted consensus 
deﬁ nition [13]. Signiﬁ cant diﬀ erences were observed among patients based on num-
ber of poor prognostic factors with respect to several parameters, including age, sex, 
race, work status, smoking status, disease duration, prior number of csDMARDs, and 
disease activity, which deserve further study. Furthermore, the study included only 
patients with a follow-up visit at 12 months, and additional analyses will be required to 
understand the impact of poor prognostic factors on long-term treatment outcomes. 
Finally, this study excluded 4930 patients due to a lack of documented data related to 
poor prognostic factors; however, these patients were similar to the population with 
poor prognostic factors included in the analyses with respect to sex, age, median 
disease duration, and mean baseline disease activity.
In conclusion, adjusted analyses showed that a greater number of poor prognostic 
factors was not associated with a greater likelihood of biologic/tsDMARD initiation or 
any treatment acceleration (biologic, tsDMARD, or csDMARD). These ﬁ ndings sug-
gest that the presence of poor prognostic factors does not notably inﬂ uence clinicians’ 
treatment decisions. This strategy warrants reconsideration as patients with a greater 
number of poor prognostic factors had worse outcomes (including reduction in CDAI 
and achievement of LDA/remission) and were less likely to be in full-/part-time work 
compared with those with fewer poor prognostic factors in adjusted analyses. As the 
deﬁ nition of a treat-to-target approach in RA evolves, providers may wish to consider 
incorporating the number of poor prognostic factors into their conversations with 
patients regarding their treatment plan.
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ABSTRACT
Objective. RA is associated with a 50-60% increase in risk of cardiovascular (CV) death. 
This study aimed to compare management of CV risk factors in RA and matched non-
RA patients. Methods. A retrospective cohort study was conducted using UK clinical 
practice data. Patients presenting with an incident RA diagnosis were matched 1:4 to 
non-RA patients based on a propensity score for RA, entry year, CV risk category and 
treatment received at index date (date of RA diagnosis). Patients tested and treated 
for CV risk factors as well as those attaining CV risk factor management goals were 
evaluated in both groups. Results. Between 1987 and 2010, 24,859 RA patients were 
identiﬁ ed and matched to 87,304 non-RA patients. At index date, groups had similar 
baseline characteristics. Annual blood pressure, lipids and diabetes-related testing 
were similar in both groups, although CRP and ESR were higher in RA patients at di-
agnosis and decreased over time. RA patients prescribed antihypertensives increased 
from 38.2% at diagnosis to 45.7% at 5 years, from 14.0 to 20.6% for lipid-lowering 
treatments and from 5.1 to 6.4% for antidiabetics. Similar treatment percentages 
were observed in non-RA patients, although slightly lower for antihypertensives. Mod-
est (2%) but signiﬁ cantly lower attainment of lipid and diabetes goals at 1 year was 
observed in RA patients. Conclusion. There were no diﬀ erences between groups in the 
frequency of testing and treatment of CV risk factors. Higher CV risk in RA patients 
seems unlikely to be driven by diﬀ erences in traditional CV risk factor management.
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INTRODUCTION
RA is associated with increased morbidity and mortality. Meta-analyses of published 
literature have shown that RA is associated with a 50-60% increase in risk of CV death 
vs the general population [1-3]. Despite improvements in RA therapies, it appears that 
the mortality gap between RA patients and the general population persists, and may 
even be increasing [2]. Cardiovascular (CV) complications are the primary cause for 
this increase in mortality and also contribute to increased risk for CV events in RA 
patients compared with the non-RA population [4, 5].
The pathogenic mechanisms underlying increased CV risk in RA have yet to be eluci-
dated. There is emerging evidence to suggest that traditional CV risk factors do not 
fully account for the increased likelihood of CV complications in RA, and the immune 
dysregulation, chronic high-grade inﬂ ammation and metabolic disturbances found in 
RA, along with RA disease activity and treatments such as corticosteroids, contribute 
to CV risk in RA patients [6-9]. Investigators have found that several treatment regi-
mens for RA reduce the risk of CV events [10]. Long-term use of DMARDs may modify 
atherosclerosis via beneﬁ cial eﬀ ects on endothelial function as well as inﬂ ammatory 
markers [11]. With regard to biologic DMARDs (bio-DMARDs), a meta-analysis re-
ported that therapy with TNF-a inhibitors was associated with a reduced risk of all 
CV events, myocardial infarction and stroke in cohort studies [12]. A meta-analysis of 
randomized controlled trials also produced a point estimate indicating a lower risk of 
CV events with TNF-a inhibitor therapies, but this was not statistically signiﬁ cant [13].
Although the literature on CV risk in RA patients is extensive, there are a few limita-
tions. The current literature does not fully address how the traditional CV risk factors 
of hypertension, lipids, weight and haemoglobin A1c (HbA1c) are managed in RA 
patients in comparison to the general population. Thus, the literature fails to inform 
whether the increased risk of CV events observed in RA patients could partly be due 
to worse CV risk management. Some studies indicate a lack of screening for CV risk 
factors by the rheumatologist (vs primary care providers) in RA patients and relatively 
low statin use among RA patients [14, 15]. However, these studies did not have a 
comparator non-RA group.
Although traditional CV risk factors may not fully explain the excess CV risk in RA pa-
tients, it is important to understand how these are managed in RA patients, especially 
with the introduction of agents such as Janus kinase inhibitors and anti-IL6 in the 
management of RA. These newer therapies are associated with changes in lipid levels, 
including increases in both low-density lipoprotein (LDL) and high-density lipoprotein 
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(HDL) [16]. The objective of this analysis was to describe the management of traditional 
CV risk factors, such as lipids, blood pressure and HbA1c, in RA patients in clinical 
practice settings and compare this management with that of matched non-RA patients.
METHODS
Study population and design
This was a retrospective cohort analysis based on the UK clinical practice database 
from 1987 to 2011. The database was obtained from the Clinical Practice Research 
Datalink (CPRD), which contains information on resources managed by general prac-
titioners. It is one of the largest computerized databases of anonymized longitudinal 
medical records from primary care. The current CPRD data set includes information on 
around 5 million currently active patients of research standard quality from about 590 
primary care practices in the UK, representing “’8% of the UK population. The CPRD 
population is representative of the general UK population. Selected laboratory data 
are available for a subset of patients. These mainly concern CV and diabetes-related 
laboratory data. The CPRD has been granted multiple research ethics committee ap-
proval (05/MRE04/87) to undertake purely observational studies, with external data 
linkages including Hospital Episode Statistics (HES) and Oﬃ  ce for National Statistics 
(ONS) mortality data. The work of CPRD is also covered by National Information 
Governance Board (NIGB)-Ethics and Conﬁ dentiality Committee (ECC) approval ECC 
5-05 (a) 2012. This study was approved by the Independent Scientiﬁ c Advisory Com-
mittee for Medicines and Healthcare products Regulatory (MHRA) database research 
(ISAC) under protocol number 12_079Ra.
The study population included all adult patients (age ≥18 years) recorded in the CPRD 
database with records of suﬃ  cient quality, identiﬁ ed through the acceptable patient 
ﬂ ag. The RA population was deﬁ ned as all patients presenting at least one RA read 
code after 1 January 1988 (index code), with no RA or juvenile RA codes before the 
index code. The read codes for RA were those that were included in group 1 or 2 of 
Thomas et al. [17], and the list of codes was also validated by clinical experts. The 
index date was deﬁ ned as the date of the ﬁ rst RA-related clinical or referral record, that 
is, index code. Patients were required to have at least 12 months of follow-up before 
the index date.
In the CPRD database, medical diagnoses and events were identiﬁ ed through read 
codes, and medcodes were used for treatments. Lists of codes were constructed to 
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deﬁ ne covariates and CV risk factors, based upon most recent values within 2 years 
preceding the index date. In order to create the code list for each condition, published 
lists of codes were used and supplemented by additional searches of the medical 
and product browsers. The list was then screened by an analyst in order to exclude 
all non-relevant codes and then a second screening was conducted by a person with 
medical qualiﬁ cation with expertise in read codes. Laboratory values were identiﬁ ed 
and calculated at the index date for baseline and updated for each subsequent year 
after the index date considering the most recent value, within 2 years of the date 
of interest. The CV risk as deﬁ ned by the National Cholesterol Education Program 
(NCEP, 2002) is composed of four categories of low, medium, high and secondary 
prevention, by summing the following risk factors: dyslipidaemia (LDL ≥4 mmol/l or 
HDL ≤1 mmol/l), hypertension (>140/90 mmHg), age (>45 years for males and >55 
years for females) and current smoker [18]. If patients had none of the risk factors they 
were considered low risk, one risk factor was medium risk and more than one risk 
factor was high risk. Patients with diabetes, heart disease, a history of a CV event or a 
history of a CV procedure were considered the target group for secondary prevention.
Matched non-RA cohort
RA patients were matched 1:4 to non-RA patients based on their year of entry in the 
CPRD database, CV risk category (NCEP classiﬁ cation), treatment status at index 
date and a propensity score estimating the probability of having RA [18]. The propen-
sity score probability was based on a logistic regression model that included gender, 
smoking, obesity, Charlson Co-morbidity Index and family history of RA as covariates. 
Each RA patient was categorized into low, medium or high CV risk at the index date. 
CV risk categories and treatment status for CV risk were calculated for all non-RA 
patients every 6 months. Non-RA patients were selected as potential matches based 
on the CV risk category and treatment status of the closest cut-oﬀ  to the case’s index 
date. Potential matches were also required to have entered the CPRD database during 
the same year as the case and to have an activity in the database within 2 months of 
the case’s index date. Based on the pool of potential matches, each RA patient was 
matched to a non-RA patient using the nearest neighbour match method of its RA risk 
score, and consequently removed from the pool of potential non-RA matches. This 
matching based on a risk score was performed in order to select patients with similar 
characteristics with the exception of RA diagnosis, thereby reducing bias due to con-
founding variables. An index date was assigned to the non-RA patient based on the 
closest observation date to the RA patient’s index date, and the match was conﬁ rmed 
based on the recalculated non-RA patient’s CV risk category at the assigned index 
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date. The process was repeated to match a maximum of four controls to each case. 
Standardized diﬀ erences were used to compare the measured baseline characteristics 
between the RA and the non-RA populations. A standardized diﬀ erence of <0.1 will be 
considered indicative of good balance [17].
Outcomes
Management of traditional CV risk factors was evaluated in terms of the percentage of 
patients evaluated for CV risk factors, the percentage of patients receiving treatment 
with lipid-lowering therapies, antihypertensive therapies and antidiabetic therapies at 
index and up to 5 years after the index date. In addition, we evaluated the percentage 
of patients attaining blood pressure, lipids and HbA1c goals annually up to 5 years 
post index date. The goals were based on UK clinical guidelines; for blood pressure 
the goal was <140/90 mmHg, for dyslipidaemia the goal was either an LDL cholesterol 
of <2 mmol/l or total cholesterol of <4 mmol/l, and for diabetes the goal was HbA1c 
<7.5%.
Statistical analyses
Baseline characteristics between RA and matched non-RA patients were compared 
using standard statistical tests and standardized diﬀ erences. Statistical analysis 
involved comparing between RA and matched non-RA patients the percentage of 
patients evaluated for CV risk factors, treated for CV risk factors and attaining CV 
risk factor management goals at baseline and at 5 years post baseline. Evaluation 
of CV risks was based on comparing the mean number of CV risk factor lab values 
(such as HDL-C, LDL-C, Total Cholesterol, Triglyceride, Diastolic BP, Systolic BP, CRP, 
ESR, HbA1c, Fast Glucose) during each year between the RA cohort and the matched 
non-RA cohort. The proportion of patients attaining blood pressure, lipid and HbA1c 
goals at yearly intervals up to 5 years was compared between RA and matched non-RA 
patients using χ² statistics. The analysis of attainment of goals for blood pressure, 
lipids and HbA1c was based on a last observation carried forward approach. No ad-
ditional adjustments besides imputation for missing values on laboratory tests using 
last observation carried forward were made because the matching was successful. The 
analysis was carried out using the statistical software SAS 9.2. Graphs were plotted us-
ing Excel 2007. An α level of 0.05 was used for determination of statistical signiﬁ cance.
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RESULTS
Between 1987 and 2010, there were 24,859 patients with RA who were identiﬁ ed in the 
CPRD data set with a mean (S.D.) follow-up of 5.8 (4.4) years, representing 144,342 
patient-years. Each RA patient was matched to four non-RA patients (n = 87,304) with 
a mean (S.D.) follow-up of 5.7 (4.4) years. At the time of RA diagnosis, the mean (S.D.) 
age for the RA cohort was 60.0 (15.1) years, and 69.2% were females. In terms of CV 
risk stratiﬁ cation, 20% of RA patients were categorized as secondary prevention; 30% 
of the primary prevention patients were high risk, 31% were medium risk and 19% low 
risk. The RA and non-RA patients received similar baseline therapies to treat hyperten-
sion, diabetes or dyslipidaemia (41.8 vs 40.7%). Overall, the RA and the non-RA cohort 
were well matched on the baseline age and baseline CV risks. Despite statistically 
signiﬁ cant diﬀ erences, the eﬀ ect size is very marginal as conﬁ rmed by standardized 
diﬀ erences close to 0. The incremental diﬀ erence in Charlson Co-morbidity Index 
Table 1. Baseline Characteristics summary
Characteristics RA patients
(N=24,859)
Non-RA patients
(N=87,304)
p-value d
Number of patient-years, sum 144,342 494,938
Follow-up (years), mean (SD) 5.8 (4.4) 5.7 (4.4) <.0001 0.023
Agea (years), mean (SD) 60.0 (15.1) 60.2 (15.9) 0.071 -0.013
Charlson comorbidity indexa, mean (SD) 1.4 (0.9) 0.3 (0.9) <.0001 1.222
Females, n (%) 17,202 (69.2) 57,939 (66.4) <.0001 0.060
Obesityb, n (%) 2,880 (11.6) 9,530 (10.9) 0.003 0.022
Current smokerb, n (%) 6,977 (28.1) 24,122 (27.6) 0.175 0.011
Hypertensionc, n (%) 9,798 (39.4) 33,382 (38.2) 0.001 0.025
Dyslipidemiac, n (%) 6,761 (27.2) 24,202 (27.7) 0.103 -0.011
Diabetesc, n (%) 1,742 (7.0) 7,012 (8.0) <.0001 -0.038
Treatment status, n (%) 10,393 (41.8) 35,530 (40.7) 0.027 0.022
Cardiovascular risk category (NCEP algorithm) <.0001 0.000
 Low 4,788 (19.3) 18,169 (20.8)
 Medium 7,683 (30.9) 24,650 (28.2)
 High 7,461 (30.0) 25,322 (29.0)
 Secondary prevention 4,927 (19.8) 19,163 (21.9)
d: standardized difference; NCEP: National Cholesterol Education Program; SD: standard deviation
Notes:
aAge and Charlson comorbidity index evaluated at time of index date;
bObesity, current smoker: based on read codes of the 2 years preceding index date;
cHypertension, dyslipidemia and diabetes based on diagnoses read codes, prescriptions and tests of the 2 
years preceding index date
122 ○ Chapter 7
between RA and non-RA patients (1.1) can be explained by the Charlson Co-morbidity 
Index calculation itself, because RA activity is counted as a co-morbidity (Table 1).
The reporting of laboratory tests was similar in both groups overall, although CRP 
and ESR were reported more often in RA vs non-RA patients (33.9 vs 5.8% and 47.0 vs 
12.2%, respectively, at index date). Overall, mean blood pressure, lipid and diabetes-
related laboratory test results were stable and similar in the RA and non-RA cohorts 
over time since diagnosis, although CRP and ESR were higher in RA patients at diag-
nosis, decreasing over time [average (S.D.) from 24.6 mg/l (34.9) at index date to 14.8 
mg/l (25.9) at 5 years for CRP, and from 31.9 mm/h (26.0) to 23.9 mm/h (20.9) for 
ESR; Table 2].
The percentage of RA patients who were prescribed treatments for hypertension, lipid-
lowering therapies and diabetes at RA diagnosis was 38.2, 14.0 and 5.1%, respectively, 
and these values were comparable to those in the non-RA cohort (37.4, 14.8 and 
Table 2. Summary of Laboratory Tests Over Time Since Index Date, in RA and Non-RA Patients
Blood test At index date 1 year after index 3 years after index 5 years after index
n (%) mean 
(SD)
n (%) mean 
(SD)
n (%) mean 
(SD)
n (%) mean 
(SD)
RA patients (N=24,859)
HDL-C, mmoL/L 5,709 
(23.0%)
1.4 
(0.5)
5,378 
(21.6%)
1.4 
(0.5)
4,474 
(18.0%)
1.5 
(0.5)
3,688 
(14.8%)
1.5 
(0.5)
LDL-C, mmoL/L 4,621 
(18.6%)
3.0 
(1.0)
4,386 
(17.6%)
3.0 
(1.0)
3,597 
(14.5%)
3.0 
(1.0)
3,030 
(12.2%)
2.9 
(1.0)
Total cholesterol, mmoL/L 8,018 
(32.3%)
5.2 
(1.2)
7,485 
(30.1%)
5.2 
(1.2)
6,025 
(24.2%)
5.1 
(1.1)
4,815 
(19.4%)
5.1 
(1.1)
Triglyceride level, mmoL/L 5,847 
(23.5%)
1.6 
(1.0)
5,458 
(22.0%)
1.6 
(1.0)
4,437 
(17.8%)
1.6 
(1.0)
3,661 
(14.7%)
1.6 
(0.9)
Diastolic BP, mmHg 17,779 
(71.5%)
79.0 
(10.1)
16,021 
(64.4%)
79.0 
(10.0)
12,173 
(49.0%)
79.0 
(10.0)
9,157 
(36.8%)
78.5 
(10.0)
Systolic BP, mmHg 17,779 
(71.5%)
136.2 
(19.2)
16,021 
(64.4%)
136.5 
(18.9)
12,173 
(49.0%)
136.5 
(18.9)
9,157 
(36.8%)
136.3 
(18.1)
CRP, mg/L 8,434 
(33.9%)
24.6 
(34.9)
8,607 
(34.6%)
18.8 
(29.8)
4,967 
(20%)
18.8 
(29.8)
3,647 
(14.7%)
14.8 
(25.9)
ESR, mm/hr 11,694 
(47.0%)
31.9 
(26.0)
11,440 
(46.0%)
27.0 
(23.5)
6,912 
(27.8%)
27.0 
(23.5)
5,165 
(20.8%)
23.9 
(20.9)
HbA1c, % 1,448 
(5.8%)
7.1 
(1.5)
1,475 
(5.9%)
6.9 
(1.5)
1,222 
(4.9%)
6.9 
(1.5)
1,009 
(4.1%)
7.0 
(1.6)
FG, mmol/L 1,645 
(6.6%)
5.5 
(1.5)
1,515 
(6.1%)
5.5 
(1.7)
1,215 
(4.9%)
5.5 
(1.7)
1,029 
(4.1%)
5.4 
(1.4)
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5.8%). When comparing these treatment percentages between baseline and 5 years, 
there was a general trend towards an increased proportion of patients being managed 
for CV risk factors in RA and non-RA patients at 5 years (Fig. 1). The trend was slightly 
higher in RA patients (+7.5%, 95% CI 6.5, 8.6) than in non-RA patients (+5.6%, 95% 
CI 5.1, 6.2) for antihypertensive use. There was no diﬀ erence in the proportion of RA 
patients treated for CV risk factors compared with matched non-RA patients treated 
for CV risk factors over the 5 year analysis based on the comparison of CIs (Fig. 1).
Within patients with the same risk factors at the index date, there was no diﬀ erence 
between RA and non-RA patients reaching goals for hypertension at 1 year (Fig. 2; 
P = 0.50) although small but signiﬁ cant diﬀ erences were found for dyslipidaemia and 
diabetes (16.4 vs 18.5%, P < 0.01 for lipid goals in RA and non-RA patients, respec-
tively, and 48.7 vs 44.3%, P < 0.01 for HbA1c goals).
Table 2. (continued)
Blood test At index date 1 year after index 3 years after index 5 years after index
n (%) mean 
(SD)
n (%) mean 
(SD)
n (%) mean 
(SD)
n (%) mean 
(SD)
Non-RA patients (N=87,304)
HDL-C, mmoL/L 19,754 
(22.6%)
1.4 
(0.5)
18,791 
(21.5%)
1.4 
(0.5)
16,092 
(18.4%)
1.5 
(0.5)
13,113 
(15.0%)
1.5 
(0.5)
LDL-C, mmoL/L 16,340 
(18.7%)
3.0 
(1.0)
15,558 
(17.8%)
3.0 
(1.0)
13,282 
(15.2%)
2.9 
(1.1)
10,953 
(12.5%)
2.9 
(1.0)
Total cholesterol, mmoL/L 27,177 
(31.1%)
5.2 
(1.2)
25,524 
(29.2%)
5.2 
(1.2)
21,041 
(24.1%)
5.1 
(1.2)
16,786 
(19.2%)
5.1 
(1.2)
Triglyceride level, mmoL/L 20,462 
(23.4%)
1.6 
(1.0)
19,361 
(22.2%)
1.6 
(1.0)
16,251 
(18.6%)
1.6 
(0.9)
13,123 
(15%)
1.6 
(0.9)
Diastolic BP, mmHg 60,889 
(69.7%)
79.3 
(10.7)
54,339 
(62.2%)
78.9 
(10.1)
40,515 
(46.4%)
78.9 
(10.1)
30,049 
(34.4%)
78.5 
(9.7)
Systolic BP, mmHg 60,889 
(69.7%)
136.4 
(19.6)
54,339 
(62.2%)
136.4 
(58.9)
40,515 
(46.4%)
136.4 
(58.9)
30,049 
(34.4%)
136.4 
(17.7)
CRP, mg/L 5,095 
(5.8%)
10.6 
(24.6)
4,915 
(5.6%)
10.8 
(25.7)
4,229 
(4.8%)
10.8 
(25.7)
3,482 
(4%)
10.7 
(25.9)
ESR, mm/hr 10,630 
(12.2%)
17.2 
(19.1)
9,986 
(11.4%)
16.8 
(17.2)
7,876 
(9.0%)
16.8 
(17.2)
6,382 
(7.3%)
17.2 
(17.0)
HbA1c, % 5,365 
(6.1%)
7.2 
(1.5)
5,116 
(5.9%)
7.2 
(1.6)
4,264 
(4.9%)
7.2 
(1.5)
3,479 
(4.0%)
7.1 
(1.5)
FG, mmol/L 5,730 
(6.6%)
5.7 
(1.8)
5,529 
(6.3%)
5.7 
(1.7)
4,751 
(5.4%)
5.7 
(1.6)
3,967 
(4.5%)
5.6 
(1.6)
BP: blood pressure; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; FG: fast blood glucose; 
HbA1c: hemoglobin A1c; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein choles-
terol; SD: standard deviation
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Figure 1. Summary of treatments prescribed at Index date
Notes:
All data are percentages
aChange in percentage of patients receiving treatment (95% conﬁ dence interval)
Figure 2. Summary of patients reaching blood pressure, lipids and A1c goals at 1 year post index date
Notes:
aPercentage (Number of patients reaching target level/number of patients followed up)
bHypertension target levels: blood pressure <140/90 mm/Hg;
cDyslipidemia target levels: low-density lipoprotein cholesterol < 2 mmol/L or total cholesterol < 4 mmol/L;
dDiabetes target levels: hemoglobin A1c <7.5%
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DISCUSSION
This study is the ﬁ rst to describe the management of CV risk factors of RA patients in 
a UK clinical practice setting and compare it with matched non-RA patients. Given that 
the risk of a CV event is dependent on multiple factors, its management is dictated by 
the evaluation of these risk factors and the determination of overall CV risk. Thus, it is 
important to control for the baseline CV risk when evaluating the management of CV 
risk factors. To our knowledge, this is the only study to have matched RA patients to non-
RA patients on baseline CV risks when evaluating the management of CV risks factors 
in RA patients. Given the large number of patients included in the study and the average 
follow-up of >5 years, we believe that the study population and its management of CV 
risk factors is representative of general RA patients seen in a clinical practice setting.
No meaningful diﬀ erences were found between RA and non-RA patients in terms of 
the frequency of CV risk factor evaluation and treatments at baseline. However, there 
were more patients managed for hypertension in the RA-cohort vs the non-RA cohort 
at 5 years, and there was a modest diﬀ erence of 2% fewer patients in the RA cohort 
reaching lipid goals. The evidence for hypertension being more prevalent in RA pa-
tients is mixed, because reports are contradictory and dependent on the deﬁ nition of 
hypertension used in the analysis [19]. However, results from a recent study indicate 
a signiﬁ cantly increased prevalence of hypertension in RA patients vs controls and 
would support our ﬁ ndings [20]. Our study also found that RA patients experienced a 
modest absolute 2% lower achievement in lipid goals. Studies of lipid levels in RA are 
inconclusive and seem to be inﬂ uenced by the duration of RA and treatment for RA. 
Studies conducted prior to RA diagnosis seem to indicate that RA patients have low 
HDL vs matched controls [21]. However, other studies have shown that RA patients 
have lower LDL and total cholesterol levels and, in spite of these lower levels, there 
is a paradoxical increase in CV risk [22, 23]. Our study was not designed to compare 
the lipid levels between RA and non-RA patients. Given that we matched patients 
on baseline CV risk factors, we could not observe a diﬀ erence in baseline lipid levels 
in our cohort. However, in spite of the similarity in testing and treatment for lipid 
lowering between RA and non-RA patients, we found that attainment of lipid goals 
was modestly lower in RA patients. Further studies would need to be conducted to 
conﬁ rm our observation and its relevance. Studying the patterns of lipid management 
in RA patients is important because new therapies introduced to manage RA have 
been associated with increasing lipid levels [17].
Some of our ﬁ ndings are contrary to those reported in the literature on management 
of CV risk factors in RA patients. A recent study concluded that RA patients were less 
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likely to be diagnosed with hypertension than patients without RA [24]. Another study 
found that one-third of eligible patients lacked appropriate lipid testing despite the 
presence of traditional CV risk factors [25], whereas others concluded that the health-
care quality in RA appears to be suboptimal for co-morbid disease [26]. We postulate 
that the diﬀ erence between our ﬁ ndings and those from other studies can be explained 
partly by the diﬀ erence in methodology and the settings of the studies. Firstly, as 
stated previously, we controlled for baseline CV risk in our study via matching, which 
was not done in the other studies. Secondly, our study was conducted in the general 
practice setting vs rheumatologist setting, because there is evidence to support that 
rheumatologists identify and manage CV risk factors signiﬁ cantly less frequently in RA 
patients when compared with primary care providers [26]. Thirdly, it is the only study 
based on data from the UK, whereas the other studies were based on US data.
Our general ﬁ nding that there is no substantial diﬀ erence in the evaluation, treatment 
and attainment of CV risk factor goals indicates that the higher incidence of CV events 
among RA patients observed in our data (CV event incidence rate in our data set of 
4.29, 95% CI 4.15, 4.44 in RA patients vs 3.11, 95% CI 3.04, 3.17 in non-RA patients 
per 100 patient-years; 8.97% of RA patients and 6.97% of non-RA primary prevention 
patients had a CV event over a 5 year follow-up) may not be driven by poor manage-
ment of traditional CV risk factors alone. This ﬁ nding indirectly supports the literature 
indicating that there might be other factors contributing to increased CV events in RA 
patients. Although traditional risk factors are known to play an important role in the 
general population, their relative contributions to CV risk in RA is less clear [19]. More-
over, there is evidence that the increased CV risk in RA patients might not be explained 
by traditional risk factors alone [27]. The mechanisms underlying increased CV events 
in RA have yet to be elucidated fully. However, there is emerging evidence to sug-
gest that the immune dysregulation, chronic high-grade inﬂ ammation and metabolic 
disturbances found in RA patients could contribute to the increased CV events in RA 
patients [6-9]. The increase in CV risk in RA patients is acknowledge by the consensus 
guidelines for the management of RA, which recommend the evaluation for CV risk 
at baseline using a traditional CV risk algorithm, such as Framingham Heart Study-
based algorithm or the MONIC Study-based SCORE algorithm. The Dutch guidelines 
recommend the application of CV risk management (CVRM) in RA patients, because 
RA is considered as an independent risk factor for CV disease. A recent study showed 
that CVRM guidelines performed poorly in RA patients, with an overall increase in 10 
year CV risk despite implementation of CVRM [28]. Given that these algorithms were 
not developed in the RA-speciﬁ c population, and to account for the increased CV risk 
in RA patients vs the general population, the EULAR guidelines recommend that the 
risk calculated, using these algorithms, should be multiplied by a factor of 1.5.
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There were several limitations to our analysis. Our study was retrospective, implying 
the potential presence of some sources of bias due to confounding factors. However, 
this was partly accounted for by propensity score matching of patients on both their 
RA and CV risk proﬁ les. Only data from a general practice setting were available, and 
no data from rheumatologists were available. This could impact the identiﬁ cation of 
RA patients into our study, which is based on read codes in groups 1 and 2 of Thomas 
et al. [17]. This list of codes did not include seronegative for RF RA codes and had a 
high sensitivity (93%) but a relative low speciﬁ city (49%); thus, there could be some 
false positives in our case cohort [15]. In addition, the present analysis used the NCEP 
guidelines, which were cited by the British Society of Cardiology and in eﬀ ect during 
the time when these patients were managed for their CV risk, that is, before 2011. 
The NCEP guidelines were used to categorize the RA into diﬀ erent CV risk categories, 
which were later used to match patients. The results could be diﬀ erent if the new ACC/
AHA guidelines were used to match patients. However, as the new guidelines were 
not in place when these patients were evaluated and managed for CV risk, it would 
not be appropriate to use the new guidelines in this analysis. There were also a large 
number of missing values for laboratory test data. The method of last observation 
carried forward was used to handle missing data after the index date. Other imputa-
tion methods were also investigated, such as the simple mean imputation approach, 
producing similar results. Finally, only prescription data were available, which are 
known to diﬀ er from dispensed or taken medications.
Despite limitations, the study was based on data with both a large sample size and a 
good follow-up period. The results are generalizable to the UK population and are rep-
resentative of its clinical practice, because the study was based on the CPRD general 
practice database, which covers a large proportion of the UK population.
CONCLUSION
There were no diﬀ erences observed between RA and non-RA patients in terms of CV 
risk management and testing, although RA patients had experienced a modest 2% 
lower achievement of lipid goals, which may not be clinically meaningful. Based on 
this analysis, it seems that the higher CV risk in patients with RA is unlikely to be 
driven by diﬀ erences in traditional CV risk factor management alone. A focus should 
be placed on CV risk stratiﬁ cation of RA patients and studies to determine how best to 
tailor management of CV risk to the diﬀ erent risk groups.
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ABSTRACT
Objectives. The aims were to compare the performance of cardiovascular risk calcula-
tors, Framingham Risk Score (FRS) and QRISK2, in RA and matched non-RA patients 
and to evaluate whether their performance could be enhanced by the addition of CRP. 
Methods. We conducted a retrospective analysis, using a clinical practice data set 
linked to Hospital Episode Statistics (HES) data from the UK. Patients presenting 
with at least one RA diagnosis code and no prior cardiovascular events were matched 
to non-RA patients using disease risk scores. The overall performance of the FRS and 
QRISK2 was compared between cohorts, and assessed with and without CRP in the 
RA cohort using C-Index, Akaike Information Criterion (AIC) and the net reclassiﬁ ca-
tion index (NRI). Results. Four thousand seven hundred and eighty RA patients met 
the inclusion criteria and were followed for a mean of 3.8 years. The C-Index for the 
FRS in the non-RA and RA cohort was 0.783 and 0.754 (P < 0.001) and that of the 
QRISK2 was 0.770 and 0.744 (P < 0.001), respectively. Log[CRP] was positively associ-
ated with cardiovascular events, but improvements in the FRS and QRISK2 C-Indices 
as a result of inclusion of CRP were small, from 0.764 to 0.767 (P = 0.026) for FRS and 
from 0.764 to 0.765 (P = 0.250) for QRISK2. The NRI was 3.2% (95% CI: -2.8, 5.7%) for 
FRS and -2.0% (95% CI: -5.8, 4.5%) for QRISK2. Conclusion. The C-Index for the FRS 
and QRISK2 was signiﬁ cantly better in the non-RA compared with RA patients. The 
addition of CRP in both equations was not associated with a signiﬁ cant improvement 
in reclassiﬁ cation based on NRI.
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INTRODUCTION
Patients with RA compared with the general population have an increased risk of 
mortality [1-3]. There is evidence to suggest that this mortality gap is increasing, 
although recent studies indicate a decreasing trend in cardiovascular (CV) fatality in 
RA patients [2, 4]. The main cause of increased mortality in RA patients is CV-related 
events [5, 6]. Several epidemiological studies have shown that the relative risk of acute 
myocardial infarction in RA patients ranges from 1.5 to 2.0, and for stroke it is 1.4 to 
2.7 fold higher [7-10].
The pathophysiological mechanism underlying the increased CV risk in RA patients is 
not fully understood. RA patients have chronic high-grade inﬂ ammation, which is an 
important contributor towards the development of premature atherosclerosis and CV 
events [11, 12]. It is unclear whether the markers of inﬂ ammation, such as CRP and 
ESR, and other markers, such as RF and RA disease activity, are more strongly associ-
ated with CV events in RA and thus could weaken the association of the traditional CV 
risk factors to CV events. In addition, there is evidence to suggest that traditional CV 
risk factors and markers of RA severity both contribute to predicting CV events in RA 
patients [2, 13, 14].
One consensus recommendation for the management of RA recommends the 
evaluation for CV risk at baseline using traditional CV risk algorithms, such as Fram-
ingham Risk Scores (FRS), which is based on the Framingham Heart Study, or the 
SCORE algorithm, which is based on the WHO MONICA Study [15]. Given that these 
algorithms were not developed in the RA-speciﬁ c population, the recommendation 
suggest adjusting the risk to account for the increased CV risk in RA patients [15]. 
Recent studies reporting RA-speciﬁ c CV risk calculators have had mixed success in 
developing an improved CV risk calculator in RA patients [14, 16].
The primary objective of this analysis was to evaluate and compare the performances 
of CV risk algorithms in RA vs matched non-RA patients. The secondary objective was 
to evaluate the association of CRP with CV events in RA patients and explore whether 
the performance of the CV risk algorithms could be enhanced by the addition of CRP, 
as was the case in the Reynolds Risk Score [17].
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METHODS
Study design and database
This was a retrospective cohort analysis, based on electronic medical records from 
the Clinical Practice Research Datalink (CPRD). The CPRD is jointly funded by the 
National Health Service (NHS), National Institute for Health Research and the Medi-
cines and Healthcare products Regulatory Agency. It currently comprises ~5 million 
active patients with long-term follow-up information. To obtain a complete picture 
of CV events, the CPRD data were linked to the Health Episode Statistics (HES) data 
from April 1997 onwards, which contain details of all admissions and outpatient ap-
pointments in NHS hospitals.
Study population
The study included all adult RA patients (age ≥18 years) with records of suﬃ  cient 
quality, identiﬁ ed through the acceptable patient ﬂ ag. The RA population was deﬁ ned 
as all patients presenting at least one RA diagnosis read code after 01/01/1988 (index 
code), with no RA or juvenile RA codes before the index code. Read codes are standard 
medical diagnosis codes used in the UK general practice system. The index date was 
deﬁ ned as the date of ﬁ rst RA-related clinical or referral record. Patients were required 
to have at least 12 months of data reported before the index date.
RA patients were matched 1:4 to non-RA patients based on their year of entry into 
the CPRD database using a disease risk score for RA, CV risk category (National Cho-
lesterol Education Program classiﬁ cation) and CV treatment status. The disease risk 
score was based on a logistic regression model evaluating the probability of having 
RA and included gender, smoking, obesity, psoriasis, Charlson Co-Morbidity Index 
and family history of RA as covariates [18]. RA patients were categorized into CV risk 
categories of low, medium or high at index date based on the number of risk factors, 
explained further in the next subsection, on exposure and outcomes deﬁ nitions. CV 
risk categorization and treatment status of CV risk for all non-RA patients were calcu-
lated for each 6-month window. Non-RA patients were selected as potential matches 
within each CV risk category and treatment status that was closest to the case’s index 
date. Potential matches were also required to have entered the CPRD database during 
the same year as the case and to have at least one health-care encounter within 2 
months of the case’s index date. From the pool of potential matches, each RA patient 
was matched to a non-RA patient, with replacement based on the disease risk score 
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and using the nearest neighbour match method [18]. An index date was assigned to 
the non-RA patient based on the closest observation date to the RA patient’s index 
date, and the match was conﬁ rmed based on the recalculated non-RA patient’s CV risk 
category at the assigned index date. The process was repeated to match a maximum 
of four controls to each case. Standardized diﬀ erences were used to compare the 
measured baseline characteristics between the RA and the non-RA populations. A 
standardized diﬀ erence of <0.1 was considered indicative of a good balance [19].
The CPRD has been granted Multiple Research Ethics Committee approval (05/
MRE04/87) to undertake purely observational studies, with external data linkages 
including HES and Oﬃ  ce of National Statistics mortality data. The work of CPRD is 
also covered by National Information Governance Board - Ethics and Conﬁ dentiality 
Committee approval ECC 5-05 (a) 2012. This study was approved by the Independent 
Scientiﬁ c Advisory Committee for Medicines and Healthcare products Regulatory 
Agency database research under protocol no. 12_079Ra.
Exposure and outcomes deﬁ nitions
Medical diagnoses and events were identiﬁ ed through read codes, whereas medical 
product codes were used for treatments. Lists of codes were constructed to deﬁ ne 
baseline covariates, CV risks and CV events. In order to create the code list for each 
condition, published lists of codes were used and supplemented by additional searches 
of the medical and product browser. Group 1 or 2 read codes were used for RA diag-
nosis as deﬁ ned in a previous published study using CPRD data [20]. The compiled 
list was then screened by an analyst in order to exclude all non-relevant codes, and 
a second screening was then conducted by a clinician. For the HES analysis, ICD 10 
codes were used to record medical diagnoses and events. Based on the Framingham 
Heart Study deﬁ nition, the CV event list was a composite of myocardial infarction, 
stroke, heart failure, aortic aneurysm, transient ischemic attack, unstable angina or 
intermittent claudication. The QRISK2 deﬁ nition of CV events included myocardial 
infarction, coronary heart disease (CHD), stroke and transient ischemic attack [21]. 
Laboratory values were identiﬁ ed and calculated at index date, considering the most 
recent value within 2 years of the date of interest. CRP values were also obtained from 
the laboratory tests data. The presence of hypertension at the index date was based 
on a record of a diagnosis of hypertension via read code or a diastolic blood pressure 
of >90 mmHg or systolic blood pressure of >140 mmHg or both within the 2 years 
prior to the index date. Dyslipidaemia at the index date was based on a diagnosis 
or treatment for dyslipidaemia or high-density lipoprotein cholesterol <1.03 mmol/l 
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or low-density lipoprotein cholesterol >4.14 mmol/l or total cholesterol (TC) >5.17 
mmol/l or triglyceride >2.26 mmol/l. Atrial ﬁ brillation, family history of CHD and renal 
disease were evaluated at the index date based on a record of corresponding diagno-
sis codes within 2 years of the index date. Obesity was identiﬁ ed by a record of a read 
code or a BMI >30 kg/m² occurring within 2 years of the index date. The covariates 
for the QRISK2 model were age, sex, smoking status (yes/ no), treated hypertension 
(yes/no, hypertension with prescribed treatment), obesity (yes/no, instead of BMI), 
diabetes (yes/no), atrial ﬁ brillation (yes/no), family history of CHD (yes/no), RA (yes/
no) and renal disease (yes/no). RA was not included as covariate because of complete 
separation of populations in the RA and non-RA populations, respectively. In addi-
tion, the Townsend deprivation score and ethnicity were not included in the analysis 
because of their unavailability in our data set.
Treatment status was deﬁ ned as a bivariate variable for patients who received therapy 
to treat diabetes, hypertension or dyslipidaemia within 2 years of the index date. The 
CV risk categories, used for the matching only, were based on National Cholesterol 
Education Program deﬁ nitions and were composed of the four categories of low, 
medium, high and very high risk by summing the following risk factors: dyslipidae-
mia (low-density lipoprotein cholesterol ≥ 4.14 mmol/l or high-density lipoprotein 
cholesterol ≤ 1.03 mmol/l), hypertension, age (>45 years for males and >55 years for 
females) and current smoker [22]. If patients had none of the risk factors they were 
considered low risk, one risk factor was medium risk and more than one risk factor 
was high risk. Patients with diabetes, heart disease, a history of cardiovascular event 
or procedure were considered in the very high-risk class.
Statistical analysis
Descriptive statistics were used to summarize the demographic characteristics of 
the RA and non-RA cohorts. The diﬀ erences in CV risk factors in the two cohorts 
were tested using χ² tests. The associations between CRP, lipids and CV events were 
evaluated by plotting Kaplan-Meier survival curves (time to CV event) by baseline CRP 
tertiles and TC categories based on UK treatment guidelines (low: <5.172 mmol/l; 
medium: 5.172-6.180 mmol/l; high: ≥6.180 mmol/l [22]) and using log rank tests. 
Negative binomial models were used to evaluate the risk of CV events (based on the 
FRS deﬁ nition) by CRP and TC categories.
The 10-year FRS and QRISK2 are Cox proportional hazard models, which include the 
traditional CV risk factors. They were compared for discriminatory ability and model 
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ﬁ t in the RA and non-RA cohorts. The proportional hazard assumption was evalu-
ated for each covariate in univariate models by testing the interaction between the 
covariate and time in its logarithm transformation: H(t) = H0(t)exp(βkxk + γkxk * log(t)). 
If the γk estimate was signiﬁ cantly diﬀ erent from 0 (P < 0.05) then the covariate xk 
was considered to violate the proportional hazard assumption. Model discriminatory 
properties were evaluated using the area under the receiver operating characteristic 
curve measured by Harrell’s C-Index, and the model ﬁ t was evaluated using the Akaike 
Information Criterion (AIC). The 95% CIs for the C-Index and the diﬀ erence in the 
C-Index were calculated using 1000 bootstrap samples. Harrell’s C-Index is a measure 
that assesses the ability of a model to distinguish subjects who will develop events 
from those who will not and can be interpreted as the conditional probability that, for 
any pair of event and non-event patients, the predicted risk of an event is higher for 
the patient with an event [23]. The net reclassiﬁ cation index (NRI) was used to evalu-
ate the reclassiﬁ cation ability of the addition of the logarithm of CRP concentration 
(log[CRP]) to the base FRS and QRISK2 prediction model. The NRI is a measure of 
the added predicted value of a new marker (CRP). In the context of survival data, it is 
calculated using a prospective approach, summarizing the upward and downward re-
classiﬁ cations, in terms of predicted risk categories, of the original model compared 
with the new model with the added covariate [24]. In the RA cohort, the base FRS and 
QRISK2 models were extended to include the baseline log[CRP] in addition to the 
traditional CV predictors. The C-Index and AIC were used to evaluate the performance 
of the FRS with and without CRP in RA patients.
RESULTS
From 1997 to 2010, 12,747 primary prevention RA and 44,452 non-RA patients met 
the inclusion criteria. On average (S.D.) at baseline, RA patients were 58.5 (14.8) 
years old, with a follow-up of 6.0 (4.5) years (76,003 patient-years) and had CRP of 
23.5 (33.5) mg/l. Females represented 71% of the population; 38% were hypertensive 
and 24% dyslipidaemic (Table 1). The median reported time between CRP record 
and the index date was 49 days (interquartile range: 14-137). Non-RA patients had 
similar characteristics at baseline, with the exception of mean CRP and ESR values, 
which were 2.5 and 1.8 times lower, respectively. The incidence of CV events based 
on FRS deﬁ nition of CV events was 4.29/100 patient-years (95% CI: 4.15, 4.44) in RA 
patients and 3.11/ 100 patient-years (95% CI: 3.04, 3.17) in non-RA patients. Using 
the QRISK2 CV deﬁ nition, the incidence of CV events was 1.78/100 patient-years (95% 
CI: 1.69, 1.88) in RA patients and 1.38/100 patient-years (95% CI: 1.33, 1.42) in non-
RA patients. Within the RA and non-RA cohorts, based on a Kaplan-Meier analysis, 
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the probability of a CV event at 5 years was 8.97 and 6.97%, respectively (log-rank 
P < 0.001; Fig. 1).
CRP and TC were categorized into three levels (low, medium and high). The threshold 
values for CRP levels (corresponding to tertiles) were CRP ≤6, 6 < CRP ≤20 and CRP 
>20 mg/l, and the values for TC were based on treatment guidelines deﬁ ned in the 
statistical analysis subsection of the Methods. Based on the Kaplan-Meier analysis, 
probabilities of a CV event at 5 years based on FRS deﬁ nition in patients with low, 
Table 1. Baseline Characteristics of RA and non-RA primary prevention patients
Characteristics
RA Patients Non-RA Patients
N Mean (SD)
or n (%)
N Mean (SD)
or n (%)
Number of patient-years (years), Sum 12,747 76,003 44,452 260,206
Years of follow-up (years) 12,747 6.0 (4.5) 44,452 5.9 (4.5)
Age at index date (years) 12,747 58.5 (14.8) 44,452 58.3 (15.4)
Charlson Comorbidity Index 12,747 1.3 (0.9) 44,452 0.3 (0.8)
Total Cholesterol (mmol/L) 3,874 5.3 (1.2) 12,801 5.4 (1.2)
HDL Cholesterol (mmol/L) 2,774 1.4 (0.4) 9,459 1.4 (0.5)
Diastolic blood pressure (mm of Hg) 9,042 79.5 (9.9) 30,300 79.8 (11.1)
Systolic blood pressure (mm of Hg) 9,042 136 (19.1) 30,300 136 (19.4)
C-reactive protein (mg/L) 4,780 23.4 (33.5) 2,816 9.9 (24)
Erythrocyte sedimentation rate (mm/hr) 6,377 30.9 (24.7) 5,477 16 (16)
HbA1c (%) 681 7.1 (1.6) 2,554 7.2 (1.6)
Females 12,747 9046 (71) 44,452 30422 (68.4)
Obesity 12,747 1423 (11.2) 44,452 4761 (10.7)
Dyslipidemia 12,747 3094 (24.3) 44,452 10883 (24.5)
Diabetes 12,747 780 (6.1) 44,452 3114 (7.0)
Hypertension 12,747 4870 (38.2) 44,452 16198 (36.4)
Current smoker 12,747 3551 (27.9) 44,452 12322 (27.7)
Atrial ﬁ brillation 12,747 127 (1.0) 44,452 343 (0.8)
Family history of CHD 12,747 372 (2.9) 44,452 1,396 (3.1)
Renal disease 12,747 152 (1.2) 44,452 530 (1.2)
CV risk category* 12,747 44,452
Low risk 2721 (21.3) 10283 (23.1)
Medium risk 4342 (34.1) 14073 (31.7)
High risk 4410 (34.6) 15093 (34.0)
Very high risk 1274 (10.0) 5003 (11.3)
aNational Cholesterol Education Program deﬁ nition. CHD: coronary heart disease; CV: cardiovascular; HbA1c: 
glycosylated haemoglobin; HDL: high-density lipoprotein.
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medium and high CRP levels were 6.57, 7.20 and 12.20%, respectively (log-rank P < 
0.001; Fig. 2). The respective probabilities by TC levels were 9.97, 9.62 and 12.68% 
(log-rank P = 0.366; Fig. 2). Within each TC category, the risk of a CV event increased 
with the CRP level (P = 0.011; Fig. 3).
The analysis of univariate models indicated no signiﬁ cant interaction between time in 
its logarithmic transformation and the covariates of the FRS and QRISK2 Cox models, 
so the proportional hazard assumption was deemed acceptable. The multivariate Cox 
analyses with the FRS and QRISK2 risk factors showed that all the traditional CV 
risk factors were signiﬁ cantly associated with CV events except for dyslipidaemia, in 
both the RA and the non-RA cohorts for the FRS based model. For the QRISK2-based 
analysis, in addition to dyslipidaemia, obesity, atrial ﬁ brillation and renal disease were 
not signiﬁ cant in RA (Table 2). Based on the hazard ratios (HRs), all risk factors had 
a similar magnitude of eﬀ ect in the RA vs non-RA cohort. The C-Index for the FRS 
in the non-RA vs RA cohort was 0.783 and 0.754 (P < 0.001) and that of the QRISK2 
was 0.744 and 0.770 (P < 0.001), respectively (Table 2). The observed and predicted 
event rates at 3 years were plotted for both RA and non-RA patients based on the 
predictions from both the FRS and QRISK2 models. Overall, similar patterns were 
observed between FRS and QRISK2 in RA and non-RA cohorts (plots as supplemen-
tary material).
Figure 1. Time to CV event (FRS CV deﬁ nition) in RA and non-RA patients
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The addition of log[CRP] was positively associated with CV events in the RA cohort 
for the FRS model (HR = 1.12; 95% CI: 1.03, 1.23) but not in the QRISK2 model (HR 
= 1.03; 95% CI: 0.91, 1.16; Table 3). The model discriminations due to the addition 
of log[CRP] were improved by very small amounts, with C-Index increments between 
the two models of 0.003 (P = 0.026) for the FRS model and 0.0005 (P = 0.250) for the 
QRISK2 (Table 3). Likewise, very small AIC diﬀ erences were observed in the models 
with and without log[CRP] (4881 vs 4877 in the FRS and 2741 vs 2743 for QRISK2). 
Figure 2. Time to CV event (FRS CV deﬁ nition) by baseline TC and CRP levels in RA patients
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The overall re-classiﬁ cation as a result of the addition of CRP was characterized by 
a non-signiﬁ cant NRI of 3.2% (95% CI: -2.8, 5.7%) in the FRS model and a negative 
improvement of -2.0% (95% CI: -5.8, 4.5%) in the QRISK2 model (Table 3).
DISCUSSION
Our study investigated the performance of the FRS and QRISK2 equations in RA and 
matched non-RA patients and assessed the additional value of including CRP, as-
sessed at the index date, to the FRS and QRISK2 risk algorithm. This is the ﬁ rst UK 
study to compare the FRS and QRISK2 risk algorithm in RA and non-RA patients 
matched on the baseline CV risk factors.
Several studies have conﬁ rmed the higher CV risks in RA patients [7-10]. The CV 
incidence rates in the RA cohort observed in our analysis are comparable to a recent 
publication from the UK using The Health Improvement Network data set, a clinical 
practice data set similar to CPRD [25]. However, the observed event rates appear 
relatively high compared with other observational studies from The Netherlands 
and Sweden, highlighting diﬀ erence in CV event rates in RA populations across 
countries [4].
There is evidence that the increased CV risk in RA patients might not be explained by 
traditional risk factors alone [26]. In addition, traditional risk calculators, such as FRS, 
underestimate the CV risk among RA patients, especially with high CV risk [27]. RA 
Figure 3. Relative Risk of CV event (FRS deﬁ nition) by TC and CRP categories in RA patients
CRP: C-reactive protein; CV: cardiovascular; TC: total cholesterol
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patients have chronic high-grade inﬂ ammation, but the only CV risk calculator that 
includes markers of inﬂ ammation is the Reynolds Risk Score, which was also devel-
oped in the general population [28]. Thus, the Reynolds Risk Score would be likely to 
underestimate the CV risk in RA patients [29, 30]. The QRISK2 score incorporates RA 
but it is not speciﬁ c and there is evidence that it overestimates CV risk [31, 32].We 
evaluated the performance of FRS and QRISK2 in RA patients and matched non-RA 
patients and tested whether the addition of CRP would improve the performance of 
these calculators in the RA cohort.
We used the FRS risk algorithm, because EULAR guidelines in RA recommends using 
FRS for CV risk stratiﬁ cation of RA patients and it is also referenced in the UK clinical 
guidelines by the Joint British Recommendations on the Prevention of CHD [27, 33]. 
The QRISK2 has been recommended for CV risk estimation by the National Institute 
of Health and Care Excellence in the UK.
To compare the algorithms in the two cohorts, we controlled for traditional CV risk 
factors by matching RA to non-RA patients based on their CV risk proﬁ le. Overall, 
we found that the algorithms had a good discrimination in RA patients, although the 
C-Index was lower compared with the CV risk-matched non-RA cohort. Similar to our 
ﬁ ndings, other studies reported that the FRS algorithm underestimates the CV risk 
in established and early RA patients, especially in patients with high baseline deciles 
of predicted risks, but ours is the ﬁ rst study having a comparator group matched for 
baseline CV risks [29, 32].
Further examination of the Cox model indicated that almost all the traditional risk 
factors in FRS had a similar magnitude of eﬀ ect in the RA and non-RA cohorts except 
smoking, hypertension and diabetes, whose HRs were ~5% higher in the RA com-
pared with the non-RA cohort. There is evidence to suggest that RA patients have 
a diﬀ erent CV risk factor proﬁ le compared with non-RA patients because they are 
more likely to be obese and more likely to be smokers and hypertensive [34]. There 
is emerging evidence to suggest that the immune dysregulation, chronic high-grade 
inﬂ ammation and metabolic disturbances found in RA patients could contribute to 
the increased CV events [26, 35-37]. We observed baseline CRP, but not TC, to be 
associated with a higher CV event risk in RA. This observation was found to hold even 
after controlling for all the traditional risk factors. We further evaluated the association 
between TC, CRP and CV events in RA patients and noticed that within each category 
of TC (low, medium and high), an increase in CRP levels increased CV events. Thus, 
we hypothesize that CRP could have a risk-modifying eﬀ ect in RA patients. However, 
the inclusion of CRP as a risk factor in the FRS and QRISK2 did not improve the 
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reclassiﬁ cation of CV risks; in fact, it worsened the reclassiﬁ cation in QRISK2. Thus, 
CRP itself might not explain the overall increased CV events observed in RA patients.
These ﬁ ndings are consistent with those observed in two other analyses using a similar 
methodology and based on electronic medical record databases from the USA [38, 39]. 
Given the ﬁ ndings of our analysis, we think that studies focusing on developing and 
validating RA-speciﬁ c risk CV algorithms are most appropriate [14, 32]. Some studies 
have reported success in developing and validating such algorithms; therefore, future 
research should focus on further testing of these RA-speciﬁ c CV algorithms [14].
There were several limitations to our analysis. First, this was a retrospective analysis, 
implying some sources of bias attributable to confounding factors. However, this was 
partly accounted for by matching patients based on disease risk score for RA and CV 
risk proﬁ les. The identiﬁ cation of RA patients was based on RA diagnosis records 
in groups 1 and 2 of Thomas et al. [20], and seronegative RF read codes were not 
included. However, the list of codes is associated with a sensitivity of 93% and a 
speciﬁ city of 49% and thus there could be some false-positive patients in our case 
cohort. As the ﬁ ndings from our study are similar to those of two other studies us-
ing similar methodology and based on US electronic medical records, we anticipate 
that false positives have minimal impact on the overall conclusion [38, 39]. In the 
non-RA cohort, neither lipids nor hypertension was predictive of future CVD events. 
This could be explained by the fact that the patient data for this analysis were from a 
general practice database and thus the patients were managed for their CV risk fac-
tors. Treatment for hypertension is on the causal pathway of risk factors for CVD and, 
in fact, we noticed that treatment for hypertension was a predictor. In our data set, 
there were a number of missing laboratory values for non-traditional CV risk factors 
and so categorical yes/no variables were used instead in both the FRS and QRISK2 
models. For example, dyslipidaemia was based on a combination of laboratory value 
thresholds, treatment and diagnosis codes. However, as this would impact the two co-
horts equally, we do not think this would aﬀ ect the overall ﬁ ndings of our analysis. In 
addition, we were not able to include some of the QRISK2 covariates, such as ethnicity 
or the Townsend deprivation score, because of their unavailability. The imputation 
of missing values for CRP and continuous laboratory values in general could have 
been undertaken. For CRP, a variety of imputation approaches could have been used. 
Although this would have enabled us to retain the full sample size, imputation can 
introduce bias. For instance, the missing information might not be random; that is, 
CRP might be tested only when general practitioners suspect a high value. This means 
that the missing CRP values might be lower than the recorded ones. Given that data 
on UK postal codes was not available via CPRD, we used the approach as stated by 
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the developers of QRISK2 [40]. As the average follow-up time was 6.0 and 3.8 years in 
the overall RA cohort and RA patients with CRP measures, respectively, we estimated 
5- and 3-year CV risks in this analysis. Although we do agree that this apparent incon-
sistency could introduce confusion, the aim of the present paper was to estimate the 
incremental improvement in prediction with the addition of inﬂ ammatory measures 
and not the 10-year estimated risk of CVD. Furthermore, focusing on patients with 
CRP data available in the second analysis may have resulted in a selection bias. Our 
analysis of the non-traditional risk factor was limited to CRP because other factors, 
such as RA disease activity, were not available for analysis. Another limitation was the 
49-day delay between the reported CRP value and the index date.
Despite limitations, the study was based on data with both a large sample size and a 
good follow-up period. Thus, the results are generalizable to the UK population and 
are representative of its clinical practice.
CONCLUSION
The FRS and QRISK2 have a good discrimination in the RA population, but it was 
signiﬁ cantly lower than the general population. Even though CRP is associated with an 
increased risk of CV events, the inclusion of CRP in the FRS equation and the QRISK2 
model did not result in an improvement in reclassiﬁ cation of CV risk.
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CHAPTER 8 SUPPLEMENT MATERIAL
Supplementary Figure S1. Observed vs. predicted 3-year cardiovascular risk in RA and non-RA patients
Supplementary table S1: Relative Risk of cardiovascular event (FRS deﬁ nition) by TC and CRP categories in 
RA patients
TC
Low TC Medium TC High TC
CRP
Low
1.000 0.776 1.489
(N=345) (N=234) (N=163)
Medium
1.366 1.060 2.034
(N=321) (N=217) (N=132)
High
2.177 1.690 3.243
(N=367) (N=197) (N=103)
P-values: TC (p=0.096); CRP (p=0.011). TC: total cholesterol.
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ABSTRACT
Objective. To examine the associations between lowering low-density lipoprotein 
cholesterol (LDL-C) and cardiovascular (CV) outcomes among patients with rheu-
matoid arthritis (RA) and patients without it. Methods. Adult patients with RA and 
2 age- and sex-matched control cohorts [RA plus general controls (RA/GN), RA plus 
osteoarthritis (OA) controls (RA/OA)] were identiﬁ ed between January 1, 2007, and 
December 31, 2011. Patients with a diagnosis of hyperlipidemia who initiated statin 
therapy without prior CV events were included. Multivariable Cox proportional hazard 
analyses were used. Results. The study identiﬁ ed 1522 patients with RA with 6511 
general controls (RA/GN cohort); and 1746 patients with RA with 2554 OA controls 
(RA/OA cohort). During followup, mean (SD) LDL-C (mg/dl) was 96.8 (32.7) for RA, 
100.1 (35.1) for general controls, and 99.1 (34.3) for OA. The relationship between 
lowering LDL-C and CV outcomes was similar for both RA and non-RA controls (p for 
interaction = 0.852 in RA/GN cohort, and p = 0.610 in RA/OA cohort). After adjusting 
for baseline CV risk factors, lowering LDL-C was associated with a 29%-50% lower 
risk of CV events (HR [95% CI] = 0.71 [0.57-0.89] in RA/GN, 0.50 [0.43-0.58] in RA/
OA). Subgroup analyses showed that lowering LDL-C was associated with a similar 
degree of reduction of CV events in RA and non-RA controls (HR of 0.67-0.68 for RA, 
0.72 for general controls, 0.76 for OA controls). Conclusion. Lowering LDL-C levels 
was associated with reduced CV events. The relationship between lowering LDL-C 
and CV outcomes in RA was similar to the relationship found in matched general and 
OA controls.
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INTRODUCTION
Cardiovascular (CV) disease is a common comorbidity for patients with rheumatoid 
arthritis (RA). It is estimated that patients with RA have a 50% increased risk of CV 
events or early mortality relative to the general population [1,2]. A high systemic in-
ﬂ ammatory burden [3] as well as traditional risk factors such as hypertension (HTN), 
diabetes, and smoking appear to be key contributors to the increased CV events in 
RA [4]. High cholesterol is an important factor for the increased risk of CV events for 
the general population; however, growing evidence suggests a complex relationship 
between lipid levels and CV risk in patients with RA [5,6,7]. Epidemiological studies 
reported lower lipid levels in patients with RA compared to the general population 
[6,8], but at the same time, patients with RA had higher rates of myocardial infarction 
(MI) and ischemic stroke [6]. These ﬁ ndings are potentially due to the altered lipid 
metabolism from systemic inﬂ ammation, drug therapy, and several genetic factors in 
RA [9].
Because of this complex relationship between lipid levels and CV diseases in RA, 
there is a lack of clinical guidelines to identify patients at high risk for CV disease and 
to manage these groups. The European League Against Rheumatism [10] currently 
recommends an annual CV risk assessment, treatment, and management according 
to guidelines that apply to the general population [11]. The hydroxymethylglutaryl CoA 
reductase inhibitor (statin) therapy has been shown to be beneﬁ cial in primary and 
secondary prevention of CV diseases in the general population [12,13]. However, evi-
dence regarding the beneﬁ ts of lowering elevated low-density lipoprotein cholesterol 
(LDL-C) in patients with RA is not clear. Although several studies suggest potential CV 
protective eﬀ ects of statin therapy in RA, the results are from posthoc analyses [14,15], 
and a recent prospective randomized controlled trial was terminated early owing to 
low CV event rates [16]. Speciﬁ cally, diﬀ erences in CV disease associated with lowering 
lipid levels between patients with RA and without need to be further investigated.
Given these uncertainties, the purpose of our study was to evaluate the association 
between lowering LDL-C levels and CV outcomes among RA subjects and age- and 
sex-matched controls who are prescribed statin therapy in a US managed care setting. 
Understanding diﬀ erences in beneﬁ ts of lowering LDL-C levels for patients with RA 
will be helpful to better manage these patients.
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MATERIALS AND METHODS
Data source
A retrospective cohort study of patients enrolled in Kaiser Permanente Southern 
California (KPSC) was conducted using information from the KPSC electronic 
medical records (EMR) and administrative databases between January 1, 2006, and 
December 31, 2011. KPSC is a nonproﬁ t, integrated health insurance provider with 
a current membership of over 4 million in Southern California. KPSC also provides 
comprehensive medical services through its own facilities, which include hospitals, 
out-patient sites, and a centralized laboratory. All aspects of care and interaction with 
the healthcare delivery system are included.
Study cohort
Adult patients aged ≥ 18 years were required to have 2 or more diagnoses of RA [Inter-
national Classiﬁ cation of Diseases, Ninth Revision, Clinical Modiﬁ cation (ICD-9-CM) 
code, 714.xx] from January 1, 2007, to December 31, 2011 (identiﬁ cation period), to be 
eligible for the RA cohort. Patients were also required to have at least 1 prescription for 
a disease-modifying antirheumatic drug (DMARD) within 12 months (before or after) 
the RA diagnosis [17]. The ﬁ rst RA diagnosis date or DMARD prescription date was 
deﬁ ned as an index date. Continuous membership with drug beneﬁ t for 12 months 
prior to the index date (baseline period) was required to be included in the RA cohort.
Two RA cohorts were identiﬁ ed. The ﬁ rst was matched to the general KPSC population 
(general controls) in a ratio of 4:1. The second RA cohort was matched to individuals 
with a diagnosis of osteoarthritis (OA; ICD-9-CM of 715.xx; OA controls) in a ratio of 
1:1. OA is a chronic condition that brings patients into regular contact with the health-
care system similar to RA. Matching of both RA cohorts to general and OA controls 
was based on sex and birth year (within a window of ± 2 yrs). Matched controls were 
required to have at least 1 outpatient or inpatient encounter so that an index date 
could be assigned during the matching process. They could not have an RA diagnosis 
or be receiving any DMARD therapy during the study period. Matched controls were 
also required to have continuous KPSC membership plus drug beneﬁ t for 12 months 
prior to the index date as well as continuous membership plus drug beneﬁ ts until 
the matched reference individual completed the qualiﬁ cation criteria. Unmatched pa-
tients with RA were dropped from the RA cohort (n = 1243 for RA matched to general 
controls; n = 165 for RA matched to OA controls).
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Patients with a hyperlipidemia diagnosis (ICD-9-CM of 272.0, 272.1, 272.2, 272.4, 
272.5, 272.8, or 272.9) and ≥ 1 statin prescription (Generic Product Identiﬁ er Class 
Codes of 3940, 3999) in the baseline period were included in the study. We excluded 
patients with a history of CV disease [MI, old MI, revascularization process, angina, 
stroke, transient ischemic attack (TIA), intermittent claudication, heart failure, ab-
dominal aortic aneurysm, acute carotid procedures] during the baseline period be-
cause the focus of our study was a primary prevention population. Patients without an 
LDL-C laboratory result during the follow-up period were excluded from the analyses. 
Patients were followed from their index date until the ﬁ rst CV outcome, end of enroll-
ment in the health plan, death from other causes, or the end of the study (December 
31, 2011), whichever occurred ﬁ rst.
Through the matching procedure, we were successful in matching 10,635 patients with 
RA to 42,540 general controls (1:4 match) and 11,713 patients with RA to 11,713 OA 
controls (1:1 match). After restricting the population to those with a hyperlipidemia 
diagnosis plus ≥ 1 statin prescription during the baseline period, no previous CV events 
and ≥ 1 LDL-C measurements during the follow-up period, our sample was reduced to 
1522 patients with RA matched with 6511 general controls, and 1746 patients with RA 
matched with 2554 OA controls (Figure 1). Median follow-up periods for the ﬁ nal study 
Figure 1. Population Cohort Diagram
Abbreviations: RA = Rheumatoid Arthritis; DMARD = Disease Modifying Anti-Rheumatic Drug; LDL-C = Low-
density Lipoprotein Cholesterol; CV = Cardiovascular
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samples were 3.1 years for RA plus general controls and 4.0 years for RA plus OA con-
trols. The study protocol was approved by the KPSC Institutional Review Board (#6331).
Lowering LDL-C levels
LDL-C during follow-up was categorized as whether the LDL-C was lowered to the 
recommended levels by the National Cholesterol Education Program Expert Panel 
— Adult Treatment Panel III guidelines [18]. Though this guideline was updated in 
2013 [19], it was the standard of care during the time period for our study. The LDL-C 
recommended levels were < 100 mg/dl (2.6 mmol/l) for individuals at high risk, < 130 
mg/dl (3.4 mmol/l) for those with moderate CV risk, and < 160 mg/dl (4.1 mmol/l) 
for those in the lowest CV risk category. The risk category was assigned to each indi-
vidual based on coronary heart disease (CHD) status or a 10-year risk for CHD using 
baseline information [18]. Multiple LDL-C measurements during the follow-up period 
were observed and the analyses were conducted using the closest LDL-C value to the 
CV event or end of follow-up.
Other variables
Baseline patient characteristics including demographics (age, race/ethnicity, sex), 
body mass index, smoking status, comorbidities (Charlson comorbidity index, HTN 
and anti-HTN medication use, and diabetes) and baseline CV risk were obtained from 
the EMR. Among these variables, age, sex, HTN, anti-HTN medication use, smoking 
status, and diabetes were used as covariates to investigate the relationship between 
LDL-C and CV events, consistent with Framingham risk prediction20.
Study outcomes
The study outcomes of interest included MI, angina, stroke, TIA, intermittent claudi-
cation, heart failure, or death from CV disease [20]. Primary hospital discharge records 
were used to deﬁ ne MI, angina, and stroke. The ICD-9-CM codes for each outcome 
are listed in Appendix 1. Outpatient and/or emergency department visit records were 
further used to deﬁ ne TIA, intermittent claudication, and heart failure. Any death 
occurring within 1 month after a deﬁ ned CV event was classiﬁ ed as death from CV 
disease. Death was identiﬁ ed from health plan databases, Social Security Administra-
tion vital status ﬁ les, and California state death ﬁ les.
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Statistical analyses
Baseline demographic information was summarized using descriptive statistics. Com-
parisons between RA and matched controls were conducted using t tests or Wilcoxon-
Mann-Whitney tests for continuous variables, and chi-square tests for categorical 
variables. To investigate the association between LDL-C and CV outcomes, univariable 
and multivariable Cox proportional hazard analyses were conducted. HR and 95% CI 
were reported. Interaction terms between having RA and LDL-C levels were investi-
gated to examine the diﬀ erences in LDL-C and CV outcomes across RA and matched 
controls. Subgroup analyses were conducted for RA and non-RA controls separately.
Kaplan-Meier survival curves with log-rank tests were used to demonstrate the event-
free survival over time for the group that lowered LDL-C to the recommended levels 
compared with the group that did not (Figure 2). Sensitivity analyses were conducted 
Figure 2. Kaplan-Meier survival curves show the event-free survival over time for the group that lowered LDL-C 
to the recommended levels compared with the group that did not.
RA: rheumatoid arthritis; LDL-C: low-density lipoprotein cholesterol; OA: osteoarthritis.
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using diﬀ erent LDL-C results (average LDL-C during followup, median LDL-C during 
followup) or diﬀ erent followup periods (starting to followup from the last LDL-C). 
Statistical analysis was performed with SAS version 9.2 (SAS Institute Inc.).
RESULTS
The baseline demographic information for the 2 cohorts is presented in Table 1. 
Overall, traditional CV risk factors were higher in patients with RA compared with 
general and OA controls. In the RA cohort matched to general controls, 74.2% had 
HTN, 40.9% had diabetes, 33.9% were obese, and 10.4% were smokers. These were 
all higher than the proportions found in the matched controls. Similarly, higher pro-
portions of CV risk factors were found in RA cohort matched to OA controls except 
for obesity, which was higher in OA controls. Patients with RA had higher CV risk at 
baseline compared to general controls (high risk: 41.3% vs 38.1%) and compared to 
OA controls (high risk: 40.3% vs 36.2%).
Identiﬁ ed statin therapy included atorvastatin 10-80 mg, simvastatin 5-80 mg, ﬂ uvas-
tatin 20-80 mg, lovastatin 10-40 mg, rosuvastatin 5-40 mg, and pravastatin 10-80 mg. 
Lower baseline lipid levels were observed in RA cohorts compared to general [mean 
LDL-C for RA vs general controls: 104.6 vs 109.6 in mg/dl; 2.70 vs 2.83 in mmol/l] and 
OA controls [mean LDL-C for RA vs OA controls: 104.5 vs 109.8 in mg/dl; 2.70 vs 2.84 
in mmol/l]. The same trend was observed for total cholesterol and triglyceride levels. 
High-density lipoprotein cholesterol (HDL-C) levels did not diﬀ er between the RA and 
the control groups.
During follow-up, mean LDL-C levels were 96.8 mg/dl (2.50 mmol/l) for RA group 
matched to general controls, 100.1 mg/dl (2.59 mmol/l) for general controls, 96.5 
mg/dl (2.50 mmol/l) for RA group matched to OA controls, and mg/dl (2.56 mmol/l) 
for OA controls. The proportion of patients who lowered LDL-C to the recommended 
levels was 78.7% for both RA and general controls, and 80.0% for OA controls.
The association between lowering LDL-C levels and CV outcomes is shown in Table 2. 
After adjusting for other risk factors (RA status, age, sex, HTN, anti-HTN medication 
use, smoking status, and diabetes), a reduction of LDL-C was associated with a 29% 
lower risk of CV events in patients with RA plus general control cohort (HR 0.71, 95% 
CI 0.57–0.89) and a 50% lower risk of CV events in RA patients plus OA control cohort 
(0.50, 0.43–0.58). Having an RA disease was associated with a 76% increased risk of 
CV events after controlling for other risk factors including LDL-C status. These factors 
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9were also associated with an increased risk of CV events: older age, male sex, having 
HTN or anti-HTN medication use, smoking, and having diabetes. The overall model 
showed that there were no diﬀ erences in relationships between lowering LDL-C and 
CV outcomes among RA and general or OA controls [p for interaction term (RA × 
LDL-C levels) was 0.852 for RA vs general controls, and 0.610 for RA vs OA controls; 
Table 2].
Although there were no signiﬁ cant diﬀ erences in the relationship between lowering 
LDL-C and CV outcomes, we conducted a priori subgroup analyses to further show 
that the LDL-C eﬀ ects on CV outcomes are in the same direction for RA and non-RA 
controls. Univariable and multivariable regression analyses for the RA and matched 
controls were conducted separately (Table 3). After adjusting for other risk factors 
Table 2. Association between Lowering Low-density Lipoprotein Cholesterol up to Clinically Recommended 
Levels and Cardiovascular Outcomes for Each Cohort
RA vs. General controls, N = 8,033
Independent Variable HR (95% CI) p-value
RA (vs. controls) 1.76 (1.43, 2.17) <.0001
Lowered LDL-C (vs. not lowered) 0.71 (0.57, 0.89) 0.003
Age 1.07 (1.06, 1.08) <.0001
Male Gender (vs. Female) 1.34 (1.10, 1.64) 0.004
Hypertension (Yes vs. No) 1.41 (1.03, 1.64) 0.031
Antihypertensive Medications (Yes vs. No) 1.45 (0.96, 2.20) 0.078
Smoker (vs. Non-smoker) 1.53 (1.10, 2.13) 0.011
Unknown Smoking Status (vs. Non-smoker) 1.21 (0.88, 1.68) 0.248
Diabetes (Yes vs. No) 1.56 (1.28, 1.90) <.0001
Interaction term of RA X lowered LDL-C - 0.852
RA vs. OA controls, N = 4,300
Independent Variable HR (95% CI) p-value
RA (vs. controls) 1.13 (0.92, 1.40) 0.245
Lowered LDL-C (vs. not lowered) 0.50 (0.43, 0.58) <.0001
Age 1.06 (1.05, 1.07) <.0001
Male Gender (vs. Female) 1.30 (1.04, 1.64) 0.024
Hypertension (Yes vs. No) 1.32 (0.93, 1.88) 0.125
Antihypertensive Medications (Yes vs. No) 1.58 (1.00, 2.48) 0.049
Smoker (vs. Non-smoker) 1.61 (1.12, 2.32) 0.011
Unknown Smoking Status (vs. Non-smoker) 0.92 (0.61, 1.40) 0.698
Diabetes (Yes vs. No) 1.32 (1.07, 1.64) 0.011
Interaction term of RA X lowered LDL-C - 0.610
Abbreviations: RA= Rheumatoid Arthritis; OA = Osteoarthritis; LDL-C= Low-density Lipoprotein Cholesterol
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(age, sex, HTN, anti-HTN medication use, smoking status, and diabetes), lowering 
LDL-C levels was associated with a similar degree in reduction of CV events in patients 
with RA identiﬁ ed from both cohorts (HR 0.68, 95% CI 0.46–1.02 for matched RA to 
general controls and HR 0.67, 95% CI 0.46–0.96 for matched RA to OA controls). A de-
crease in LDL-C was also associated with a reduction in CV events in general controls 
(HR 0.72, 95% CI 0.55–0.95), and similar HR results were found in OA controls (HR 
0.76, 95% CI 0.53–1.07). Sensitivity analyses showed that the results were consistent, 
applying average or median LDL-C values to deﬁ ne LDL-C status instead of the closest 
value to the end of followup.
DISCUSSION
We investigated the eﬀ ect of lowering LDL-C in patients with RA compared with 
age- and sex-matched general and OA controls. Among patients with a diagnosis of 
hyperlipidemia and taking statins, we found that a decrease in LDL-C to the clinically 
recommended levels based on baseline CV risk was associated with 29% and 50% 
reduced CV events in RA plus matched general controls, and in RA plus matched 
OA controls, respectively. Interaction terms consistently showed that the eﬀ ect of 
lowering LDL-C levels on CV outcomes was similar for both RA and matched general 
as well as matched OA controls. These ﬁ ndings are meaningful due to the complex 
relationship between lipid proﬁ les and CV events for patients with RA. Myasoedova, 
Table 3. Association between Lowering Low-density Lipoprotein Cholesterol to Clinically Recommended Levels 
and Cardiovascular Outcomes for Each Subgroup
Cohort RA vs. General Controls RA vs. OA Controls
RA patients
N=1,522
RA patients
N=1,746
RA patients HR (95% CI) p-value HR (95% CI) p-value
Lowered LDL-C (vs. not lowered)* 0.72 (0.49, 1.07) 0.104 0.70 (0.49, 1.00) 0.053
Lowered LDL-C (vs. not lowered)§ 0.68 (0.46, 1.02) 0.060 0.67 (0.46, 0.96) 0.028
General controls
N=6,511
OA controls
N=2,554
Non-RA patients HR (95% CI) p-value HR (95% CI) p-value
Lowered LDL-C (vs. not lowered)* 0.83 (0.63, 1.09) 0.179 0.93 (0.65, 1.31) 0.659
Lowered LDL-C (vs. not lowered)§ 0.72 (0.55, 0.95) 0.021 0.76 (0.53, 1.07) 0.118
* Results from univariable analyses
§ Results from multivariable analyses adjusting for age, sex, hypertension, antihypertensive medication use, 
smoking, diabetes
Abbreviations: RA= Rheumatoid Arthritis; OA = Osteoarthritis; LDL-C = Low-density Lipoprotein Cholesterol
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et al [5] reported increased CV risk with low and high levels of total cholesterol and 
LDL-C. This nonlinear relationship was also observed in independent RA cohorts by 
Zhang, et al [21] and Liao, et al [22].
Our results of reduced CV eﬀ ects associated with lowering LDL-C conﬁ rm previous 
ﬁ ndings. A recent prospective statin-placebo controlled clinical trial in patients with 
RA found that treatment with atorvastatin 40 mg daily resulted in a 34% risk reduction 
for major CV events compared to placebo, although these ﬁ ndings are not statistically 
signiﬁ cant because of early termination of the trial16. Posthoc analyses from 2 large 
clinical trials also reported that patients with inﬂ ammatory joint disease (IJD) includ-
ing RA and non-IJD patients had comparable lipid reduction and protection against CV 
events both regarding intensive and conventional lipid lowering with statins [14.15].
It is important to note that our inclusion criteria allowed patients with hyperlipid-
emia who initiated statin therapy. From previous studies investigating LDL-C and CV 
outcomes in RA, only 17%–30% among patients with RA received a statin [5, 21]. 
Other interventional studies compared statin users and placebo [14,15,16]. Our study 
design requiring only statin initiators was intended to avoid treatment selection bias; 
patients who initiated statin therapy may be diﬀ erent from patients who did not. Also, 
additional antiinﬂ ammatory properties of statin may further bias the results [23, 24] . 
Thus, our study shows the beneﬁ ts of lowering LDL-C levels in hyperlipidemia patients 
who initiated statin treatment.
Similar reductions in CV outcomes were found in subgroup analyses. The HR ranged 
from 0.67 to 0.76 in 4 diﬀ erent subgroups. Although 2 of the HR (1 in RA subgroup, 
1 in matched OA controls) are not statistically signiﬁ cant, this should be interpreted 
with caution [25, 26, 27]. False-negatives and false-positives due to small sample sizes 
may lead to these ﬁ ndings [25].
Our RA study population is currently taking DMARD therapy, with 11% taking biologic 
DMARD. About 30% of patients with RA were positive either for rheumatoid factor 
(RF) or anticitrullinated protein antibodies (ACPA). Also, 50% of patients with RA 
were considered positive for either C-reactive protein (CRP) or erythrocyte sedimenta-
tion rate (ESR) even if a large proportion of data was missing (45% missing for either 
RF or ACPA, and 24% missing for either CRP or ESR). It may be important to note 
the treatment and inﬂ ammatory status in this study population because these could 
inﬂ uence the study results. Studies showed that inﬂ ammatory status may change 
lipid levels; lower levels of total cholesterol, HDL-C, and LDL-C were found among RA 
patients with active inﬂ ammation [8, 28].
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Consistent with previous ﬁ ndings, patients with RA in this study reported lower levels 
of LDL-C and total cholesterol compared to lipid levels in matched general or OA con-
trols at baseline. During the followup, the mean LDL-C levels were further decreased, 
and patients with RA still had lower lipid levels compared to matched controls. How-
ever, the proportion of patients who lowered their LDL-C to recommended levels was 
the same in RA and general controls, and the beneﬁ ts of lowering LDL-C levels were 
also similar.
Our analyses further veriﬁ ed that having RA itself increased CV risk by 76% even after 
adjusting for traditional risk factors such as age, sex, smoking, HTN, and diabetes. 
These ﬁ ndings are consistent with previous ﬁ ndings, which suggest about a 50% 
higher risk of CV events and mortality among patients with RA relative to the general 
population [1,2]. High inﬂ ammation may explain these ﬁ ndings [29, 30, 31, 32]; cur-
rently emerging studies on this matter may determine the reasons for the additional 
CV risk for patients with RA.
Our study has several potential limitations. First, this observational study design 
limits the causal inferences that can be made between the LDL-C levels and CV out-
comes. Patients with lower LDL-C levels may have healthier lifestyles or may adhere to 
other CV prevention measures compared to patients with higher LDL-C levels. These 
factors are usually unmeasured and may result in biased eﬀ ect estimates. Therefore, 
we should emphasize that this study investigated an “association” between LDL-C 
and CV outcomes rather than a “causal relationship” between the two. This study was 
not designed to address the CV beneﬁ ts of a speciﬁ c LDL-C treatment target. Instead, 
we emphasize that the relationship between lowering LDL-C levels and CV outcomes 
was not diﬀ erent between patients with RA and non-RA controls. Moreover, this study 
was not able to disentangle the beneﬁ ts of lowering LDL-C and statin adherence. Our 
ﬁ ndings might be better explained by the beneﬁ ts from higher adherence to statin 
therapy rather than lowering LDL-C.
Another limitation is that our study population is solely from 1 healthcare system and 
thus our results may not be generalizable to other settings. However, the relationship 
between LDL-C and CV outcomes should be similar in other populations, and the 
KPSC population has been shown to be generalizable to that of Southern California 
[33]. Moreover, we assumed that patients continue their statin therapy during the 
followup. Also, we considered that 1-time LDL-C measurement during the followup 
represents the LDL-C status for the entire followup period. This may not be plausible; 
statin medication adherence and/or LDL-C levels may change over time and this may 
aﬀ ect the CV outcomes. However, results were consistent from sensitivity analyses 
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using diﬀ erent LDL-C values (average or median LDL-C instead of closest LDL-C to 
the end of followup) or a diﬀ erent followup period (start to followup from the last 
LDL-C to the end of followup). We were unable to evaluate inﬂ ammatory factors in this 
study investigating CV outcomes because about 50% of the data on those factors were 
missing. Also, our study focused only on patients already taking statin therapy with a 
hyperlipidemia diagnosis. There may be higher-risk patients who did not initiate statin 
therapy or who were not diagnosed with hyperlipidemia and who were not included 
in our study. However, we believed that investigating LDL-C status and comparing 
outcomes among the treated hyperlipidemia patients may be reasonable because the 
population is homogeneous.
Despite these limitations, our study has a number of strengths. This study investi-
gated the association between lowering LDL-C and CV outcomes in a relatively large 
patient cohort having RA. Also, we were able to create age- and sex-matched non-RA 
and OA controls based on an ethnically diverse population so that we could examine 
the LDL-C and CV outcome across a diverse cohort. An additional strength is the 
relatively rich and high-quality clinical data. Most of the statin users (89% for patients 
with RA and 79% for non-RA controls) had at least 1 followup LDL-C value so that we 
could minimize missing data.
Our study showed that lowering LDL-C levels to clinically recommended levels based 
on baseline CV risk was associated with a decreased CV risk. The relationship between 
LDL-C and CV outcomes in RA was similar to the relationship found in matched gen-
eral and OA controls. These ﬁ ndings are consistent with a previous study showing 
the similar relationship in LDL-C and CV outcomes in RA and non-RA subjects [22], 
and support CV protective eﬀ ects of lowering LDL-C with statins in RA suggested 
by interventional studies [14, 15, 16]. Even though speciﬁ c LDL-C treatment targets 
are no longer recommended, our study supports the beneﬁ ts of lowering LDL-C for 
patients using statin therapy, for both RA and non-RA controls. Future prospective 
studies to address this matter will be essential to better understand the beneﬁ ts of 
lowering LDL-C in patients with RA. Further, our study showed that patients with RA 
still had a 76% higher risk of CV even after controlling for LDL-C status. Future studies 
should address excessive CV risk management strategies in addition to LDL-C in RA.
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CHAPTER 9: SUPPLEMENTARY MATERIAL
APPENDIX 1. Deﬁ nition of cardiovascular outcomes.
Outcome Deﬁ nition
CV death Fatal CV events deﬁ ned as death occurring within 1 month after CV 
events
Myocardial infarction Primary hospital discharge record with ICD-9-CM of 410.x0, 410.x1
Angina Primary hospital discharge record with ICD-9-CM of 411.x
Stroke Primary hospital discharge record with ICD-9-CM of 430.x, 431.x, 433.x, 
434.x, 436.x
TIA Hospital or emergency visit with ICD-9-CM of 435.x
Intermittent claudication Any encounter with ICD-9-CM of 440.21, 443.9
Heart failure Primary hospital discharge record of 428.x, 402.01, 402.11, 402.91, 
404.01, 404.03, 404.11, 404.13, 404.91, and 404.93, OR ≥ 3 ambulatory, 
nonemergency department visits coded for heart failure, with at least 1 
of the visits being with a cardiologist
CV: cardiovascular; ICD-9-CM: International Classiﬁ cation of Disease, Ninth Revision, Clinical Modiﬁ cation; 
TIA: transient ischemic attack.
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ABSTRACT
Objectives: To assess cost-eﬀ ectiveness of abatacept versus adalimumab, each 
administered with methotrexate, in treating patients with rheumatoid arthritis (RA) 
stratiﬁ ed according to baseline anticitrullinated protein antibody (ACPA) levels 
(marker of poor prognosis in RA). Methods: A payer-perspective cost-eﬀ ectiveness 
model simulated disease progression in patients with RA who had previously failed 
conventional disease-modifying anti-rheumatic drugs and were starting biologic 
therapy. Patients commenced treatment with abatacept or adalimumab plus metho-
trexate and were evaluated after 6 months. Therapy continuation was based on the 
European League Against Rheumatism treatment response; disease progression was 
based on the Health Assessment Questionnaire Disability Index score. These score 
changes were used to estimate health state utilities and direct medical costs. Quality-
adjusted life-years (QALYs) and incremental cost per QALY gained were calculated 
by baseline ACPA groups (Q1, 28–234 AU/ml; Q2, 235–609 AU/ml; Q3, 613–1045 
AU/ml; and Q4,1060–4894 AU/ml). Scenario analysis and one-way and probabilistic 
sensitivity analyses were used to evaluate robustness of model assumptions. Results: 
Abatacept resulted in QALY gain versus adalimumab in ACPA Q1, Q3, and Q4; 
between-treatment diﬀ erence (diﬀ erence: Q1, -0.115 Q2, -0.009 Q3, 0.045; and Q4, 
0.279). Total lifetime discounted cost was higher for abatacept versus adalimumab in 
most quartiles (Q2, £77,612 vs. £77,546; Q3, £74,441 vs. £73,263; and Q4, £78,428 
vs. £76,696) because of longer time on treatment. Incremental cost per QALY for 
abatacept (vs. adalimumab) was the lowest in the high ACPA titer group (Q4, £6,200/
QALY), followed by the next lowest titer group (Q3, £26,272/QALY). Conclusions: 
Abatacept is a cost-eﬀ ective alternative to adalimumab in patients with RA with high 
ACPA levels.
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INTRODUCTION
Rheumatoid arthritis (RA) imposes substantial economic burden on patients, their 
carers, and the health care system. In 2009, the economic burden of RA was esti-
mated to be up to £4.75 billion per year in the United Kingdom [1], with other sources 
estimating the overall cost to the UK economy of productivity losses at almost £8 
billion per year [2]. About 30% of patients give up work within 1 year of diagnosis, 
whereas 60% do so within 6 years [2]. RA is characterized by progressive disability, 
systemic complications, and early mortality [3]. Autoantibody production, including 
rheumatoid factor (RF) and anticitrullinated protein antibody (ACPA), is believed to 
play a role in RA disease pathogenesis, and both RF and ACPA assays may be used to 
detect RA [4]. Although the sensitivities of ACPA and RF appear to be similar, ACPA 
has demonstrated a higher speciﬁ city than RF in detecting early RA [4], resulting in the 
incorporation of ACPA testing into RA diagnostic criteria in 2010 [5].
In ACPA-positive patients, ACPA is associated with the human leukocyte antigen - 
antigen D related, which is associated with severe RA through the involvement of 
CD4+ T cells [3,6]. Thus, patients with RA who are ACPA-positive have a less favorable 
prognosis and develop a more aggressive disease than those who are ACPA-negative 
[7,8], suggesting that this distinction may be of clinical value [3]. ACPA is relatively 
stable over time for an individual patient [9] and, as a biomarker, has been shown to 
improve the identiﬁ cation of those at risk of developing clinical RA [10,11]. In addition, 
it appears that ACPA positivity may be important in assessing the mortality risk in 
patients presenting with early RA [12].
Although clinical practice data demonstrate that presence of ACPA is people with RA 
is a strong predictor of structural damage (joint erosions) and radiographic progres-
sion, its predictive value for treatment outcomes is not well understood [4,13]. Recent 
studies have shown that outcomes of biologic treatment can vary by ACPA status, and 
certain biologic disease-modifying antirheumatic drugs (DMARDs) such as abatacept 
(Orencia®, Bristol-Myers Squibb, New York, NY, USA) have demonstrated a better 
clinical response in ACPA-positive patients compared with ACPA-negative patients 
[14].
In the phase IIIB, multinational, prospective, randomized Abatacept versus adaliMum-
ab comParison in bioLogic naivE (AMPLE) study of subjects with RA with background 
methotrexate (MTX), abatacept was compared directly with adalimumab (Humira®, 
AbbVie Inc, North Chicago, IL, USA) in biologic-naive patients with analysis by base-
line ACPA levels, each treatment was more eﬀ ective in ACPA-positive patients than in 
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ACPA-negative patients observed for patients who received abatacept compared with 
those who received adalimumab in the highest ACPA quartiles with regard to the Dis-
ease Activity Score 28 (DAS28) and the Health Assessment Questionnaire Disability 
Index (HAQ-DI) score [17]. Notably, the mean improvements in DAS28 and HAQ-DI 
scores with abatacept were signiﬁ cantly greater for the highest ACPA concentration 
quartile than for the lower three quartiles combined, whereas for adalimumab the 
improvements were similar for patients with higher ACPA titers may be driven in part 
by modulator of T-cell activation [6]. Abatacept is thought to block CD28 costimulatory 
signals required for T-cell activation, thereby limiting the activation of T cells [19].
Given the observed clinical beneﬁ ts of abatacept in ACPA-positive patients, the objec-
tive of this analysis was to assess the beneﬁ ts and costs of abatacept compared with 
those of adalimumab, each administered with MTX, in treating patients with RA who 
had inadequate response to MTX and stratiﬁ ed by their baseline ACPA levels. The 
choice of adalimumab as a comparator was driven by data availability, and the AMPLE 
study was the only published study to provide a direct comparison with another agent 
and presented data by patient ACPA level. Anti–tumor necrosis factors (TNFs), and 
in particular adalimumab, are currently the standard of care in patients who fail MTX; 
thus, the choice of the comparator is appropriate from a payer perspective. Given 
the mechanism of action of the anti-TNFs, one could assume that the results of this 
analysis could be similar to non-adalimumab anti-TNFs.
METHODS
Overall Model Structure
A cost-eﬀ ectiveness simulation model was developed on the basis of an individual 
patient simulation (IPS) approach. The model concept is similar to that of the 
“Birmingham rheumatoid arthritis model” [20] with certain elements incorporated 
from the “Sheﬃ  eld rheumatoid arthritis health economic model” [21], and it was 
programmed in Microsoft Excel. The model (Fig. 1) adopted a payer perspective and 
tracked a large number of individual patients with diﬀ erent baseline characteristics 
(age, sex, and HAQ-DI score) over a lifetime, with the follow-up time being divided 
into 6-month cycles. Model simulation began after a patient had failed conventional 
DMARDs and was eligible for a biologic DMARD and assumed that each patient 
received a given treatment until switching to an alternative treatment. All eligible 
patients were prescribed a biologic DMARD in the model. Patients were generated 
by sampling from baseline distributions of sex, age, and HAQ-DI score on the basis 
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of the AMPLE study population. Each generated patient commenced treatment with 
either abatacept or adalimumab in combination with MTX and was evaluated on that 
treatment after a ﬁ xed time period (i.e., 6 months), after which the patient either 
remained on treatment, if the therapy was eﬀ ective and there were no adverse eﬀ ects, 
or switched to another biologic DMARD, that is, anti-TNF drug etanercept. Patients 
failing on etanercept were switched to palliative care.
Treatment responses for adalimumab and abatacept were based on the European 
League Against Rheumatism (EULAR) criteria at 6 months as measured in the AMPLE 
study. The EULAR response criteria classify patients as good responders, moderate 
responders, or nonresponders, on the basis of the DAS28-C- reactive protein (CRP) 
value at baseline and the change in DAS28-CRP from baseline to 6 months, using the 
method of Fransen and van Riel [22]. Patients who achieved EULAR good or moder-
ate response were retained on therapy. Apart from lack of response, switching could 
also be due to a patient experiencing adverse eﬀ ects. For patients who continued on 
therapy, the length of time on each treatment was estimated from data presented in 
a health technology assessment of RA treatments [23]. Similar to current modeling 
Fig. 1 − Overview of the patient-level simulation model
ACPA, anti-citrullinated protein antibodies; HAQ, Health Assessment Questionnaire; MTX, methotrexate
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approaches in RA, we do not discriminate between primary treatment failure and 
secondary treatment. The ﬁ rst treatment switch was treated as a single event, that is, 
a composite of lack of eﬃ  cacy and/or adverse events [24].
Change in the HAQ-DI score (a measure of physical functioning) over a lifetime was 
used to simulate disease progression for each patient (including mortality). The HAQ-
DI score ranged from 0 (best) to 3 (worst) in multiples of 0.125 [25]. If a patient 
responded to therapy, then the therapy was assigned with an initial drop in the HAQ-
DI score (i.e., improvement). This HAQ-DI score change was subtracted from the 
baseline HAQ-DI score to simulate the impact of treatment on disease progression. 
Any improvement in the HAQ-DI score was lost on quitting the treatment over the 
6-month cycle. At the point of treatment failure, the patient experienced a further in-
crease in the HAQ-DI score (rebound eﬀ ect) before commencing the next predeﬁ ned 
treatment within the sequence, at which point the process started again. The baseline 
HAQ-DI score and the treatment-speciﬁ c HAQ-DI score change were derived from 
the AMPLE study. The HAQ-DI score change was used to estimate health state utility 
(quality of life) and direct medical costs (disease-related hospitalization and joint 
replacement costs); change in the HAQ-DI score was therefore the prime driver of 
both beneﬁ ts and costs in the model. It was assumed that a patient’s HAQ-DI score 
remained constant over time while receiving treatment with biologic DMARDs, which 
was tested in a sensitivity analysis. Patients experienced disease progression after 
their initial response to therapy if they discontinued biologic DMARD and moved to 
palliative care, in which case the HAQ-DI score increased at the rate of 0.06/y [23]. 
HAQ-DI progression was separated into initial response (i.e., the ﬁ rst 6 months) and 
subsequent response on the basis of treatment and long-term disease progression.
Death was able to occur at any time within the model (at 6-month intervals) and was 
RA- and HAQ-DI–dependent. The probability of mortality was a function of age, sex, 
and having RA, using age and sex-speciﬁ c mortality rates for the general population 
and estimates of increased mortality risk by the HAQ-DI score. Mortality rates were 
related to the HAQ-DI score over a given period [26]. A relative risk of 1.33 per unit 
HAQ-DI was applied to the general population mortality probabilities [26].
Quality-adjusted life-years (QALYs) were calculated on the basis of the National Institute 
for Health and Care Excellence (NICE) reference case [27]. An inverse relationship be-
tween the HAQ-DI score (disease progression) and quality of life was applied using the 
EuroQol ﬁ ve-dimensional questionnaire (EQ-5D) utility score based on UK tariﬀ s [23]. 
The regression equation used in the model to link the HAQ-DI score to EQ-5D scores 
was a quadratic equation, of the form EQ-5D utility = 0.804 − 0.203 × HAQ-DI − 0.045 
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× HAQ-DI2 (see Fig. 2) [23]. This equation estimates utilities less than 0 for the highest 
values of the HAQ-DI score. Other linear mapping equations were tested in a sensitiv-
ity analysis. We chose the nonlinear mapping algorithm for the base case because it 
provided a better overall model ﬁ t compared with a linear regression model. It was 
assumed that events (transitions) occurred about halfway through a cycle and hence 
a half-cycle correction was applied by taking the average of the HAQ-DI score at the 
beginning and the end of a cycle. Parameter uncertainty from the mapping algorithm re-
gression equations was taken into account in the probabilistic sensitivity analysis (PSA).
MODEL INPUTS
Patient Baseline Characteristics
The initial run of the model simulated 15,000 patients with baseline characteristics 
taken from the AMPLE study [15,16]. Of the 646 patients randomized and treated in 
the AMPLE study, 86.2% (274 of 318) of the abatacept-treated patients and 82% (269 
of 328) of the adalimumab-treated patients completed the study. The overall AMPLE 
study population is described elsewhere [15,16]. Patients had baseline ACPA levels in 
the range of 28 to 4894 AU/ml. In line with the AMPLE study [15,16], patients were 
divided into four ACPA groups based on quartiles: Q1 (28–234 AU/ml), Q2 (235–609 
AU/ml), Q3 (613–1045 AU/ml), and Q4 (1060–4894 AU/ml). The use of ACPA level 
quartiles rather than ACPA level as a continuous measure enabled the analysis of 
subgroups on the basis of ACPA level while overcoming the limitation of skewed pa-
tient distribution across the ACPA level range. The baseline patient characteristics of 
Fig.2 − Correlation of HAQ score to EQ-5D utility (EQ-5D = 0.804 −0.203 × HAQ − 0.045 × HAQ2) [23]
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patients in the AMPLE study according to baseline ACPA groups are presented in Table 
1. The model was run for each ACPA group separately, with eﬃ  cacy data (Tables 2 and 
3) for the individual quartile groups being derived from the AMPLE study in each case.
Table 1 − Key baseline characteristics of patients modelled in the economic model.
Character-
istic
Quartile by ACPA (anti-CCP2 concentration, AU/mL)
Q1: 28–234 Q2: 235–609 Q3: 613–1045 Q4: 1060–4894
ABA
(n=42)
ADA
(n=55)
ABA
(n=51)
ADA
(n=46)
ABA
(n=46)
ADA
(n=51)
ABA
(n=46)
ADA
(n=51)
Age, years 52.0
(24.0, 80.0)
58.0
(21.0, 83.0)
50.0
(22.0, 70.0)
50.0
(19.0, 78.0)
52.0
(21.0, 78.0)
49.0
(22.0, 73.0)
47.5
(25.0, 73.0)
52.0
(26.0, 78.0)
Female, % 84.8 85.2 88.1 83.6 80.4 87.0 82.6 80.4
HAQ 1.3
(0.0, 2.9)
1.4
(0.0, 2.6)
1.4
(0.0, 2.5)
1.3
(0.0, 2.5)
1.7
(0.0, 2.8)
1.6
(0.0, 2.9)
1.4
(0.0, 2.8)
1.6
(0.0, 3.0)
CRP (mg/
dL)
0.8
(0.1, 8.4)
0.6
(0.0, 4.8)
0.9
(0.0, 9.4)
1.3
(0.1, 5.8)
0.9
(0.1, 11.3)
1.0
(0.0, 9.0)
0.9
(0.0, 13.9)
0.7
(0.0, 11.8)
DAS28 5.0
(3.1, 7.6)
5.5
(3.1, 7.3)
5.6
(3.5, 7.6)
6.0
(2.8, 7.4)
5.5
(2.8, 8.1)
5.7
(3.7, 7.9)
6.0
(2.7, 7.8)
5.3
(1.7, 7.8)
ABA, abatacept; ACPA, anti-citrullinated protein antibodies; ADA, adalimumab; CCP2, cyclic citrullinated pep-
tide-2; CRP, C-reactive protein; DAS28, Disease Activity Score 28; HAQ, Health Assessment Questionnaire–
Disability Index score; Q, quartile.
Data are expressed as median (min, max), unless otherwise stated.
Table 2 − EULAR response probabilities at six months.
Treatment EULAR response at six months (% probability)
Q1 Q2 Q3 Q4
Good Moderate Good Moderate Good Moderate Good Moderate
ABT + MTX 55.00 22.50 47.92 39.58 40.00 46.67 62.22 33.33
ADA + MTX 56.00 34.00 52.27 36.36 51.02 30.61 52.08 35.42
ENT + MTX 49.67 31.74 46.36 33.95 45.25 28.58 46.19 33.06
ABT, abatacept; ADA, adalimumab; ENT, etanercept; EULAR, European League Against Rheumatism; MTX, 
methotrexate; Q, quartile.
Table 3 − Estimated mean HAQ change from baseline for each therapy by quartile
HAQ change from baseline (SE) at six months
Q1 Q2 Q3 Q4
ABT + MTX −0.58 (0.09) −0.62 (0.08) −0.67 (0.09) −0.95 (0.09)
ADA +MTX −0.64 (0.08) −0.59 (0.09) −0.63 (0.09) −0.75 (0.09)
ENT + MTX −0.59 −0.54 −0.58 −0.69
Source: [15]
ABT, abatacept; ADA, adalimumab; ENT, etanercept; HAQ, Health Assessment Questionnaire–Disability Index 
score; MTX, methotrexate; Q, quartile; SE, standard error
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Disease Progression and Treatment Sequence
Clinical inputs applied to determine treatment switching and simulate disease pro-
gression comprised EULAR responses for abatacept and adalimumab at 6 months, 
on the basis of the AMPLE study. Patients in the AMPLE study were categorized by 
the type of response they achieved at 6 months. No data were available for etanercept 
by quartile; its EULAR response by quartile was derived by estimating the relative rate 
of response between each quartile and the overall population for adalimumab in the 
AMPLE arm and applying these relative rates to the EULAR response rate for etaner-
cept in an overall population obtained from a previous mixed treatment comparison 
[28] (Table 2). Patients who did not achieve a good or moderate EULAR response 6 
months after switching to etanercept were switched to palliative care for the remain-
ing duration of the time horizon.
Treatment Duration
Patients who attained a good or moderate response continued on therapy, with the 
length of treatment based on a time on treatment survival curve derived from the 
British Society for Rheumatology Biologics Registry data using a Weibull model [23]. 
Following the approach used previously, the time on treatment was sampled from 
this distribution [23]. A curve was generated for each treatment and a random sample 
estimate was drawn from this distribution to determine a time on each treatment for 
each simulated patient (mean 4.06 years for abatacept plus MTX and for adalimumab 
plus MTX) [23]. In the base case, mean time on treatment was assumed to be the 
same for abatacept and adalimumab in patients with an initial moderate or good 
response. In a sensitivity analysis, the mean time on treatment was allowed to dif-
fer between abatacept and adalimumab. A lifetime time horizon was applied in the 
base case, aligning with NICE guidance [27]. Further time horizons were analyzed in 
sensitivity analyses. Age-speciﬁ c yearly mortality probabilities were sourced for the UK 
population and converted to 6-monthly rates by applying the methodology of Briggs 
et al. [29].
Treatment Costs and Outcomes
Costs comprised drug costs and monitoring costs and were calculated in 2015 
pound sterling. The model included an annual drug cost for each treatment, includ-
ing any initial loading cost reﬂ ecting higher dosage and additional monitoring early 
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in treatment. Drug costs were applied within the model on the basis of the recom-
mended dosage over each of the model’s 6-month cycles. Drug cost data inputs 
for the United Kingdom and annual administration and drug monitoring costs are 
presented in Table 4. Unit costs for adalimumab and etanercept were drawn from the 
British National Formulary [30]. Given that a patient access scheme for abatacept is 
in place in the United Kingdom, the cost of abatacept was estimated to be the average 
cost of a number of biologic DMARDs approved in the United Kingdom (£9244), to 
fairly reﬂ ect actual treatment costs for abatacept in the country. Additional sensitivity 
analyses were conducted on the abatacept cost using average cost across ﬁ ve major 
markets as well as using the British National Formulary list price. To reﬂ ect clinical 
practice, no additional loading dose cost was assumed in the ﬁ rst year; this assump-
tion was also tested in a sensitivity analysis. Monitoring resource use and costs 
(biochemical proﬁ le, chest x-ray, full blood cell count, and erythrocyte sedimentation 
rate) for MTX were calculated to be £137.13 for the ﬁ rst 6 months and £59.63 after 6 
months. It was assumed that monitoring for biologic therapies was included within 
the monitoring for MTX or administration costs. Cossts for hospitalization and joint 
replacement were assumed to increase as the HAQ-DI score increased and were 
derived from a previous study [28] and inﬂ ated to 2015 costs using the National 
Health Service pay and prices index [31]. The values assumed in the base case are 
presented in Table 5.
The cost of ACPA testing was not included in the model because it is routinely con-
ducted in clinical practice [32] and EULAR guidelines [33] recommend testing for se-
ropositivity irrespective of the treatment selected. In addition, the exclusion of ACPA 
testing cost is not expected to change the study ﬁ ndings because, if included, it would 
have incurred the same cost for both treatment arms. Outcomes included discounted 
Table 4 − Drug treatment costs, treatment monitoring costs, and acquisition costs.
Treatment Drug cost (steady state annual cost) (£)
ABT 9244
ADA 9156
ETN 9295
MTX 31.20
Monitoring cost
(in ﬁ rst 6 months only) (£)
Monitoring cost
(subsequent 6-month cycles) (£)
ABT + MTX 904.53 164.88
ADA + MTX 904.53 164.88
ETN + MTX 904.53 164.88
ABT, abatacept; ADA, adalimumab; ETN, etanercept; MTX, methotrexate.
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disaggregated costs, QALY, and incremental cost per QALY gained (incremental cost-
eﬀ ectiveness ratio [ICER]) as well as undiscounted life-years. Costs and outcomes 
were discounted at 3.5% annually, as speciﬁ ed for NICE reference case [27]
Sensitivity and Scenario Analyses
Outcomes included discounted disaggregated costs, QALY, and incremental cost per 
QALY gained (incremental cost-eﬀ ectiveness ratio [ICER]) as well as undiscounted life-
years. Costs and outcomes were discounted at 3.5% annually, as speciﬁ ed for NICE 
reference case [27] Outcomes included discounted disaggregated costs, QALY, and 
incremental cost per QALY gained (incremental cost-eﬀ ectiveness ratio [ICER]) as well 
as undiscounted life-years. Costs and outcomes were discounted at 3.5% annually, 
as speciﬁ ed for NICE reference case [27] Univariate sensitivity analysis was used to 
determine the key drivers in the model; these were then applied to ACPA Q4, because 
this had shown the lowest ICER for abatacept versus adalimumab. Each variable was 
varied individually to assess the proportional eﬀ ect on model results. The variables 
investigated were abatacept drug cost, abatacept EULAR response rate (good), initial 
6-month HAQ-DI score change, and annual HAQ-DI score change while on long-term 
treatment. Additional scenario analyses were conducted on the basis of diﬀ erent time 
horizons, the incorporation of an additional (ﬁ rst year) loading dose cost for abata-
cept, the application of alternative utility mapping equations, and the incorporation of 
a longer term of treatment (6.17 years) for abatacept.
A PSA was performed for ACPA Q4 for 1000 sets of 1000 patients to assess the impact 
of parameter uncertainty around major model inputs. Key model parameters were 
sampled from parametric distributions to generate 1000 estimates of the costs and 
eﬀ ects in each arm. EULAR response rates followed beta distributions, nondrug costs, 
and HAQ-DI score changes; parameters of the utility equation followed normal distri-
Table 5 − Annual cost of hospitalization by HAQ score.
HAQ score range Annual cost (£)
0 < 0.5 173.69
0.5 < 1.0 106.39
1 < 1.5 378.36
1.5 < 2.0 543.33
2.0 < 2.5 1,293.02
2.5 < 3.0 2,788.83
HAQ, Health Assessment Questionnaire–Disability Index score.
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butions; mortality relative risk followed a lognormal distribution; and hospitalization 
costs followed gamma distributions (Table 6)
RESULTS
Primary Economic Analyses
The primary analysis considered the cost-eﬀ ectiveness of abatacept plus MTX as a 
ﬁ rst-line treatment after conventional DMARD failure compared with a base-case 
strategy of adalimumab plus MTX as a ﬁ rst-line treatment in ACPA-positive patients 
with varying ACPA concentration levels. For patients with poor prognosis (Q3 and 
Q4), the analysis resulted in increased costs for abatacept but additional beneﬁ ts 
(QALYs).
The costs incurred by abatacept treatment compared with adalimumab treatment for 
patients categorized by ACPA groups are presented in Table 7. With the exception 
of Q1, treatment with abatacept resulted in higher treatment costs, because of the 
higher response rates for abatacept and hence higher proportion of patients on long-
term therapy, but generally lower hospitalization costs because of various factors, in-
cluding greater HAQ-DI score reductions after initiating therapy, and delayed disease 
progression. Treatment and administration/monitoring costs were broadly equivalent 
for patients who received abatacept and adalimumab across all quartiles. The QALYs 
gained with abatacept versus adalimumab tended to increase with increase in ACPA 
titer groups, ranging from -0.115 QALYs for Q1 to 0.279 QALYs for Q4 (Table 8). The 
Table 6 – Parameters considered in PSA (applied to quartile 4).
Parameter Distribution Mean Standard error
ABT and ADA EULAR response rates Beta See Table 2 Assumed 10% of mean
Utility mapping algorithm parameters
a Normal 0.804 0.05
b1 Normal 0.203 0.08
b2 Normal 0.045 0.03
Mortality per unit HAQ Lognormal 1.33 0.13
ABT and ADA HAQ reductions Normal See Table 3 See Table 3
Annual cost of hospitalization by HAQ 
score
Gamma See Table 5 Assumed 10% of mean
ABT, abatacept; ADA, adalimumab; HAQ: Health Assessment Questionnaire–Disability Index score; QALY: 
quality-adjusted life year.
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diﬀ erence between treatments in life-years gained was small and tended to increase 
with ACPA titer groups.
In terms of cost-eﬀ ectiveness for Q3 and Q4, the ICER for abatacept (vs. adalimumab) 
reduced as the baseline ACPA level increased with an ICER of £26,272/QALY in Q3 
to £6,200/QALY in Q4 (Table 8). In the ﬁ rst ACPA group (Q1), abatacept had a lower 
QALY gain and a lower cost, resulting in an ICER of £18,397/QALY in the southwest 
quadrant. In the southwest quadrant, the incremental cost reduction should be much 
larger to accept an intervention with lower beneﬁ ts; thus, to be considered cost-
eﬀ ective, the ratios should be higher. In the second ACPA group (Q2), abatacept was 
dominated because it cost slightly more than adalimumab (+£66) and resulted in a 
slight decrease in QALYs (-0.009).
Sensitivity Analyses
The consequences of modifying model parameters applied in the sensitivity and 
scenario analysis for Q4 are presented in Table 9, which presents the range of the 
Table 7 − Lifetime per-patient costs of treatment with abatacept vs. adalimumab for patients categorized by 
ACPA quartile.
Treatment cost (£)
Administration and 
monitoring costs (£)
Hospitalisation
costs (£)
Total lifetime cost (£)
ABT ADA ABT ADA ABT ADA ABT ADA
Q1 50,188 47,680 9,519 9,488 16,511 16,189 73,710 75,825
Q2 49,212 49,172 9,452 9,451 18,949 18,923 77,612 77,546
Q3 47,314 45,976 9,178 9,211 17,949 18,076 74,441 73,263
Q4 50,685 48,491 8,939 8,971 18,803 19,234 78,428 76,696
ABT, abatacept; ACPA, anti-citrullinated protein antibodies; ADA, adalimumab.
Table 8 − Cost-effectiveness of abatacept vs. adalimumab for patients categorized by ACPA quartile.
Diﬀ erencea
in total cost (£)
Life years (undiscounted) QALYs ICER
(£/QALY)ABT ADA Diﬀ erencea ABT ADA Diﬀ erencea
Q1 -2115 28.12 28.14 -0.02 5.546 5.661 -0.115 18397b
Q2 66 28.32 28.32 -0.01 4.700 4.709 -0.009 Dominated
Q3 1178 26.62 26.61 0.00 4.697 4.652 0.045 26272
Q4 1732 25.92 25.84 0.08 4.343 4.064 0.279 6200
ABT, abatacept; ACPA, anti-citrullinated protein antibodies; ADA, adalimumab; ICER, incremental cost effec-
tiveness ratio; Q, quartile; QALY, quality-adjusted life year.
aDifference refers to abatacept − adalimumab.
bLower costs and lower beneﬁ ts.
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ICER between the diﬀ erent assumptions tested in the analysis. For time horizon, the 
ICER ranged from £5046/QALY for 5 years to £5954/QALY for 10 years. Changes in the 
HAQ-DI score reduction on abatacept treatment had the highest impact on the ICER 
result; even with a 20% decrease in the HAQ-DI score reduction on abatacept, the 
abatacept treatment strategy remained cost-eﬀ ective at £21,159 per QALY, which was 
less than the accepted National Health Service threshold for the cost-eﬀ ectiveness of 
new therapies [34]. Incorporating the loading dose cost for the ﬁ rst year of abatacept 
treatment and extending the abatacept time on treatment to 6.17 years to reﬂ ect a 
more severe population [23] increased the ICER but the abatacept treatment strategy 
remained cost-eﬀ ective.
The model was stable when diﬀ erent HAQ-DI score to utility mapping algorithms 
were applied, in terms of the ICER. Nevertheless, using the HAQ-DI score utility algo-
rithm, which estimated all utilities greater than 0 (0.89 − [0.28 x HAQ-DI]), had a major 
impact on total QALYs calculated compared with the base case (6.298 vs. 4.343 for 
abatacept and 6.057 vs. 4.064 for adalimumab), although the incremental diﬀ erence 
Table 9 − Sensitivity analysis of the effect of alternative assumptions (applied to quartile 4).
Analyses Base case Sensitivity analysis Cost per QALY 
(£)
Base-case 6,200
Time horizon 40 years 10 years 5954
5 years 5046
ABT HAQ reduction -0.950 -1.14 (+20%) 4365
-0.76 (-20%) 21,456
ADA HAQ reduction -0.750 -0.9 (+20%) 9337
-0.6 (-20%) 4253
ABT Response rate (Good) 62.22% 49.78% (-20%) Dominant
ABT annual cost £9,275 £15,756
(Full UK list price)
81,345
£12,257 39,775
ABT loading dose cost included in ﬁ rst 
year (£907.20)
£0 £907.20 8770
ABT time on treatment = 6.17 years 4.06 6.17 12,539
Utility equation 0.804 − 0.203 ×
HAQ − 0.045 × HAQ2
EQ-5D =
0.89 − (0.28 × HAQ)
6447
EQ-5D =
0.76 − (0.28 × HAQ)
6299
ABT, abatacept; ADA, adalimumab; HAQ: Health Assessment Questionnaire–Disability Index score; QALY, 
quality-adjusted life year.
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between abatacept and adalimumab was similar when using the diﬀ erent algorithms 
(0.241 vs. 0.279, respectively). The analysis indicated that the cost-eﬀ ectiveness 
results remained robust in the face of plausible variations of the main assumptions 
used in the model.
Probabilistic Sensitivity Analysis
In the PSA of abatacept versus adalimumab for Q4 patients, 98.5% of all 1000 simula-
tion results fell in the northeast quadrant of the cost-eﬀ ectiveness plane, indicating 
that the abatacept strategy was more eﬀ ective but also more costly in all simulated 
runs for the model (Fig. 3). On the basis of the PSA, the probability of each treatment 
strategy being cost-eﬀ ective at diﬀ erent decision-making thresholds (i.e., willingness 
to pay per QALY gained) is presented in Fig. 4. There was a 94.2% likelihood that the 
abatacept strategy was cost-eﬀ ective at a willingness-to-pay threshold of £30,000 per 
QALY gained.
Fig. 3 − Cost-effectiveness plot of probabilistic sensitivity analysis results (abatacept vs. adalimumab).
QALY: quality-adjusted life year.
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DISCUSSION
This is the ﬁ rst published economic evaluation to estimate the cost-eﬀ ectiveness of 
RA treatments stratiﬁ ed by subgroups of patients with RA on the basis of prognostic 
factor deﬁ ned by baseline ACPA levels. This model projected abatacept to be a cost-
eﬀ ective alternative to adalimumab in Q3 and Q4 of ACPA-positive patients with RA, 
showing trends toward increasing incremental total cost and QALY gain with abatacept 
versus adalimumab with increasing ACPA level. The ICER for abatacept compared 
with that for adalimumab was the lowest for patients with the poorest prognosis 
(ACPA Q4 ICER = £6200/QALY). An intervention with an ICER lower than £20,000/
QALY to £30,000/ QALY gained is generally considered to be cost-eﬀ ective in the UK 
health care setting [34]. In the group with the lowest ACPA level, the ICERs were in the 
southwest quadrant, that is, lower cost and lower QALY gains, and therefore the ICERs 
should be interpreted with caution.
Previous studies have identiﬁ ed serum parameters such as RF and ACPA to be associ-
ated with destructive RA [35–38]. Although the predictive value of RF for joint erosion 
is mixed, the data on ACPA are more uniform, with several studies linking ACPA to 
erosive disease, comprising structural damage (joint erosions) and radiographic pro-
gression [4,7,8,13]. A systematic review by Jilani and Mackworth-Young [13] concluded 
the presence of ACPA to be a strong predictor of erosive disease. Because established 
Fig. 4 − Cost-effectiveness acceptability curve (abatacept vs. adalimumab).
MTX: methotrexate.
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RA is a heterogeneous disease, some patients experience aggressive disease in spite 
of treatment. These patients also have higher use of direct medical resource as well 
as overall and RA-speciﬁ c costs [39–41]. Thus, targeting these patients with biologic 
DMARDs is important.
Reliable markers of prognoses of aggressive RA, such as ACPA, can provide at base-
line the rationale for aggressive therapy in patients with a substantial risk of develop-
ing destructive disease. In addition to evaluating the clinical beneﬁ t of aggressive 
treatments in patients at risk, one would need to consider the cost-eﬀ ectiveness of 
pursuing such a policy. Our analysis was geared toward evaluating the appropriate 
cost-eﬀ ective alternative biologic DMARD intervention in managing patients with poor 
prognosis and thus at risk of disease progression. Similar to our ﬁ ndings, another 
analysis has also shown biologic DMARDs to be cost-eﬀ ective in patients at risk of 
rapid disease progression [42]. Our analysis, however, takes this work a step further by 
specifying the prognostic factors and comparing one biologic DMARD with another, 
demonstrating that abatacept provided a cost-eﬀ ective alternative to adalimumab in 
patients with poor prognosis who had an inadequate response to MTX.
The AMPLE study was chosen as a source of model inputs by way of it being the only 
head-to-head, randomized, controlled study between two biologics that incorporates 
radiographic progression end points, provides data on erosions and joint space nar-
rowing in patients with RA, and includes data presented by patient ACPA level [15,16]. 
The demographic and clinical characteristics of the patients at AMPLE study baseline 
were balanced across the treatment groups and were considered to be typical for 
RA studies (the mean age of the patients was 51 years and the mean DAS28-CRP 
score was 5.5 ± 1.1 in both groups, with equal proportions of patients with moderate 
and high disease activity in each group [15]). Abatacept and adalimumab provided 
similarly eﬀ ective treatment outcomes in patients with RA [15,16]. As in the AMPLE 
study, the model compared abatacept with adalimumab; the lack of ACPA quartile 
data for other treatments currently prohibits running such comparisons for other 
treatment combinations. Apart from the AMPLE study, data based on real-world RA 
registries have demonstrated an association between higher ACPA concentrations 
and improved abatacept eﬃ  cacy and retention [14,42–45]. Therefore, we believe that 
the AMPLE study provided the model with reliable comparative eﬃ  cacy data for a 
population representative of the general RA population and for two agents where 
patient ACPA level could be expected to inﬂ uence outcomes and costs.
A key strength of this model is the application of the approach considered by evidence 
review groups responsible for assessing the cost-eﬀ ectiveness of RA treatments in the 
186 ○ Chapter 10
United Kingdom [1,23]. Decision making on the use of treatments for RA in the United 
Kingdom is based on IPS models, such as the Birmingham rheumatoid arthritis 
model [20] and the Sheﬃ  eld rheumatoid arthritis health economic model [21]. As with 
other IPS models, this cost-eﬀ ective analysis enabled patient progression while on a 
certain treatment if a speciﬁ c disease level was met, allowed treatment sequences to 
be evaluated rather than single therapy, and incorporated the uncertain duration of 
treatment eﬀ ect on each patient [21].
As with any economic evaluation study, it is important to acknowledge the limitations 
of the analysis and to reﬂ ect on the assumptions and data upon which the conclu-
sions have been drawn.
In terms of the patient population characteristics taken from the AMPLE study, al-
though the study population was reasonably large (646 participants), the number of 
patients in each trial arm by ACPA quartile was relatively small (42–55 participants), 
which may reduce conﬁ dence in the eﬀ ectiveness estimates by ACPA quartile that 
were used as inputs.
The present analysis explored the relationship between ACPA level and ICER using 
ACPA level quartiles and did not attempt to identify any ACPA threshold correspond-
ing to a single ICER value or model outcomes according to ACPA levels of clinical 
signiﬁ cance. As such, the association is deserving of further study. Such an analysis 
might require an alternative outcome, such as response rate. Thresholds at which the 
best response rate occurs could then be investigated using, for example, a receiver-
operating characteristic curve to determine the best combination of sensitivity and 
speciﬁ city. This is not possible using the model in its current form because the model 
uses response rate as an input parameter rather than as an outcome. A future eco-
nomic analysis might also consider the cost-eﬀ ectiveness of a treatment algorithm 
incorporating screening for ACPA level and subsequent treatment of a pre-determined 
patient subset versus no screening and the treatment of all patients. The present study 
evaluated the impact of prognostic factor such as ACPA levels on cost-eﬀ ectiveness 
and not the impact of a screening strategy.
In addition, the base case assumed that HAQ-DI score progression while on biologic 
therapy was 0. This assumption is used in most cost-eﬀ ectiveness models and the 
literature is mixed because some analyses show that patients with RA treated with 
a TNF inhibitor have continued disease activity [23]. For patients on palliative care, 
a constant annual rate of HAQ-DI score progression was assumed. A recent NICE 
appraisal (Technology Appraisal 375 [28]) has suggested a nonlinear HAQ-DI score 
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progression model, derived from an early RA data registry, for patients on conventional 
DMARDs and palliative care is a more appropriate reﬂ ection of a chronic disease, 
and that the choice of model to inform HAQ-DI score progression had an impact on 
ICERs. It is not clear how the use of a cubic representation of HAQ-DI score progres-
sion would aﬀ ect the results of the current model, but it is expected that because the 
treatment strategy after failure of ﬁ rst-line treatment is the same for both treatment 
arms, the incremental results would not change greatly.
The utility measures of the EQ-5D were based on a mapping of the HAQ-DI score to 
utility described by Malottki et al. [23] and used in multiple cost-eﬀ ectiveness models. 
Such mapping studies usually overestimate the utilities of bad health states and 
underestimate the utilities of good health states. It has been suggested that a sub-
stantially better estimate of utility is obtained by the inclusion of pain alongside the 
HAQ-DI than via the HAQ-DI alone [28]. The application of diﬀ erent utility mapping 
algorithms in this study was investigated in sensitivity analyses and had little impact 
on the incremental results, but the use of a mapping algorithm incorporating pain as 
well as the HAQ-DI score should be investigated in future work.
Finally, because of availability of data, the model evaluated abatacept against one anti-
TNF agent only (adalimumab) and incorporated clinical data for these two agents 
only from the observational trial. The model also did not assess the introduction of a 
second conventional. DMARD after MTX failure because the model and the AMPLE 
trial were reﬂ ecting treatment guidelines for the patients with poor prognosis. The 
limited use of comparators in this study creates an opportunity for further research 
to assess the cost-eﬀ ectiveness of abatacept versus other conventional and biologic 
treatment options.
For the next treatment in the sequence (etanercept), it was assumed that the relative 
diﬀ erence in EULAR response probabilities observed for adalimumab between the 
AMPLE study and a recent previous mixed treatment comparison [28] would be simi-
lar for etanercept. It is, however, unlikely that this would have favored either abatacept 
or adalimumab, because patients in each treatment arm moved on to etanercept after 
failure on the ﬁ rst line of therapy. We tested the impact of these assumptions on 
the ﬁ ndings via various sensitivity and scenario analyses. Overall, we found that the 
results were robust in the face of changes in input parameters, yet the opportunity 
remains to evaluate abatacept against other agents and to increase the clinical data 
inputs contributing to the robustness of the model.
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CONCLUSIONS
Abatacept provided a cost-eﬀ ective alternative to adalimumab in ACPA-positive pa-
tients with RA with an inadequate response to MTX. For ACPA-positive patients with 
higher ACPA levels (Q4 and Q3), higher EULAR response rates for abatacept patients 
compared with adalimumab patients resulted in higher proportions of patients on 
long-term therapy resulting in increased treatment costs, but these were partially 
oﬀ set by a greater reduction in disability (HAQ-DI) and lower hospitalization costs. 
The increased cost per QALY gained for abatacept was lower in those patients with 
higher ACPA levels. This economic evaluation, therefore, suggests that the use of 
abatacept in patients with RA with poor prognosis should be seen as a cost-eﬀ ective 
approach to the management of RA in the United Kingdom, with clear advantages 
seen in health-related quality of life.
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ABSTRACT
Objective: To evaluate current approaches to economic modeling in rheumatoid arthri-
tis (RA) and propose a new conceptual model for evaluation of the cost-eﬀ ectiveness 
of RA interventions. Methods: We followed recommendations from the International 
Society of Pharmacoeconomics and Outcomes Research-Society of Medical Deci-
sion Making (ISPOR-SMDM) Modeling Good Research Practices Task Force-2. The 
process involved scoping the decision problem by a working group and drafting a 
preliminary cost-eﬀ ectiveness model framework. A systematic literature review (SLR) 
of existing decision-analytic models was performed and analysis of an RA registry was 
conducted to inform the structure of the draft conceptual model. Finally, an expert 
panel was convened to seek input on the draft conceptual model. Results: The pro-
posed conceptual model consists of three separate modules: 1) patient characteristic 
module, 2) treatment module, and 3) outcome module. Consistent with the scope, 
the conceptual model proposed six changes to current economic models in RA. These 
changes proposed are to: 1) use composite measures of disease activity to evaluate 
treatment response as well as disease progression (at least two measures should be 
considered, one as the base case and one as a sensitivity analysis); 2) conduct utility 
mapping based on disease activity measures; 3) incorporate subgroups based on 
guideline-recommended prognostic factors; 4) integrate realistic treatment patterns 
based on clinical practice/registry datasets; 5) assimilate outcomes that are not joint 
related (extra-articular outcomes); and 6) assess mortality based on disease activity. 
Conclusions: We proposed a conceptual model that incorporates the current under-
standing of both clinical and real-world evidence in RA, as well as of existing modeling 
assumptions. The proposed model framework was reviewed with experts and could 
serve as a foundation for developing future cost-eﬀ ectiveness models in RA.
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INTRODUCTION
Rheumatoid arthritis (RA) is a progressive disease characterized by inﬂ ammation of 
synovial tissue with symmetric involvement of peripheral joints of the hand, feet, and 
wrists[1-2]. The prevalence of RA ranges from 0.4% to 1.3% [3]. RA not only contributes 
to reduced survival, health related quality of life (HRQOL), activities of daily living and 
work productivity, but is also associated with higher health resource utilization and 
costs [4-7]. Most RA-related direct costs are associated with biologic disease modify-
ing anti-rheumatic drugs (bDMARDs), which have improved outcomes in RA patients 
[8-10]. Since the introduction of these agents, our knowledge of RA as a disease has 
greatly increased and new therapies as well as combination therapies (of diﬀ erent 
bDMARDs or of bDMARDs in combination with synthetic (sc)DMARDs) targeting 
multiple immune pathways are being developed [11,12]. Accompanying development 
of novel interventions is the introduction of bioequivalents or biosimilars of existing 
bDMARDs. In an environment featuring multiple therapeutic options to manage RA 
patients, and in the face of constrained health resources, cost-eﬀ ectiveness models 
in drug treatment that enable more precise estimations of cost and beneﬁ ts could 
reduce the risk of ineﬃ  cient resource allocation.
The framework for cost-eﬀ ectiveness models for treatments in RA has evolved since 
ﬁ rst published in early 2000s, with the introduction of bDMARDs [13,14]. The current 
modeling approach has served to establish economic beneﬁ ts of bDMARDs in most 
countries, in moderate to severe RA patients with inadequately respond to methotrex-
ate [15,16]. In our opinion previously, published models have potential room for im-
provement in six areas. First, current models base treatment response on composite 
measures of disease activity such as European League Against Rheumatism (EULAR) 
response [17], American College of Rheumatology (ACR) response [18], and Disease 
Activity Scores in 28 joints C-reactive protein (DAS28-CRP)[19]. These disease activity 
measures are not aligned to guideline-recommended target measures of remission 
and hence cannot evaluate the cost-eﬀ ectiveness of policies designed to implement 
treatment guideline-based targets [20,21]. In addition, these measures are biased 
(favorably) to certain therapeutic interventions, as discussed further in results section 
under new conceptual model.
Second, disease progression in these models is based on physical functioning mea-
sured by the Health Assessment Questionnaire (HAQ) [22]. More rapid decline in 
HAQ on treatment has been observed in patients with RA of recent onset, compared 
to those with established RA [23]. Hence change in HAQ is greater in patients with 
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early (versus established) RA, potentially underestimating treatment beneﬁ ts in pa-
tients with established RA, as HAQ might have a ceiling eﬀ ect.
Third, contemporary models derive utility scores from the HAQ, based on mapping 
algorithms. Nonlinear models are now recommended, and overall mapping of HAQ 
to European Quality of life 5 dimension (EQ-5D) [24] has been improved by including 
disease activity and pain in these models [25,26]. However, no study (to our knowl-
edge) has evaluated the impact of other dimensions of RA or of diﬀ erent composite 
measures on utility scores.
Fourth, certain baseline characteristics, such as age, gender, and HAQ score, are 
accounted for in current models. However, most of these models do not report incre-
mental cost-eﬀ ectiveness ratios (ICERs) according to important subgroups. Recent 
studies have evaluated ICER within a limited number of RA subgroups [27,28].
Fifth, current modeling approaches focus on joint-related outcomes in RA, largely at 
the expense of extra-articular manifestations. Extra-articular manifestations occur in 
18% to 41% of patients with RA [29-32]. A growing body of evidence—mainly derived 
from observational databases and registries—suggests that speciﬁ c RA therapies, 
including methotrexate and bDMARDs, may reduce the risk of extra-articular cardio-
vascular disease [CVD] manifestations with RA [33,34].
Sixth and ﬁ nally, long-term treatment discontinuation in current models is based on 
real-world registry data, and these models allow for patients to cycle through tumor 
necrosis factor (TNF-α) inhibitor via limited sequential use of bDMARDs [26,35]. 
However, these same models do not allow for data in which health providers escalate 
doses or re-initiate bDMARDs once treatment has been discontinued. These factors 
may result in underestimating both increasing therapeutic beneﬁ ts and costs. Although 
contemporary RA therapy is moving toward lowering the dose of the bDMARDs in 
patients once they have attained a predeﬁ ned target disease activity state, such dose 
de-escalation is not incorporated in previously reported models [36-39].
Taken together, these factors point to unmet needs related to pharmacoeconomic 
modeling in RA. Consideration of these aspects in future economic modeling of RA 
treatments could enable evaluation of costs and beneﬁ ts of therapies in manner that 
reﬂ ects prevailing clinical realities with the aim of producing more accurate cost-
eﬀ ectiveness estimates. The objective of this analysis was to review current economic 
models in RA and propose a revised conceptual model framework.
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METHODS
In developing the conceptual model, the recommendations outlined by the Interna-
tional Society of Pharamacoeconomic and Outcomes Research-Society of Medical 
Decision Making (ISPOR-SMDM) Modeling Good Research Practices Task Force-2 
were followed [40]. As depicted in Figure 1, the process involved scoping out the deci-
sion problem by a working group and drafting a preliminary cost eﬀ ectiveness model 
framework. A systematic literature review (SLR) of existing decision-analytic models 
was performed and analysis of a RA registry was conducted to inform the structure of 
the draft conceptual model. Finally, an expert panel was convened to seek input on the 
draft conceptual model.
Scoping: The knowledge gaps in current models as explained in the introduction were 
elucidated in a three-member (EA, MA, MR) working group. The working group focused 
on various aspects of the model, such as 1) measures to access treatment responses/
treatment targets, 2) measure to assess RA disease progression, 3) utility mapping, 
4) RA subgroups, 5) treatment patterns (e.g. dose escalation, dose de-escalation) 6) 
Figure 1: Schematic overview of the development process of the conceptual model
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extra-articular outcomes, and mortality. Based on these aspects the working group put 
together a list of revisions of existing models (S1 Appendix) and drafted a conceptual 
model (S2 Appendix). The draft conceptual model was based on the working group 
analyses of a RA registry to explore treatment targets and extra-articular manifestation 
of RA, and RA subgroups, which have been published elsewhere [41-44]. In addition, 
the working group relied on literature and knowledge of clinical guidelines to inform 
model development.
SLR: A review of existing decision-analytic models on the cost-eﬀ ectiveness of RA 
therapies published in English since 2006 was conducted as part of the scoping 
process. The search strategy is depicted in S3 Appendix. Primary searches were con-
ducted in Medline, EMBASE, and EconLit simultaneously using Ovid® based on the 
search strategy outlined. In addition to the SLR, recent publication on methodologies 
of economic modeling in RA was also reviewed [45]. To supplement the database 
search, a manual search of previous health technology assessment (HTA) reports was 
conducted on the UK National Institute for Health and Clinical Excellence website 
(https://www.nice.org.uk/guidance/ta375/history [last accessed Nov 2017]). The 
primary objective of the SLR was to identify published economic evaluations of bD-
MARDs for RA to evaluate model structure, short-term treatment targets/responses, 
RA disease progression (long-term response when treatment is initially successful), 
utility mapping, patient subgroups (with characteristics that could be treatment eﬀ ect 
modiﬁ ers), treatment aspects (e.g. switching, does escalation, dose-escalation), time 
horizon, and mortality associated with RA.
Analysis to Inform Conceptual Model: To inform disease progression and utility map-
ping in the conceptual model, the WG conducted a retrospective analysis of a RA reg-
istry. A longitudinal sequential registry of primarily established RA patients was used 
for this analysis in which disease activity was measured annually during rheumatology 
visits using multiple composite functional measures [46]. These included the DAS28-
CRP, Simpliﬁ ed Disease Activity Index (SDAI) and Clinical Disease Activity Index 
(CDAI) [47]. The generic HRQOL index EQ-5D was evaluated every 6 months via both 
mailed questionnaires and in-person interview (during annual visit). The progression 
of RA using various composite measures as well as changes in these disease activity 
over time was evaluated using general linear models. Mapping algorithms based on 
DAS28-CRP, SDAI, and CDAI were compared to the physical functioning (HAQ)-based 
mapping algorithm. Fixed-eﬀ ects models were used to estimate the best predictors of 
EQ-5D, because within-patient variability over time is more important than between 
patient variability in economic models [48].
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Expert Panel: An expert panel comprising two rheumatologist (AB, MW), one health 
economist (MS), and two epidemiologists/health services researchers (KM, SV) was 
convened to provide input to the conceptual model. The draft conceptual model was 
presented to each expert in a multistep approach. In the ﬁ rst step, a member of the 
working group (EA) shared the discussion guide developed by the working group 
with the expert panel members. The discussion guide contained an overview and 
limitations of current modeling approaches in RA as well as the proposed conceptual 
model structure. It also included a brief questionnaire that focused on the proposed 
modiﬁ cations to the cost-eﬀ ectiveness model. In the second step, opinions from all 
experts of the panel were gathered via individual interviews. The third step involved 
updating the draft conceptual model and collating all responses to questions and 
comments. The revised document was shared with all experts for additional inputs. 
Additional updates were then incorporated, and the conceptual model was sent back 
to the panel for a ﬁ nal opportunity to provide suggestions.
RESULTS
Scoping: The decision problem that the conceptual model would address was deﬁ ned 
as identifying cost-eﬀ ective drug interventions for moderate-to-severe RA that result 
in the most health beneﬁ ts for the overall RA population as well as for speciﬁ c sub-
groups (such as those with poor prognostic factors). This includes current and novel 
interventions that are being developed and may be introduced in clinical practice in 
the future as monotherapy or combination therapies.
SLR: A total of 32 economic evaluation studies were identiﬁ ed by the initial SLR, 5 of 
which were review articles. The remaining 27 manuscripts evaluated are summarized 
in S3 Appendix Table 3 [27,34,49-73]. The primary model structures were cohort based 
or individual patient simulations, which included discrete event simulations and indi-
vidual patient Markov models. More recent published models tended to be primarily 
individual patient simulations.
The assumed relationship between diﬀ erent model variables is summarized in the 
inﬂ uence diagram represented in Figure 2. Each solid arrow represents a direct ef-
fect of one variable on the other, while the dashed lines represent the mathematically 
derived structural relationships. In general, these models evaluate short-term (3 to 
6 months) treatment eﬀ ects based on clinical trial eﬃ  cacy. Based on the short-term 
eﬃ  cacy and probability of adverse events (AEs), a decision rule was included in the 
model for a patient to continue treatment or not. If treatment is continued, then 
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disease progression is estimated based on HAQ change over time. In recent models 
HAQ change over time is based on mixture models, while earlier models used linear 
progression (0 per annum for bDMARDs and 0.03 to 0.045 per annum for cDMARDs) 
[27, 60]. HAQ scores are then mapped to HRQOL, mortality rates and resource use, 
using mapping algorithms. The long-term treatment duration in the majority of the 
simulation models is based on real-world registry data, extrapolated using survival 
models with time to treatment discontinuation as outcomes. The endpoint driving 
cost-eﬀ ectiveness models in RA is primarily physical functioning, whereas other end-
points such as radiographic progression are rarely used [72].
New Conceptual Model: The conceptual model drafted by the working group is repre-
sented in Figure 3. The proposed conceptual model is an individual patient simulation 
model with a lifetime horizon proposed to capture short-term and long-term beneﬁ ts 
and cost of interventions. Outcomes are deﬁ ned as quality-adjusted life years (QALYs) 
and life-years gained (LYG). This model is intended for HTA and is based on the 
payer’s perspective and has three distinct modules: 1) patient characteristic module, 2) 
treatment module and 3) outcome module. This framework enables addressing issues 
of treatment responses, RA subgroups, real world treatment patterns and extra-artic-
ular manifestation of RA mentioned in the introduction. This proposed conceptual 
model should be seen as “aspirational” because not all data elements required to 
populate the model are not available (at the time of writing) but are likely to become 
available in the future. The ISPOR-SMDM Modeling Good Research Practices Task 
Force-2 stresses that conceptual models should not be driven solely by the presence 
or absence of clinical data [40].
Figure 2: RA Economic Model Inﬂ uence Diagram for Structural Relationship
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To improve the clinical relevance of the economic models in RA, it is important to align 
treatment responses to guideline-recommended targets [20,21]. The working group 
proposed the expert panel to consider CDAI as a measure of treatment response in 
the conceptual model (change 1a). This was primarily based on observed associations 
between treatment targets and outcomes of physical functioning (HAQ), HRQOL 
(i.e. EQ-5D), and health resource use. A greater improvement was observed in these 
outcomes among patients attaining (vs. not attaining) a CDAI based target, compared 
to SDAI and DAS28-CRP based targets [43]. In addition, CDAI has acceptable psycho-
metric properties, including validity and sensitivity to change [74-77]. CDAI remission 
does not include levels of CRP or erythrocyte sedimentation rate (ESR) which are pri-
marily impacted by therapies such as interleukin-6 and janus kinase inhibitors. Thus, 
the new conceptual model includes a CDAI score of <2.8 (remission) or ≤10 (LDA) as 
a deﬁ nition for responder for treatment continuation. In terms of disease progression, 
the working group proposed CDAI change over time (change 1b). This was based on 
analysis of changes in CDAI, SDAI and DAS28-CRP in a cohort of patients with mostly 
established RA [46]. Results of these analyses indicate that CDAI is most responsive 
to change over time (S4 Appendix).
Finally, the mapping exercise of disease activity measures and physical functioning 
to EQ-5D indicates that mapping models predicated on CDAI and Routine Assess-
ment of Patient Index Data-3 (RAPID-3) measures have the best ﬁ t according to r² and 
root mean square error values (Table 1). Based on these ﬁ ndings, the working group 
proposed to the expert panel that the conceptual framework should include utilities 
based on disease activity measure (CDAI) and patient reported outcomes of physical 
function such as RAPID-3 (change 2).
Based on current evidence, the conceptual model accommodates subgroups with 
a high risk of disease progression such as those with multiple prognostic factors 
(change 3). Additional subgroups that the working group considered important for 
inclusion were patients with susceptible to infections. The patient characteristic module 
accounts for patient characteristics when entering the model and at subsequent time 
points. This module enables risk stratiﬁ cation of RA patients based on prognostic 
factors. Some commonly reported prognostic factors for a more rapid and aggressive 
disease are double seropositivity for anti-cyclic citrullinated peptide antibody (ACPA) 
and rheumatoid factor (RF), as well as erosions, disease activity and measures of 
inﬂ ammation (CRP/ESR) [78-82]. There is evidence that certain prognostic factors 
can be considered as treatment eﬀ ect modiﬁ ers [83-85]. Subgroups based on patients’ 
risks of infections were considered as there is evidence that corticosteroids and certain 
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DMARDs increase the risk of infection in RA patients [86,87] and because prevalent 
RA patients tend to be elderly and thus at increased risk for infections.
The treatment module accommodates all treatment changes (change 4), including; 
patients who do not attain remission or low disease activity (LDA) or patients who 
experience AEs within 6 months (or secondary failure) after treatment initiation. In 
addition, the proposed conceptual model allows for ﬂ exibility in dose escalation. 
Data from observational studies have shown that some patients require upward dose 
adjustments, reduced dose interval for bDMARDS, or addition of corticosteroids and/
or nonsteroidal anti-inﬂ ammatory drugs (CS/NSAIDs) to some bDMARDs in order to 
achieve or maintain a clinical response [88,89]. Upward dose adjustments are associ-
ated with increased medication costs and potentially adverse reactions.
Table 1: Fixed Effects Regression Models for EQ5D
Models R-Square Root MSE F- value
Patient global, Patient pain scale RADAI Joint Score 0.702795 0.093454 14.20
RAPID3, RADAI Joint Score 0.717904 0.091493 14.33
RAPID3 0.708717 0.092986 13.76
RAPID3, CDAI 0.750240 0.091260 7.35
mHAQ 0.677473 0.095895 15.36
mHAQ, RADAI Joint Score 0.696132 0.093075 16.68
mHAQ, CDAI 0.713277 0.094982 7.80
mHAQ, mHAQ square 0.677589 0.095883 15.35
mHAQ, pain 0.705025 0.092921 14.38
mdHAQ, RADAI Joint Score 0.699629 0.092616 17.00
mdHAQ 0.682759 0.095187 15.77
Models with baseline co-variates of age, duration, CRP and 
serostatus
Patient global, Patient pain scale RADAI Joint Score 0.742697 0.091409 7.49
RAPID3, RADAI Joint Score 0.725320 0.090025 15.11
RAPID3 0.708010 0.092828 13.96
RAPID3, CDAI 0.748709 0.090882 7.41
mHAQ 0.675191 0.095998 15.38
mHAQ, RADAI Joint Score 0.694265 0.093129 16.71
mHAQ, CDAI 0.710554 0.094827 7.78
mHAQ, mHAQ square 0.675278 0.095990 15.37
mHAQ, pain 0.703512 0.092886 14.49
mdHAQ, RADAI Joint Score 0.704798 0.092786 14.61
mdHAQ 0.680225 0.095338 15.7
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The outcome module incorporates disease progression and its impact on both joint 
and extra-articular outcomes. The conceptual model accommodates extra-articular 
disease outcomes, principally CVD events (change 5). These events were considered 
by the working group primarily based on available epidemiologic data, as well as on 
the treatment eﬀ ects and the cost implications of these outcomes. The working group 
proposed incorporation of RA-speciﬁ c mortality risk based on disease activity in the 
economic model once more data become available (change 6).
Expert Panel: Members of the expert panel debated the draft model structure, chal-
lenging the level of evidence to support several proposed changes. Nevertheless, 
a majority of the panel agreed that the model should enable subgroup analysis by 
prognostic factors, and also investigate the need to accommodate increased risk of 
infection (change 3). The experts agreed on QALYs should be the main outcomes of, 
mortality based on RA disease activity (change 6), and should explore the impact of 
including extra-articular manifestations on cost eﬀ ectiveness ratios (change 5).
The expert panel also acknowledged the advantage of having a disease activity mea-
sure for both treatment response and disease progression (change 1). Questions 
were raised on CDAI data availability from historic phase 3 programs and concerns 
were mentioned about the subjective elements of CDAI, such as estimation of tender 
joint counts, patient and physician global health, which are unweighted and can 
make the measure less reliable. At the same time, the members of the expert panel 
acknowledged that this perceived limitation might also apply to other currently avail-
able composite measures. The least agreement among experts was on the proposed 
mapping of only disease activity (change 2) to HRQOL utilities (i.e. EQ-5D). Recom-
mendation was to explore the use of mixed logit models, based on disease activity and 
HAQ with other dimensions of RA such as pain, fatigue. Strengths and limitations of 
the recommended changes, along with expert inputs and level of agreement among 
experts concerning the proposed changes, are summarized in Table 2.
After expert panel inputs had been incorporated, the draft conceptual model was 
further modiﬁ ed and these further changes are reﬂ ected in the updated conceptual 
model (Figure 4). Because there is no clinical criterion or reference standard disease 
activity measure, the conceptual framework was revised to incorporate at least two 
disease activity measures: one as a “base case” and the other for sensitivity analyses 
concerning treatment eﬀ ect as well as disease progression (change 1). For example 
CDAI could be used as the base case and DAS28-CRP for a sensitivity analysis. The 
updated conceptual model also includes, in the same framework, patients who have 
not been exposed to csDMARDs or who have not responded adequately to them. 
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Table 2: Summary of pros and cons of proposed changes, expert input and agreement
Changes 
 proposed
Pros and Cons Expert Inputs Expert 
Agree-
ment*
Model Structure Pros: aligned with clinical 
practice and guidelines; 
allows to captures patient 
subgroups, treatment 
heterogeneity, non-joint 
outcomes;
Cons: increase in complex-
ity; data availability
1. This is ideal, however the data may not be 
available to populate.
2. Include cDMARD-naïve and cDMARD 
inadequate responders
3. Changes may not materially impact 
ICER. The time involved in incorporating 
the changes might not be worth the extra 
accuracy
3 of 5
1) Use of (at least 
two) disease 
activity measures 
for treatment 
response and dis-
ease progression
Pros: Aligns to treatment 
guidelines; less biased esti-
mates (vs. single measure)
Con: Data availability;
1. Data might not be available to populate 
the model
4 of 5
2) Disease activity 
based mapping of 
utilities
Pros: Overcomes the 
limitation of HAQ changes, 
which is dependent on 
disease duration and sever-
ity; Allows the model to be 
based entirely on disease 
activity; could lead to further 
improvements in mapping 
of utility
Cons: Data availability
1. HAQ would still be an unbiased estimator 
of disease progression
2. Reasons for the RA models to be based 
on HAQ was its association to cost in RA.
3. Would not recommend RAPID3 by itself 
as it based entirely on patient report. Good 
to see that we are combining disease activity 
and RAPID3
3 of 5
3) Incorporation 
of subgroups
Pros: Allows for more 
speciﬁ c and targeted HTA 
evaluations;
Cons: No general agreement 
that the prognostic factors 
are well established in RA; 
data availability
1. Double sero-positives are at a higher risk 
of progressing vs. single positive patients. 
Also, the double positive represents a signiﬁ -
cant population of RA patients.
2. Patients who have erosive disease at 
baseline are high risk of progression.
3. Additional subgroups could include 
elderly (age >65 yrs) as these are increased 
risk of infections, CV and other RA related 
extra-articular manifestations.
4. These are not just baseline factors.
5 of 5
4) Real world 
treatment pat-
terns:
Pros: Allows for realistic es-
timates of cost and clinical 
beneﬁ ts of standard of care; 
Cons: data availability;
1. Generalizability of real world data to those 
in the trials where efﬁ cacy was gained
2. No controlled studies that have examined 
switching therapy in patients who are well 
controlled on their existing therapy
3. GPs behavior cannot be clearly deﬁ ned 
and consistent when it comes to dose reduc-
tion
4 of 5
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According to input from the expert panel, the conceptual model included treatment 
intensiﬁ cation (corticosteroids and/or NSAIDs) before the patient received bDMARD 
switch and also de-escalation of bDMARD dose in patients attaining remission 
(change 4). The ﬁ nal update based on expert input was the inclusion of pulmonary 
extra-articular manifestation in addition to CV extra-articular eﬀ ects of RA (change 5).
DISCUSSION
This study used a well-established methodology to propose a conceptual framework 
for developing future models in RA to evaluate the cost eﬀ ectiveness of therapies [40]. 
The current cost eﬀ ectiveness modeling framework in RA was introduced with the 
advent of anti-TNFs. Since then our knowledge of RA disease mechanism, impact on 
joints as well as on other organ systems has greatly increased. In addition, matura-
tion of existing electronic medical records, claims datasets and registries enable us to 
better understand RA treatment patterns. Thus, the proposal of an updated concep-
tual model that incorporates these understandings may be timely. In proposing the 
conceptual model we leveraged the earlier modeling approaches as certain aspects 
are well established.
Overall, the proposed conceptual model reﬂ ects on 6 preselected areas of modelling 
cost-eﬀ ectiveness of drug treatment in moderate to severe RA in the 21th century. 
The major changes that this conceptual model proposes are 1) use of at least two 
Table 2 (continued)
Changes 
 proposed
Pros and Cons Expert Inputs Expert 
Agree-
ment*
5) Incorporating 
extra-articular 
manifestations of 
RA:
Pros: Allows for improved 
estimation of beneﬁ t and 
cost of interventions; Cons: 
data availability;
1. CV and lung disease should considered in 
the economic evaluations.
2. These would be important if treatment 
would differentially impact extra-articular 
manifestations
3. The strength of this evidence, particularly 
with respect to changes in markers and 
changes in hard outcomes is limited
5 of 5
6) Mortality As-
sociated with RA
Pros: allows for disease 
activity be the driver of 
beneﬁ ts Cons: potential for 
overestimation of survival; 
data availability
No comments 5 of 5
*Agreement in principal that these need to be evaluated in future economic models
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composite measures of disease activity, with one used in sensitivity analyses, to evalu-
ate both treatment response as well as disease progression; 2) utility mapping based 
on disease activity 3) the consideration of subgroups based on prognostic factors and 
potential treatment eﬀ ect modiﬁ ers 4) the incorporation of realistic treatment pat-
terns based on clinical practice/registry datasets 5) incorporation of non-joint related 
(extra-articular) outcomes and 6) mortality based on disease activity.
Implementation of these structural changes could be prioritized based on the ex-
pected impact on model estimates and on availability of data to populate the model. 
Incorporation of subgroups based on prognostic factors ranked high on the prioritiza-
tion order as this is relatively straightforward. In addition, recent cost eﬀ ectiveness 
analyses have demonstrated the importance of incorporation of subgroups as these 
patients may have characteristics which are potentially eﬀ ect modiﬁ ers [27,28]. How-
ever, these analyses are still limited and further work needs to be done to understand 
and deﬁ ne RA subgroups with combinations of prognostic factors. Stratiﬁ cation of 
cost-eﬀ ectiveness analysis by subgroups could have implication for targeting speciﬁ c 
therapies or combination of therapies to certain subgroups improving the overall 
clinical outcomes and cost. This could pave the way for policies leading to personal-
ized medicine in RA.
The second priority is deemed to be the use of a disease activity measure, to model 
treatment response/stopping, disease progression, mapping of utility and mortality. 
The conceptual model allows for at least two disease activity measures one as base 
case and one as sensitivity analysis. Until an objective measure of disease activity is 
established in RA and used in routine clinical practice, impact of treatment on multiple 
disease activity measures will have to be evaluated in the same model/analysis. Based 
on the available evidence the working group considered CDAI appropriate for the base 
case model and DAS28 for sensitivity analysis. Though current mapping algorithms 
for utility use mixed models based on HAQ, pain and disease activity. We believe 
further research is required comparing mapping algorithms using diﬀ erent disease 
activity measures. In addition, future research should also evaluate the beneﬁ ts of 
having direct measure of utility from RA clinical trials vs. mapping EQ5D.
Next on the priority list is the incorporation of more realistic treatment algorithms into 
the cost eﬀ ectiveness model. Components of this proposed change such as CS and 
NSAID intensiﬁ cation, treatment discontinuation, dose escalation can be informed 
by current RA registries, administrative claims and EMR database analysis. However, 
bDMARD dose de-escalation is a new development based on a recent de-escalation 
trial design [33-36]. Current evidence on real world dose de-escalation will be limited 
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and hence the model will have to be informed by clinical trial data at present. The 
last prioritized item is the incorporation of extra-articular manifestation since more 
research is needed to develop RA-speciﬁ c risk models for both CV and pulmonary 
disease however, in the interim, treatment-speciﬁ c risk reduction of CV could be 
incorporated in sensitivity analysis.
The conceptual model presented in this manuscript concurs with some of the recom-
mendations of the consensus recommendations from the 2015 ‘Consensus Working 
Party’ such as incorporation of AE based discontinuation, mapping of utility to disease 
activity [90]. However, there are also some major diﬀ erences between the Consensus 
Working Party’s recommendation and the current proposed conceptual model. The 
reliance by the Consensus Working Party on DAS28 for treatment response could lead 
to biased estimates for therapies such as anti-IL6 that have a disproportionate impact 
on acute phase reactants in DAS28. Additional diﬀ erences include incorporation of 
detailed treatment patterns versus only treatment discontinuation, speciﬁ cation of 
prognostic factors and incorporation of extra-articular manifestations.
This analysis represent the ﬁ rst step in a model building exercise, the appropriate 
next step would be to build a model prototype and evaluate the feasibility of opera-
tionalizing the proposed changes. Limitations of the current analysis is that it was 
beyond scope to empirically evaluate the impact of the diﬀ erent proposed changes in 
reducing the current uncertainty in economic models. Secondly, we did not evaluate 
the association between CDAI reduction and resource use/cost. However, there is evi-
dence that attainment of CDAI remission and LDA is associated with lower resource 
utilization, higher quality of life and improved physical functioning [41].
Though we developed this conceptual model to meet payer/HTA needs, the focus 
has been on payers using cost per QALY or cost per life year gained as a metric for 
decision-making. Thus, our proposed model might not be applicable to address cer-
tain payer needs. For example US payers are interested in shorter time horizon with 
outcomes such as remission. In addition, treatment modules will have to be adapted 
to each country based on clinical practice data. Due to our focus on HTA bodies that 
consider only direct cost in economic evaluations, our model does not accommodate 
the indirect cost of RA into the analysis. Further work is required to speciﬁ cally address 
modeling of cost eﬀ ectiveness from the societal perspective. Finally, it was beyond the 
scope of this analysis to evaluate the impact of the availability of robust, compara-
tive, head-to-head clinical trials in reducing the short-term eﬃ  cacy uncertainties in 
economic evaluations of RA products.
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Despite these limitation the conceptual model presented in this manuscript is based 
on a comprehensive approach that aims to incorporate both clinical and real-world 
evidence in the economic evaluation of RA interventions. We believe that the pro-
posed model framework can potentially serve as a foundation for developing future 
cost eﬀ ectiveness models in RA.
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SUPPLEMENTARY MATERIAL
Appendix S1: Working Groups RA CEA Model Framework “Wish List”
Model Parameters Common to most current 
 modeling approaches
Proposed Model
Technique Discrete event simulation, Indi-
vidual patient simulation, Markov 
cohort
TBD*
Baseline Patient Characteristics Age, gender, HAQ & weight Demographic: age, gender, dura-
tion of disease, weight
Prognostic factors: Sero positivity 
(RF and/or ACPA), auto immune 
co-morbidities
Risk of infections: age, diabetes, 
BMI, corticosteroid use
Extra-articular manifestation None CVD: CV related risk factors
Treatment effect ACR20, DAS28, EULAR (DAS28 
baseline & change from baseline)
TBD*
Disease progression HAQ TBD*
Utility through HAQ TBD*
Treatment patterns Sequential switching Real world based
Dose escalation
Treatment adverse effects Same across all treatments Treatment class speciﬁ c
Same across all patients Subgroups of patients at high risk 
for AEs and infections
* To be determined based on literature and database analysis
Appendix S2: RA Draft Cost Effectiveness Model Concept
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Appendix S3: Systematic Literature Review Results
S3 Table 1: Literature Search Strategy
# Search Strategy
1 rheumatoid arthritis.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, ps, rs, nm, ui, ct]
2 arthritis, rheumatoid/ or rheumatoid arthritis/
3 (tocilizumab or Actemra or RoActemra or golimumab or simponi or adalimumab or humira or 
etanercept or enbrel or rituximab or mabthera or abatacept or orencia or inﬂ iximab or remicade or 
certolizumab pegol or cimzia).mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, ps, rs, nm, ui, ct]
4 (Anakinra or Rituxan or Methotrexate or Rhemumatrex or Trexall or Sulfasalazine or Azulﬁ dine or 
Salazopyrin or Hydroxychloroquine or Plaquenil).mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, ps, 
rs, nm, ui, ct]
5 (1 or 2) and (3 or 4)
6 limit 5 to english language
7 limit 6 to human
8 limit 7 to yr=”2001 -Current”
9 (economic evaluation or economic model or cost effectiveness or cost beneﬁ t or cost utility).ti,ab.
10 “cost beneﬁ t analysis”/
11 (9 or 10) and 8
12 (Predict$ and (Outcome$ or Risk$ or Model$)).mp.
13 (Prognostic and (History or Variable$ or Criteria or Scor$ or Characteristic$ or Finding$ or Factor$ 
or Model$)).mp.
14 predict*.ti.
15 (13 or 12 or 14) and 8
16 11 or 15
17 remove duplicates from 16
18 limit 17 to (editorial or letter or note or autobiography or bibliography or biography or case reports 
or clinical conference or clinical trial, phase i or clinical trial, phase ii or comment or in vitro or 
interactive tutorial or interview or lectures or legal cases or legislation or news or newspaper article 
or periodical index or portraits) [Limit not valid in Embase,Ovid MEDLINE(R),Ovid MEDLINE(R) 
In-Process,Econlit; records were retained]
19 17 not 18
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S3 Figure 1. Flowchart of study identiﬁ cation and selection
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Appendix S4: Disease activity (change) overtime and association of HAQ change by baseline DAS categories
S4 Fig 1: CDAI, SDAI and DAS28-CRP overtime
Means are based on generalized linear models adjusted for baseline age, disease activity, gender, disease dura-
tion, serostatus, CRP, time since baseline
S4 Fig 2: CDAI, SDAI and DAS28-CRP overtime by disease duration and change overtime
Means are based on generalized linear models adjusted for baseline age, disease activity, gender, disease dura-
tion, serostatus, CRP, time since baseline
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S4 Table 1: HAQ change by DAS28 categories
DAS28 ≤ 2.6 
(remission)
N = 1820
< 2.6 DAS28 ≤ 3.2 
(LDA)
N = 608
< 3.2 DAS28 ≤ 5.1 
(MDA)
N = 1350
> 5.1 DAS28 ≤ 5.2 
(SDA)
N = 516
Mean (SE) Mean (SE) Mean (SE) Mean (SE)
mHAQ 0.254 (0.008) 0.320 (0.013) 0.399 (0.009) 0.603(0.015)
mHAQ change from 
baseline*
0.140 (0.008) -0.073 (0.013) 0.004 (0.009) 0.209 (0.015)
* negative change is worsening of HAQ; means based on general linear model adjusted for baseline co-variates
Das_cat : 1= DAS28 ≤ 2.6 ; 2 ≤ 2.6 DAS28 ≤ 3.2 ; 3 ≤ 3.2 DAS28 ≤ 5.1 ;4 ≥ 5.1 DAS28 ≤ 5.2
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A CASE FOR A COMPREHENSIVE APPROACH TO EVALUATING COST AND 
BENEFITS IN RA
Recent years have seen a tremendous progress in our understanding of the autoim-
mune mechanism underlying RA leading to rapid development of innovative disease 
modifying anti-rheumatic Drugs (DMARDs) for RA patients [1,2]. Various combina-
tion therapies of diﬀ erent biologic (b)DMARDs or of bDMARDs in combination with 
synthetic (sc)DMARD blocking multiple immune pathways are being explored for 
development [3]. Complemented by ‘Big Data’, these innovations in drug develop-
ment can enable interventions to be targeted to speciﬁ c RA patients and/or patient 
populations with the highest unmet needs [4]. At the same time various currently 
available biologic therapies will have biosimilars, potentially expanding the pool of 
RA patients managed with bDMARDs by lowering the price of bDMARD treatment. 
To accurately capture the beneﬁ ts and costs of therapies in RA and enable stratiﬁ ed 
medicine for speciﬁ c subgroups, it will be important to take a comprehensive ap-
proach when modeling disease progression and cost drivers for RA patients in future 
cost eﬀ ectiveness evaluations. In this thesis, the ﬁ rst three Parts focused on exploring 
multiple aspects of RA that could inform a framework for evaluating the potential 
value of future therapies in RA. Primarily, we focused on deﬁ ning the appropriate 
disease target measures and the impact of the various deﬁ nitions on resource use and 
health related quality of life (HRQOL), the heterogeneous nature of RA both in terms 
of baseline characteristics of RA patients (through considerations of subgroups) and 
outcomes that are non-joint related. The ﬁ rst chapter in the ﬁ nal Part, focused on the 
conventional cost eﬀ ectiveness modeling approach to evaluate the cost eﬀ ectiveness 
of bDMARD stratiﬁ ed by baseline level of anti-citrullinated protein antibody (ACPA) 
levels (marker of poor prognosis in RA). While, the ﬁ nal chapter was devoted to in-
corporating the learnings from previous chapters into a new conceptual model that 
potentially improves the evaluation of the cost eﬀ ectiveness of future therapies in RA.
The following list of hypotheses was addressed in the diﬀ erent Parts of this thesis:
Part I: Real world evidence on treatment targets and outcomes
Hypothesis tested: Achieving guideline recommended disease target measures in es-
tablished RA patients is associated with higher health related quality of life (HRQOL), 
lower hospitalization and durable medical equipment use
Part II: Presence of multiple poor prognostic factors
Hypothesis tested 1: Established RA patients that are seropositive, have higher odds 
of erosive disease and greater bone loss [hand Digital X-Ray Bone Mineral Density 
(DXR–BMD)]
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Hypothesis tested 2: Changes in anti-citrullinated protein antibody (ACPA) levels are 
directly associated to outcomes such as durable medical equipment use, hospitaliza-
tions, and disease activity, in patients with established RA.
Hypothesis tested 3: RA patients with multiple prognostic factors compared to those 
without multiple prognostic factors have worse clinical and economic outcomes.
Hypothesis tested 4: The presence of poor prognostic factors in RA patients leads to 
treatment acceleration in clinical practice setting.
Part III: Extra-articular manifestation of cardiovascular (CV) risk in RA
Hypothesis tested 1: Traditional CV risk factors are managed poorly in RA patients 
compared to matched non-RA patients
Hypothesis tested 2: Markers of inﬂ ammation such as C-reactive protein (CRP) improve 
the CV risk prediction in RA
Hypothesis tested 3: Higher low-density lipoprotein cholesterol (LDL-C) in RA patients 
is associated with increase in CV events.
Part IV: Improvements of future cost eﬀ ectives studies in RA
Hypothesis tested: The cost-eﬀ ectiveness of disease modifying anti-rheumatic drugs in 
RA is higher (lower ICER) with increasing levels of anti-citrullinated protein antibody 
titers
In this chapter, the clinical and policy implications of the ﬁ ndings are discussed, as 
well as some methodological considerations. The chapter is concluded with recom-
mendations about some main areas for future research.
CLINICAL IMPLICATIONS OF THE FINDINGS
Summary of ﬁ ndings and clinical implications of “Real World Evidence of Treatment 
Targets and Outcomes”
The major ﬁ ndings in Part I were based on a longitudinal observational study and 
demonstrated that achieving (versus not achieving) guideline-recommended target 
measures of disease activity of Disease Activity Score-28 joints C-reactive protein 
(DAS28-CRP < 2.6), Standardized Disease Activity Index (SDAI ≤ 3.3), and/or Clinical 
Disease Activity Index (CDAI ≤2.8) was associated with signiﬁ cant improvements in 
physical functioning as measured by modiﬁ ed Health Assessment Questionnaire 
(mHAQ), HRQOL (measured by EQ-5D), and health care resource utilization. More 
importantly, this analysis found that subjects who achieved the most desirable target 
of DAS28-CRP < 2.6 did not diﬀ er signiﬁ cantly compared to those with low disease 
activity (LDA; 2.6 ≤ DAS28-CRP < 3.2) in terms of physical functioning as measured 
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by the mHAQ. Attainment of DAS28-CRP < 2.6, SDAI ≤ 3.3, or CDAI ≤ 2.8 did not 
result in signiﬁ cant reductions in hospitalization compared to achievement of LDA 
(although there were trends toward reduced odds of hospitalization in subjects achiev-
ing target measures across all 3 indices) but did diﬀ er in HRQOL (patients attaining 
remission vs. LDA had improved HRQOL) and similar results were observed with 
durable medical equipment use except for DAS28-CRP (which was borderline signiﬁ -
cant). These ﬁ ndings therefore suggest that diﬀ erentiation on outcome measures for 
achieving target remission versus LDA is not uniform. Clear beneﬁ ts were observed 
with HRQOL and durable medical equipment use across all composite measures. 
However, the evidence for lower mHAQ and reduced hospitalizations with remission 
depended on the composite measure being used. DAS28-CRP remission vs. LDA did 
not diﬀ erentiate on mHAQ or hospitalization, whereas SDAI and CDAI diﬀ erentiated 
on mHAQ but not hospitalizations. We also observed that attainment of LDA [versus 
moderate disease activity (MDA) or severe disease activity (SDA)] was associated with 
favorable clinical and economic outcomes.
Taken together, these ﬁ ndings support both the value of treating to target and the 
assertion that LDA is a plausible alternative clinical objective for treat to target strate-
gies when guideline-recommended goals of remission cannot be achieved in clinical 
practice. This is an important ﬁ nding from a clinical as well as health policy perspec-
tive, speciﬁ cally for patients with longstanding disease since guideline targets might 
not be a viable option for all patients. In addition, we also noticed that not all disease 
measures performed consistently in discriminating physical functioning, HRQOL, 
and health care resource utilization across guideline-recommended target measures. 
Compared to DAS28-CRP, measures of SDAI and CDAI were more consistent in their 
diﬀ erentiations on outcomes evaluated. There is evidence to suggest that DAS28-
CRP < 2.6 might not be an appropriate measure of remission as there might still be 
some underlying disease present [5]. The SDAI and CDAI include both patient and 
evaluator ratings of global disease activity, which are frequently discrepant. Perhaps 
the inclusion of both perspectives on global disease activity in the SDAI and CDAI 
(but not DAS28-CRP) renders these indices more eﬀ ective assessments of physical 
functioning on the mHAQ (versus DAS28-CRP). Thus, evaluation of beneﬁ ts in health 
economic evaluations should consider multiple composite endpoints.
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Summary of ﬁ ndings and clinical implication of “Presence of Multiple Poor 
Prognostic Factors”:
The key ﬁ ndings in Part II were the association between single and multiple prog-
nostic factors and clinical and economic outcomes. The ﬁ rst major ﬁ nding in this 
section demonstrates that, among patients with long-standing RA, hand DXR–BMD 
is negatively associated with the presence of ACPA. Patients with ACPA+ status, par-
ticularly those with high ACPA titers, had lower hand BMD. In addition, we observed 
that patients with low DXR–BMD were less likely to have high disease activity and low 
likelihood of attaining remission. Hand BMD loss has also been shown to indicate 
an increased risk of erosive disease. Data from an observational study demonstrated 
that BMD loss at 6 months was associated with higher erosion scores, and a higher 
proportion of patients with BMD loss at 6 months had ≥1 erosion and a higher risk of 
erosion progression at 12 months. In a separate analysis, a decrease in ACPA levels 
(compared to no change or increase in ACPA levels) was associated with a reduction 
in durable medical equipment use and hospitalizations. Adjusted mean changes in 
DAS28-CRP, total and swollen joint counts and pain scores were signiﬁ cantly greater 
in patients with decreased ACPA levels versus those with no change or increase. Other 
studies supported the ﬁ nding that patients with seropositivity and joint erosions 
were signiﬁ cantly less likely (than their counterparts without these prognostic factors 
together) to have DAS28-CRP < 2.6 or SDAI ≤ 3.3. With regard to direct health-care 
costs, the likelihoods of hospitalization and durable medical equipment use were sig-
niﬁ cantly higher in patients with adverse prognostic factors. With respect to indirect 
health-care costs, greater proportions of patients without the adverse prognostic fac-
tors were employed, lower proportions were on short-term and long-term disabilities 
and in the lower income bracket. The ﬁ nal study in this Part of the thesis, again fo-
cused on RA patients with multiple prognostic factors and observed that the changes 
in both CDAI and LDA/remission from baseline (enrollment) to 12-month follow-up 
were signiﬁ cantly lower in patients with a greater number of poor prognostic factors. 
In addition, the worst prognostic factor category i.e. those with 3+ prognostic factors 
had the lowest proportion of patients working full or part-time at both baseline and 
after the 12-month follow-up, whereas those with 0–1 prognostic factors had the high-
est proportion of patients working at baseline and still working at follow-up. However, 
in this analysis it was observed that despite high disease activity and worst clinical 
outcomes, the number of poor prognostic factors was not a signiﬁ cant predictor of 
biologic/targeted synthetic DMARD use.
Taken together, the ﬁ ndings of this section warrant consideration of the importance of 
poor prognostic factors in treat-to-target strategies. Given that patients with a greater 
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number of poor prognostic factors have the worse clinical and social outcomes, it 
would be beneﬁ cial to consider use of prognostic factors to guide decisions on the 
treatment for RA. Recent EULAR treatment guidelines have highlighted the impor-
tance of stratiﬁ cation of RA patients by prognostic factors by prominently calling it 
out as a separate recommendation i.e. recommendation #8. However, ﬁ ndings from 
studies in this thesis indicate that prognostic factors are not associated with treat-
ment accelerations in RA patients. This could be partly driven by a lack of understand-
ing on the Part of clinicians and payers on the unmet need associated with patients 
having multiple prognostic factors. Current economic analysis and payer policies 
do not distinguish patients based on poor prognostic factors and physicians do not 
systematically document all prognostic factors in clinical practice. Thus, it could be 
beneﬁ cial for patients, physicians and payers if health care providers engage patients 
in conversations about poor prognostic factors and how they may wish to tailor their 
RA care, based on a treat-to-target approach.
Summary of ﬁ ndings and clinical implication of “Extra-articular Manifestation of 
Cardiovascular Risk in RA”
The major ﬁ ndings of Part III suggest that the traditional CV risk factors are equally 
important in RA patients as in the general non-RA population. Additionally, ﬁ ndings 
in this Part indicate that the increased CV risks experienced by RA patients cannot 
be fully explained by the traditional risk factors. Analysis based on data from two 
diﬀ erent health care systems, one from the UK and one from the US, indicate that 
there were no diﬀ erences between RA and matched non-RA patients in the frequency 
of testing and treatment of traditional CV risk factors. Thus, it is unlikely that the 
higher CV risk in RA patients is driven by diﬀ erences in the management of traditional 
CV risk factor by rheumatologists. More importantly, when the associations between 
higher LDL-C and CV outcomes among patients with RA and patients without RA was 
examined, we observed that higher LDL-C levels were associated with increased CV 
events. The relationship between LDL-C and CV outcomes in RA was similar to the 
relationship found in matched general and OA controls. Hence, lowering LDL-C levels 
in RA patients would provide similar beneﬁ ts in RA patients as in non-RA patients 
leading to the conclusion that LDL-C levels is not anticipated to explain the increased 
CV risk observed in RA patients. The ﬁ nal study in this Part of the thesis evaluated if 
other markers of inﬂ ammation such as CRP could explain some of the increased CV 
risk observed in RA patients. The study aimed to compare the performance of CV risk 
calculators, Framingham Risk Score (FRS) and QRISK2, in RA and matched non-RA 
patients and to evaluate whether their performance could be enhanced by the addition 
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of CRP. Findings from this study indicate that the C-Index for the FRS and QRISK2 was 
signiﬁ cantly better in the non-RA compared with RA patients. The addition of CRP in 
both equations was not associated with a signiﬁ cant improvement in reclassiﬁ cation 
based on net reclassiﬁ cation index (NRI).
Based on this body of research, it should be concluded that it is important to manage 
the traditional CV risk factors in RA patients and ensure that RA patients meet the 
guideline recommend targets of hypertension, lipids, A1C, weight, smoking etc. In 
addition, these ﬁ ndings demonstrate that RA patients are being managed similarly to 
non-RA patients with similar CV risks for their traditional CV risk factors. Hence, the 
increase in CV events in RA patients could be due to factors other than the traditional 
CV risk factors or a combination of traditional CV risk factors and non-traditional CV 
risk factors in RA patients. In terms of the management of traditional risk factors 
our ﬁ ndings indicate that rheumatologist are managing RA patients in accordance 
with the current guidelines that state when treating RA patients, health care providers 
and policy makers should consider the impact of RA therapies on traditional CV risk 
factors and CV events. In the Netherlands, the Dutch guidelines recommend the ap-
plication of CV risk management (CVRM) in RA patients, because RA is considered 
as an independent risk factor for CV disease.6 However, a recent study showed that 
CVRM guidelines performed poorly in RA patients, with an overall increase in 10 year 
CV risk despite implementation of CVRM [7].
Though our ﬁ ndings indicate the importance of traditional risk factors in RA they did 
not explain the increased CV risk observed in RA patients. Our attempts to improve 
the traditional CV risk calculators (algorithms) by including measures of inﬂ ammation 
was not successful. Others have attempted in recent years to develop such algorithm 
but with mixed success [8.9]. Given that the traditional CV risk algorithms were not 
developed in the RA-speciﬁ c population, and to account for the increased CV risk in 
RA patients vs the general population, the EULAR guidelines recommend that the risk 
calculated, using these algorithms, should be multiplied by a factor of 1.5. Further 
development and testing of RA speciﬁ c CV algorithm is warranted.
Summary of ﬁ ndings and clinical implication of “Improvements of Future Cost 
Eﬀ ectiveness Studies in RA”:
Part IV of the thesis evaluated the impact of incorporation of subgroups, primarily 
based on poor prognostic factors of ACPA levels and proposed the development of a 
revised conceptual model for evaluating the cost eﬀ ectiveness of future therapies in RA.
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As mentioned above, in Part II, patients having multiple poor prognostic factor tended 
to have worst clinical and economic outcomes, highlighting that the cost eﬀ ective-
ness ratios might not be uniform across all RA patients. We evaluated this hypothesis 
by conducting a cost eﬀ ectiveness analysis by worsening prognostic factors (based 
on ACPA titers) and were able to show that the ICERs of intervention reduced when 
prognosis worsened. In addition there is now evidence that certain mechanism of 
actions might perform diﬀ erently in patients with certain prognostic factors. [10, 11].
Based on the ﬁ ndings from Parts I to III of this thesis as well as our understanding of 
the current modeling approaches in RA we propose a revised conceptual framework 
that will potentially improve the modeling of cost and beneﬁ ts of future innovative 
technologies in RA. The proposed conceptual model consists of three separate mod-
ules: 1) patient characteristic module, 2) treatment module, and 3) outcome module. 
Consistent with the scope, the conceptual model proposed six changes to current 
economic models in RA. These changes proposed are to: 1) use composite measures 
of disease activity to evaluate treatment response as well as disease progression 
(at least two measures should be considered, one as the base case and one as a 
sensitivity analysis); 2) conduct utility mapping based on disease activity measures; 
3) incorporate subgroups based on guideline-recommended prognostic factors; 4) 
integrate realistic treatment patterns based on clinical practice/registry datasets; 5) 
assimilate outcomes that are not joint related (extra-articular outcomes); and 6) as-
sess mortality based on disease activity.
METHODOLOGICAL CONSIDERATIONS
One of the main limitation of the body of work presented in this thesis is that it very 
much focused on established RA patients. In recent years tremendous strides have 
been made in the understanding of the disease in early phases and how the disease 
progresses from arthralgia to undiﬀ erentiated RA to fully established disease. Experts 
believe that early treatment interventions might be clinically as well as economically 
beneﬁ cial as it could cure the disease in some patients. However, the evidence is still 
debatable and evolving. Cost eﬀ ectiveness analysis for bDMARD based on early RA 
studies have not shown these therapies to be cost eﬀ ective. However, it could be dif-
ferent in subgroups of early RA patients who are at risk of rapid progression of disease 
and could beneﬁ t from early bDMARD use, especially at the prices of the biosimilar.
Another limitation of the body of work in Parts II and III is that it only focused on certain 
prognostic factors (i.e. erosive disease and seropositivity) and certain extra-articular 
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manifestation of RA (CV events). In recent years, seropositivity, particularly ACPA has 
gained importance both for its diagnosis as well as for its prognostic abilities. Histori-
cally, the worst outcomes were associated with the presence of erosive disease, which 
was in turn associated with the presence of seropositivity. However, the simultaneous 
presence of multiple prognostic factors had not been evaluated prior to this body of 
work. Other prognostic factors that were not considered in our work include functional 
disability, imaging markers, and novel multi-biomarkers. The reason to focus on these 
particular prognostic factors is because they are correlated and there is evidence that 
these could be treatment modiﬁ ers.
It is increasingly understood that RA is a systemic disease and thus aﬀ ects multiple 
organ system; this thesis focused on the CV aspect of RA. Other extra-articular condi-
tions like lung abnormalities in RA are gaining attention because of evidence that 
certain RA treatments such as methotrexate, leﬂ unomide and anti-TNFs are associ-
ated with new onset and acceleration of existing interstitial lung disease (ILD).13 The 
reasons to focus on CV aspects of RA in this thesis were multiple and included overall 
impact on disease burden, cost and ability of treatment to impact outcomes as well as 
the availability of data in clinical practice settings.
In the ﬁ nal, ‘Improvement of Future Cost Eﬀ ectiveness Studies in RA’ Part, the ISPOR-
SMDM Modeling Good Research Practice Task Force-2 recommended method was 
used to arrive at the conceptual frame. However, no model prototype was built and 
thus the importance of the diﬀ erent variables in reducing the current uncertainty in 
economic models was not evaluated. Additionally, though the model concept was 
developed to meet payer/HTA needs, the focus has been on payers using cost per 
QALY or cost per life year gained as a metric for decision-making. Thus, the proposed 
conceptual model might not be applicable to certain payer needs, for example, US 
payers are interested in time horizons of 1 to 5 years and outcomes of remission to 
calculate the cost per remission. Finally, the treatment module will have to be adapted 
to each country based on clinical practice data. Another aspect that was not included in 
the conceptual model, due to its focus on the payer perspective, was the costs of pro-
duction loss, the costs of informal care and the costs borne by the patients themselves.
Given the overall objective of the thesis and nature of the research hypothesis tested, 
we considered that the most relevant data source to inform this thesis was real world 
clinical practice data. Unlike randomized clinical trials, real world registry data are less 
prescriptive in their inclusion/exclusion criteria as well as the treatments and hence 
provide an appropriate data source for evaluating the beneﬁ ts of various RA disease 
health states (remission, LDA, MDA, SDA) on outcomes. In addition, a real world data 
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source is the only economically viable option when the research hypothesis requires 
a longitudinal follow-up of large numbers of patients as is in the case of evaluating 
the impact of RA on CV risk/events. Finally, since results of cost eﬀ ectiveness analysis 
are used to implement health policy decisions basing these analyses on real world 
data that represent the entire target population is preferable. However, the hypothesis 
tested in the cost eﬀ ectiveness of interventions by ACPA titers in chapter 10 is based 
on data from just one randomized clinical trial data and would beneﬁ t from additional 
data from real world setting. Besides the advantages of using real world data to ad-
dress research questions in health services research, there are also some limitations 
of this type of research. Firstly, given the nature of the data and confounders, conclu-
sions drawn from this type of work are associational at best.
Secondly, these datasets seldom have complete information and can either suﬀ er 
from missing information and/or censored information. We tried to control for selec-
tion biases and confounders by using statistical methods and procedures such as 
propensity score matching and by using appropriate mixed eﬀ ects models to control 
for missing information. In spite of these measures caution should be exercised in 
implying causality and further research is needed to support these ﬁ ndings. Despite 
these limitations, the studies presented in this thesis highlight the importance of 
considering the following aspects in future cost eﬀ ectiveness models – 1) use com-
posite measures of disease activity to evaluate treatment response as well as disease 
progression (at least two measures should be considered, one as the base case and 
one as a sensitivity analysis); 2) conduct utility mapping based on disease activity 
measures; 3) incorporate subgroups based on guideline-recommended prognostic 
factors; 4) integrate realistic treatment patterns based on clinical practice/registry 
datasets; 5) assimilate outcomes that are not joint related (extra-articular outcomes); 
and 6) assess mortality based on disease activity
POLICY CONSIDERATIONS:
As biosimilar therapies get wider acceptance from rheumatologist and with health care 
policy makers, it is possible that more RA patients would be treated with bDMARDs. 
This could even open up the possibility of treating early RA patients (6 months from 
diagnosis) with clinically eﬃ  cacious and cost eﬀ ective interventions. Thus, biosimi-
lars can improve the overall clinical and societal beneﬁ ts by making bDMARDs af-
fordable to a wider patient population. This is likely to increases the total number 
of RA patients being treated with bDMARDs. This phenomenon of expansion of the 
treated patient pool has been observed in other therapeutic areas that experienced 
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entry of generics. However, current bDMARD therapies do have limitations in terms of 
adverse eﬀ ects as well as eﬃ  cacy (remission rates are still in the range of 10% to 30% 
depending on measures used) and there will continue to be groups of patients with 
high unmet need in RA with even lower remission rates. Patients failing on biosimilars 
will require branded bDMARDs or newer targeted synthetic DMARDs and hence the 
cost savings/reductions anticipated by healthcare systems might be challenging. 
However, incorporating our knowledge on the nature of RA being a heterogeneous 
and systemic disease, availability of newer interventions with multiple mechanism of 
actions, complemented with availability of large data, policies could be implemented 
that are more targeted rather than one size ﬁ ts all i.e. implementing a personalized 
medicine approach in managing RA patients.
The research in this thesis has highlighted that treatment and reimbursement policies 
in RA should consider treatment targets that are better associated to multiple out-
comes such as physical functioning, quality of life and resource use. This is especially 
true in RA, since the primary outcomes of ACR and DAS28-CRP measured in clinical 
trials are not generally measured in clinical practice settings and might only be infor-
mative from a drug eﬃ  cacy point of view for regulatory drug approval requirements. 
However, these measures are less sensitive to other outcomes relevant for payer 
needs compared to CDAI/SDAI.
In addition, future policy in RA should consider exploring the management of RA based 
on subgroups of high unmet need, as has been done in multiple other therapeutic 
areas such as cardiovascular, diabetes, hepatitis etc. Finally, future health policies in 
RA should take a more holistic approach for managing RA, since there is increasing 
evidence of the systemic inﬂ ammatory nature of the disease. Thus, focusing on only 
the joint aspects of the condition in cost eﬀ ectiveness evaluations does not provide 
the estimate of the true cost and beneﬁ t of interventions and incorporation of the 
non-joint aspect of the condition will be important. Though our work did not focus 
on the patient reported outcomes measures (PROMS) or patient reported experience 
measures (PREMS), incorporation of these measures in future policy considerations 
for RA will be important. The current measures of treatment responses (ACR, DAS28-
CRP, SDAI and CDAI), though informative from an eﬃ  cacy perspective and including 
certain PRO components such as patient global assessment measure, are not very 
meaningful to patients. Patients are more concerned and familiar with their daily 
symptoms of RA such as morning stiﬀ ness, fatigue, joint pains etc. (vs. a state of 
DAS28-CRP < 2.6).
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IMPLICATIONS FOR FUTURE RESEARCH
The ﬁ rst Part of the thesis evaluated the impact of attaining remission, LDA, MDA, 
SDA through various disease activity measures on outcomes such as physical func-
tioning, HRQOL, hospitalizations and durable medical equipment use. Other impor-
tant endpoints such as PROMS and radiographic progression were not considered. 
Future studies should evaluate the beneﬁ t of remission on these outcomes. Part II, 
highlighted that not all RA patients are alike in terms of their disease proﬁ le and that 
patients with certain prognostic factors have worse clinical and economic outcomes. 
In addition, there is evidence that some of the prognostic factors are treatment ef-
fect modiﬁ ers [10, 11]. Future research should be devoted to the understanding the 
impact of treatments by prognostic factors and the inclusion of multiple prognostic 
factors into economic evaluations. In Part III, the extra-articular CV eﬀ ects of RA were 
studied. However, in treating RA patients the focus is primarily on the joints and the 
impact of current treatment on extra-articular manifestation is ignored. There is now 
evidence that anti-inﬂ ammatory therapy can reduce the risk of CV events [14]. Also, 
there is evidence that certain RA therapy might contribute to worsening of RA lung 
conditions.13 Future research should consider the non-joint impact of RA treatment 
and the inclusion of these aspect into the economic modeling.
In addition to the above, future economic models should devote more eﬀ ort to under-
standing how the composite measures of disease change over time and the impact 
of measures such as CDAI on EQ-5D. In addition, the treatment patterns considered 
in these models should be real world based and include aspects of drug holiday, de-
escalation and dose escalation. Evidence generated through these research topics will 
inform the future economic models in terms of treatment responses, subgroups and 
clinical beneﬁ ts. This will enable to more accurately characterize the treatment ben-
eﬁ ts and cost of intervention and implement policies that are more targeted paving 
the way for personalized medicine in RA.
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Background
Rheumatoid Arthritis (RA) is described as a chronic progressive inﬂ ammatory dis-
ease of the joint synovium, leading to progressive disability and loss of function. RA 
through its articular as well as extra-articular impact contributes not only to reduced 
survival, health related quality of life (HRQOL), activities of daily living and work 
productivity, but is also associated with higher health resource utilization and costs. 
The prevalence of RA ranges from 0.4% to 1.3%.
RA treatments include corticosteroids (CS), non-steroidal anti-inﬂ ammatory drugs 
(NSAIDs), and disease-modifying antirheumatic drugs (DMARDs). Traditional or 
conventional (c)DMARDs include gold, sulfasalazine, azathioprine, cyclophospha-
mide, antimalarials and methotrexate. Biologic (b)DMARDs were introduced around 
2000 and more recently targeted synthetic (ts)DMARDs; these agents have greatly 
improved overall clinical outcomes, and HRQOL of patients. However, these therapies 
are expensive compared to the cDMARDs. Recently, biosimilars have been approved 
by regulatory and payer authorities in the EU and these agents have considerable 
lower cost. In parallel, new therapies as well as combination therapies (of diﬀ erent 
bDMARDs or of bDMARDs in combination with tsDMARDs) targeting multiple im-
mune pathways are being developed. In this type of environment, tools that enable 
a broader and more precise estimation of cost and beneﬁ ts will reduce the risk of 
ineﬃ  cient resource allocation.
This thesis builds towards taking a comprehensive approach in evaluating beneﬁ ts 
and costs of future therapies in RA. It focuses on the heterogeneous nature of RA, 
both in terms of baseline characteristics of RA patients through considerations of 
subgroups as well as outcomes that are not joint related. It is important to consider 
these aspect of the disease as future economic analysis will need to take these into 
account to further diﬀ erentiate vs. standard of care.
The thesis is divided into 4 parts:
Part I: Real world evidence on treatment targets and outcomes
Part II: Presence of multiple poor prognostic factors
Part III: Extra-articular manifestation of cardiovascular risk in RA
Part IV: Improvements of future cost eﬀ ectives studies in RA
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Part I: Real world evidence on treatment targets and outcomes
Consensus treatment guidelines by EU League Against Rheumatism (EULAR 2016) 
focus on the joint aspect of the disease and have advocated a treat to target approach. 
In Chapter 2 of the thesis, data from clinical practice was utilized to conduct an obser-
vational study to test the hypothesis that achieving target measures of disease activity 
would lead to improved outcomes in clinical practice in a longitudinal follow-up of RA 
patient cohort. Outcomes evaluated in this analysis included both clinical i.e. physical 
functioning (daily activities) according to the modiﬁ ed Health Assessment Question-
naire (M-HAQ), quality of life measured by EuroQol 5-domain (EQ-5D) measure and 
economic i.e. resource utilization according to hospitalizations and durable medical 
equipment (DME) use. Disease activity measures used in this analysis were those 
recommended by guidelines and included the Disease Activity Score in 28 joints us-
ing C-reactive protein level (DAS28-CRP) <2.6, the Simpliﬁ ed Disease Activity Index 
(SDAI) ≤3.3, or the Clinical Disease Activity Index (CDAI) ≤2.8.
Data from the Brigham and Women’s Hospital Rheumatoid Arthritis Sequential Study 
(BRASS; Clinical- Trials.gov identiﬁ er NCT01793103) was utilized to address research 
objectives. BRASS was initiated in 2003–2004. The BRASS Registry is a single-center, 
prospective, observational longitudinal cohort of 1,200 adults with established or 
recent-onset RA. Physicians assessed patient demographic and clinical characteris-
tics, disease activity, and laboratory parameters at baseline and annually thereafter. 
To control for intraclass correlation of the panel data, mixed models with Toeplitz 
covariance structure were utilized to estimate both the eﬀ ects of the achievement of 
target measures or other levels of disease activity on the dependent variables, i.e., 
the primary outcome measure of physical functioning assessed by the M-HAQ and 
the secondary outcome measure of HRQOL assessed by the EQ-5D. Generalized es-
timating equations with binomial distribution and logit link function were utilized for 
binary outcomes such as DME use and all-cause hospitalization. Baseline covariates 
included in these models were sociodemographic, laboratory measures, subjective 
(patient-reported), and physician-diagnosed comorbidities.
The ﬁ ndings of the analysis suggest that attaining recommended target disease-activity 
measures was associated with enhanced physical functioning and health-related qual-
ity of life. Some health outcomes were similar in subjects attaining guideline targets 
versus LDA. Achieving LDA is a worthy clinical objective in some patients.
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Part II: Presence of multiple poor prognostic factors
Contemporary RA management guidelines recommend more intensive treatment of 
patients with poor prognostic factors. The new 2016 EULAR RA treatment guidelines 
give stratiﬁ cation of RA patients by prognostic factors more prominence and call it out 
as a separate recommendation i.e. recommendation #8. The guidelines do mention 
that the combination of these factors as having poor prognosis. However, there is no 
empirical data in established RA on the impact of multiple prognostic factors on clini-
cal and economic outcomes. Part II of the thesis focuses on the presence of multiple 
poor prognostic factors on clinical and economic outcomes in established RA.
The following research hypothesis were tested in the various studies conducted in this 
part of the thesis: 
a) Established RA patients that are anti-cyclic citrullinated peptide antibody (ACPA) 
positive, have increased odds of erosive disease and greater bone loss [hand 
Digital X-Ray Bone Mineral Density (DXR–BMD)], indicating prognostic factors 
are inter-related.
b) Reduction in ACPA titers is associated with reduction in disease activity and re-
source utilization.
c) The presence of multiple poor prognostic factors leads to poor clinical and eco-
nomic outcomes in RA patients.
d) The presence of poor prognostic factors in RA patients leads to treatment accelera-
tion in clinical practice setting.
Data from the BRASS registry and CORRONA RA registry were used to address 
hypothesis in this section. In Chapter 3, the BRASS database, was used to evaluate 
the associations between ACPA positivity and the binary outcome variable of the pres-
ence or absence of joint erosions as well as the loss of DXR-BMD. In this analysis 
we used logistic regression models controlling for baseline covariates. Models also 
tested associations between the presence of multiple prognostic factors and the 
categorical variables of: 1) having DAS28-CRP < 2.6 or SDAI ≤ 3.3 (SDAI remission), 
2) hospitalization (yes or no), 3) DME use (yes or no), and 4) employment status 
(proportions employed, retired, disabled, and earning <$70,000 annually). For as-
sociations between seropositivity and/or joint erosions and the likelihood of having a 
DAS28-CRP score < 2.6 or SDAI ≤ 3.3 (SDAI remission), Forest plots based on logistic 
regression models were constructed showing odds ratios (OR) and 95% conﬁ dence 
intervals (CIs). Covariates in these models included patient age, gender, race, body 
mass index (BMI), number of comorbidities, corticosteroid use and DMARDs. The 
ﬁ ndings demonstrated that that ACPA seropositive patients, particularly those with 
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high ACPA titres, have lower hand BMD, and patients with lower hand BMD are less 
likely to achieve DAS28 (CRP) <2.6.
In Chapter 4 the associations between changes in ACPA levels and outcomes, includ-
ing DME use, hospitalizations, and disease activity, in patients with established RA 
was evaluated using BRASS registry data. Findings from this analysis highlight that 
decrease in ACPA levels was associated with reduction in DME use (adjusted odds 
ratio [aOR]: 0.64; 95% conﬁ dence interval [CI]: 0.44–0.93; P = 0.019) and hospital-
izations (aOR: 0.62; 95% CI: 0.41–0.95; P = 0.029) versus no change or increase. 
Adjusted mean changes in disease activity score in 28 joints (C-reactive protein), total 
and swollen joint counts, and pain scores were signiﬁ cantly greater in patients with 
decreased ACPA levels versus those with no change or increase (P < 0.05). Thus, 
among patients with established RA, reductions in ACPA levels of >10% were associ-
ated with reductions in DME use, hospitalizations, and disease activity.
Chapters 5-6 focused on the presence of multiple prognostic factors in RA patients. In 
Chapter 5 logistic regression models were used to test associations between ACPA/ 
rheumatoid factor (RF) seropositivity and erosive disease and the presence of ACPA/
RF seropositivity plus erosive disease and (1) RA severity; (2) hospitalizations; (3) 
durable medical equipment (DME) use; and (4) worker productivity (e.g., employ-
ment status). Covariates in these models included patient age, gender, race, body 
mass index (BMI), number of comorbidities, and treatment. The ﬁ ndings indicated 
that ACPA positive (vs. negative) RA patients were 2.72 times more likely to have ero-
sions (OR = 2.72; 95% CI: 1.77−4.18; P < 0.001). Patients with ACPA seropositivity and 
erosions were signiﬁcantly more likely to: (1) have higher disease activity as measured 
by the DAS28-CRP ≥ 2.6; (2) be hospitalized; (3) use DME; and (4) be unemployed, 
disabled, or long-term disabled. This analysis was the ﬁ rst “real-world” study in pa-
tients with both recent-onset and chronic RA, that demonstrated the combination of 
ACPA seropositivity and erosions were signiﬁcantly associated with adverse clinical 
and health-economic outcomes, including a lower probability of low disease activity 
and higher health resource utilization, despite use of bDMARDs by many patients. 
Thus highlighting that the presence of multiple prognostic factors may signal a need 
for more intensive therapies, even when observed in patients with chronic, as well as 
recent-onset, RA.
Chapter 6 is based on data from the CORRONA RA registry. The objective of this 
analysis was to characterize patients with RA by number of poor prognostic factors 
(such as functional limitation, extra-articular disease, seropositivity, erosions) and 
evaluate treatment acceleration, clinical outcomes, and work status over 12 months 
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by number of poor prognostic factors. Changes in medication, CDAI, and work status 
(baseline–12 months) were evaluated using linear and logistic regression models. The 
relationship between poor prognostic factor groups and work status was investigated 
at baseline and 12-month follow-up using chi-squared tests. A frequency-matching ap-
proach (coarsened exact matching) was used to match patients across poor prognos-
tic factor categories according to age group (18–44, 45–54, 55–64, 65–74, 75+ years) 
as the relationship between poor prognostic factor category and work status could 
be driven by age diﬀ erence (retirees are generally older). At baseline, patients with 
greater number of poor prognostic factors (vs. those with fewer prognostic factors) 
were older, and had longer RA duration and higher CDAI (p = 0.011). B/tsDMARD use 
was similar in patients with/without prognostic factors. After adjusting for baseline 
CDAI, mean (standard error) change in CDAI was −4.95 (0.24), −4.53 (0.27), and 
−2.52 (0.34) for no-prognostic factor group, 1, 2, and ≥3 prognostic factor groups, 
respectively. More patients were working at baseline but not at 12-month follow-up in 
2 (13.9%) and ≥3 (12.5%) versus 0–1 (7.3%) prognostic factor groups. This analysis 
again highlights that patients with multiple prognostic factors had suboptimal clinical 
and work status outcomes. More importantly, the ﬁ ndings indicate that despite high 
disease activity and worse clinical outcomes, prognostic factors did not signiﬁ cantly 
predict b/tsDMARD use. This may warrant reconsideration of the importance of poor 
prognostic factors in treat-to-target approaches.
Part III: Extra-articular manifestation of cardiovascular risk in RA
Treatment guidelines in RA have focused on the joint aspect of the disease however; 
extra articular manifestation of RA represents the signiﬁ cant and important outcome. 
The thesis focuses on the cardiovascular (CV) manifestation of RA, primarily because 
CV events impact overall patients survival, HRQOL and have substantial cost implica-
tions. Since RA is associated with a 50 to 60% increase in risk of CV death, Chapter 7 
assessed the management of traditional CV risk factors in RA patients so as to evalu-
ate if the increased CV risk could be explained by poor management by traditional CV 
risk factors in RA. Data were utilized from the UK Clinical Practice Research Datalink 
(CPRD) for the analysis. RA patients were matched 1:4 to non-RA patients based on 
their year of entry in the CPRD database, CV risk category (NCEP classiﬁ cation), treat-
ment status at index date and a propensity score estimating the probability of having 
RA. 24,859 RA patients were identiﬁ ed and matched to 87,304 non-RA patients. An-
nual blood pressure, lipids and diabetes-related testing were similar in both groups, 
although CRP and ESR were higher in RA patients at diagnosis and decreased over 
time. RA patients prescribed antihypertensives increased from 38.2% at diagnosis 
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to 45.7% at 5 years, from 14.0 to 20.6% for lipid-lowering treatments and from 5.1 
to 6.4% for antidiabetics. Similar treatment percentages were observed in non-RA 
patients, although slightly lower for antihypertensives. Modest (2%) but signiﬁ cantly 
lower attainment of lipid and diabetes goals at 1 year was observed in RA patients. 
This analysis indicated that there were no diﬀ erences between groups in the frequency 
of testing and treatment of CV risk factors. Higher CV events in RA patients seems 
unlikely to be driven by diﬀ erences in traditional CV risk factor management.
Another aspect of CV manifestation of RA investigated in Chapter 8 was the perfor-
mance of CV risk prediction algorithms in RA. The aim was to compare the perfor-
mance of cardiovascular risk calculators, Framingham Risk Score (FRS) and QRISK2, 
in RA and matched non-RA patients and to evaluate whether their performance could 
be enhanced by the addition of CRP. Retrospective analysis using CPRD linked to 
Hospital Episode Statistics (HES) data was performed. RA patients with no prior CV 
were matched to non-RA patients using disease risk scores. The overall performance 
of the FRS and QRISK2 was compared between cohorts, and assessed with and with-
out CRP in the RA cohort using C-Index, Akaike Information Criterion (AIC) and the 
net reclassiﬁ cation index (NRI). The C-Index for the FRS in the non-RA and RA cohort 
was 0.783 and 0.754 (P < 0.001) and that of the QRISK2 was 0.770 and 0.744 (P < 
0.001), respectively. Log[CRP] was positively associated with cardiovascular events, 
but improvements in the FRS and QRISK2 C-Indices as a result of inclusion of CRP 
were small, from 0.764 to 0.767 (P = 0.026) for FRS and from 0.764 to 0.765 (P = 
0.250) for QRISK2. The NRI was 3.2% (95% CI: -2.8, 5.7%) for FRS and -2.0% (95% CI: 
-5.8, 4.5%) for QRISK2. The C-Index for the FRS and QRISK2 was signiﬁ cantly better 
in the non-RA compared with RA patients. The addition of CRP in both equations was 
not associated with a signiﬁ cant improvement in reclassiﬁ cation based on NRI.
The ﬁ nal Chapter 9 of the section focused on the association between lowering low-
density lipoproteins cholesterol (LDL-C) levels and CV outcomes among RA patients. 
Adult patients with RA and 2 age- and sex-matched control cohorts [RA plus general 
controls (RA/GN), RA plus osteoarthritis (OA) controls (RA/OA)] were analyzed. Mul-
tivariable Cox proportional hazard analyses were used. During study follow-up, mean 
(SD) LDL-C (mg/dl) was 96.8 (32.7) for RA, 100.1 (35.1) for general controls, and 
99.1 (34.3) for OA. The relationship between lowering LDL-C and CV outcomes was 
similar for both RA and non-RA controls (p for interaction = 0.852 in RA/GN cohort, 
and p = 0.610 in RA/OA cohort). After adjusting for baseline CV risk factors, lowering 
LDL-C was associated with a 29%-50% lower risk of CV events (HR [95% CI] = 0.71 
[0.57-0.89] in RA/GN, 0.50 [0.43-0.58] in RA/OA). Subgroup analyses showed that 
lowering LDL-C was associated with a similar degree of reduction of CV events in RA 
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and non-RA controls (HR of 0.67-0.68 for RA, 0.72 for general controls, 0.76 for OA 
controls). Lowering LDL-C levels was associated with reduced CV events. The relation-
ship between lowering LDL-C and CV outcomes in RA was similar to the relationship 
found in matched general and OA controls.
Part IV: Improvements of future cost eﬀ ectives studies in RA
The ﬁ nal Part of the thesis is based on evaluating the cost eﬀ ectiveness of interventions 
in RA, primarily focusing on the application of existing model in certain subgroups of 
RA patients to evaluate the cost-eﬀ ectiveness to two branded bDMARDs. The ﬁ nal 
chapter builds on the learning from the earlier Parts of the thesis namely, treatment 
targets (Part I), subsgroups based on prognostic factors (Part II) and extra-articular 
manifestations (Part III) to propose a new conceptual framework for evaluating future 
innovative technologies in RA.
In Chapter 10, an individual patient simulation model is used to simulate the impact 
of treatment in subgroups of RA patients with various titers of ACPA, a marker of 
poor prognosis in RA as demonstrated in Part II. The model simulated disease pro-
gression in patients with RA who had previously failed cDMARDs and were starting 
bDMARD therapy. Patients commenced treatment with abatacept or adalimumab 
plus methotrexate and were evaluated after 6 months. Therapy continuation was 
based on the EULAR treatment response; disease progression was based on the 
HAQ-DI score. Quality adjusted life years (QALYs) and incremental cost per QALY 
gained were calculated by baseline ACPA quartile groups (Q1, 28–234 AU/ml; Q2, 
235–609 AU/ml; Q3, 613–1045 AU/ml; and Q4,1060–4894 AU/ml). Scenario analysis 
and one-way and probabilistic sensitivity analyses were used to evaluate robustness 
of model assumptions. Results indicated that abatacept resulted in QALY gain versus 
adalimumab in ACPA Q1, Q3, and Q4; between-treatment diﬀ erence (diﬀ erence: Q1, 
-0.115 Q2, -0.009 Q3, 0.045; and Q4, 0.279). Total lifetime discounted cost was higher 
for abatacept versus adalimumab in most quartiles (Q2, £77,612 vs. £77,546; Q3, 
£74,441 vs. £73,263; and Q4, £78,428 vs. £76,696) because of longer time on treat-
ment. Incremental cost per QALY for abatacept (vs. adalimumab) was the lowest in 
the high ACPA titer group (Q4, £6,200/QALY), followed by the next lowest titer group 
(Q3, £26,272/QALY).
The current modeling approach has advantages and has served to establish economic 
beneﬁ ts of bDMARDs, in moderate to severe RA patients who inadequately respond 
to methotrexate. In our opinion previously, published models have potential room 
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for improvement. In Chapter 11 a new conceptual model for evaluation of the cost-
eﬀ ectiveness of RA interventions is proposed. Recommendations from the Interna-
tional Society of Pharmacoeconomics and Outcomes Research-Society of Medical 
Decision Making (ISPOR-SMDM) Modeling Good Research Practices Task Force-2 
were followed in developing the conceptual model. The process involved scoping the 
decision problem by a working group and drafting a preliminary cost-eﬀ ectiveness 
model framework. A systematic literature review (SLR) of existing decision-analytic 
models was performed and analysis of an RA registry was conducted to inform the 
structure of the draft conceptual model. Finally, an expert panel was convened to seek 
input on the draft conceptual model. The proposed conceptual model consists of 
three separate modules: 1) patient characteristic module, 2) treatment module, and 
3) outcome module. Consistent with the scope, the conceptual model proposed six 
changes to current economic models in RA. These changes proposed are to: 1) use 
composite measures  of disease activity to evaluate treatment response as well as dis-
ease progression (at least two measures should be considered, one as the base case 
and one as a sensitivity analysis); 2) conduct utility mapping based on disease activity 
measures; 3) incorporate subgroups based on guideline-recommended prognostic 
factors; 4) integrate realistic treatment patterns based on clinical practice/registry 
datasets; 5) assimilate outcomes that are not joint related (extra-articular outcomes); 
and 6) assess mortality based on disease activity. The conceptual model incorporates 
the current understanding of both clinical and real-world evidence in RA, as well as 
of existing modeling assumptions. The proposed model framework was reviewed 
with experts and could serve as a foundation for developing future cost-eﬀ ectiveness 
models in RA.
Discussion
Given the overall objective of the thesis and nature of the research hypothesis tested, 
we considered that the most relevant data source to inform this thesis was real world 
clinical practice data. Unlike randomized clinical trials, real world registry data are less 
prescriptive in their inclusion/exclusion criteria as well as the treatments and hence 
provide an appropriate data source for evaluating the beneﬁ ts of various RA disease 
health states (remission, LDA, MDA, SDA) on outcomes. One of the main limitation 
of the body of work presented in this thesis is that it very much focused on established 
RA patients. Another limitation of the body of work in Parts II and III is that it only 
focused on certain prognostic factors (i.e. erosive disease and seropositivity) and 
certain extra-articular manifestation of RA (CV events).
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The research in this thesis has highlighted that treatment and reimbursement policies 
in RA should consider treatment targets that are better associated to multiple out-
comes such as physical functioning, HRQOL and resource use. This is especially true 
in RA, since the primary outcomes of ACR and DAS28-CRP measured in clinical trials 
are not generally measured in clinical practice settings and might only be informative 
from a drug eﬃ  cacy point of view for regulatory drug approval requirements. How-
ever, these measures are less sensitive to other outcomes relevant for payer needs 
compared to CDAI/SDAI. In addition, future policy in RA should consider exploring 
the management of RA based on subgroups of high unmet need, as has been done in 
multiple other therapeutic areas such as cardiovascular, diabetes, hepatitis etc. Finally, 
future health policies in RA should take a more holistic approach for managing RA, 
since there is increasing evidence of the systemic inﬂ ammatory nature of the disease. 
Thus, focusing on only the joint aspects of the condition in cost eﬀ ectiveness evalua-
tions does not provide the estimate of the true cost and beneﬁ t of interventions and 
incorporation of the non-joint aspect of the condition will be important. Though our 
work did not focus on the patient reported outcomes measures (PROMS) or patient 
reported experience measures (PREMS), incorporation of these measures in future 
policy considerations for RA will be important.
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Achtergrond
Reumatoïde Artritis (RA) wordt beschreven als een chronische progressieve ontste-
kingsziekte van het synovium (slijmvlies) in gewrichten, wat in toenemende mate leidt 
tot beperkingen en verlies van functie. Via haar articulaire evenals extra-articulaire 
eﬀ ecten draagt RA niet alleen bij tot een vermindering van de overleving, de gezond-
heid gerelateerde kwaliteit van leven (HRQOL), activiteiten in het dagelijks leven en 
de arbeidsproductiviteit, maar is tevens verbonden aan hogere zorgvoorzieningen en 
kosten. De prevalentie van RA varieert van 0,4% tot 1,3%.
RA therapien omvatten corticosteroïden (CS), niet-steroïdale anti-inﬂ ammatoire 
geneesmiddelen (NSAIDs), en ziekteremmende antireumatische geneesmiddelen 
(DMARDs). Onder de traditionele of conventionele (c)DMARDs vallen goud, sulfa-
salazine, azathioprine, cyclophosphamide, anti-malaria middelen en methotrexaat. 
Biologisch (b)DMARDs werden geintroduceerd rond 2000 en meer recent werden 
de gerichte synthetisch (ts)DMARDs geintroduceerd; deze middelen hebben de 
algemene klinische resultaten en HRQOL van patiënten aanzienlijk verbeterd. Deze 
behandelingen zijn echter duur in vergelijking met de cDMARDs. Onlangs zijn bio-
similars goedgekeurd door regelgevende en payer instanties in de EU en deze mid-
delen hebben aanzienlijk lagere kosten. Tegelijkertijd worden nieuwe therapieën en 
combinatie therapieën (van verschillende bDMARDs of bDMARDs in combinatie met 
tsDMARDs) die zich op meerdere immuun trajecten richten ontwikkeld. In dit soort 
omgeving zullen hulpmiddelen waarmee een bredere en meer precieze schatting van 
de kosten en baten gemaakt kan worden het risico van een ineﬃ  ciënte toewijzing van 
middelen beperken.
Deze scriptie werkt toe naar het nemen van een alomvattende benadering van de 
evaluatie van de kosten en baten van toekomstige behandelingen in RA. De focus is 
op de heterogene aard van RA, zowel in de baseline karakteristieken van RA patiënten 
door het overwegen van subgroepen alswel in het overwegen van uitkomsten die 
niet gewrichts gerelateerd zijn. Het is belangrijk om deze aspecten van de ziekte in 
overweging te nemen omdat toekomstige economische analyses deze in acht zullen 
moeten nemen om verdere diﬀ erentiatie versus standaardzorg mogelijk te maken.
De scriptie is onderverdeeld in 4 delen:
Deel I: Real world evidence over behandel doelen en resultaten
Deel II: Aanwezigheid van meerdere factoren voor een slechte prognose
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Deel III: Extra-articulaire manifestatie van cardiovasculair risico in RA
Deel IV: verbetering van toekomstige kosten eﬀ ectiviteits studies in RA
Deel I: Real world evidence over behandel doelen en resultaten
Consensus richtlijnen voor de behandeling van EU-Liga tegen reuma (EULAR 2016) 
focussen op de gewrichts aspecten van de ziekte en hebben gepleit voor een ‘treat to 
target’ benadering. In hoofdstuk 2 van het proefschrift zijn gegevens uit de klinische 
praktijk gebruikt voor een observationele studie die de hypothese testte dat het be-
reiken van streef maatregelen voor ziekte-activiteit zou leiden tot betere resultaten 
in de klinische praktijk in een longitudinale follow-up van een RA patienten cohort. 
Uitkomstmaten die in deze analyse geevalueerd werden omvatte zowel klinische, 
d.w.z. fysiek functioneren (dagelijkse activiteiten) volgens de modiﬁ ed Health As-
sessment Questionnaire (M-HAQ), kwaliteit van leven gemeten door de EuroQol 
5-domain (EQ-5D) en economisch d.w.z. hulpbronnen gebruik gemeten door middel 
van ziekenhuisopnamen en duurzame medische apparatuur (DME). De ziekteactivi-
teits maten die gebruikt zijn in deze analyse zijn deze die werden aanbevolen door de 
richtlijnen en omvatte de Disease Activity Score in 28 joints using C-reactive protein 
(DAS28-CRP) <2.6, de Simpliﬁ ed Disease Activity Index (SDAI) =<3.3, en de Clinical 
Disease Activity Index (CDAI) =<2.8.
Gegevens van de Brigham and Women’s Hospital Rheumatoid Arthritis Sequential 
Study (BRASS; Clinical-Trials.gov identiﬁ er NCT01793103) werden gebruikt voor het 
addresseren van de onderzoekdoelstellingen. BRASS werd geinitieerd in 2003-2004. 
De BRASS registry is een single-centrum, prospectief, observerend longitudinaal 
cohort van 1.200 volwassenen met gevestigde of recent gediagnosticeerde RA. Artsen 
beoordeelden patiëntgegevens en klinische kenmerken, ziekteactiviteit en laborato-
rium parameters op baseline en daarna jaarlijks. Om te controleren voor de intraclass 
correlatie van de panel data, werden mixed models met Toeplitz covariance structuur 
gebruikt voor het schatten van de eﬀ ecten van het bereiken van streef maatregelen 
of andere niveaus van ziekte-activiteit op de afhankelijke variabelen, namelijk de 
primaire uitkomstmaten van fysiek functioneren beoordeeld volgens de M-HAQ en 
de secundaire uitkomstmaten van HRQOL volgens de EQ-5D. Generalized estima-
ting equations met binomiale verdeling en logit link-functie werden gebruikt voor de 
binaire uitkomsten zoals DME gebruik en all-cause hospitalisatie. Baseline covariates 
geincludeerd in deze modellen waren sociaal-demograﬁ sche gegevens, laboratorium 
gegevens, subjectieve (patiënt-gerapporteerde) gegevens en arts-gediagnosticeerde 
comorbidities.
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De bevindingen van de studie suggereren dat het bereiken van de aanbevolen streef-
maatregelen in ziekteactiviteit werd geassocieerd met verbeteringen in fysiek functio-
neren en gezondheidsgerelateerde levenskwaliteit. Sommige gezondheidsresultaten 
waren vergelijkbaar in patienten die de streefmaatregelen bereikten versus LDA (lage 
ziekte activiteit). Het bereiken van LDA is een waardige klinische doelstelling voor 
sommige patiënten.
Deel II: Aanwezigheid van meerdere factoren voor een slechte prognose
Hedendaagse RA richtlijnen bevelen een meer intensieve behandeling van patiënten 
met slechte prognostische factoren aan. De nieuwe 2016 EULAR RA behandelrichtlij-
nen geven stratiﬁ catie van RA patiënten door prognostische factoren meer prominen-
tie en vermelden het als een afzonderlijke aanbeveling namelijk aanbeveling #8. De 
richtlijnen vermelden uitdrukkelijk dat de combinatie van deze factoren duidt op een 
slechte prognose. Er zijn echter geen empirische gegevens in RA over het eﬀ ect van 
meerdere prognostische factoren op klinische en economische resultaten. Deel II van 
het proefschrift richt zich op de aanwezigheid van meerdere slechte prognostische 
factoren op klinische en economische resultaten in gevestigd RA.
De volgende hypotheses werden getest in de verschillende studies in dit deel van het 
proefschrift: 
a) Patienten met gevestigd RA die anti-cyclic citrullinated peptide antistoﬀ en (ACPA) 
positief zijn, hebben een grotere kans op erosieve ziekte en groter botverlies [hand 
Digital X-Ray Bone Mineral Density (DXR-BMD)], wat aan duidt dat prognostische 
factoren onderling verbonden zijn.
b) Vermindering van de ACPA titers wordt geassocieerd met vermindering van ziekte 
activiteit en gebruik van resources.
c) De aanwezigheid van meerdere slechte prognostische factoren leidt tot slechte 
klinische en economische uitkomsten in RA patiënten.
d) De aanwezigheid van slechte prognostische factoren bij RA patiënten leidt tot ac-
celeratie van de behandeling in de klinische praktijk.
Gegevens van de BRASS registry en de CORRONA RA registry werden gebruikt om de 
hypothese in dit hoofdstuk the onderzoeken. In hoofdstuk 3 wordt de BRASS database, 
gebruikt voor het evalueren van de associaties tussen ACPA positiviteit en de binaire 
uitkomst variabele van de aanwezigheid of afwezigheid van erosies in de gewrichten 
en ook het verlies van DXR-BMD. In deze analyse gebruikten we logistische regressie 
modellen gecorrigeerd voor baseline covariates. Modellen testten de associaties tus-
260 ○ Samenvatting
sen de aanwezigheid van meerdere prognostische factoren en de categoriale variabe-
len: 1) DAS28-CRP < 2,6 of SDAI ≤ 3,3 (SDAI remissie), 2) hospitalisatie (ja of nee), 3) 
DME (ja of nee), en 4) arbeidsstatus (aandeel werkend, gepensioneerd, gehandicapt, 
en inkomen <$70.000 per jaar). Voor de associaties tussen seropositiviteit en/of 
gewrichts erosies en de waarschijnlijkheid van een DAS28-CRP score < 2,6 of SDAI ≤ 
3,3 (SDAI remissie), werden Forest plots ontwikkeld op basis van logistische regressie 
modellen met odds ratio’s (OR) en 95% betrouwbaarheidsintervallen (CI). De cova-
riates die in deze modellen zijn opgenomen omvatten de patient’s leeftijd, geslacht, 
ras, body mass index (BMI), aantal comorbiditeiten, gebruik van corticosteroiden en 
DMARDs. De resultaten tonen aan dat ACPA seropositieve patiënten, met name die 
met hoge ACPA titers, een lagere hand BMD hebben en patiënten met lagere hand 
BMD hebben kleinere kans op het bereiken van een DAS28 (CRP) <2.6.
In hoofdstuk 4 werden de associaties tussen veranderingen in ACPA levels en uitkom-
sten, inclusief DME, ziekenhuisopnamen en ziekte activiteit, onderzocht in patiënten 
met gevestigd RA met behulp van data in de BRASS registry. Uit bevindingen van deze 
analyis blijkt dat daling van ACPA levels werd geassocieerd met een vermindering in 
gebruik van DME (aangepast odds ratio [aOR]: 0,64; 95% betrouwbaarheidsinterval 
[CI]: 0,44-0,93; P = 0,019) en het aantal ziekenhuisopnames (aOR: 0.62; 95% CI: 0,41-
0,95; P = 0,029) versus geen verandering of toename. De gecorrigeerde gemiddelde 
verandering in de ziekte activiteit’s score in 28 gewrichten (C-reactive protein), totaal 
en gezwollen gewrichten nummers, en pijn scores waren aanzienlijk groter bij patiën-
ten met een vermindering in de ACPA levels versus degenen zonder veranderingen of 
verhoging (p < 0,05). In patiënten met gevestigd RA werden verlaging van ACPA levels 
van >10% geassocieerd met een vermindering van DME gebruik, ziekenhuisopnamen 
en ziekte-activiteit.
De hoofdstukken 5-6 richten zich op de aanwezigheid van meerdere prognostische fac-
toren in RA patiënten. In hoofdstuk 5 werden logistische regressie modellen gebruikt 
voor het testen van associaties tussen ACPA/ reumatoïde factor (RF) seropositiviteit 
en erosieve ziekte en de aanwezigheid van ACPA/RF seropositiviteit plus erosieve 
ziekte en (1) ernst van RA; (2) ziekenhuis opnames; (3) duurzaam medische appara-
tuur (DME) gebruik; en (4) werk productiviteit (bijv. arbeidsstatus). De covariates 
gebruikt in deze modellen includeren de patiënt’s leeftijd, geslacht, ras, body mass 
index (BMI), aantal comorbiditeiten, en behandeling. De bevindingen geven aan dat 
ACPA positieve (vs. negatieve) RA patiënten een 2,72 maal hogere kans hebben op 
erosies (OR = 2,72; 95% CI: 1,77-4,18; P < 0,001). Patiënten met ACPA seropositiviteit 
en erosies hadden een aanzienlijk grotere kans op: (1) een hogere ziekte-activiteit, 
gemeten door DAS28-CRP ≥ 2,6; (2) ziekenhuis opname; (3) gebruik van DME; en 
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om (4) werkeloos, gehandicapt of langdurig uitgeschakeld te zijn. Deze analyse was 
de eerste “real-world”-studie bij patiënten met zowel recent gediagnosticeerde als 
chronische RA, waaruit bleek dat de combinatie van ACPA seropositiviteit en erosies 
signiﬁ cant geassocieerd zijn met negatieve klinische en economische resultaten, 
waaronder een geringere kans op een lage ziekte-activiteit en hoger zorg gebruik, 
ondanks het gebruik van bDMARDs door veel patiënten. Daarmee werd duidelijk dat 
de aanwezigheid van verschillende prognostische factoren mogelijk een signaal is 
voor een behoefte aan meer intensieve behandeling, zelfs wanneer waargenomen in 
patiënten met chronische RA, evenals recente gediagnosticeerde RA.
Hoofdstuk 6 is gebaseerd op gegevens van de CORRONA RA-registry. Het doel van 
deze analyse was om patiënten met RA te typeren door het aantal slechte prognosti-
sche factoren (zoals functionele beperking, extra-articulaire aandoeningen, seroposi-
tiviteit, erosies) en om versnelling van de behandeling, klinische uitkomsten en status 
van het werk over een periode van 12 maanden, te evalueren op basis van het aantal 
slechte prognostische factoren. Veranderingen in medicatie, CDAI en werkstatus 
(baseline-12 maanden) werden geëvalueerd aan de hand van lineaire en logistische 
regressie modellen. De relatie tussen slechte prognostische factor groepen en werk-
status werd onderzocht op baseline en 12 maanden follow-up met behulp van de chi-
squared test. Een frequency-matching approach (coarsenend exact matching) werd 
gebruikt om patiënten the matchen over de slechte prognostische factor categorieën 
volgens leeftijdsgroep (18-44, 45-54, 55-64, 65-74, 75+ jaar) omdat de relatie tussen 
slechte prognostische factor categorie en werkstatus kan worden veroorzaakt door 
het leeftijdsverschil (gepensioneerden zijn over het algemeen ouder). Op baseline 
waren patiënten met een groter aantal slechte prognostische factoren (vs. die met 
minder prognostische factoren) ouder en hadden RA voor een langere duur en had-
den een hogere CDAI (p = 0,011). B/tsDMARD gebruik was vergelijkbaar bij patiënten 
met/zonder prognostische factoren. De gemiddelde (standard error) verandering in 
CDAI was, na corrigeren voor baseline CDAI, -4.95 (0.24), -4.53 (0.27) en -2,52 (0,34) 
voor de geen-prognostische factor groep, 1, 2 en ≥3 prognostische factor groepen, 
respectivelijk. Meer patiënten werkten op baseline maar niet na 12 maanden follow-
up in 2 (13,9%) en ≥3 (12,5%) versus 0-1 (7.3%) prognostische factoren groepen. 
Deze analyse benadrukt opnieuw dat patiënten met meerdere prognostische factoren 
suboptimale klinische en werkstatus uitkomsten hebben. Daarnaast gaven de bevin-
dingen aan dat ondanks de hoge ziekte activiteit en slechtere klinische resultaten, 
de prognostische factoren niet signiﬁ cant het gebruik van b/tsDMARD voorspellen. 
Dit kan een heroverweging van het belang van slechte prognostische factoren in de 
treat-to-target aanpak rechtvaardigen.
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Deel III: Extra-articulaire manifestatie van cardiovasculair risico in RA
Behandelrichtlijnen in RA hebben aandacht besteed aan het gewrichts aspect van 
de ziekte, echter de extra-articulaire manifestatie van RA vertegenwoordigt een sig-
niﬁ cante en belangrijke uitkomst. Het proefschrift richt zich op de cardiovasculaire 
(CV) manifestatie van RA, vooral omdate CV incidenten een impact hebben op de 
overleving van de patient, HRQOL en aanzienlijke kosten hebben. Aangezien RA is 
gekoppeld aan een toename van 50 tot 60% in het risico op een cv sterfgeval, evalu-
eert hoofdstuk 7 de behandeling van de traditionele CV-risicofactoren in RA patiënten 
zodat vast gesteld kan worden of het toegenomen CV risico kan worden verklaard 
door slecht management van traditionele CV-risicofactoren in RA. Voor deze analyse 
werden de gegevens uit de UK Clinical Practice Research Datalink (CPRD) gebruikt. 
RA patiënten werden 1:4 gematched aan niet-RA-patiënten op basis van hun entry 
in de CPRD database, CV risicocategorie (NCEP classiﬁ catie), behandeling’s status 
op de index datum en een propensity-score die het risico van het hebben van RA 
inschatte. 24,859 RA patiënten werden geïdentiﬁ ceerd en gematched met 87,304 niet-
RA-patiënten. De jaarlijkse bloeddruk, lipiden en diabetes-gerelateerde tests waren 
vergelijkbaar in beide groepen, hoewel CRP en ESR hoger waren in RA patiënten 
ten tijde van de diagnose en daalden in de loop van de tijd. Het voorschrijven van 
antihypertensiva in RA patiënten steeg van 38,2% bij de diagnose tot 45,7% na 5 jaar, 
lipideverlagende behandelingen steeg van 14,0 tot 20,6% en antidiabetica stegen van 
5,1 tot 6,4%. Soortgelijke percentages in geneesmiddel gebruik werden waargenomen 
bij niet-RA-patiënten, hoewel iets minder voor antihypertensiva. Een bescheiden (2%) 
maar beduidend lagere verwezenlijking van de lipiden en diabetes doelen na 1 jaar 
werd waargenomen bij RA patiënten. Deze analyse toont aan dat er geen verschillen 
zijn tussen de groepen in de frequentie van de testen en de behandeling van CV-
risicofactoren. Het lijkt onwaarschijnlijk dat de hogere CV incidenten in RA patiënten 
worden veroorzaakt door verschillen in de traditionele behandeling van de CV risico 
factoren.
Een ander aspect van CV manifestatie in RA dat wordt onderzocht in hoofdstuk 8 was 
de prestatie van CV predictie algoritmen in RA. Het doel was om de prestatie van CV 
risico calculators, de Framingham risicoscore (FRS) en QRISK2, te vergelijken in RA 
en matched niet-RA-patiënten, en te beoordelen of hun prestaties kunnen worden 
verbeterd door de toevoeging van CRP. Een retrospective analyse is uitgevoerd met de 
gegevens van CPRD gekoppeld aan Hospital Episode Statistics (HES). RA patiënten 
zonder voorafgaande cardiovasculaire gebeurtenissen werden gematched met niet-RA 
patiënten met ziekte risicoscores. De algehele prestatie van de FRS en QRISK2 werd 
vergeleken tussen de cohorten en beoordeeld met en zonder CRP in het RA cohort met 
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de C-index, Akaike Information criterion (AIC) en de net reclassiﬁ cation index (NRI). 
De C-index voor de FRS in de niet-RA en RA cohorten was 0.783 en 0.754 (P < 0,001) 
en dat van de QRISK2 was 0.770 en 0.744 (P < 0,001) respectivelijk. Log[CRP] werd 
positief geassocieerd met cardiovasculaire gebeurtenissen, maar verbeteringen in de 
FRS en QRISK2 C-indexcijfers ten gevolge van de inclusie van CRP waren klein, van 
0.764 naar 0.767 (P = 0,026) bij FRS en van 0.764 naar 0.765 (P = 0.250) voor QRISK2. 
De NRI was 3,2% (95% CI: -2,8, 5,7%) voor FRS en -2,0% (95% CI: -5,8, 4,5%) voor 
QRISK2. De C-index voor de FRS en QRISK2 was signiﬁ cant beter in de niet-RA in 
vergelijking met de RA patiënten. De toevoeging van CRP in beide algorithmes was 
niet geassocieerd met een signiﬁ cante verbetering van de herclassiﬁ catie op basis van 
NRI.
Het laatste hoofdstuk 9 van de deze sectie richt zich op de associatie tussen het ver-
lagen van low-density lipoproteïn cholesterol (LDL-C) levels en CV-uitkomsten in RA 
patiënten. Volwassen patiënten met RA en 2 leeftijd- en geslacht gematchte controle 
cohorten [RA plus algemene controles (RA/GN), RA plus osteoartritis (OA) controls 
(RA/OA)] werden geanalyseerd. Hiervoor zijn multivariable Cox proportionele hazard 
analyses gebruikt. Tijdens de studie follow-up was de gemiddelde (SD) LDL-C (mg/
dl) 96,8 (32,7) voor RA, 100,1 (35,1) voor general controls en 99.1 (34.3) voor OA 
controls. De relatie tussen het verlagen van LDL-C en CV uitkomsten was vergelijkbaar 
voor beide RA en niet-RA controls (p voor interactie = 0,852 in RA/GN cohort, en p = 
0,610 in RA/OA cohort). Na corrigeren voor baseline CV risicofactoren werd verlaging 
van LDL-C geassocieerd met een 29%-50% lager risico op cv events (HR [95% CI] 
= 0.71 [0.57-0.89] RA/GN, 0.50 [0.43-0.58] RA/OA). Een subgroep analyse toonde 
aan dat het verlagen van LDL-C was geassocieerd met een vergelijkbare mate van 
vermindering van CV events in RA en niet-RA controls (HR van 0.67-0.68 voor RA, 
0,72 voor general controls, 0,76 voor OA controls). Het verlagen van LDL-C levels was 
geassocieerd met een vermindering in CV events. De relatie tussen het verlagen van 
LDL-C en CV uitkomsten in RA was vergelijkbaar met de relatie die werd gevonden in 
de matched general controls en de OA controls.
Deel IV: verbetering van toekomstige kosten eﬀ ectiviteit studies in RA
Het laatste deel van het proefschrift is gebaseerd op de beoordeling van de kostenef-
fectiviteit van interventies in RA; met een focus op de toepassing van een bestaand 
model in bepaalde subgroepen van RA patiënten om de kosteneﬀ ectiviteit van twee 
niet-generieke bDMARDs te beoordelen. Het laatste hoofdstuk is gebaseerd op in-
zichten uit de eerdere delen van het proefschrift namelijk behandelingsdoelstellingen 
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(deel I), subgroepen gebaseerd op prognostische factoren (deel II) en extra-articulaire 
manifestaties (deel III) om een nieuw conceptueel kader voor de beoordeling van 
toekomstige innovatieve technologieën in RA voor te stellen.
In hoofdstuk 10 wordt een individueel patiënt simulatie-model gebruikt voor het 
simuleren van het eﬀ ect van behandeling in subgroepen van RA patiënten met ver-
schillende ACPA titers, een teken van een slechte prognose in RA zoals aangetoond 
in deel II. Het model simuleerd ziekte progressie in patiënten met RA waarbij eerdere 
behandeling met cDMARDs is gefaald en die beginnen aan bDMARD therapie. Pa-
tiënten begonnen behandeling met abatacept of adalimumab plus methotrexaat en 
werden geëvalueerd na 6 maanden. De voortzetting van de middelen was gebaseerd 
op de EULAR treatment response criteria; ziekteprogressie was gebaseerd op de 
HAQ-DI-score. Kwaliteit gecorrigeerde levens jaren (QALYs) en incrementele kosten 
per gewonnen QALY werden berekend per baseline ACPA kwartiel groep (Q1, 28-234 
AU/ml; Q2, 235-609 AU/ml; Q3, 613-1045 AU/ml; Q4,1060-4894 AU/ml). Scenario-
analyses en one-way en probabilistische sensitiviteitsanalyses werden gebruikt voor 
het evalueren van de robuustheid van de aannames gebruikt in het model. Uit de 
resultaten bleek dat abatacept resulteerde in QALY winst versus adalimumab in ACPA 
Q1, Q3 en Q4; tussen-behandeling verschil (verschil: Q1 -0.115 Q2 -0.009 Q3, 0.045; 
en Q4, 0.279). De totale gedisconteerde lifetime kosten waren hoger voor abatacept 
versus adalimumab in de meeste kwartielen (Q2, £77,612 vs. £77,546; Q3, £74,441 vs. 
£73,263; Q4, £78,428 vs. £76,696) vanwege de langere behandel duur met abatacept. 
De incrementele kosten per QALY voor abatacept (vs. adalimumab) was het laagste 
in de hoogste ACPA titer groep (Q4, £6.200/QALY), gevolgd door de een na hoogste 
titer groep (Q3, £26,272/QALY).
De huidige aanpak van modellen heeft voordelen en heeft bijgedragen tot de totstand-
koming van de economische voordelen van bDMARDs in patienten met matige tot 
ernstige RA die onvoldoende reageren op methotrexaat. Naar onze mening hebben 
eerder verschenen modellen potentiële ruimte voor verbetering. In hoofdstuk 11 wordt 
een nieuw conceptueel model voor de evaluatie van de kosteneﬀ ectiviteit van RA inter-
venties voorgesteld. Aanbevelingen van de International Society of Pharmacoecono-
mics and Outcomes Research-Society of Medical Decision Making (ISPOR-SMDM) 
Modeling Good Research Practices Task Force-2 werden gevolgd bij de ontwikkeling 
van het conceptuele model. Het volledige proces betrok het vaststellen van het beslis-
sings probleem door een werkgroep en het opstellen van een voorafgaand kosten-
eﬀ ectiviteits model kader. Een systematische literatuur review (SLR) van bestaande 
analytische modellen werd uitgevoerd en analyse van een RA-registry werd gedaan 
om de structuur van het voorgestelde conceptmodel te informeren. Tenslotte werd 
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een panel van deskundigen bijeengeroepen om input op het draft conceptmodel te 
krijgen. Het voorgestelde conceptuele model bestaat uit drie afzonderlijke modules: 
1) patiënt karakteristieken module, 2) behandelings module en 3) uitkomsten mo-
dule. In overeenstemming met de scope stelt het conceptmodel zes wijzigingen op de 
huidige economische modellen in RA voor. Deze voorgestelde wijzigingen zijn: 1) het 
gebruik van een samengestelde parameter van de ziekte-activiteit om de respons op 
de behandeling te evalueren en ook de ziekteprogressie (ten minste twee maatregelen 
moeten worden overwogen, een in de base case en een in de gevoeligheidsanalyse); 
2) utility mapping gebaseerd op ziekteactiviteit maten; 3) integreren van subgroepen 
gebaseerd op de door de richtlijn aanbevolen prognostische factoren; 4) integreren 
van realistische behandel patronen die gebaseerd zijn op de klinische praktijk/registry 
datasets; 5) verwerken van niet gewrichts-gerelateerde uitkomsten (extra-articulaire 
uitkomsten); en 6) vaststellen van sterfte op basis van ziekteactiviteit. Het conceptuele 
model integreert het huidige denkbeeld van zowel klinische als real-world gegevens 
in RA, als ook bestaande modeleer aannames. Het voorgestelde model kader is be-
sproken met deskundigen en zou kunnen dienen als basis voor de ontwikkeling van 
toekomstig kosteneﬀ ectiviteits modellen in RA.
Discussie
Gezien de algemene doelstelling van het proefschrift en de aard van de geteste 
onderzoeks hypothese, waren we van mening dat de meest relevante bron voor dit 
proefschrift real world clinical practice data was. In tegenstelling tot gerandomiseerde 
klinische trials, zijn real world registries minder normatief in hun opneming/uitslui-
tingscriteria en de behandelingen en dus een gegevensbron voor de evaluatie van de 
baten van de verschillende RA ziekte gezondheidstoestanden (remissie, LDA, MDA, 
SDA) op de uitkomstmaten. Een van de belangrijkse beperkingen van het werk gepre-
senteerd in dit proefschrift is dat het met name gericht is op gevestigd RA patiënten. 
Een andere beperking van het werk in de delen II en III is dat het zich alleen concen-
treerd op bepaalde prognostische factoren (d.w.z. erosieve ziekte en seropositiviteit) 
en bepaalde extra-articulaire manifestatie van RA (CV events).
Het onderzoek beschreven in dit proefschrift geeft aan dat het beleid voor de behan-
deling en vergoeding van RA, behandelingsdoelstellingen die beter gekoppeld zijn 
aan meerdere uitkomstmaten, zoals fysiek functioneren, HRQOL en het hulpbronnen 
gebruik, zou moeten overwegen. Dit is vooral het geval bij RA, aangezien de primaire 
uitkomstmaten in klinische studies, ACR en DAS28-CRP, in het algemeen niet gemeten 
worden in de klinische praktijk en mogelijk alleen informatief zijn voor de werkzaam-
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heid van het geneesmiddel voor goedkeuringseisen van regelgevende instanties. Deze 
uitkomstmaten zijn echter minder gevoelig voor andere uitkomsten relevant voor de 
behoeften van de payer ten opzichte van CDAI/SDAI. Daarnaast zou het toekomstige 
beleid in RA moeten overwegen de behandeling van RA gebaseerd op subgroepen 
met een hoge onvervulde behoefte te onderzoeken, zoals is gedaan in meerdere 
andere therapeutische gebieden zoals hart- en vaatziekten, suikerziekte, hepatitis enz. 
Tenslotte zou toekomstig gezondheidsbeleid in RA een meer holistische benadering 
moeten nemen voor de behandeling van RA omdat er steeds meer bewijs is voor de 
systemische inﬂ ammatoire aard van de ziekte. Zodoende zullen kosteneﬀ ecitviteits 
evaluaties die alleen focussen op de gewrichts aspecten van de aandoening geen 
schatting van de werkelijke kosten en baten van interventies leveren, en het integreren 
van de niet-gewrichts gerelateerde aspecten van de ziekte zal dan ook van belang zijn. 
Hoewel onze werkzaamheden niet zijn gericht op patiënt gerapporteerde uitkomst 
maten (patient reported outcomes measures (PROMS)) of patiënt gerapporteerde 
ervarings maten (patient reported experience measures (PREMS)) zal integratie van 
deze uitkomstmaten in toekomstige beleidsoverwegingen voor RA belangrijk zijn.
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